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Regulatory T cells (Treg) therapy using autologous Tregs expanded ex vivo is currently being 
assessed clinically as a means of limiting graft rejection. However, pre-clinical data has 
demonstrated that graft-specific Tregs protect from graft rejection more effectively than 
polyclonal Tregs. Chimeric antigen receptor (CAR) technology is currently being investigated 
clinically as a means of conferring tumour antigen-specificity onto T cells in cancer research. CARs 
are synthetic fusion proteins which translate the engagement of extracellular target antigens into 
the activation of intracellular T cell signalling cascades. The hypothesis tested in this thesis was 
that the efficacy of polyclonal Treg therapy to inhibit transplant rejection could be enhanced by 
using CARs to confer specificity for donor MHC class I, alloantigens which are ubiquitously 
expressed in allografts. 
A human CAR was constructed to incorporate a patient-derived HLA-A2-targeting moiety and a 
CD28-CD3ζ signalling domain. Delivery of this CAR into human Tregs which were isolated using 
GMP-compatible protocols did not influence the phenotype or suppressive capacity of these cells. 
Compared to polyclonal Tregs, A2 CAR Tregs exhibited a greater suppressive function in the 
presence of HLA-A2+ antigen presenting cells, without eliciting cytotoxic activity. Furthermore, 
these cells preferentially transmigrated across HLA-A2-expressing endothelial cell monolayers, 
suggesting a favoured migration in to HLA-A2+ target tissues. In a human skin xenograft transplant 
model, A2 CAR Tregs alleviated alloimmune-mediated damage of HLA-A2+ skin more effectively 
than polyclonal Tregs. 
A second CAR was designed to redirect mouse Tregs towards BALB/c MHC class I (Kd) with the 
rationale of comparing the efficacy of CAR Tregs and Tregs with different allospecificities at 
reducing graft rejection. Murine CAR Tregs maintained their phenotype and suppressive ability 
and appeared to proliferate in the presence of Kd in vivo although conclusive evidence for the 
functionality of this CAR remained to be acquired. 
The results obtained demonstrated that CARs can be used to generate MHC class I-allospecific 
Tregs which are functionally superior to polyclonal Tregs at protecting from  
alloimmune-mediated transplant rejection, suggesting that CAR technology is a clinically 
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 ORGAN TRANSPLANTATION 
Improvements in surgical techniques and the development of modern immunosuppressive 
regimens during the 20th century (Watson and Dark 2012) promoted organ transplantation to 
become the gold-standard treatment option for treating the dysfunction and failure of various 
organs (Sagoo, Lombardi et al. 2012, Safinia, Leech et al. 2013). However, the therapeutic benefits 
of this treatment option are limited by graft rejection, a complex process by which recipient 
immune cells recognise and destroy transplanted tissues, ultimately resulting in allograft 
dysfunction and failure (Rogers and Lechler 2001, Tsang, Tanriver et al. 2009, Booth, 
Grabauskiene et al. 2011, Sagoo, Lombardi et al. 2012, Pasquet, Douet et al. 2013). 
Graft rejection is currently managed with life-long drug-based immunosuppression which has 
facilitated improvements in short-term survival rates (Safinia, Leech et al. 2013). However, these 
approaches are non-specific and as such, associated with severe side-effects: recipients are under 
consistent nephrotoxic insult with an increased susceptibility to acquiring infections and 
developing cancer. More importantly, these approaches do not effectively tackle the issue of 
chronic rejection, thus the half-life of allografts remains limited to approximately 10-15 years 
(Burgos, Gonzalez-Molina et al. 2012, Gruessner and Gruessner 2013). This compounds another 
limitation of organ transplantation which relates to a shortage of available donor organs (Testa 
and Siegler 2014). 
In light of these issues, various approaches are currently under investigation as potential means 
of inducing a state of “transplant tolerance”, whereby transplanted tissues are accepted 
indefinitely, negating the requirement for life-long immunosuppression. 
 
 PATHWAYS OF ALLORECOGNITION  
Although the innate immune response has been shown to contribute to graft rejection 
(Oberbarnscheidt and Lakkis 2014), studies conducted in neonatally thymectomised (Miller 1961) 
and irradiated adult (Hall, Dorsch et al. 1978, Hall, Dorsch et al. 1978, Hall, de Saxe et al. 1983) 
mice have demonstrated that the most deleterious immune responses are driven by  
recipient-derived T cells. These cells have been described to recognise alloantigens via three 
pathways of allorecognition: the direct, indirect and semi-direct pathways. The direct pathway is 
initiated by donor-derived antigen presenting cells (APC) which present intact allogeneic major 
histocompatibility complex (MHC)-peptide complexes to recipient T cells (Figure 1-1A). 
Conversely, the indirect pathway relies on recipient-derived APCs which uptake, process and 
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present allopeptides in the context of self-MHC class II (Figure 1-1B). More recently, the  
semi-direct pathway was described in which recipient-derived APCs present both acquired, intact 
allo-MHC-peptide complexes (direct presentation) and allopeptides in the context of self-MHC 
(indirect presentation) (Figure 1-1C).  
 
Figure 1-1 │ Schematic diagram detailing the three distinct pathways of allorecognition. A: In the direct 
pathway of allorecognition, donor APCs migrate from the transplanted allograft to secondary lymphoid 
organs where they present donor antigen in the context of donor MHC molecules. Recipient CD4+ T cells 
binding allopeptides presented by allo-MHC class II are then capable of facilitating the activation of 
recipient CD8+ T cells recognising allopeptides presented by allo-MHC class I. B: In the indirect pathway of 
allorecognition, recipient APCs infiltrate the transplanted allograft where they acquire donor antigen. 
These APCs then migrate to secondary lymphoid organs where they present these allopeptides in the 
context of self-MHC class II to recipient CD4+ T cells which, in turn, can facilitate the activation of recipient 
B cells. C: In the semi-direct pathway of allorecognition, recipient APCs infiltrate the transplanted allograft 
and uptake intact donor class I and class II MHC/peptide complexes. In addition, these APCs also uptake, 
process and present peptides derived from donor MHC molecules in the context of self-MHC class II. 
Therefore, in the secondary lymphoid organs, these recipient APCs are capable of presenting allopeptides 
in the context of self-MHC class II to recipient CD4+ T cells (indirect) and in the context of allo-MHC class I 
to recipient CD8+ T cells (direct), enabling the CD4+ T cells to facilitate in the activation of the CD8+ T cells. 
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 Direct pathway of allorecognition 
A review article pertaining to the direct pathway of allorecognition is included at the end of this 
thesis. 
One of the most striking features of the direct pathway is the strength and vigour with which a 
subsequent immune response is elicited. This was first demonstrated in vitro through the use of 
mixed leukocyte reactions (MLR) (Bain, Vas et al. 1964) and subsequently in vivo using allogeneic 
rodent transplant models (Sherman and Chattopadhyay 1993). This vigour was attributed to the 
presence of donor-derived “passenger” leukocytes which are co-transferred into the recipient, 
during a transplant procedure. Indeed, depletion of these cells from thyroid (Talmage, Dart et al. 
1976) or pancreatic (Bowen, Andrus et al. 1980) allografts has been shown to prolong allograft 
survival. In 1982, Lechler and Batchelor (Lechler and Batchelor 1982, Lechler and Batchelor 1982) 
demonstrated that the principle passenger leukocytes responsible for activating recipient T cells 
were dendritic cells (DC). In these studies, prolonged survival of rat kidney allografts could be 
achieved by “parking” the allograft in an intermediate recipient to deplete passenger leukocytes, 
prior to engraftment in a terminal recipient. However, this prolongation was prevented by the 
repletion of donor DCs. 
The vigour of a direct alloimmune response can be attributed to the fact that individuals have a 
disproportionately high precursor frequency of T cells with direct allospecificity. Approximately 
1-10% of the T cells in an individual are capable of engaging an intact foreign MHC-peptide 
complex. This is orders of magnitude greater than the ~0.01% of T cells which typically recognise 
foreign peptides presented in the context of self-MHC (Veerapathran, Pidala et al. 2011). Two 
models have been proposed to explain this unusually high precursor frequency, each of which 
places an emphasis on one of the components which comprises an MHC-peptide complex: the 
allopeptide and the allo-MHC molecule. 
 
1.1.1.1.1 Models explaining direct allorecognition 
The “multiple binary complexes” model  suggests that allo-MHC molecules “mimic” specific 
structural components of self-MHC molecules, specifically the components which are recognised 
by an imposing T cell receptor (TCR) (Matzinger and Bevan 1977). However, as the binding groove 
of the allo-MHC differs greatly from the self-MHC molecule, the pool of peptides naturally 
presented is different, despite being derived from similar endogenous proteins. As such, in this 
model it is the allopeptide presented which drives direct allorecognition (Figure 1-2A). In support 
of this, Eckels et al. (Eckels, Gorski et al. 1988) demonstrated in 1988 that T cell proliferation 
Chapter I │ General introduction 
 
5 
induced by the presentation of allopeptides in the context of human leukocyte antigen (HLA)-DR1 
was abrogated when the allopeptides were displaced by competing influenza  
haemagglutinin-based peptides. It has also been shown that presentation of allo-MHC molecules 
Figure 1-2 │ Comparison of the two principle theories explaining the high frequency of T cells with direct 
allospecificity. A: Multiple binary complexes hypothesis. The elements of the allogeneic MHC molecule 
which interact with the TCR mimic those which are found in self-MHC molecules. As such, it is the presence 
of the allopeptide (red) which drives recognition of the allogeneic MHC-peptide complex. Allograft 
presentation of various allopeptides in the contexts of MHC molecules which are perceived as ‘self’ results 
in the activation of a range of T cells, each expressing a TCR specific for a different MHC-peptide complex. 
B: High determinant density hypothesis. Structural differences in the polymorphic regions of the allo-MHC 
molecule are detected by the TCR (red). The high density of cognate allo-MHC molecules which possess 
these polymorphisms on donor-derived APCs facilitates the efficient activation of recipient T cells which 
recognise the allogeneic MHC molecule with a low, medium or high affinity. 
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lacking allopeptides, achieved through the use of MHC mutants (Heath, Kane et al. 1991) or  
acid-treatment of target cells (Wang, Man et al. 1998), trigger limited responses from alloreactive 
T cells. 
The “high determinant density” model focuses on the fact that allo-MHCs are structural different 
to self-MHCs (Bevan 1984). Whilst the majority of elements recognised by a TCR are conserved 
across various MHC subtypes (Huseby, White et al. 2005), specific amino acid polymorphisms 
present in the exposed parts of the allo-MHC molecule modify the manner by which a  
self-restricted TCR docks with an MHC, irrespective of the peptide presented. These residues 
cause the MHC-peptide complex to be recognised as foreign, thus the peptide presented 
stabilises the MHC-peptide complex but has little influence in the recognition process. The high 
density of ligands expressed by donor APCs can further facilitate the activation of alloreactive  
T cells (Figure 1-2B). Additionally, the affinity with which this TCR:allo-MHC interaction occurs 
may have implications in the alloresponse observed. Whilst T cells are selected to bind  
self-MHC-peptide complexes with a low affinity, it is possible that they would bind allo-MHC-
peptide complexes with a high affinity, suggesting that a high affinity cross-reaction is responsible 
for the allorecognition observed. In support of this model, Lombardi et al. demonstrated that site 
directed mutagenesis of specific TCR contact regions within allogeneic HLA-DR molecules resulted 
in inhibition of T cell binding and subsequent effector responses (Lombardi, Barber et al. 1991). 
As such, it was evident that specific sites of the allo-MHC molecule were critical for direct 
allorecognition to occur. These findings were later confirmed by Villadangos et al. who employed 
a similar approach whilst mutating HLA-B27 (Villadangos, Galocha et al. 1994). 
 
1.1.1.1.2 Conundrum of direct allorecognition 
It is well-established that T cell progenitors must undergo a stepwise “education” process in the 
thymus to develop into mature T cell. The cells which typically result from this process are able 
to recognise self-MHC-peptide complexes with a low affinity (discussed in section 1.1.3.1). 
However, the existence of this process reveals a conundrum: why do self-restricted T cells 
(Zinkernagel and Doherty 1974) recognise allo-MHC-peptide complexes? Studies have 
demonstrated that cross-reactivity between self and allogeneic MHC-peptide complexes is key 
for this mode of allorecognition. In other words, T cells specific for peptide “x” presented by  
self-MHC “A” are also able to recognise peptide “y” presented by allo-MHC “B” (Game and Lechler 
2002). 
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Studies supporting this have demonstrated that lymphocyte function-associated antigen (LFA)-3+ 
(Lombardi, Sidhu et al. 1990) and CD45RO+ (Merkenschlager, Ikeda et al. 1991) memory T cells 
primed against peptide “x” presented by self-MHC “A” also respond to allo-MHC-peptide 
complexes (peptide “y” presented by allo-MHC “B”). Furthermore, these cross-reacting memory 
T cells comprise a significant proportion of the total T cells which respond in a direct manner. This 
cross-reactivity concept was further accentuated by Lombardi et al. in 1989 (Lombardi, Sidhu et 
al. 1989). In this study, human alloreactive T cell clones which were specific for HLA-DR1 were  
co-cultured with autologous APCs presenting Candida albicans-derived antigens in the context of 
HLA-DR4/HLA-DR13. Half of the alloreactive T cell clones analysed responded in these co-cultures, 
suggesting that cells which were capable of recognising the allo-MHC molecule HLA-DR1 were 
also activated by APCs presenting peptides in the context of self-MHC. 
Overall, the aforementioned high determinant density and multiple binary complex models 
provide two explanations for why T cells with direct allospecificity exist with a high precursor 
frequency. With functional and structural data supporting both hypotheses (Boardman, Jacob et 
al. 2016), it is likely that in vivo, the high frequency of direct allorecognition can be attributed to 
a combination of these theories. 
 
1.1.1.1.3 Consequences of direct allorecognition 
Allorecognition typically leads to an effector response in which CD8+ T cells with direct 
allospecificity actively kill donor-derived target cells (Yu, Xu et al. 2006), leading to allograft 
dysfunction and failure. Various studies have investigated how recipient graft-specific CD8+ and 
CD4+ T cells contribute to acute and chronic transplant rejection (Rosenberg and Singer 1992, 
Lee, Grusby et al. 1994, Krieger, Yin et al. 1996, Game and Lechler 2002, Benichou, Yamada et al. 
2011). For example, in 2000, Pietra et al. investigated the contribution of CD4+ T cells in acute 
graft rejection through the use of severe combined immunodeficiency (SCID) and  
recombination-activating-gene (RAG)-1 deficient mice which lack functional T and B cells  
(Pietra, Wiseman et al. 2000). C57BL/6 heart allografts, which survived indefinitely in SCID mice, 
were acutely rejected (mean survival time (MST) of 12 days) when BALB/c CD4+ T cells were 
adoptively transferred on the day of transplant. Conversely, heart allografts which lacked donor 
C57BL/6 MHC class II molecules (C2D donor mice) were not rejected (7/8 allografts survived >60 
days), demonstrating that CD4+ T cells directly specific for donor MHC class II molecules were 
necessary for acute allograft rejection. 
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More recently, Brown et al. further demonstrated the contribution of recipient CD4+ T cells to 
allograft rejection using a fully-mismatched kidney transplant model in which donor APCs were 
specifically depleted (Brown, Nowocin et al. 2016). In this study, one native kidney of recipient 
mice (FVB strain) was replaced with an allogeneic (C57BL/6 × CBA F1) kidney. In the absence of 
treatment, transplanted kidneys were rejected acutely in 40% of cases. However, in recipients 
which were treated with an immunotoxin-conjugated antibody specific for donor MHC class II  
(I-Ak) to depleted donor APCs, kidney allografts were completely protected: histological analysis 
showed no evidence of rejection and upon removal of the second native kidney, the function of 
the transplanted kidney (blood urea nitrogen (BUN) score) was found to be intact. 
Analysis of blood samples acquired from stable renal transplant recipients has revealed that 
recipient CD4+ T cells with direct allospecificity become hyporesponsive towards alloantigens but 
are not deleted (Ng, Baker et al. 2001). This work was extended by demonstrating that that 
human CD4+ T cells co-cultured with MHC class II-expressing thyroid follicular cells (TFC) 
(Lombardi, Arnold et al. 1997) or epithelial cells (Marelli-Berg, Weetman et al. 1997) do not 
proliferate or produce cytokines in the absence of co-stimulation and are hyporesponsive upon 
subsequent challenge with Epstein-Barr virus (EBV)-transformed Lymphoblastoid B cell lines  
(B-LCL) (Marelli-Berg and Lechler 1999). Together, these results suggested that in the absence of 
donor-derived professional APCs, recipient CD4+ T cells engaged MHC class II molecules 
presented by transplanted tissue parenchymal cells which lacks co-stimulatory molecules. As a 
result, these T cells become anergic (Marelli-Berg, Weetman et al. 1997) or polarised towards a 
Th2 phenotype (Lombardi, Arnold et al. 1997), suggesting that prolonged alloimmune responses 
depend on an alternative mode of allorecognition. 
  
 Indirect pathway of allorecognition 
The indirect pathway was originally proposed as a distinct “route” of alloimmunisation by Lechler 
and Batchelor et al. in 1982 as part of the aforementioned rat kidney “parking” studies (Lechler 
and Batchelor 1982, Lechler and Batchelor 1982). In these studies, it was noted that although 
depletion of donor DCs prolonged the survival of rat kidney allografts, rejection still occurred, 
albeit at a slower rate compared to allografts which contained allogeneic DCs. This led to the 
proposal that alloreactive T cells were activated via a second pathway of allorecognition which 
did not rely on donor-derived APCs (Game and Lechler 2002). 
The MHC locus is one of the most polymorphic regions of the genome in vertebrates (Sommer 
2005). Consequently, graft rejection is believed to principally be driven through the recognition 
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of donor MHC molecules, either in an intact form (direct allorecognition) or as peptides presented 
in the context of recipient-MHC molecules (indirect allorecognition). In the early 1990s, various 
studies indeed demonstrated that recipient APCs were able to present peptides derived from 
donor-MHC molecules and that this process contributed to allograft rejection (Benichou, 
Takizawa et al. 1992, Fangmann, Dalchau et al. 1992, Liu, Sun et al. 1993, Benham, Sawyer et al. 
1995). At this time, it was also estimated that the frequency of T cells with indirect allospecificity 
prior to transplantation was approximately 100-fold lower than T cells with direct allospecificity 
(Liu, Sun et al. 1993), a finding which has subsequently been confirmed on numerous occasions 
(Veerapathran, Pidala et al. 2011). As such, the intensity of this alloimmune response was not 
believed to be as vigorous as a direct alloimmune response (Benichou, Takizawa et al. 1992) but 
the consistent availability of donor antigens in the allograft meant that this pathway could persist 
long-term. Consequently, the indirect pathway was proposed to be the main mode of chronic 
allograft rejection (Hornick and Lechler 1997). 
The first experimental evidence for the contribution of the indirect pathway to graft rejection was 
provided by Auchincloss et al. in 1993 (Auchincloss, Lee et al. 1993). In this study, skin grafts from 
MHC class II knockout mice were transplanted onto recipient mice which were depleted of CD4+ 
or CD8+ T cells. A key finding was that MHC class II-deficient skin was rejected in recipients which 
were depleted of CD8+ T cells. This attributed an important role to CD4+ T cells in the rejection 
process. Furthermore, it suggested that these CD4+ T cells were primed by recipient APCs 
presenting allopeptides, not donor APCs as these cells were MHC class II-deficient. The 
importance of these CD4+ T cells to aid the activation of CD8+ T cells was subsequently 
demonstrated by Lee et al. in 1994 using the same model (Lee, Grusby et al. 1994). 
 
1.1.1.2.1 Cross-presentation 
The studies described above principally demonstrated how CD4+ T cells with indirect 
allospecificity contributed to allograft rejection. However, it is now clear that CD8+ T cells with 
indirect allospecific can also be activated. This relies on recipient APCs presenting acquired 
peptides in the context of recipient MHC class I, a process termed “cross-presentation”. Although 
the concept of cross-presentation was first demonstrated in 1976 (Bevan 1976, Bevan 2006), the 
implications of this for allograft rejection were not realised for many years. In 2002, Valujskikh et 
al. demonstrated that recipient CD8+ T cells which were cross-primed by recipient APCs 
contributed to graft rejection in an IFNγ-dependent manner (Valujskikh, Lantz et al. 2002). 
However, the relative contribution of these CD8+ T cells with indirect allospecificity to ultimate 
allograft rejection may be limited (Valujskikh, Zhang et al. 2006). 
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 Semi-direct pathway of allorecognition 
As alluded to above, donor antigens acquired from exogenous origins are naturally presented in 
the context of MHC class II. Consequently, it is primarily CD4+ T cells which recognise alloantigens 
in an indirect manner, not CD8+ T cells which are typically responsible for eliciting cytotoxicity. 
Furthermore, efficient CD8+ T cell activation requires help from CD4+ T cells (Krieger, Yin et al. 
1996). As such, it is reasonable to conclude that a link between the direct and indirect pathways 
of allorecognition exists and that CD4+ T cells with indirect allospecificity facilitate the activation 
of CD8+ T cells with direct allospecificity (Lee, Grusby et al. 1994, Lee, Grusby et al. 1997). 
Theoretically, for this to occur, two separate APCs should be present: a recipient APC presenting 
allopeptides indirectly to the CD4+ T cell and a donor APC presenting antigen directly to the CD8+ 
T cell. However, from a practical viewpoint, it is highly unlikely that these two APC:T cell 
interactions naturally occur in such close proximity, leading to a conundrum termed the  
“four-cell conundrum”. This was resolved by the discovery of APCs which present intact  
donor-MHC-peptide complexes in a direct manner and allopeptides in an indirect manner 
(Herrera, Golshayan et al. 2004, Jiang, Herrera et al. 2004, Smyth, Harker et al. 2008), the basis 
of a more recently described third pathway of allorecognition: the semi-direct pathway (Herrera, 
Golshayan et al. 2004). 
 
1.1.1.3.1 Cross-dressing 
In a similar manner to the indirect pathway, the semi-direct pathway relies on recipient-derived 
APCs which infiltrate the allograft. However, in addition to presenting allopeptides indirectly, 
these cells also acquire intact donor MHC-peptide complexes from donor-derived cells/tissues, a 
phenomenon termed “cross-dressing”. This allows recipient APCs presenting allopeptides 
indirectly to also present allogeneic MHC-peptide complexes in a direct manner (Smyth, Harker 
et al. 2008). 
Indeed, recipient DCs presenting both donor MHC class I-peptide complexes (direct presentation) 
and allopeptides in the context of self-MHC (indirect presentation) have been observed in various 
contexts including following kidney (Brown, Sacks et al. 2011) and heart (Sivaganesh, Harper et 
al. 2013, Harper, Ali et al. 2015) transplantation. Through this pathway, direct alloimmune 
responses can continue long after donor-derived APCs have died, but the extent to which this 
pathway contributes to allograft rejection is not yet known. Recently, the host laboratory has 
shown that after removal of the direct pathway and in the absence of cross-presentation, 
acquired allo-MHC-peptide complexes on recipient DCs can drive allograft rejection throughout 
the life-span of the transplant (Smyth, Lechler et al. 2016). 
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 IMMUNOSUPPRESSION  
Organ transplantation would not be a viable treatment option if approaches had not been 
developed to reduce the effects of graft rejection. Immunosuppression is an approach which 
been explored extensively over the past century as a potential means of solving this problem 
(Barker and Markmann 2013). 
In 1914, working on the hypothesis that tumour xenograft rejection was a consequence of 
recipient lymphocyte activation, Murphy demonstrated that irradiation of recipient rats using a 
low dose of x-rays facilitated the prolonged survival of mouse-derived tumours (Murphy 1914, 
Murphy 1914). However, the significance of these findings was not truly appreciated until 1955, 
when Main and Prehn demonstrated that radiation of adult mice weakened the immune system 
to an extent that allowed for the engraftment of allogeneic bone marrow cells (Main and Prehn 
1955). Importantly, resultant chimeric mice were able to accept skin grafts which were 
transplanted from the same donor as the bone marrow cells (Barker and Markmann 2013). These 
findings proposed that immunosuppression through irradiation could prolong allograft survival, 
thus this concept was quickly translated to the clinic. In the late 1950s and early 1960s, kidney 
transplant procedures between non-identical twins were performed where recipients were  
pre-conditioned with total body irradiation (TBI). These procedures were a resounding success 
whereby the two recipients survived for 20 and 26 years post-transplant (Barker and Markmann 
2013). 
In 1962, Küss and Hamburger began to explore the benefits of coupling chemical-based 
immunosuppression with TBI in humans (Kuss, Legrain et al. 1962). Using 6-mercoptopurine  
(6-MP), which had previously been demonstrated to prolong the survival of skin allografts in 
rabbits (Schwartz and Dameshek 1960), and adrenal cortical steroid-based immunosuppression 
in addition to TBI, Küss et al. performed two kidney transplant procedures between non-related 
patients and achieved long-term survival (>9 months) in both cases. Studies performed over the 
following decades saw TBI superseded by various immunosuppressive drugs including the 
cytotoxic drug “azathioprine” (Murray, Merrill et al. 1963), the non-cytotoxic fungal derivative 
“cyclosporine A” (Calne, Rolles et al. 1979), and the powerful anti-inflammatory drug 
“prednisone” (Starzl, Weil et al. 1980), the latter two of which are still used today. 
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 Current immunosuppressive drugs in transplantation 
Modern immunosuppressive regimens principally target lymphocytes due to their particularly 
deleterious contribution to allograft rejection. To achieve this, a variety of drugs are used in 
combination to target different pathways involved with lymphocyte activation/proliferation. 
Although the precise drugs used varies between institution, the regimen adopted will typically 
include a combination of calcineurin inhibitors (CNI), corticosteroids, anti-proliferative agents and 
potentially mammalian target of rapamycin (mTOR) inhibitors. For example, the standard drugs 
prescribed for kidney transplant recipients at Guy’s Hospital are tacrolimus (a CNI inhibitor), 
prednisone (a corticosteroid) and mycophenolate mofetil (MMF; an anti-proliferative agent). 
CNIs function by inhibiting calcineurin, a fundamental serine-threonine phosphatase involved in 
T cell activation (Hamawy 2003). Typically, TCR engagement causes an increase in the 
concentration of intracellular Ca2+ which results in the activation of calcineurin (Yamashita, 
Katsumata et al. 2000). Calcineurin then activates nuclear factor of activated T cells (NFAT) which 
is important for transcribing key genes including interleukin (IL)-2 (Hogan, Chen et al. 2003). Two 
drugs are commonly used to inhibit this process in transplantation: cyclosporine A and the 
bacterial derivative tacrolimus. These drugs function by forming complexes with immunophilins, 
a family of intracellular cis-trans peptidyl-prolyl isomerases (Marks 1996). Cyclosporine A binds 
to cyclophilins and tacrolimus binds to the 12 kDa FK-binding protein (FKBP12) (Hamawy 2003). 
The complexes formed bind calcineurin which in turn inhibits the action of calcineurin and 
ultimately prevents activation of the T cell. Rapamycin and everolimus inhibit T cell signalling in a 
similar manner to these drugs but instead of targeting calcineurin, these drugs inhibit mTOR. The 
use of rapamycin and its relation with regulatory T cell (Treg) therapy is discussed in Chapter IV. 
Corticosteroids such as prednisone are steroid hormones which function by inhibiting the 
activation of numerous pro-inflammatory genes in a wide variety of cells (Barnes 2006). To 
achieve this, corticosteroids readily diffuse across cell membranes and bind gluorcortocoid 
receptors (GR) in the cytoplasm. “Active GRs” can then translocate into the nucleus where they 
encourage an anti-inflammatory state through a variety of mechanisms. Active GRs can promote 
the expression of specific target genes by binding glucocorticoid response elements (GRE) 
(Dostert and Heinzel 2004). Alternatively, active GRs interact with, and inhibit, pro-inflammatory 
transcription factors such as activator protein (AP)-1 and nuclear factor (NF)-κB, thus indirectly 
suppress the synthesis of cytokines, inflammatory enzymes, adhesion molecules and 
inflammatory receptors (Barnes 2006). 
Anti-proliferative drugs are used to inhibit the growth of T and B lymphocytes. In the past, this 
was achieved through the use of cytotoxic drugs such as cyclophosphamide. However, due to 
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severe side-effects, these drugs have been replaced with azathioprine and MMF (Ostraat, Qi et 
al. 1997, Meier-Kriesche, Morris et al. 2004, Clayton, McDonald et al. 2012). Azathioprine is a 
purine analogue which blocks purine synthesis and incorporates into replicating DNA, preventing 
successful replication (Maltzman and Koretzky 2003). Similarly, MMF blocks inosine 
monophosphate dehydrogenase (IMPDH) thus prevents the synthesis of guanine nucleotides 
required for DNA replication (Fulton and Markham 1996). 
All three of the drug categories described above reduce the rate of allograft rejection but 
concurrently elicit numerous side effects. CNIs are associated with neurotoxicity (Anghel, 
Tanasescu et al. 2013), nephrotoxicity (Fioretto, Najafian et al. 2011) and development of 
diabetes (van Hooff, Christiaans et al. 2004), with up to 20% of non-renal transplant recipients 
developing chronic renal failure after using CNIs for 5 years (Ojo, Held et al. 2003). Corticosteroids 
have a particular influence on the endocrine system, thus can cause a wide variety of side effects 
including osteoporosis, gain of weight and changes in mental state (e.g. aggression, agitation, 
depression and anxiety) (Buchman 2001, Barnes 2006) whilst anti-proliferative drugs primarily 
result in gastrointestinal side effects such as nausea and diarrhoea (Stolk, Boerbooms et al. 1998, 
Martinez, Nos et al. 2001, Ginzler, Dooley et al. 2005). These side effects are coupled with the 
inherent effects caused by immunosuppression, leaving recipients with an increased 
susceptibility to acquiring infections and developing cancer (Niethammer, Kummerle-Deschner 
et al. 1999, Bustami, Ojo et al. 2004). 
 
 Induction therapy and drug weaning 
Intensive immunosuppression is often given over the first few months following a transplant 
procedure as this is when the risk of acute graft rejection is highest (Brennan, Daller et al. 2006, 
Kirk 2006). However, as this risk diminishes over time, the immunosuppression prescribed is 
typically reduced to a life-long “maintenance” level, such that the potency of the accompanying 
side-effects is limited (Turner and Knechtle 2013). 
The therapy provided during the initial months following the transplant procedure is of particular 
importance for the long-term outcome of the allograft. As such, additional immunosuppressive 
agents may be used at this time as part of an “induction therapy” protocol and weaned over the 
forthcoming months. These additional agents are often antigen-specific antibodies which target 
lymphocytes, in particular T cells. Examples include muromonab-CD3 (OKT3 clone), 
antithymocyte globulin (ATG; horse/rabbit-derived antibodies specific for human T cells), IL-2 
receptor-specific antibodies (declizumab or basiliximab) and alemtuzumab, an antibody specific 
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for CD52 which is expressed on mature lymphocytes (Rosenberg, Vriesendorp et al. 2005, 
Goldfarb-Rumyantzev, Smith et al. 2006, Watson and Dark 2012). 
This induction therapy period is of particular importance when considering the use of alternative 
therapeutic approaches such as Treg therapy (Scotta, Fanelli et al. 2016) which is described below 
(section 1.2.4). 
 
 MECHANISMS OF TOLERANCE  
Immunological tolerance is a state in which an immune response is not initiated towards an 
antigen which would normally be expected to provoke a response. Tolerance towards self-
antigens is essential to prevent the development of autoimmune diseases. The ultimate goal of 
research in the transplant field is to induce a state of tolerance towards allogeneic antigens, 
thereby negating the requirement for immunosuppression. Mechanisms which prevent the 
development and maturation of autoreactive cells are referred to as “central tolerance” 
mechanisms. Autoreactive cells which escape these mechanisms are often suppressed by 
“peripheral tolerance” mechanisms. These two branches of tolerance are discussed in detail 
below. 
 
 Central Tolerance 
Central tolerance mechanisms are implemented in primary lymphoid organs, namely the bone 
marrow (BM) for B cells and the thymus for T cells. In these organs, common lymphoid progenitor 
(CLP) cells undergo variable-diversity-joining (V(D)J) recombination to generate a B cell receptor 
(BCR) or TCR with a given specificity. This process is almost entirely random and as such, the 
receptor generated has the potential to recognise self-antigens with a high affinity. Central 
tolerance mechanisms are in place to delete autoreactive lymphocytes before they develop into 
immunocompetent cells. 
In the thymus, T cell progenitors, or “thymocytes”, must undergo two selection processes before 
they can mature into T cells. The first of these is termed “positive selection” which ensures that 
the TCR presented by the thymocyte is capable of recognising peptides presented in the context 
of self-MHC molecules. Thymocytes which do not meet this requirement are neglected and 
undergo programmed cell death (PCD). Surviving thymocytes then undergo a “negative selection” 
process whereby cells presenting a TCR which binds self-MHC-peptide complexes with a high 
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affinity are deleted. This latter process is aided by medullary stromal cells which express the 
autoimmune regulator (AIRE) gene, allowing for the presentation of tissue-specific antigens which 
would otherwise not be expressed in the thymus. The majority of cells which survive these 
processes are able to recognise self-MHC-peptide complexes with a low affinity and are released 
into the periphery as naïve T cells. However, a small proportion of the CD4+ thymocytes which 
recognise self-MHC-peptide complexes with a higher than average affinity are induced to express 
the transcription factor Forkhead box protein 3 (FOXP3) and commit to the Treg lineage. These 
cells are described in detail in section 1.2. 
 
 Peripheral Tolerance 
Although lymphocytes undergo rigorous selection processes, it is possible for autoreactive cells 
to escape negative selection and to be released into the periphery. The potentially deleterious 
effects of these cells are managed by mechanisms of peripheral tolerance which act at numerous 
levels, as described below. 
 
1.1.3.2.1 Induction of anergy 
For naïve T cells to be successfully activated, three signals must be received. “Signal 1” is provided 
by the TCR complex as a result of the TCR engaging a cognate MHC-peptide complex. During this 
process, CD4 or CD8 co-receptors from the T cell make additional contacts with the MHC 
molecule, restricting CD8+ T cells to recognise peptides presented in the context of MHC class I 
and CD4+ T cells to recognise peptides presented in the context of MHC class II. In rare cases, this 
restriction can be overcome if a TCR engages an MHC-peptide complex with a particularly high 
affinity (Plesa, Zheng et al. 2012). 
“Signal 2” is a co-stimulatory signal which is provided by various proteins present in an 
immunological synapse (IS). The paradigmatic co-stimulatory signal is delivered by CD28 which 
typically engages CD80 or CD86, co-stimulatory molecules present on the surface of the APC. 
Additional co-stimulatory signals can be provided by 4-1BB (CD137), OX40 (CD134), inducible  
T cell co-stimulator (ICOS; CD278), CD30 and CD40 ligand (CD40L) which engage 4-1BBL, OX40L 
(CD252), ICOSL (CD275), CD153 and CD40, respectively. The latter molecules are present on APCs 
(Acuto and Michel 2003) which have been activated as a consequence of signalling through 
pattern recognition receptors (PRR). As such, co-stimulatory molecules are not expressed by the 
majority of cells in the periphery. Delivery of signal 1 without signal 2 induces a state of 
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unresponsiveness in T cells, known as a state of “anergy”, which may proceed active deletion of 
the T cell. Consequently, autoreactive T cells which engage self-MHC-peptide complexes 
presented by peripheral tissues are rendered anergic, thus cannot undergo clonal expansion and 
initiate an immune response. 
 “Signal 3” is provided by the detection of polarising cytokines. These signals are most relevant 
for determining the subtype which the T cell will differentiate into. However, mechanisms which 
disrupt cytokine detection, particularly IL-2 signalling which is essential for  
T cell proliferation and differentiation, can greatly influence the maturation of T cells. This is of 
relevance to a mechanism by which CD25+ Tregs function, as described below (sections 1.1.3.2.4 
and 1.2.3). 
 
1.1.3.2.2 Activation-induced cell death 
Activation-induced cell death (AICD) is a natural consequence of T cell activation and clonal 
expansion. It ensures that T cell clones diminish in number following clearance of a target antigen 
and facilitates in the elimination of autoreactive T cells (Waring and Mullbacher 1999). T cells 
naturally express Fas (CD95) and following TCR engagement, upregulate the expression of Fas 
ligand (FasL; CD178) (Zhang, Xu et al. 2004). Consequently, apoptosis is induced in T cell clones 
through the Fas/FasL pathway in an autocrine manner (Dhein, Walczak et al. 1995). Indeed, mice 
lacking either Fas (homozygous lpr) or FasL (homozygous gld) suffer from uncontrolled 
lymphoproliferation and autoimmunity (Watanabe-Fukunaga, Brannan et al. 1992, Takahashi, 
Tanaka et al. 1994). Similarly, apoptosis induced through Bim and Bcl-2/Bcl-xL-dependent 
permeabilisation of the outer mitochondrial membrane has also been demonstrated to be 
important for efficient deletion of autoreactive lymphocytes (Marrack and Kappler 2004, Mueller 
2010, Xing and Hogquist 2012). As a tolerance mechanism, AICD results in deletion of 
autoreactive T cell clones which are activated in the periphery. 
 
1.1.3.2.3 Immunological ignorance 
Efficient lymphocyte activation inherently requires the lymphocyte to engage with its target 
antigen. However, in certain scenarios, this is not possible due to physical constrictions (Mueller 
2010). A prime example is the blood-brain barrier (BBB) which severely limits lymphocyte 
trafficking into the central nervous system (CNS) (Engelhardt 2006). As such, lymphocytes which 
may be autoreactive and recognise a target antigen in the brain are segregated from their target 
antigen and consequently not activated. 




Suppression of autoreactive T cell activation in the periphery is a key mechanism of tolerance 
which is principally enforced by Tregs. Indeed, depletion of Tregs, achieved either through 
targeted killing (Kim, Lahl et al. 2009) or mutations in the FoxP3 locus (Brunkow, Jeffery et al. 
2001), has been shown to cause severe and often fatal autoimmunity. Tregs mediate the 
activation of target cells, including autoreactive lymphocytes, using a plethora of different contact 
dependent and independent mechanisms, as discussed below (section 1.2.3). 
 
 REGULATORY T CELLS 
The idea of cells suppressing and regulating the immune system has been around for many years. 
In 1969, Nishizuka and Sakakura published the first experimental evidence which suggested the 
existence of thymus-derived cells which were capable of suppressing autoimmunity in mice 
(Nishizuka and Sakakura 1969). These findings were confirmed by Gershon and Kondo in the early 
1970s in a series of publications which culminated in the coinage of the term “suppressor T cell”. 
However, a shadow of scepticism was cast over this research area when subsequent studies 
pertaining to a key I-J suppressor molecule were proved wrong. This scepticism was accentuated 
by the lack of a definitive suppressor T cell marker and limited data relating to the mechanisms 
employed to suppress target cells. As such, despite the discovery of the FoxP3 gene in 1991, 
interest in suppressive lymphocytes was not reignited until 1995 when Sakaguchi et al. published 
a seminal paper describing a population of CD4+CD25+ T cells which were capable of inhibiting 
autoimmunity upon adoptive transfer. In this study, the authors showed that the onset of 
autoimmunity in athymic nude mice injected with CD4+CD25‒ T cells was hindered by the co-
injection of CD4+CD25+ T cells. Furthermore, they showed prolonged survival of skin allografts 
following adoptive transfer of CD4+CD25+ T cells. Over the years that followed, various studies 
demonstrated the existence of CD4+CD25+ Tregs in humans, suggesting an important role for 
these cells in the maintenance of tolerance in vivo (Dieckmann, Plottner et al. 2001, Ng, Duggan 
et al. 2001, Taams, Smith et al. 2001, Taams, Vukmanovic-Stejic et al. 2002). 
 
 REGULATORY T  CELL SUBSETS  
Subsequent studies proceeded to demonstrate that murine CD4+CD25+ T cells were a unique 
lineage of T cells (Suri-Payer, Amar et al. 1998) which were capable of suppressing undesired 
immune responses in a plethora of different contexts ranging from organ transplantation 
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(Kingsley, Karim et al. 2002, Golshayan, Jiang et al. 2007, Tsang, Tanriver et al. 2008, Tsang, 
Tanriver et al. 2009, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013) to various autoimmune 
diseases (Kohm, Carpentier et al. 2002, Mottet, Uhlig et al. 2003, Tang, Henriksen et al. 2004, 
Zheng, Wang et al. 2004, Morgan, Flierman et al. 2005). Although the definition of what 
constitutes a Treg subset is a matter of debate, it is widely accepted that multiple subtypes of 
Tregs exist. At the most fundamental level, Tregs can be split into three distinct groups: CD4+ 
Tregs which are derived from the thymus (tTregs), CD4+ T cells which are induced in the periphery 
(pTregs) or in vitro (iTregs) to exhibit a suppressive function and suppressive CD8+ T cells. A brief 
description of these suppressive T cell subtypes is provided below. 
 
 Thymus-derived Tregs 
Colloquial references to “regulatory T cells” can stereotypically be interpreted as references to 
tTregs which were previously termed “naturally-occurring Tregs”. tTregs constitute 
approximately 5-10% of all peripheral CD4+ T cells (Tang, Henriksen et al. 2004, Tsang, Tanriver 
et al. 2009) and develop from a proportion of thymocytes which recognise self-antigens with a 
comparatively high affinity. In the thymus, these cells are induced to constitutively expressed the 
lineage-determining transcription factor FOXP3. In mice, mutations in the FoxP3 gene has been 
shown to induce a “scurfy” phenotype which is characterised by scaly/ruffled skin, reddened eyes, 
secondary lymphoid organ enlargement and premature death (Ramsdell and Ziegler 2014). 
Similarly, FOXP3 mutations in humans have been directly linked with the severe autoimmune 
disease immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), 
accentuating the critical role of these cells in vivo (Bennett, Christie et al. 2001). In 2009, Miyara 
et al. delineated three phenotypically and functionally distinct subpopulations of human tTregs 
which were differentiated by their expression of FOXP3 and CD45RA (Miyara, Yoshioka et al. 
2009): CD45RA+FOXP3lo resting Tregs, CD45RA–FOXP3hi activated Tregs and CD45RA–FOXP3lo  
T cells which secreted cytokines but were non-suppressive. 
 
 Periphery-derived and in vitro-induced Tregs 
The nomenclature relating to T cells which are induced to be suppressive can be confusing. Tregs 
which are derived in vivo in the periphery are termed pTregs. However, cells which are generated 
under similar conditions ex vivo are termed induced Tregs (iTregs) (Abbas, Benoist et al. 2013, 
Shevach and Thornton 2014, Guo and Zhou 2015). 
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Although not as well characterised as tTregs, pTregs have been implicated with the induction and 
maintenance of tolerance, mostly through the secretion of immunosuppressive cytokines. It is 
believed that at least two types of pTregs exist, namely Type-I regulatory T cells (Tr1) and  
T helper 3 cells (Th3) which secrete high levels of IL-10 (Roncarolo, Bacchetta et al. 2001) and 
transforming growth factor (TGF)-β, respectively (Weiner 2001). Tr1 cells were initially described 
in 1997 and characterised by their ability to suppress colitis (Groux, O'Garra et al. 1997) whilst 
Th3 cells were first identified in 1994 by their role in oral tolerance induction in a multiple sclerosis 
(MS) context (Chen, Kuchroo et al. 1994). Both of these cell types are now primarily associated 
with mucosal immunity, as demonstrated by the clinical application of Tr1 cells in the treatment 
of Crohn’s disease (Desreumaux, Foussat et al. 2012). However, the inherent instability of these 
cells is a cause for concern (Chen, Kim et al. 2011, Shevach and Thornton 2014, Kanamori, 
Nakatsukasa et al. 2016). 
Over the years, various groups have performed microarrays on tTregs and iTregs to identify genes 
which are differentially expressed between these two cell types. From these studies, two 
molecules were proposed as potential markers of tTregs: Helios (Ikzf2) and neuropilin-1 
(Thornton, Korty et al. 2010, Yadav, Louvet et al. 2012). However, subsequent analyses have 
demonstrated that not all tTregs express these markers thus their use to delineate tTregs is 
controversial (Singh, Hjort et al. 2015, Elkord 2016, Kanamori, Nakatsukasa et al. 2016). 
 
 Suppressive CD8+ T cells 
In a similar manner to CD4+ Tregs, murine studies have demonstrated that CD8+ Tregs can be 
derived naturally or induced (Pomie, Menager-Marcq et al. 2008). In rodents, at least four types 
of suppressive CD8+ T cell have been described, although the exact nature and phenotype of these 
cells varies between studies: CD8+CD25+FOXP3+CD28– T cells (Najafian, Chitnis et al. 2003, 
Churlaud, Pitoiset et al. 2015), CD8+Qa-1+ T cells (Hu, Ikizawa et al. 2004), CD8+CD122+CD49lo  
T cells (Akane, Kojima et al. 2016) and CD8+CD45RClo T cells (Xystrakis, Dejean et al. 2004).  
Mouse-based studies have demonstrated the suppressive capacity of CD8+ Tregs for preventing 
experimental autoimmune encephalomyelitis (EAE) (Najafian, Chitnis et al. 2003, Hu, Ikizawa et 
al. 2004, Lee, Ishida et al. 2008) and colitis (Menager-Marcq, Pomie et al. 2006), with an important 
role attributed to the secretion of suppressive cytokines (Pomie, Menager-Marcq et al. 2008). 
Recently, Bézie et al. demonstrated that rodent and human CD8+CD45RClo Tregs produced IL-34 
which was shown to induce transplant tolerance in a rat cardiac allograft model (Bezie, Picarda 
et al. 2015). Together, these findings reflected observational studies performed in humans which 
correlated low numbers of CD8+ Tregs (particularly CD8+CD25+FOXP3+ T cells) with an increased 
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incidence of systemic erythematosus (SLE) (Filaci, Bacilieri et al. 2001, Tulunay, Yavuz et al. 2008), 
inflammatory bowel disease (IBD) (Brimnes, Allez et al. 2005) and MS (Frisullo, Nociti et al. 2010, 
Baughman, Mendoza et al. 2011). 
Given the principle focus of this thesis, henceforth descriptions of “Tregs” are references to 
thymic-derived tTreg cells, unless stated otherwise. 
 
 REGULATORY T  CELL PHENOTYPE  
Over the past 20 years, various markers have been suggested to define Tregs. However, this has 
developed into a particularly complex field and to date, has not alluded a definitive Treg marker. 
As such, Tregs are often described using a combination of different markers (Corthay 2009). A 
description of the most importance markers is provided below.  
 
 CD25 
In 1995, Sakaguchi et al. described CD25 as a fundamental marker of Tregs in mice (Sakaguchi, 
Sakaguchi et al. 1995). However, as CD25 is the α chain of the IL-2 receptor and IL-2 is a critical  
T cell growth factor, this marker is transiently upregulated on activated conventional T cells 
(Tconv) in both mice and humans. As such, CD25 is not an exclusive marker of Tregs. This is 
complicated further in humans as conventional T cells can express an intermediate level of CD25, 
necessitating Tregs to be defined as CD25hi. Despite these caveats, the constitutively high 
expression of CD25 on Tregs makes it a useful marker for enriching these cells for a variety of in 
vitro applications and as such, enrichment of CD25+ cells is currently used to isolate Tregs for 




Various studies in 2003 revealed FoxP3 as the “master regulator” of Tregs (Fontenot, Gavin et al. 
2003, Hori, Nomura et al. 2003, Khattri, Cox et al. 2003). In mice, FoxP3 is almost exclusively 
expressed in Tregs and as such, it is a suitable marker for defining these cells. However, this 
situation is more complicated in humans as FOXP3 is upregulated in human CD4+CD25– Tconvs 
following activation. Currently, one of the only approaches which exists for identifying bona fide 
Tregs is to analyse the methylation state of the Treg specific demethylation region (TSDR) which 
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is located in the FOXP3 gene. The TSDR is demethylated in Tregs but methylated in Tconvs 
although the methylation state of the TSDR cannot be used to isolate clinically-applicable Tregs 
as the cells must be lysed to perform this analysis. 
 
 CD127 
Although TSDR analysis provides a conclusive means of defining Tregs in vitro, the cell lysis 
required for this analysis means that it cannot be employed for isolating Tregs for clinical use. 
Similarly, FOXP3 expression cannot be employed as this requires the cells to be permeabilised. To 
facilitate the isolation of Tregs for clinical use, it was necessary to identify a cell surface marker 
which was differentially expressed in Tregs and activated CD25+ Tconvs. This was achieved in 2006 
when Liu et al. demonstrated that CD127 expression was inversely correlated with FOXP3 
expression. CD127 is the IL-7 receptor α chain and is commonly used in combination with CD4 
and CD25 expression to define human Tregs for various in vitro assays. Furthermore, 
CD4+CD25hiCD127lo Tregs are currently isolated by cell sorting as the cell product for various 
clinical trials outside of the UK. 
 
 Helios 
In 2010, Thornton et al. described Helios, a member of the Ikaros transcription factor family, as a 
key molecule which was differentially expressed in tTregs and pTregs (Thornton, Korty et al. 
2010). However, a plethora of subsequent studies disputed this claim, demonstrating that Helios, 
which was supposedly tTreg specific, could be induced in pTregs and that Helios+ and Helios– 
Tregs existed within a standard human tTreg pool. Despite this somewhat sketchy history, Helios 
expression defines a stable population of Tregs with an enhanced suppressive capacity, compared 
to Helios– Tregs, although the precise mechanisms as to how this is achieved remain unsolved. 
 
 CD45RA 
CD45RA is an isoform of CD45 which is primarily expressed on naïve T cells. Following TCR 
activation, an alternative splicing approach is adopted for CD45 such that CD45RA expression is 
downregulated and CD45RO expression is upregulated (Zikherman and Weiss 2008). 
Consequently, naive T cells are often defined as CD45RA+CD45RO– whilst memory T cells are 
CD45RA–CD45RO+. CD45RA expression can define a population of naïve Tregs which constitutively 
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express CD25 and/or FOXP3, circumventing the aforementioned issues regarding the inadvertent 
isolation of activated Tconvs. In 2006, Hoffmann et al. demonstrated that CD4+CD25hiCD45RA+ 
Tregs were highly suppressive cells which maintained constitutive expression of FOXP3 in contrast 
to CD4+CD25hiCD45RA– cells which were moderately suppressive and lost FOXP3 expression 
following in vitro expansion (Hoffmann, Eder et al. 2006). This work was expanded on by Miyara 
et al. who used the expression of CD45RA in combination with FOXP3 expression to define three 
subpopulations of tTregs (section 1.2.1.1). From this study, population III, which consisted of cells 
defined as CD4+CD25+FOXP3loCD45RA–, was of particular interest as these cells were shown to 
secrete cytokines not elicit suppression (Miyara, Yoshioka et al. 2009). However, this finding is 
controversial as unpublished data from the host laboratory and Prof Irma Joosten (Radboud 
University Medical Center, Nijmegen, Netherlands) has suggested that population III Tregs may 




HLA-DR is the most prevalent HLA class II molecule expressed in humans. Along with the HLA  
class I molecules HLA-A and HLA-B, particular efforts are made to match the alleles of the  
HLA-DR locus between donors and recipients in a transplant setting to minimise graft rejection. 
In 2006, Baecher-Allan et al. used HLA-DR expression on Tregs to distinguish two Treg 
subpopulations: HLA-DR+ cells which elicited an early (within 72 hours) suppressive response, 
primarily in a contact-dependent manner, and HLA-DR– cells which elicited an early response 
through the secretion of immunosuppressive cytokines, such as IL-10 (Baecher-Allan, Wolf et al. 
2006). 
 
 Co-stimulatory and co-inhibitory receptors 
As previously discussed (section 1.1.3.2.1), successful activation of T cells requires multiple signals 
including co-stimulatory signals. In a similar manner to Tconvs, activation and expansion of Tregs 
requires the engagement of co-stimulatory signals. Certain members of the tumour necrosis 
factor (TNF) receptor superfamily are selectively expressed on Tregs in the absence of immune 
activation including OX40, GITR, TNFR2 and CD27 although their expression is upregulated in 
Tconvs upon activation. Interestingly, higher CD27 expression by human Tregs has also been 
correlated with a greater suppressive potency (Koenen, Fasse et al. 2005). 
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Treg expression of co-inhibitory molecules is a particularly important mechanism which is 
employed for suppressing target cells. Cytotoxic T lymphocyte antigen (CTLA)-4 is a potent  
co-inhibitory receptor which is expressed constitutively on Tregs. Similarly, programmed death 
(PD)-1 receptor is also expressed at high levels on Tregs (Baecher-Allan, Brown et al. 2003). Both 
of these molecules are members of the immunoglobulin (Ig) superfamily and are upregulated on 
Tconvs upon activation. However, in contrast to the aforementioned co-stimulatory molecules, 
these receptors transmit inhibitory signals into the T cell upon engagement. In Tregs, CTLA-4 
employs numerous different approaches to elicit a regulatory function, as discussed in section 
1.2.3. 
 
 Homing receptors  
The in vivo trafficking of Tregs is an important feature of these cells which is primarily dictated 
through the expression of different homing receptors. Although not exclusive to Tregs, the 
expression profile of homing receptors is commonly used to define Tregs, particularly in humans. 
Naïve CD45RA+ Tregs typically express a range of lymphoid tissue homing receptors such as 
CD62L, chemokine receptor (CCR)7 and CXCR4 (Hoffmann, Eder et al. 2006) whilst the homing 
receptors expressed by memory Tregs is dependent on the initial site of activation for each cell. 
For Tregs expanded ex vivo, the presence of specific drugs can have a dramatic effect on the range 
of homing receptors expressed. Tregs expanded in the presence of retinoic acid express high 
levels of gut homing receptors such as CCR9 and integrin α4β7 whilst Tregs expanded in the 
presence of rapamycin express more skin homing receptors such as CCR4, CCR6, CCR10 and 
cutaneous lymphocyte antigen (CLA) (Scotta, Esposito et al. 2013). Additional homing receptors 
may also be considered for characterising Tregs including CCR2, CCR5, CXCR3, CXCR5, CXCR6 
(Campbell and Koch 2011, Duhen, Duhen et al. 2012). 
 
 Functional markers 
In addition to the various markers described above, Tregs are often characterised by their 
expression of functional markers such as CTLA-4, CD39, CD73, glucocorticoid-induced TNF 
receptor (GITR), lymphocyte-activation gene (LAG)3 and Nrp-1. A detailed description of these 
molecules is provided in section 1.2.3. 
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 REGULATORY T  CELL MECHANISMS OF SUPPRESSION  
Tregs function to maintain tolerance in vivo by suppressing a wide range of target cells including 
CD4+ T cells, CD8+ T cells, B cells, natural killer (NK) cells and APCs such as DCs. In order to 
accomplish this, Tregs employ a range of contact dependent and contact independent 
mechanisms (Sojka, Huang et al. 2008, Lee, Kim et al. 2011). With new mechanisms consistently 
being discovered, it is difficult to comprehensively describe how Tregs function but it is safe to 
assume that a combination of these approaches must be employed to maintain tolerance in vivo. 
A non-exhaustive description of the mechanisms Tregs employ is provided below.  
 
 Mechanisms influencing APC activation of T cells 
Efficient activation of naïve T cells typically requires stimulation by professional APCs such as DCs. 
Tregs employ numerous mechanisms to disrupt this process and hinder the activation of T cells 
(Vignali, Collison et al. 2008, Corthay 2009, Sakaguchi, Wing et al. 2009, Shevach 2009). This is 
paradigmatically achieved through the high expression of CTLA-4 which, as mentioned in section 
1.2.2.7, elicits a regulatory function through a number of approaches. CTLA-4 binds the B7  
co-stimulatory molecules CD80 and CD86 on the surface of APCs with a high affinity, compared 
to CD28. This allows CTLA-4 to outcompete CD28, consequently sequestering the ability of the 
APC to activate Tconvs (Walunas, Bakker et al. 1996). CTLA-4 is also capable of reverse-signalling 
through CD80/CD86 and upregulating indoleamine 2,3-dioxygenase (IDO) in DCs which, as 
described below, has an immunoregulatory effect (Grohmann, Orabona et al. 2002, Fallarino, 
Grohmann et al. 2003). However, the most eminent mechanism by which CTLA-4 functions was 
discovered in 2011 when it was demonstrated that CTLA-4 could facilitate the physical removal 
of CD80 and CD86 from the cell surface of APCs (Qureshi, Zheng et al. 2011), a process termed 
trans-endocytosis (Figure 1-3A). Consequently, without these fundamental co-stimulatory 
molecules, APCs inadvertently induce anergy in target T cells instead of activating them. 
Various other molecules are expressed on the surface of Tregs and, in a similar manner to  
CTLA-4, function to decrease the ability of APCs to activate T cells. Nrp-1 expressed by Tregs binds 
intercellular adhesion molecule (ICAM)-1 on the surface of DCs with a high affinity which causes 
the DCs to interact with the Tregs for a prolonged period of time (Figure 1-3B). During this period, 
the DCs are less able to activate Tconvs which may be in the vicinity (Sarris, Andersen et al. 2008). 
Alternatively, LAG3 expressed by Tregs can bind MHC class II with a high affinity and induce 
immunoreceptor tyrosine-based activation motif (ITAM)-mediated inhibitory signalling pathways 
in DCs (Figure 1-3C). This signalling causes the DCs to become resistant to maturation 




Figure 1-3 │ Mechanisms of Treg suppression adapted from (Shevach 2009) and (Vignali, Collison et al. 
2008). A: CTLA-4 expressed by Tregs binds CD80/CD86 on the DC surface with a high affinity enabling the 
Tregs to remove these co-stimulatory molecules from the DC membrane (Qureshi, Zheng et al. 2011).  
B: Nrp-1 binds ICAM-1 present on the DC surface extending the interaction time with the Treg thus 
decreasing the length of time available for Tconv activation by the DC (Sarris, Andersen et al. 2008).  
C: LAG3 binding of MHC class II induces inhibitory intracellular signalling within a DC via SHP-1 which 
results in inhibition of DC maturation (Liang, Workman et al. 2008). D: Binding of CD45/43/7 by galectin-
1 induces growth cycle arrest and apoptosis of activated Teffs (Garin, Chu et al. 2007). E: Tregs can induce 
DCs to produce IDO which catabolises tryptophan thus suppresses T cell proliferation (Mellor and Munn 
2004). F: CD25 binding of IL-2 deprives Tconvs of this necessary T cell growth factor (de la Rosa, Rutz et al. 
2004). G: ATP hydrolysis by CD39/73 produces adenosine which inhibits T cell function (Borsellino, 
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(LPS-induced upregulation of CD86) and have a decreased capacity to activate T cells (Liang, 
Workman et al. 2008). 
As previously mentioned, DC expression of IDO can have an immunoregulatory effect on T cells. 
IDO is an enzyme which catabolises indole-containing molecules, such as tryptophan, into 
kynurenines (Mellor and Munn 2004). This consequently depletes the local environment of 
tryptophan, an essential amino acid required for T cell proliferation (Figure 1-3E). Furthermore, 
the increase in kynurenine production also has a suppressive effect on T cell (Terness, Bauer et 
al. 2002). 
 
 Mechanisms directly affecting T cells 
In addition to inhibiting T cell activation indirectly through manipulating APCs, Tregs can also 
directly suppress T cells. One mechanism is elicited by galectin-1 which is expressed on Tregs. 
Galectin-1 binds glycoproteins present on the surface of target T cells, such as CD7, CD43 and 
CD45 (Figure 1-3D). Through this binding, Tregs can induce cell cycle arrest and/or apoptosis in 
the target T cell (Garin, Chu et al. 2007). Similarly, PD-L1 engagement of PD-1 on the surface of 
target T cells triggers inhibitory signalling pathways in T cells, preventing T cell activation and 
proliferation (Baecher-Allan, Brown et al. 2003). 
Tregs also manipulate their microenvironment to suppress local T cells in a contact-independent 
manner. Through expressing high levels of CD25, Tregs are able to bind IL-2 in the vicinity and 
deprive local T cells of this crucial growth factor (de la Rosa, Rutz et al. 2004) (Figure 1-3F). 
Furthermore, Tregs also express CD73 and CD39 (Figure 1-3G). These are ectoenzymes which 
function together to facilitate the conversion of pro-inflammatory adenosine triphosphate (ATP) 
into the anti-inflammatory adenosine: CD39 hydrolyses ATP/adenosine diphosphate (ADP) into 
adenosine monophosphate (AMP) (Borsellino, Kleinewietfeld et al. 2007, Yegutkin 2008) and 
CD73 catalyses the conversion of AMP into adenosine (Antonioli, Pacher et al. 2013). 
 
Kleinewietfeld et al. 2007). H: Tregs can secrete inhibitory cytokines to suppress DC maturation/function 
(Shevach 2009). I: Tregs can use granzymes to kill target cells utilising a similar mechanism to NK cells 
(Cao, Cai et al. 2007). J: Small molecules including cAMP can be intercellularly transferred via gap junctions 
into the cytoplasm of DCs to target specific processes within DCs as a mechanism of regulation (Bopp, 
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 Mechanisms affecting APCs and T cells 
Certain mechanisms employed by Tregs can affect both the function of APCs and T cells. These 
mechanisms tend to rely on the secretion of immunuoregulatory molecules or vesicles which 
influence local cells. The most established means by which this is achieved is through the 
secretion of immunosuppressive cytokines (Figure 1-3H). Following activation, Tregs secrete high 
levels of IL-10, TGFβ and IL-35 (Levings, Bacchetta et al. 2002, Shevach 2009, Francisco, Sage et 
al. 2010) which are known to suppress a wide range of immune cells including APCs and T cells 
(Del Prete, De Carli et al. 1993, Yoshimura and Muto 2011). Tregs also secrete microvesicles called 
exosomes to exert a suppressive function. These exosomes can facilitate the intercellular transfer 
of a variety of molecules including surface proteins and cytoplasmic molecules including 
microRNAs. In 2013, Smyth et al. demonstrated that murine Tregs secreted exosomes which 
contained functional CD73 and had an immunosuppressive capacity (Smyth, Ratnasothy et al. 
2013). Treg-derived exosomes were subsequently shown to also facilitate the intercellular 
transfer of microRNAs as a mechanism of suppression (Okoye, Coomes et al. 2014). Tregs can also 
exert a suppressive function though eliciting cytotoxicity towards target cells. It has been 
demonstrated that Tregs are capable of secreting granzymes and perform (Figure 1-3I) in a similar 
manner to CD8+ T cells and NK cells and this has been used to kill CD4+ T cells, CD8+ T cells and 
monocytes (Grossman, Verbsky et al. 2004, Grossman, Verbsky et al. 2004, Cai, Cao et al. 2010) 
as well as tumour cells (Cao, Cai et al. 2007). 
In addition to the secretion of suppressive species, Tregs can also inhibit target cells in a  
contact-dependent manner through the intercellular transfer of immunoregulatory molecules. 
One mechanism involves the formation of gap junctions (GJ) between Tregs and target cells  
(Figure 1-3J) (Ring, Karakhanova et al. 2010). GJ are specialised channels which provide a direct 
cytoplasmic link between cells, allowing the intercellular transfer of small molecules (Evans and 
Martin 2002). To date, Tregs have been shown form GJs with DCs (Ring, Karakhanova et al. 2010) 
and T cells (Bopp, Becker et al. 2007). In the latter study, Tregs elicited a suppressive function 
over T cells by transferring the secondary messenger cyclic (c)AMP. However, it is possible that 
alternative regulatory molecules may also be transferred via GJs such as microRNAs (Zong, Zhu et 
al. 2016). 
 
 REGULATORY T  CELL THERAPY  
A wide range of studies have noted a link between the proportion of Tregs in vivo and tolerance 
induction. This was most pertinently observed in human transplant recipients where a clear 
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correlation between the number of Tregs in a graft and allograft survival has been made (Louis, 
Braudeau et al. 2006, Safinia, Leech et al. 2013). To apply these findings in a clinical setting, two 
approaches can be taken to increase the number of Tregs in vivo: i) to use drugs, compounds 
or cells (such as tolerogenic DCs) which preferentially expand Tregs in situ (Giannoukakis, 
Phillips et al. 2011, Klawitter, Nashan et al. 2015), or; ii) to infuse a population of Tregs 
expanded ex vivo (Bluestone 2005, Sagoo, Ali et al. 2011, Singer, King et al. 2014, Safinia, 
Vaikunthanathan et al. 2016). 
As detailed above, various immunosuppressive drugs are used following a transplant procedure 
to limit graft rejection (section 1.1.2.1) including mTOR inhibits such as rapamycin and 
everolimus (Klawitter, Nashan et al. 2015) which facilitate the preferential expansion of Tregs 
(Singh, Horvath et al. 2009, Lu, Qian et al. 2010). Furthermore, clinical trials have investigated 
the safety and efficacy of low dose IL-2 therapy in Type I diabetes (T1D) (Hartemann, Bensimon 
et al. 2013, Rosenzwajg, Churlaud et al. 2015), SLE (Humrich, von Spee-Mayer et al. 2015) and 
graft-versus-host disease (GvHD) (Kennedy-Nasser, Ku et al. 2014) as a means of promoting the 
expansion of Tregs in vivo. A limited therapeutic efficacy was observed in the T1D patients but 
more promising results were obtained in the SLE and GvHD patients. Recently, success has also 
been achieved in the preferential expansion of Tregs in vivo through the use of IL-2/anti-IL-2 
complexes which can be manipulated such that they are selectively recognised by Tregs in vivo. 
In 2013, Kim et al. demonstrated in mice that renal ischemia reperfusion injury could be 
attenuated by the administration of IL-2/anti-IL-2 complexes prior to injury induction (Kim, Koo 
et al. 2013). Similarly, Webster et al. demonstrated the efficacy of IL-2/anti-IL-2 complexes at 
protecting against EAE and rejection of islet allografts in mice (Webster, Walters et al. 2009). 
In both studies, protection was shown to be mediated through the expansion of Tregs. 
However, it has also been demonstrated that this Treg promotion is not sufficient for allowing 
engraftment of BM transplants in mice whilst adoptive Treg therapy is, calling into question the 
ultimate therapeutic potential of these approaches (Mahr, Unger et al. 2016).  
 
 Pre-clinical studies of regulatory T cell therapy 
The potential for Treg therapy using CD4+CD25+ Tregs was initially demonstrated by Sakaguchi et 
al. in 1995 (Sakaguchi, Sakaguchi et al. 1995). As previously mentioned (section 1.2), this study 
showed that the onset of autoimmune diseases in athymic nude mice injected with CD4+CD25‒  
T cells was hindered by the co-injection of CD4+CD25+ T cells. Furthermore, the authors 
demonstrated prolonged survival of skin allografts following adoptive transfer of CD4+CD25+  
T cells. Following on from this seminal paper, various groups demonstrated the potential for 
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CD4+CD25+ Treg therapy in a variety of animal models including GvHD (Taylor, Lees et al. 2002), 
organ transplantation (Kingsley, Karim et al. 2002), MS (Kohm, Carpentier et al. 2002), colitis 
(Mottet, Uhlig et al. 2003), lupus erythematosus (Zheng, Wang et al. 2004), T1D (Tang, Henriksen 
et al. 2004) and rheumatoid arthritis (RA) (Morgan, Flierman et al. 2005). 
In a solid tissue transplant context, Treg therapy has been shown to significantly prolong the 
survival of skin (Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009, Smyth, Lechler et al. 2016), 
kidney (Brown, Sacks et al. 2011), heart (Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009, 
Sivaganesh, Harper et al. 2013, Harper, Ali et al. 2015) and islet (Xiao, Ma et al. 2014) allografts. 
In these studies, the specificity of the Tregs was shown to be of particular importance and 
significantly influenced the efficacy with which the Tregs protected the allografts. 
 
1.2.4.1.1 Importance of antigen-specificity for Treg function 
As alluded to above, the efficacy of Treg therapy can be improved by using Tregs with a defined 
antigen-specificity. This is supported by a substantial number of studies conducted in pre-clinical 
animal models which have demonstrated that Tregs specific for a desired antigen are functionally 
superior to polyclonal Tregs (Taylor, Lees et al. 2002, Tang, Henriksen et al. 2004, Joffre, Santolaria 
et al. 2008, Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009, Sagoo, Ali et al. 2011, Putnam, 
Safinia et al. 2013). 
One of the first studies to compare the efficacy of antigen-specific and self-specific Tregs upon 
adoptive transfer in vivo was conducted by Taylor et al. in the context of GvHD (Taylor, Lees et al. 
2002). In addition to being one of the first papers to explore the potential for Treg therapy using 
ex vivo-expanded Tregs, this study also demonstrated that murine Tregs preferentially expanded 
using allogeneic splenocytes were more effective at protecting from GvHD than Tregs expanded 
using anti-CD3, upon adoptive transfer. In 2004, Tang et al. demonstrated a similar superior 
efficacy of antigen-specific Tregs using a T1D model (Tang, Henriksen et al. 2004). In this study, 
T1D induced by the transfer of 25x106 diabetogenic cells was blocked by the transfer of 2x106 
Tregs specific for islet β-cell antigens, but not as efficiently blocked by the transfer of 8x106  
self-specific Tregs, suggesting that the antigen-specific Tregs were over four times more potent 
at preventing disease manifestation. Furthermore, these antigen-specific Tregs could not only 
prevent the development of T1D but were also able to reverse diabetes following disease onset, 
further accentuating the potency of these cells for clinical use. 
In a transplant context, numerous studies have demonstrated Tregs with direct allospecificity 
enhance allograft survival more effectively than self-specific Tregs. In most cases, these cells are 
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obtained using a preferential expansion approach where Tregs are stimulated with allogeneic 
APCs (Joffre, Santolaria et al. 2008, Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009). These 
findings have been confirmed in a human setting using a human skin xenograft transplant model 
(sections 5.1 and 5.3.3.2). In these latter studies, human Tregs were expanded using allogeneic 
DCs (Sagoo, Ali et al. 2011) or B cells (Putnam, Safinia et al. 2013) and demonstrated a superior 
efficacy at protecting human skin allografts from alloimmune-mediated skin injury compared to 
polyclonal Tregs. However, the expansion of Tregs with indirect allospecificity has proved more 
challenging due to the low frequency of these cells naturally present in the periphery 
(Veerapathran, Pidala et al. 2011). 
Antigen-specific Tregs may also be generated by transducing Tregs to express specific α and β 
TCR chain genes. The superior efficacy of TCR-modified antigen-specific Tregs, as compared to 
self-specific Tregs, has been demonstrated in mouse models for the treatment of colitis (Zhou, 
Borojevic et al. 2004), MS (Stephens, Malpass et al. 2009), autoimmune gastritis (DiPaolo, Brinster 
et al. 2007), RA (Fujio, Okamoto et al. 2006, Wright, Notley et al. 2009), T1D (Tang, Henriksen et 
al. 2004, Tarbell, Petit et al. 2007), GvHD (Taylor, Lees et al. 2002, Trenado, Sudres et al. 2006) 
and organ transplantation (Golshayan, Jiang et al. 2007, Tsang, Tanriver et al. 2008, Tsang, 
Tanriver et al. 2009, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). In 2008, this TCR 
transduction approach was adopted by Tsang et al. to generate Tregs with indirect allospecificity 
(Tsang, Tanriver et al. 2008). In this study, Tregs with indirect allospecificity were shown to protect 
skin and heart allografts significantly more effectively than self-specific Tregs. This approach was 
expanded on in 2009 when Tregs with dual direct and indirect allospecificity were generated 
(Joffre, Santolaria et al. 2008, Tsang, Tanriver et al. 2009). These Tregs were able to prolong graft 
survival more effectively than any population of Tregs found naturally, highlighting the potential 
for gene-modified cell therapy in the clinic. 
 
 Regulatory T cell therapy clinical trials 
In light of the various studies described above which demonstrated the efficacy of Treg therapy, 
strategies have been developed over the past decade to adopt Treg therapy in the clinic (Safinia, 
Leech et al. 2013). Progress was hampered for many years due to difficulties in isolating a 
sufficient number of Tregs with a reasonable purity, as well as complications in expanding a 
therapeutically relevant number of cells under good manufacturing practice (GMP) conditions 
(Bluestone 2005). However, with solutions to these problems being identified, Treg therapy is 
now a reality in the clinic (Tang and Bluestone 2013). 
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Although in its infancy, Treg therapy is being investigated in a wide variety of settings ranging 
from transplantation to various autoimmune diseases, as shown in Table 1-1. The majority of 
trials in the transplant field employ a similar protocol which is outlined in Figure 1-4. Tregs are 
isolated from the recipient prior to the transplant procedure, these cells are expanded ex vivo 
and this expanded population of cells is re-infused back into the recipient after the transplant 
procedure. Further details relating to the isolation and expansion of these cells are discussed in 
sections 4.1.1 and 4.1.2. 
Many factors have been debated to ensure the full potential of the Tregs is exploited, such as the 
timing, location and dose of administered Tregs. Immediately following the transplant  procedure, 
recipients are typically under a high level of immunosuppression (section 1.1.2.2) which has been 
shown to dramatically influence the functionality of Tregs in both a positive (Chen, Oppenheim 
et al. 2006, Lopez, Clarkson et al. 2006, Zeiser, Nguyen et al. 2006, Strauss, Whiteside et al. 2007, 
Wang, Shi et al. 2009) and negative (Baan, van der Mast et al. 2005, Lopez, Clarkson et al. 2006, 
Segundo, Ruiz et al. 2006, Zeiser, Nguyen et al. 2006) manner. Combined with the fact that drug 
use is usually tapered in the months following the transplant procedure, identifying the optimal 
time to administer the Treg therapy is difficult, although it is clear that a “Treg-supportive” 
environment is required (Safinia, Leech et al. 2013, Tang and Bluestone 2013). A recent study 
published by the host laboratory has demonstrated that treating human Tregs in vitro with the 
cocktail of drugs used in The ONE Study compromises the viability of these cells, although their 
function and stability remains intact (Scotta, Fanelli et al. 2016). 
Regarding the location of Treg injection, practical considerations dictate that injection into a 
peripheral vein is preferable. However, this relies on Tregs expressing the correct homing 
receptors to ensure they traffic to the graft site or associated lymph nodes. The environment in 
which the Tregs are expanded dramatically influences the nature of the homing receptors 
expressed (Scotta, Esposito et al. 2013). Conversely, direct injection into the required site of 
action (the allograft) may allow the Tregs to exert their protective capacity in a more efficacious 
manner (Safinia, Leech et al. 2013). 
Trials performed to date are Phase I or Phase I/II and as such, are principally investigating the 
safety of Treg therapy. Consequently, cautious approaches using a limited number of Tregs have 
been employed thus far. In kidney transplant recipients, polyclonal Treg doses of up to 10x106 
Tregs/kg have been demonstrated to be safe in the GMP facility at King’s College London. 
However, in GvHD and T1D contexts, doses of up to 30x106 Tregs/kg have been tolerated 
(Trzonkowski, Bieniaszewska et al. 2009, Brunstein, Miller et al. 2011, Di Ianni, Falzetti et al. 2011, 
Marek-Trzonkowska, Mysliwiec et al. 2014, Bluestone, Buckner et al. 2015). 
Chapter I │ General introduction 
 
32 
Context Treg specificity Trial number Trial name and location 
Kidney transplantation Polyclonal NCT02129881 The ONE Study (UK) 
Kidney transplantation Polyclonal NCT02371434 The ONE Study (Germany) 
Kidney transplantation Polyclonal NCT02091232 The ONE Study (USA) 
Kidney transplantation Polyclonal NCT02088931 TASK (USA) 
Kidney transplantation Polyclonal NCT02145325 TRACT (USA) 
Kidney transplantation Polyclonal NCT01446484 N/A (Russia) 
Kidney transplantation Direct allospecificity NCT02711826 TASK (USA) 
Kidney transplantation Direct allospecificity NCT02244801 The ONE Study DART (USA) 
Liver transplantation Polyclonal NCT02166177 ThRIL (UK) 
Liver transplantation Direct allospecificity NCT01624077 N/A (USA) 
Liver transplantation Direct allospecificity NCT02188719 delta (USA) 
Liver transplantation Direct allospecificity NCT02474199 ARTEMIS (USA) 
GvHD following BMT Donor-derived NCT02385019 TREGeneration (Portugal) 
GvHD following BMT Donor-derived NCT01903473 N/A (Belgium) 
GvHD following BMT Donor-derived NCT02749084 N/A (Italy) 
GvHD following BMT Donor-derived NCT01937468 N/A (USA) 
GvHD following BMT Donor-derived NCT01911039 N/A (USA) 
GvHD following BMT Donor-derived NCT02526329 N/A (USA) 
GvHD following BMT Donor-derived NCT01795573 N/A (USA) 
GvHD following BMT Donor-derived NCT00376519 N/A (USA) 
GvHD following BMT Donor-derived NCT00725062 N/A (USA) 
GvHD following BMT Cord-derived NCT00602693 N/A (USA) 
GvHD following BMT Cord-derived NCT02423915 N/A (USA) 
GvHD following BMT Cord-derived NCT02118311 N/A (USA) 
GvHD following BMT Cord-derived NCT01163201 N/A (USA) 
T1D Polyclonal NCT01210664 N/A (USA) 
T1D Polyclonal NCT02691247 N/A (USA) 
T1D Polyclonal NCT02772679 TILT 
Lupus erythematosus Polyclonal NCT02428309 N/A (USA) 
Uveitis Polyclonal NCT02494492 UVEREG (France) 
Autoimmune hepatitis Polyclonal NCT02704338 N/A (USA) 
 
Table 1-1 | List of clinical trials investigating the safety and efficacy of Treg therapy using tTregs, according 
to clinicaltrials.gov. In cases where Tregs were not isolated from the recipient, this is stated under the 
“Treg specificity” column. GvHD = graft-versus-host disease, BMT = bone marrow transplantation, T1D = 
Type 1 diabetes, TASK = Treg adoptive therapy for subclinical inflammation in kidney transplantation, 
TRACT = Treg adoptive cellular transfer, DART = Donor-alloantigen reactive regulatory T cell, ThRIL = 
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Taken together, it is clear that due diligence should be employed regarding the timing, location 
and dose of Treg therapy. However, another fundamental factor to consider is the specificity of 
the Tregs. As previously mentioned, current trials expand Tregs in either a polyclonal manner or 
with allogeneic APCs to yield Tregs with direct allospecificity. With numerous studies supporting 
the increased efficacy of allospecific Tregs, the latter is preferable. However, this is not the only 
approach which may be employed to acquire allospecific Tregs. As previously described, Tregs 
with indirect allospecificity may be generated by transducing polyclonal cells to express specific 
α and β TCR genes (Joffre, Santolaria et al. 2008, Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 
2009). Another approach to generate antigen-specific Tregs is to use chimeric antigen receptors 
(CAR) (Elinav, Waks et al. 2008, Elinav, Adam et al. 2009, Lee, Hayman et al. 2011, Fransson, Piras 
et al. 2012, Blat, Zigmond et al. 2014, Jethwa, Adami et al. 2014, MacDonald, Hoeppli et al. 2016). 
The generation of alloantigen-specific Tregs using CARs is the main topic of this thesis. 
 
therapy of regulatory T cells in liver transplantation, delta = donor-alloantigen-reactive regulatory T cell 
in liver transplantation, ARTEMIS = Alloantigen reactive Tregs to facilitate minimisation and/or 
discontinuation of immunosuppression, TILT = T1D immunotherapy using polyclonal Tregs, UVEREG = 
uveitis regulatory T cell. 
Figure 1-4 │ Schematic diagram outlining the process of Treg therapy. To acquire an autologous population 
of Tregs which may be applied in a Treg therapy protocol, peripheral blood is drawn from the patient and 
Tregs are isolated either through the use of GMP-compatible fluorescence-assisted cell sorting (FACS) or 
in vitro negative and positive selection protocols using magnetic beads (red section). The Tregs are then 
activated, usually in a polyclonal manner using anti-CD3/CD28 beads, and undergo a single or multiple 
rounds of stimulation in order to expand the number of Tregs ex vivo (yellow section). This expanded 
population of Tregs is then infused back into the patient, typically as part of a combination therapy 
protocol (blue section). 
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 CHIMERIC ANTIGEN RECEPTORS 
The successful generation of antigen-specific T cells is a goal which is sought-after in various fields 
of research. In a cancer setting, various approaches have demonstrated the therapeutic benefits 
of adoptive T cell therapy with particular success in the treatment of melanoma (Dudley, 
Wunderlich et al. 2002, Mackensen, Meidenbauer et al. 2006, Dudley, Yang et al. 2008, Hunder, 
Wallen et al. 2008). In these trials, tumour infiltrating lymphocytes (TIL) with tumour  
antigen-specificity are expanded ex vivo prior to re-infusion. However, these cells are rare and as 
such, isolating and expanding clinically applicable number of cells can be complicated.  
As described above, one solution that may overcome this shortcoming involves the generation of 
genetically-engineered antigen-specific T cells. The obvious approach which may be employed is 
to transduce the T cell with specific α and β TCR chain genes which combine to yield a TCR with a 
desired specificity. However, early studies which adopted this approach were hampered by the 
fact that T cells inherently contain their own endogenous TCR genes. Consequently, ¾ of the TCR 
complexes presented on the surface of these cells were not specific for the desired MHC-peptide 
complex: ¼ of the TCRs comprised endogenous TCR chains and a further ½ consisted of a mixture 
of endogenous and transduced α and β chains (Thomas, Xue et al. 2007). It was subsequently 
demonstrated that these hybrid TCR complexes had the potential to direct the T cell towards  
self-antigens, promoting the development of autoimmunity (Bendle, Linnemann et al. 2010). 
Various strategies have been explored to reduce this issue. One such solution is to target T cells 
with α and β TCR chains which are structurally modified in the constant region, such that they 
pair with endogenous chains with a low efficiency (Cohen, Li et al. 2007, Kuball, Dossett et al. 
2007, Thomas, Xue et al. 2007). Alternatively, strategies to decrease the expression of 
endogenous α and β chain TCR genes have also been explored using either RNA-interference to 
knockdown endogenous TCR expression (Ochi, Fujiwara et al. 2011, Provasi, Genovese et al. 2012)  
or genome editing techniques such as transcription activator-like effector nucleases (TALEN) to 
knockout endogenous TCR genes (Berdien, Mock et al. 2014). 
With an ever-increasing number of solutions to this endogenous/exogenous TCR dimerisation 
problem coming to light, research into the use of TCR genes to redirect the specificity of T cells 
prevailed. This approach has had particular success in the generation of melanoma-specific  
T cells. In 2006, Morgan et al. published the results of a T cell therapy-based clinical trial in which 
autologous T cells were transduced with specific TCR α and β chain genes (Morgan, Dudley et al. 
2006). The resulting TCR complex (DMF4) facilitated the recognition of a peptide derived from 
the melanoma antigen recognised by T cells (MART)-1 antigen (residues 27-35) presented in the 
context of HLA-A2. TCR transduction increased the proportion of CD8+ T cells presenting the Vβ12 
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TCR chain from ~1% to 30%. This TCR expression allowed 15% of the transduced T cell to bind a 
HLA-A*0201 tetramer presenting the MART-1 peptide, compared to ~0.1% of the untransduced 
T cells. Tumour regression (defined by Response Evaluation Criteria in Solid Tumours (RECIST) 
criteria (Therasse, Arbuck et al. 2000)) was observed in 2 out of the 15 patients treated. This was 
improved upon by Johnson et al. who used 576 TCR gene sequences from the TILs of three 
individual melanoma patients to generate a consensus TCR clone (DMF5). This TCR recognised 
the same MHC-peptide complex as DMF4 but with a higher affinity (Johnson, Heemskerk et al. 
2006). When investigated in a similar clinical setting (NCI07C0175), T cells expressing the DMF5 
TCR achieved tumour regression (RECIST criteria) in 6 out of 20 patients treated (Johnson, Morgan 
et al. 2009). Various other successes have been achieved using TCR-transduced T cell therapy for 
the treatment of various melanomas and sarcomas (Robbins, Morgan et al. 2011, Morgan, 
Chinnasamy et al. 2013, Morrison 2014). 
Although TCR transduction has been successful in the generation of melanoma-specific T cells, 
this approach is fundamentally flawed as TCRs recognise peptides presented in the context of 
MHC molecules. MHC molecules are frequently downregulated in tumours and the high 
Figure 1-5 │ Schematic diagram detailing the components of a CAR. CARs consist of four components: an 
antigen-specific targeting moiety such as an scFv domain (grey), a hinge domain (red), a transmembrane 
domain (orange) and an intracellular signalling domain (purple/gold). These various components are 
obtained from different molecules such as antigen-specific antibodies (blue) which provide the 
extracellular antigen-binding domain or T cell surface protein complexes and co-stimulatory molecules 
which make up the intracellular signalling domain. The resulting fusion protein is capable of translating 
the binding of specific extracellular antigen (green) into intracellular T cell activation signals. Diagram 
adapted from image provided by Maher (Maher 2012). 
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variability of these molecules between patients necessitates the generation of a TCR library for 
each target antigen presented in the context of each HLA allele, a significant impracticality for 
translating this to the clinic. This can be circumvented by employing an approach which was first 
demonstrated by Eshhar et al. in 1989 (Gross, Gorochov et al. 1989, Gross, Waks et al. 1989), 
namely to use CARs to direct the specificity of T cells. 
 
 COMPONENTS OF CHIMERIC ANTIGEN RECEPTORS  
CARs are synthetic fusion proteins which comprise sequences of various protein complexes to 
facilitate in the redirection of the specificity of T cells towards desired antigens of interest. Their 
development has principally been driven by research in a cancer setting which has aimed to 
generate T cells with tumour antigen specificity. In essence, CARs contain three discrete domains: 
an extracellular antigen-targeting moiety, a hinge/transmembrane domain and an intracellular 
signalling entity (Figure 1-5). Together, these domains allow a CAR to translate the extracellular 
binding of specific antigens into the intracellular activation of desired T cell signalling cascades 
(Maher 2012). 
 
 Antigen-targeting moiety 
The specificity of a CAR is dictated by the antigen-targeting moiety it incorporates. Although a 
variety of different macromolecules can be used to dictate the specificity of a CAR (Chmielewski, 
Hombach et al. 2013), the most common and arguably most robust approach is to use the 
sequence of an single-chain variable fragment (scFv). Since an scFv is derived from an antibody, 
this enables CARs to engage target antigens in an MHC-independent manner, a significant 
advantage over TCRs which recognise peptides presented in the context of MHC molecules. 
 
 Hinge domain 
The antigen-targeting moiety of the CAR is linked to the transmembrane domain via a flexible 
hinge domain. Over the years, these domains have comprised sequences acquired from many 
different proteins such as the extracellular region of CD28, CD8, CD4 or the fragment 
crystallisable (Fc) region of an IgG (Guest, Hawkins et al. 2005, van der Stegen, Hamieh et al. 
2015). However, the nature and length of the hinge domain selected can have a dramatic 
influence on the functionality of a CAR. In 2015, Hudecek et al. used a human xenograft tumour 
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model to demonstrate that T cells expressing a CD19-specific CAR which incorporated a short 
hinge domain (12 amino acids (aa)) were able to eradicate CD19+ Raji tumours whilst T cells 
expressing the same CAR with a longer hinge domain (228 aa) could not (Hudecek, Sommermeyer 
et al. 2015). This response was attributed to the fact that CAR T cells with a long hinge domain 
underwent AICD. However, Guest et al. demonstrated that different length hinges were required, 
depending on the nature of the target antigen. For epitopes which were physically closer to the 
cell membrane, a longer, more flexible hinge was required (Guest, Hawkins et al. 2005). Taken 
together, these studies demonstrated that if a hinge domain was not of a sufficient length, the 
flexibility of the antigen-targeting moiety was compromised and target antigens were not 
efficiently engaged. However, if the hinge was too long, the functional efficacy of the T cell was 
compromised. 
 
 Transmembrane domain 
The transmembrane domain is often considered as a mere structural element which links the 
extracellular antigen-targeting moiety to the intracellular signalling domain. However, in 2010, 
Bridgeman et al. demonstrated that the nature of this domain can influence how the CAR 
interacts with other cell surface proteins (Bridgeman, Hawkins et al. 2010). In this study, the 
authors compared the functionality of various CARs which incorporated the same 
carcinoembryonic antigen (CEA)-specific targeting moiety but different transmembrane and 
signalling domains. Through point mutational analysis, it was noted that key residues in the 
transmembrane domain facilitated dimerisation of the CAR. Similar mutations also abrogated 
interactions made between the CARs and endogenous members of the TCR/CD3 complex such as 
the TCRβ chain which was confirmed by Förster resonance energy transfer (FRET). T cells 
expressing the CARs which contained these mutations were significantly compromised in their 
ability to respond to immobilised CEA, compared to T cells expressing unmodified CARs. This 
correlates with findings that T cells require a “threshold” of TCR-mediated signals to be activated 
(Viola and Lanzavecchia 1996). In this context, it appears that CARs must dimerise and form 
complexes with endogenous signalling complexes to reach this threshold. As such, the 
transmembrane domains which are incorporated into CARs are typically derived from proteins 
which accumulate in the TCR/CD3 complex, namely CD3, CD4, CD8 and CD28. 
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 Signalling domain 
Since their inception, CARs have evolved through three generation which are defined by the 
signalling domains incorporated. The first generation CARs, such as those developed by Eshhar et 
al. (Eshhar, Waks et al. 1993) were engineered to mimic endogenous TCRs thus incorporated 
domains derived from the TCR/CD3 signalling complex such as CD3ζ (Irving and Weiss 1991), 
providing “signal 1” only (section 1.1.3.2.1). However, despite being functional, these CARs had a 
low efficacy which was attributed to the lack of a co-stimulatory domain to provide “signal 2” 
(Heslop 2010, Jena, Dotti et al. 2010, Maher 2012). This was a particular issue in the cancer setting 
where CARs were originally developed, as tumour cells not only downregulate MHC molecules 
(Bubenik 2003) but also, do not usually express co-stimulatory molecules (Driessens, Kline et al. 
2009). Consequently, second generation CARs were developed to incorporate both a  
TCR/CD3-derived signalling element to provide “signal 1” and a co-stimulatory molecule-derived 
element to provide “signal 2” (Maher, Brentjens et al. 2002, Heslop 2010, Maher 2012). The 
success of these second generation CARs inevitably led to the development of third generation 
CARs which incorporated multiple co-stimulatory domains from different sources (Maher 2012). 
Different research groups have developed second and third generation CARs to incorporate 
signalling domains from a wide variety of co-stimulatory molecules including CD28, 4-1BB, OX40, 
Lck, ICOS, CD27, 2B4 and DAP10 (Zhao, Wang et al. 2009, Heslop 2010, Jena, Dotti et al. 2010, 
Maher 2012, van der Stegen, Hamieh et al. 2015). 
 
 CHIMERIC ANTIGEN RECEPTORS IN CANCER RESEARCH 
Reflecting the application for which they were originally developed, the majority of published CAR 
studies focus on their use in a cancer context. Indeed, promising results from pre-clinical studies 
performed using a variety of animal models warranted the adaptation of CAR technology into the 
clinic (Sadelain, Brentjens et al. 2009). CARs have been assessed clinically for the treatment of a 
range of cancers with the results of approximately 30 trials published to date (Dai, Wang et al. 
2016). 
Resounding success has been demonstrated for the treatment of various B cell malignancies using 
CARs targeting CD19 such as acute (ALL) and chronic lymphocytic leukaemia (CLL) (Kalos, Levine 
et al. 2011, Porter, Levine et al. 2011, Brentjens, Davila et al. 2013, Grupp, Kalos et al. 2013, 
Porter, Hwang et al. 2015), non-Hodgkin’s lymphoma (Till, Jensen et al. 2012) and B cell 
lymphoma (Kochenderfer, Wilson et al. 2010, Kohn, Dotti et al. 2011). For example, in the context 
of ALL, complete remission has been observed in approximately 90% of patients treated in two 
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clinical trials (27/30 patients by Maude et al. (Maude, Frey et al. 2014) and 14/16 patients by 
Davila et al. (Davila, Riviere et al. 2014)) with encouraging results from additional trials 
consistently being published. 
Unfortunately, these successes were not matched when CAR T cells were investigated as a means 
of destroying solid tumours. Fewer trials have been performed to assess the efficacy of CAR T 
cells in solid tumour contexts (Dai, Wang et al. 2016) and where trial data has been published, 
complete remission is rarely observed (Kershaw, Westwood et al. 2006, Park, Digiusto et al. 2007, 
Pule, Savoldo et al. 2008, Louis, Savoldo et al. 2011, Ahmed, Brawley et al. 2015, Brown, Badie et 
al. 2015). The most promising results to date were published by Louis et al. where complete 
remission was observed in 3/19 neuroblastoma patients (Louis, Savoldo et al. 2011). These less 
promising results have attributed to various unique factors of solid tumours such as the lack of 
infiltrating blood vessels which complicates T cell trafficking into the core of the tumour and once 
in the tumour, the presence of an immunosuppressive microenvironment. 
 
 VARIATIONS ON THE CHIMERIC ANTIGEN RECEPTOR 
As a consequence of the modest results which have been achieved with CAR T cells in solid 
tumour settings, various approaches have been investigated to improve the efficacy of CAR  
T cells. These approaches typically involve transducing T cells to express multiple exogenous 
genes. For example, T cells redirected for universal cytokine killing (“TRUCK”) are T cells which 
are engineered to express a CAR and an exogenous cytokine gene (Chmielewski, Hombach et al. 
2014, Chmielewski and Abken 2015). In 2011, Chmielewski et al. developed TRUCKs which 
expressed a CEA-specific CAR and secreted high levels of the pro-inflammatory cytokine IL-12 
(Chmielewski, Kopecky et al. 2011). The exogenous gene which encoded the IL-12 p35 and p40 
subunits was under the control of the NFAT6 minimal promoter and as such, was induced upon 
CAR engagement (Hooijberg, Bakker et al. 2000). The rationale behind this system was to 
generate CAR T cells which both elicited an anti-tumour response and attracted innate immune 
cells such as NK cells and macrophages which could launch a “second wave” immune insult within 
the tumour (Chmielewski, Hombach et al. 2014). “Armoured CAR” T cells function along similar 
lines but instead of being restricted to secreting additional cytokines, these cells can instead 
express ligands which enhance the functionality of the CAR T cell, such as CD40L or 4-1BBL 
(Pegram, Park et al. 2014, Yeku and Brentjens 2016). 
Chimeric cytokine receptor (CCR) are also designed to be used in combination with a CAR. These 
are cell surface receptors which detect one cytokine but deliver a stimulatory signal which would 
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naturally come from the detection of a different cytokine. Examples include the IL-4/2 (Wilkie, 
Burbridge et al. 2010) and IL-4/7 (Leen, Sukumaran et al. 2014) receptors detect extracellular  
IL-4 using an IL-4 ectodomain, but trigger IL-2 and IL-7 intracellular signalling cascades through 
the use of IL-2 and IL-7 endodomains, respectively. These receptors can be exploited both in vitro, 
for selectively expanding transduced T cells, and in vivo, for promoting the expansion of CAR  
T cells as IL-4 is present at elevated levels in many tumours (Li, Chen et al. 2009). 
Recently, Ellebrecht et al. applied CAR technology in a particularly intelligent and elegant manner 
to generate T cells which targeted autoreactive B cells (Ellebrecht, Bhoj et al. 2016). This study 
was performed in the context of pemphigus vulgaris, a rare autoimmune blistering disease which 
is fuelled by autoreactive antibodies which recognise the keratinocyte adhesion protein 
desmoglein (Dsg)3 (Koga, Tsuruta et al. 2013). To target the B cells which would proceed to 
secrete this antibody, a chimeric autoantibody receptor (CAAR) was developed which presented 
Dsg3 extracellularly and contained a CD137-CD3ζ intracellular signalling domain. B cells 
presenting an antibody specific for Dsg3 engaged the CAAR presented by the T cells and were 
specifically lysed. This novel approach was shown to effectively eliminate anti-Dsg3 B cells in vivo 
which resulted in the protection of human skin xenografts without off-target toxicity. 
 
 ALTERNATIVE USES FOR CHIMERIC ANTIGEN RECEPTORS 
CARs have principally been developed to confer antigen specificity onto Tconvs. However, as 
Tregs are activated in a similar manner to Tconv, it is fathomable that CARs can be used to impose 
antigen-specificity onto Tregs (Boardman, Maher et al. 2016). This has been achieved in mouse 
and human cells to treat various autoimmune diseases and prevent undesired immune 
responses. 
In 2008, Elinav et al. (Elinav, Waks et al. 2008) generated murine Tregs which expressed a CAR 
specific for 2,4,6-trinitrophenol (TNP), a colitis-associated model antigen. In this study, Tregs were 
isolated from transgenic mice expressing the TNP-specific CAR under the control of the CD2 
promoter. Upon adoptive transfer, these Tregs prevented the development of  
2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis, but not oxazolone-induced colitis, 
highlighting the antigen-specific nature of these Tregs. Furthermore, in vivo fluorescence imaging 
of these cells showed that they accumulated in the colon, suggesting that CAR Tregs trafficked to 
sites where their cognate antigen is present. These authors also demonstrated that self-specific 
Tregs retrovirally transduced to express the TNP-specific CAR were equally capable of preventing 
Chapter I │ General introduction 
 
41 
colitis (Elinav, Adam et al. 2009) and that similar results could be obtained through targeting 
different colitis-associated antigens (Blat, Zigmond et al. 2014).  
The protective capacity of CAR Tregs has also been demonstrated for the treatment of MS. In 
2012, Fransson et al. transduced murine CD4+ T cells to express both a CAR specific for myelin 
oligodendrocyte glycoprotein (MOG) and the FoxP3 gene, resulting in cells which elicited both a 
suppressive capacity and functioned in a MOG-dependent manner (Fransson, Piras et al. 2012). 
These cells were found to localise to the CNS where they alleviated the symptoms of EAE, 
following adoptive transfer. 
The functionality of CARs has also been demonstrated in human Tregs which were developed as 
a proof of concept (Hombach, Kofler et al. 2009) or as controls for CAR T cells in a cancer study 
(Lee, Hayman et al. 2011, Jethwa, Adami et al. 2014). However, despite premonitions (Jethwa, 
Adami et al. 2014), little data was published on CAR Tregs until earlier this year, when MacDonald 
et al. demonstrated the efficacy of human CAR Tregs in a xeno-GvHD model (MacDonald, Hoeppli 
et al. 2016). In this study, a CAR specific for HLA-A2 was developed, remarkably similar to that 
which is described in Chapters III and IV. Tregs expressing this CAR were shown to inhibit  
xeno-GvHD more effectively than polyclonal Tregs in two separate mouse models. In the first 
model, non-obese diabetic (NOD) severe combined immunodeficiency (SCID) common γ-chain–/– 
(γc; NSG) mice were injected with HLA-A2+ peripheral blood mononuclear cells (PBMC) ±  
HLA-A2-specific or irrelevant CAR Tregs. In the second model, HLA-A2-transgenic NSG mice were 
injected with HLA-A2– PBMCs ± HLA-A2-specific CAR Tregs. Mice in the first model survived 
significantly longer when HLA-A2-specific CAR Tregs were injected, compared to irrelevant CAR 
Tregs, whilst in the second model, less damage was observed in the liver and lungs of mice which 
received HLA-A2-specific CAR Tregs, compared to PBMCs alone. 
In addition to these published findings, numerous abstracts pertaining to CAR Tregs have recently 
been presented at conferences (Naumann, Kim et al. 2014, Skuljec, Chmielewski et al. 2014, 
Belmonte, Gertner-Dardenne et al. 2016, Fu, Lyle et al. 2016). The biotechnology company 
“TxCell” has also recently announced the approval of a patent for the development of CAR Tregs 
for treating various autoimmune and inflammatory diseases (patent identification number: EP 
2126054 A2), a pursuit led by Prof Zelig Eshhar (Courme 2016). Furthermore, a partnership 
between TxCell and “Ospedale San Raffaele” has been announced for the development of CAR 
Tregs to treat lupus (Courme and Gardini 2016). Taken together, it is evident that an era of 
research into CAR Tregs is emerging. 
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 HYPOTHESES AND AIMS 
Allospecific Tregs protect allografts significantly more effectively than polyclonal Tregs upon 
adoptive transfer. However, given the nature of a TCR complex, these CD4+ cells are inherently 
restricted to recognise peptides presented in the context of MHC class II complexes which are 
almost exclusively presented by professional APCs. Conversely, donor MHC class I is an 
alloantigen which is ubiquitously expressed by all donor-derived cells including those which 
comprise the allograft. 
 
 HYPOTHESIS  
In a transplant setting, the protection offered by polyclonal Treg therapy could be enhanced by 
manipulating the Tregs to express a CAR which recognises donor MHC class I in a  
peptide-independent manner. 
 
 A IMS 
This project aimed to generate and characterise Tregs which were redirected towards donor MHC 
class I through the use of CAR technology. This was to be investigated using human Tregs which 
were redirected towards HLA-A2, and mouse Tregs which were redirected towards Kd. For each 
CAR, the following aims were set: 
 Design and generate a gene encoding a CAR which was specific for the target MHC 
molecule of interest 
 
 Confirm the functionality and specificity of the CARs using Tconv assays 
 
 Optimise protocols for delivering the CAR genes into target Tregs 
 Confirm this process did not influence fundamental characteristics of these cells 
 
 Compare various functional characteristics of polyclonal and CAR Tregs in vitro 
 






 –  
MATERIALS AND METHODS 
  




 HUMAN SAMPLES 
All human samples were acquired from anonymised healthy donors with informed consent and 
full ethical approval. Peripheral blood was obtained in the form of leukocyte-enriched blood 
cones through the National Blood Service (NHS Blood and Transplantation, Tooting, London, UK) 
with ethical approval from the Institutional Review Board of Guy’s Hospital; reference 
09/H0707/86. Human umbilical cord endothelial cells (HUVEC) were isolated from umbilical cords 
provided by the midwifery staff of the Maternity Unit at the Royal London Hospital and prepared 
using protocols approved by the East London & The City Local Research Committee; reference 
05/Q0603/34. Skin explants were obtained from routine abdominoplasty or reduction 
mammaplasty surgical procedure with ethical approval from Guy’s and St. Thomas’ NHS 
Foundation Trust and King’s College London; reference 06/Q0704/18. 
 
 MICE 
A list of the mouse strains used in this thesis is provided in Table 2-1. Mice were delivered to the 
Biological Services Unit (BSU) of New Hunt’s House, King’s College London, at least one week prior 
to any experimental procedure and housed under specific pathogen free (SPF) conditions. All 
experimental procedures were conducted under sterile conditions in accordance to Home Office 
regulations; procedure individual licence (PIL) number 70/26014 or I10D8A9CD and procedure 
project licence (PPL) number 70/7302. 
 
 CELL ISOLATION AND CULTURE 
All cell-based procedures and protocols were conducted under sterile conditions in a class II 
biological safety cabinet using 0.22 μm filtered reagents/solutions. Unless stated otherwise, all 
cells were cultured in ventilated cell culture flasks or tissue culture treated plates at 37°C in the 
presence of 5% (v/v) CO2. All cells were pelleted via centrifugation at a relative centrifugal force 
(RCF) of 350 g, unless stated otherwise, and counted using a haemocytometer and trypan blue 
dye (Sigma-Aldrich). 
 




C57BL/6 (B6) Wild-type mice Harlan N/A 
BALB/c Wild-type mice Harlan N/A 
B6.Kd B6 mice transgenic for BALB/c MHC class I (Kd) Charles River Prof Ralph Patterson Bucy (Department of 
Pathology, University of Alabama, USA) 
OT-II B6 mice transgenic for TCR α- and β-chain genes which specifically 
recognised chicken ovalbumin peptide residues 323-339 (OVA323-339) 
presented in the context of B6 MHC class II (I-Ab)  
Charles River Charles River 
BALB/c RAG2–/–γc–/–  
(BRG) 
BALB/c mice with a knockout of the recombination-activating gene 2 
(RAG2) and the IL-2 common γ chain (γc) gene 
Charles River Prof Adrian Hayday (Division of 
Immunology and Infectious Diseases, 
King’s College London, UK) 
Ch1-2hSa B6 mice with a knockout of the RAG, γc, complement C5,  
β2-microglobulin and MHC class II β-chain (I-Aβb) genes. These mice 
were also transgenic for HLA-A2, HLA-DR1 and human signal-regulatory 
protein (SIRP)α. The SIRPα gene was under the macrophage  
colony-stimulating factor (CSF)-1 receptor (c-fms) promoter 
Charles River Dr Sylvie Garcia (Department of 
Immunology, Pasteur Institute, France) 
(Serra-Hassoun, Bourgine et al. 2014) 
    
















Chapter II │ Materials and methods 
 
46 
 CELL CULTURE MEDIA  
– Roswell Park Memorial Institute (RPMI)-1640 human complete cell media – RPMI-1640, 
5% heat-inactivated human serum (HS; Biosera, Nuaille, France), 100 units (U)/mL 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine (all from Thermo Fisher 
Scientific, Paisley, UK). 
 
– X-vivo complete cell media – X-vivo 15 (Lonza, Basel, Switzerland) and 5%  
heat-inactivated HS. 
  
– Dulbecco’s Modified Eagle Medium (DMEM) complete cell media – DMEM (Lonza) 
supplemented with 4.5 g/L glucose, 10% heat-inactivated foetal calf serum (FCS; Thermo 
Fisher Scientific), 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine. 
 
– Iscove’s Modified Dulbecco’s Medium (IMDM) complete cell media – Iscove’s Modified 
Dulbecco’s Medium (IMDM; Lonza) supplemented with 4.5 g/L glucose and 25 mM  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Thermo Fisher Scientific), 
10% heat-inactivated FCS, 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM  
L-glutamine. 
 
– B-LCL media – RPMI-1640, 10% heat-inactivated FCS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Thermo Fisher Scientific). 
 
– Standard RPMI cell media – RPMI-1640, 10% heat-inactivated FCS, 100 U/mL penicillin,  
100 μg/mL streptomycin and 2 mM L-glutamine. 
 
– HUVEC media – Medium (M)199 (Lonza), 20% heat-inactivated HS (Lonza), 100 U/mL 
penicillin (Sigma-Aldrich), 100 μg/mL streptomycin (Sigma-Aldrich), 2 mM L-glutamine 
and 2.5 μg/mL Fungizone (Thermo Fisher Scientific) 
 
– RPMI-1640 mouse complete cell media – RPMI-1640, 10% heat-inactivated FCS (General 
Electric (GE) Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK), 100 U/mL 
penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 10 mM HEPES and 50 μM  
β2-mercaptoethanol (Thermo Fisher Scientific). 
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 HUMAN PBMC  ISOLATION AND CULTURE  
Human PBMCs were isolated from leukocyte-enriched blood cones by density gradient 
centrifugation. Cone blood was diluted 8-fold with sterile phosphate buffered saline (PBS; no Ca2+ 
or Mg2+) and carefully layered on top of 15 mL Lymphoprep™ (StemCell™ Technologies, 
Vancouver, British Columbia, Canada) in a 50 mL Falcon™ tube. The blood was centrifuged at  
940 g for 20 minutes at room temperature with an acceleration at 40% of the maximum possible 
rate and no brake. Buffy coat cells were harvested and washed 3 times with PBS – once at 940 g 
for 10 minutes followed by 2 washes at 235 g for 10 minutes to remove contaminating platelets. 
For experiments in which the isolated PBMCs were to be used for in vitro experiments, the cells 
were suspended at a concentration of 3x106/mL in “RPMI-1640 human complete cell media” 
(section 2.2.1), activated with 5 μg/mL leucoagglutinin (PHA-L; Sigma-Aldrich, St. Louis, Missouri, 
USA) and cultured in 6-well plates (4 mL/well) in the presence of 100 U/mL recombinant human 
IL-2 (Proleukin®, Prometheus Laboratories Inc., San Diego, California, USA). 
 
 Depletion of CD25+ PBMCs 
Total PBMCs were depleted of Tregs using a positive selection protocol for CD25+ cells. PBMCs 
were suspended in MACS buffer (PBS without Ca2+ or Mg2+ supplemented with 0.5% bovine serum 
albumin (BSA; Sigma-Aldrich) and 5 μM EDTA (Ethylenediaminetetraacetic acid; Thermo Fisher 
Scientific)) at a concentration of 10x106 cells/mL. Cells were mixed with CD25 MicroBeads II 
(Miltenyi Biotec, Cologne, Germany) at a 4:1 v/v ratio and incubated for 15 minutes at 4°C under 
rotation. The cells were then washed once with MACS buffer in a volume of 50 mL to remove 
excess beads and then suspended in 3 mL MACS buffer. 
An LS column with accompanying pre-separation filter (Miltenyi Biotec) was inserted into a MACS 
separator magnet and rinsed with 3 mL MACS buffer. The PBMC suspension prepared above was 
added to the column and the effluent containing unlabelled CD25‒ PBMCs was collected. The 
column was washed 3 times with 3 mL MACS buffer to collect as many CD25‒ PBMCs as possible 
and the column containing the CD25+ PBMCs was discarded. The CD25‒ PBMCs were then 
cryopreserved in freezing medium (90% heat-inactivated FCS and 10% Dimethyl sulfoxide 
(DMSO)) and stored in liquid nitrogen until use. 
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 HUMAN CD4+CD25+  TREG AND CD4+CD25‒  TCONV 
ISOLATION AND CULTURE 
Human CD4+CD25+ Tregs and CD4+CD25‒ Tconvs were isolated concurrently from  
leukocyte-enriched blood cones using a negative selection protocol for CD4+ T cell followed by a 
positive selection protocol for CD25+ cells. Cone blood was diluted 2-fold with PBS (without Ca2+ 
or Mg2+) and incubated with RosetteSep™ Human CD4+ T Cell Enrichment Cocktail (150 μL 
RosetteSep™ per 5 ml blood; StemCell™ Technologies) for 30 minutes at room temperature. This 
process crosslinked the unwanted CD4‒ cells (expressing CD8, CD16, CD19, CD36, CD56, CD66b 
or TCRγ/δ) with the red blood cells (RBC). The blood was then diluted an additional 4-fold with 
PBS, layered on top of 15 mL Lymphoprep™ and centrifuged as detailed above (section 2.2.2). 
Buffy coat (CD4+) cells were harvested and CD25 MicroBeads II were used to separate the 
CD4+CD25+ Tregs and CD4+CD25‒ Tconvs, as detailed above (section 2.2.2). CD4+CD25+ Tregs were 
eluted by removing the column from the magnet, adding 5 mL MACS buffer to the column and 
using a low pressure generated with a plunger. The purity of the CD4+CD25+ Tregs was assessed 
by flow cytometry immediately following isolation using an anti-human CD4 APC antibody (OKT4 
clone) and an anti-human CD25 PE antibody (2A3 clone) and was consistently found to be >90% 
(Figure 4-1A). Alternatively, an extensive phenotype was conducted using the antibodies detailed 
in Table 2-4 (Figure 4-1B). 
In order to establish a Treg cell line, freshly-isolated cells were suspended in “X-vivo complete cell 
media” (section 2.2.1) at a concentration of 1x106 cells/mL and activated with anti-human 
Figure 2-1 │ Timeline showing when human Tregs were re-stimulated and used for experiments, relative to 
the time of isolation. Human Tregs were activated with anti-human CD3/CD28 beads and cultured in the 
presence of 100 nM rapamycin on the day of isolation (day 0). On day 2, cultures were supplemented with 
fresh rapamycin and 1,000 U/mL recombinant human IL-2. IL-2 and rapamycin was replenished on days 4 
and 6 of culture. On day 10, the Tregs were harvested, washed and re-cultured in fresh media with IL-2, 
rapamycin and anti-human CD3/CD28 beads. IL-2 and rapamycin was replenished on days 12, 14 and 16 
and the cells were used for experimentation on day 20.   
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CD3/CD28 Dynabeads® Human T-Activator beads (Thermo Fisher Scientific) at a 1:1 cell:bead 
ratio. The Tregs were cultured in 24-well plates with 1x106 cells/well in the presence of 100 nM 
rapamycin (LC-Laboratories, Woburn, Massachusetts, USA). On days 2, 4 and 6 post-stimulation, 
cultures were supplemented with 1,000 U/mL human recombinant IL-2 and rapamycin was 
replenished. A timeline for the Treg expansion protocol is provided in Figure 2-1. 
On day 10 of culture, resting Tregs were harvested and the anti-CD3/CD28 beads were removed 
using a magnet. The cells were washed with PBS and suspended in “X-vivo complete cell media” 
supplemented with IL-2 and rapamycin. The cells were then re-stimulated with anti-human 
CD3/CD28 beads at a 1:1 cell:bead ratio and cultured as detailed above. Tregs were starved of  
IL-2 and harvested before being used in experiments on day 20 (Figure 2-1). 
 
 IMMORTALISED ADHERENT CELL LINE CULTURE 
Human Embryonic Kidney (HEK) 293T cells were kindly donated by Dr Gilbert Fruhwirth (Division 
of Imaging Sciences and Biomedical Engineering, King’s College London, UK). H29D, PG13,  
MCF-7 and T-47D were all kindly provided by Dr John Maher (Division of Cancer Studies, King’s 
College London, UK). Phoenix-Ecotropic (Eco) cells were kindly donated by Dr Angelika Holler and 
Prof Hans Stauss (Institute of Immunity and Transplantation, University College London, UK). 
HEK293T cells are a derivative of HEK293 cells (Graham, Smiley et al. 1977) which have been 
modified to stably express the Simian Vacuolating Virus 40 (SV40) large T-antigen. The presence 
of this SV40 T-antigen allows HEK293Ts to efficiently replicate vectors which contain the SV40 
origin of replication (DuBridge, Tang et al. 1987). 
H29D cells are a derivative of HEK293 cells which have been modified to express the Moloney 
murine leukaemia virus (MoMuLV) gag-pol polyprotein (Ory, Neugeboren et al. 1996). 
Furthermore, these cells have been engineered to express the vesicular stomatitis virus-G  
(VSV-G) envelope (env) protein under the control of a tetracycline-regulatable gene expression 
system (Gossen and Bujard 1992), as constitutive expression of VSV-G is toxic in HEK293 cells. 
Consequently, the VSV-G protein is only expressed when these cells are grown in the absence of 
tetracycline (Suzuki and Suzuki 2011). 
PG13 cells are derived from NIH/3T3-thymidine kinase (TK)– mouse fibroblasts (Wei, Gibson et al. 
1981). Like H29D cells, these cells have been modified to express the MoMuLV gag-pol 
polyprotein but instead of producing VSV-G-pseudotyped retroviral particles, PG13 cells produce  
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Gibbon ape leukaemia virus (GaLV)-pseudotyped particles (Miller, Garcia et al. 1991, Gallardo, 
Tan et al. 1997). 
MCF-7 and T-47D cells are well-established human breast cancer epithelial cell lines. MCF-7 is an 
adenocarcinoma cell line which was first isolated in 1970 from a 69-year-old patient (Soule, 
Vazguez et al. 1973) whilst T-47D is a carcinoma cell line which was first isolated in 1979 from a 
54-year-old patient (Keydar, Chen et al. 1979). 
Phoenix-Eco cells are a derivative of HEK293T cells which have been modified by Nolan G. et al. 
(Stanford University, California, USA) to express a gag-pol polyprotein in addition to an ecotropic 
env protein. As such, retroviral particles produced by this cell line are capable of infecting mouse 
and rat cells only. 
HEK293T, PG13, MCF-7 and T-47D cells were all maintained in “DMEM complete cell media” 
(section 2.2.1). H29D cultures were supplemented with 2 μg/mL tetracycline which was 
replenished every two days, unless expression of the env glycoprotein VSV-G was desired (section 
2.4.1), in which case the cells were grown in the absence of tetracycline. Phoenix-Eco cells were 
maintained in “IMDM complete cell media” (section 2.2.1). To harvest the cells, all cell culture 
media was removed and the cells were washed once with PBS before being incubated with 
Trypsin-EDTA (0.05%; Thermo Fisher Scientific) for 2-3 minutes. The cells were then washed with 
their respective culture media and pelleted before being re-seeded at a desired concentration in 
cell culture flasks. Freshly thawed cells were grown for at least 1 week before use in experiments. 
Cells were passaged when they reached a confluency of 80-90% and were expanded for a 
maximum of 20 passages. 
 
 HUVEC  ISOLATION AND CULTURE 
HUVECs were isolated and cultured by Dr Dianne Cooper (William Harvey Research Institute, 
Queen Mary University of London, UK). 
Umbilical cords were transported and stored in cord buffer (Hank’s Balanced Salt Solution (HBSS; 
Thermo Fisher Scientific) containing 100 U/mL penicillin (Sigma-Aldrich), 100 μg/mL streptomycin 
(Sigma-Aldrich) and 2.5 μg/mL Fungizone) at 4°C until processing. HUVECs were isolated from the 
interior umbilical vein by collagenase digestion (Jaffe, Nachman et al. 1973). Residual blood was 
washed from the cord using approximately 30 mL PBS and a butterfly needle. The cord was 
clamped at both ends, filled with approximately 20-25 mL pre-warmed collagenase solution 
(serum-free medium M199 containing 0.1% collagenase type II (Sigma-Aldrich), 100 U/mL 
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penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine and 2.5 μg/mL Fungizone) and incubated 
at 37°C for 15 minutes. The collagenase solution was collected and the cord was rinsed with  
30 mL PBS. Wash out solution was also collected. Cells were pelleted at 300 g for 10 minutes and 
suspended in HUVEC media (section 2.2.1). 
HUVECs were cultured in T75 flasks pre-treated with 0.5% bovine gelatin. All cells isolated from 
each cord (1-2x106 cells/cord) were incubated in the T75 flask. The cell culture media was 
changed after 24 hours and every 48 hours from this point onwards. Cells were split 1:3 when a 
confluency of 90-95% was reached using 0.5% Trypsin-EDTA (Thermo Fisher Scientific), as 
detailed in section 2.2.4. HUVECs were used in experiments at passage 2-3. 
 
 B-LCL  CELL CULTURE 
Four B-LCLs were purchased from the International Histocompatibility Working Group (IHWG, 
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA): DBB (IHW09052;  
HLA-A2+DR7+), MOU (IHW09050; HLA-A2–DR7+), SPO (IGW09036; HLA-A2+DR11+) and BM21 
(IGW09043; HLA-A2–DR11+). These cells were grown in “B-LCL media” (section 2.2.1). Freshly 
thawed cells were grown for at least 1 week before use in experiments and were expanded for a 
maximum of 20 passages. 
 
 K562  CELL CULTURE  
Three K562 cell lines were kindly donated by Dr Marc Martinez-Llordella (Institute of Liver 
Sciences, King’s College London, UK): empty K562s and K562s stably transfected with either  
HLA-A2 or HLA-A1. These cells were cultured in “standard RPMI cell media” (section 2.2.1) which 
was supplemented with 5 μg/mL puromycin (Thermo Fisher Scientific) to selectively expand  
HLA-transfected cells, where appropriate. Freshly thawed cells were grown for at least 1 week 
before use in experiments and were expanded for a maximum of 20 passages.  
 
 HYBRIDOMA CELL CULTURE AND ANTIBODY PRODUCTION  
A BALB/c MHC class I (Kd)-specific hybridoma cell line (HB-159™, clone SF1-1.1.10) was purchased 
from the American Type Culture Collection (ATCC®, Manassas, Virginia, USA). These cells were 
cultured in “standard RPMI cell media” (section 2.2.1), as per supplier’s protocols. Kd-specific 
antibody was purified from these cells using Two-Compartment Bioreactor cell culture flasks 
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(CELLine CD350, Integra Biosciences, Zizers, Switzerland), as per manufacturer’s protocols. 
Briefly, 5-8x106 cells were suspended in 5 mL Protein-Free Hybridoma Media (PFHM-II; Thermo 
Fisher Scientific) and carefully added to the ‘cell compartment’ of the Two-Compartment 
Bioreactor cell culture flask whilst the ‘medium compartment’ was filled with 250 mL “standard 
RPMI cell media” with 5% FCS (section 2.2.1). After 1 week of culture, the cells were harvested 
from the cell compartment, pelleted and the supernatant containing anti-Kd antibody was 
collected and stored at 4°C. 5-8x106 cells were then suspended in 5 mL PFHM-II and re-cultured 
in the cell compartment with a fresh 250 mL media in the medium compartment. This process 
was repeated twice a week until 15 mL supernatant containing anti-Kd antibody was collected. 
Anti-Kd antibody was concentrated using a two-step filtration approach. Supernatant containing 
the antibody was filtered using a 0.22 μm filter. Contaminants of <30 kDa were removed using a 
Centriprep® 30K Centrifugal Filter Device (Merck Millipore, Darmstadt, Germany). These devices 
utilise a membrane filter which allows molecules of ≤30 kDa to pass through, separating them 
from molecules of >30 kDa. Devices were washed with 15 mL PBS prior to use. 15 mL of the 
supernatant was added to the ‘sample container’ of the device, after which the ‘filtrate collector’ 
was added. Devices were centrifuged at 1,500 g for 20 minutes at 4°C and supernatant remaining 
in the ‘sample container’ (depleted of molecules ≤30 kDa) was collected. This supernatant was 
further concentrated using an Amicon® Ultra-15 100K Centrifugal Filter Device (Merck Millipore). 
These devices use a similar membrane-based approach to retain molecules ≥100 kDa. As before, 
the device was washed with 15 mL PBS before use. Supernatant was added to the ‘filter device’ 
of the implement which was centrifuged at 4,000 g for 30 minutes at 4°C. Concentrated 
supernatant remaining in the ‘filter device’ was collected and stored at 4°C for future use. 
Concentrated anti-Kd antibody was quantified using the Pierce™ bicinchoninic acid (BCA) Protein 
Assay Kit (Thermo Fisher Scientific). 25 μL samples of the antibody (neat, 1:10 and 1:100 diluted) 
were added to wells of a 96-well U-bottom plate alongside a 2-fold serial dilution of BSA (ranging 
from 2 mg/mL to 16 μg/mL) which was used to generate a standard curve. All conditions were 
performed with 2 technical replicates. A ‘working reagent’ (WR) was prepared by mixing BCA 
Reagent A with BCA Reagent B in a 50:1 (v/v) ratio. 200 μL of this WR was added to each sample 
in the 96-well plate and the plate was incubated at 37° for 30 minutes. Absorbance was measured 
at 540 nm and the protein concentration was calculated using the standard curve. 
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 MURINE BM-DC  ISOLATION AND CULTURE 
DC progenitors were isolated from B6 mice using a negative selection protocol. BM from the tibia, 
femur and pelvic bones was extracted and passed through a 70 μm nylon cell strainer to produce 
a single cell suspension. RBCs were lysed by incubating the cells in ammonium chloride potassium 
(ACK) buffer (H2O containing 40.3 mM NK4Cl, 10.0 mM KHCO3 and 0.127 mM EDTA) at room 
temperature for 1.5 minutes after which the cells were washed with RPMI-1640. Leukocytes were 
incubated with rat anti-mouse CD8 (YTS-169), CD4 (YTS-191), MHC class II (M5-114) and B220 
(RA3-3A1) antibodies (all made in house from hybridomas) for 30 minutes at 4°C, under rotation. 
Leukocytes were then washed to remove excess antibodies and incubated with pre-washed 
magnetic beads coated with polyclonal anti-rat IgGs (Dynal® beads, Thermo Fisher Scientific) for 
a further 30 minutes at 4°C, under rotation. Dynal® beads binding contaminating cells were 
removed using a magnet, according to the manufacturer’s protocol. DC progenitors were washed 
with RPMI-1640 and cultured in “RPMI-1640 mouse complete cell media” (section 2.2.1) 
supplemented with granulocyte macrophage colony-stimulating factor (GM-CSF; 20 ng/mL; made 
in house) in 24-well plates (1x106 cells/mL/well). Media was changed on days 2 and 4 post-
isolation. Day 6 BM-DCs were irradiated (30 Gray (Gy)) and used for mouse Treg stimulation. 
 
 MOUSE TREG CULTURE 
A B6 self-specific Treg cell line which was previously generated by Tsang et al. was used in this 
thesis (Tsang, Tanriver et al. 2008). This cell line was established by using CD4+CD25+ T cells which 
were enriched from the secondary lymphoid organs of B6 mice using the Dynabeads® 
FlowComp™ Mouse CD4+CD25+ Treg Cells Kit (Thermo Fisher Scientific), as per manufacturer’s 
protocols. These cells were then stimulated once a week with irradiated syngeneic BM-DCs 
(section 2.2.9). 
To re-stimulate the cells, the Tregs were harvested, washed twice with RPMI-1640 and suspended 
at 2x106 cells/mL in “RPMI-1640 mouse complete cell media” (section 2.2.1). Day 6 immature 
BM-DCs were irradiated (30 Gy), washed with RPMI-1640 and suspended at 1x106 cells/ml in 
“RPMI-1640 mouse complete cell media” (section 2.2.1). The Tregs and irradiated DCs were 
cultured together at a 1:4 ratio (1 mL of Tregs with 0.5 mL of irradiated DCs) in 24-well plates.  
10 U/mL recombinant human IL-2 was added on days 1, 2 and 4 of culture and day 7 Tregs were 
used for experiments. 
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 MOLECULAR BIOLOGY 
 PCR  AMPLIFICATION OF TARGET GENES 
Custom polymerase chain reaction (PCR) primers (Table 3-1) were synthesised by Sigma-Aldrich 
and reconstituted at a concentration of 50 μM in distilled (d)H2O. PCR reactions were set up to 
consist of 10 ng template DNA (SFG_A2-28ζ (Table 2-3)), 0.25 μM of a forward and reverse primer, 
25 μL Phusion® High-Fidelity DNA Polymerase (New England BioLabs® Inc., Ipswich, 
Massachusetts, USA) and DNase-free H2O to a final volume of 50 μL. Reactions were then run on 
the following PCR program to yield the desired PCR product: 
– 98°C for 3 minutes 
– 35 cycles of: 
– 98°C for 30 seconds 
– A ramp cooling at a rate of 0.5°C/second from 98°C to 72°C 
– 72°C for 50 seconds 
– 72°C for 5 minutes 
– Hold at 4°C 
 
 RESTRICTION DIGESTION  
Restriction digestions were performed in a total volume of 10-50 μL with a maximum final DNA 
concentration of 40 ng/μL using enzymes provided by New England Biolabs® Inc., according to 
manufacturer’s protocols. Target DNA was diluted with DNase-free H2O and mixed with a buffer 
appropriate for the enzyme being used (Table 2-2). Where NEBuffer 3.1 was used, digestion 
mixtures were supplemented with 100 μg/mL BSA. Respective restriction enzymes were then 
added to the reaction mixtures with a minimum final concentration of 0.2 U/μL. Reaction 
mixtures were incubated at a respective temperature suitable for the restriction enzyme being 
used (Table 2-2) for a minimum of 1 hour which was adjusted accordingly when >1 μg DNA was 
being digested (1 hour per μg DNA). For double enzyme digests, the most suitable buffer was 
identified using the “NEB Double Digest Finder”. If 2 enzymes had different working 
temperatures, sequential digests were performed starting at the lower temperature. Where 
appropriate, re-ligation of digested plasmids was inhibited by adding alkaline phosphatase (AP; 
New England Biolabs® Inc.) at a final concentration of 0.4 U/μL into the digestion mixture and 
incubating for 45 minutes at 37°C. 
Chapter II │ Materials and methods 
 
55 
Digestion products were separated on a 0.8% agarose gel prepared by mixing 0.8 g agarose 
(Sigma-Aldrich) with 100 mL Tris-acetate-EDTA (TAE) buffer (Severn Biotech Ltd., Kidderminster, 
Worcestershire, UK). Digest products were mixed with a 6X loading buffer (5:1 DNA:loading buffer 
v/v ratio; New England BioLabs® Inc.) and loaded into the gel. Gels were run with limits of  
130 mA and 80 V until a sufficient separation was achieved. 
 
 DNA  PURIFICATION FROM PCR  AMPLIFICATION PRODUCTS 
AND AGAROSE GEL 
DNA was extracted and purified from PCR amplifications and agarose gel bands using the Wizard® 
SV Gel and PCR Clean-Up System (Promega), as per manufacturer’s protocols. DNA fragments 
from restriction digestions (section 2.3.2) were separated using a 0.6% agarose gel and fragments 
containing DNA of interest were excised. 1 μL Membrane Binding Solution was added per mg of 
DNA/agarose gel and the mixture was incubated at 60°C until the agarose gel dissolved. 
Alternatively, Membrane Binding Solution was added to PCR amplification products (section 
2.3.1) at a 1:1 (v/v) ratio. 
Dissolved agarose gel or PCR product mixtures were added to SV Minicolumns and incubated for 
1 minute at room temperature before being centrifuged at 16,000 g for 1 minute. Minicolumns 
containing the DNA of interest were washed twice by adding 500-700 μL Membrane Wash 
Solution and centrifuging at 16,000 g for 1 minute. A final 1 minute centrifuge at 16,000 g was 
performed in the absence of Membrane Wash Solution to ensure all residual buffer was removed. 
The DNA was then eluted into 30 μL Nuclease-Free Water by centrifugation at 16,000 g for  
Enzyme Buffer Temperature Company 
BamHI NEBuffer 3.1 37°C New England BioLabs® Inc. 
BstBI CutSmart® Buffer 60°C New England BioLabs® Inc. 
ClaI CutSmart® Buffer 37°C New England BioLabs® Inc. 
MluI NEBuffer 3.1 37°C New England BioLabs® Inc. 
NcoI NEBuffer 3.1 37°C New England BioLabs® Inc. 
NotI NEBuffer 3.1 37°C New England BioLabs® Inc. 
PvuII CutSmart® Buffer 37°C New England BioLabs® Inc. 
XhoI NEBuffer 3.1 37°C New England BioLabs® Inc. 
    
Table 2-2 | List of restriction enzymes and the respective conditions in which they were used. 
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1 minute. Eluted DNA was re-centrifuged through the same SV Minicolumn to maximise DNA 
recovery. 
 
 PLASMID LIGATION  
The quantity of DNA from restriction digested inserts and target vectors was estimated by running 
specific volumes of the DNA on a 0.8% agarose gel and comparing the band intensities to 
Hyperladder™ I (Bioline Reagents, London, UK) bands. Ligation reactions were performed using a 
total of 40-100 ng DNA with insert:vector molar ratios ranging from 1:1 to 3:1. 
To blunt-end ligate inserts into the pCR™ vector, the ZeroBlunt® PCR Cloning Kit (Thermo Fisher 
Scientific) was used, as per manufacturer’s protocols. Insert and vector DNA was mixed with 1X 
ExpressLink™ T4 DNA Ligase Buffer and DNase-free H2O to a final volume of 9 μL. 1 μL (5 U) of the 
ExpresLink™ T4 DNA Ligase was then added to the mixture before being incubated at room 
temperature for 30 minutes. 
For ligation reactions in which sticky ends were available, insert and vector DNA was mixed in 
DNase-free H2O to a final volume of 17 μL. This DNA was mixed with 2 μL 10X T4 DNA Ligase 
Reaction Buffer (New England BioLabs® Inc.). T4 DNA Ligase (New England BioLabs® Inc.) was 
then added to each reaction at a final concentration of 20 U/μL which was then run on the 
following ligation program in a PCR machine: 
– 160 cycles of: 
– 16°C for 3 minutes 
– 10°C for 30 seconds 
– 24°C for 30 seconds 
– 16°C for 5 hours 
– 65°C for 15 minutes 
– Hold at 4°C 
 
 BACTERIAL TRANSFORMATION 
Constructs were replicated by transforming either MAX Efficiency® DH5α™ competent or One 
Shot® Stbl3™ chemically competent Escherichia coli cells (both from Thermo Fisher Scientific). 
Cells were thawed on ice and 100 ng DNA in a volume of <2.5 μL was added to a vial containing 
25 μL cells. The DNA and cells were mixed gently and incubated on ice for 30 minutes. The cells 
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were then heat-shocked for 45 seconds at 42°C and placed on ice for a further 2 minutes. 250 μL 
pre-warmed super optimal broth with catabolite repression (SOC) media (37°C) was added to 
each vial which was subsequently incubated under shaking conditions for 1 hour at 37°C. 80 μL 
of the transformed cells were then spread on pre-warmed Lysogeny broth (LB)-agar (Sigma-
Aldrich) plates supplemented with an antibiotic appropriate for the construct of interest  
(100 μg/mL ampicillin (Sigma-Aldrich) or 50 μg/mL kanamycin (Sigma-Aldrich)). Plates were 
incubated at 37°C overnight to yield bacterial colonies which were picked using a sterile pipette 
tip and expanded as detailed in section 2.3.6. 
 
 MINIPREPARATION  
Minipreps were performed using the Promega Wizard® Plus SV Minipreps DNA Purification 
System, according to manufacturer’s protocols. Bacterial colonies, prepared as detailed in section 
2.3.5, were picked and inoculated in LB broth (Sigma-Aldrich) supplemented with an appropriate 
antibiotic (100 μg/mL ampicillin or 50 μg/mL kanamycin). Cells were initially grown in a volume 
of 2 mL for 6-8 hours at 37°C under shaking conditions. The culture media volume was then 
increased to 10 mL and the bacteria were incubated at 37°C overnight. 
Glycerol stocks of each bacterial culture were prepared by mixing 100 μL of an overnight culture 
with 50 μL sterile solution of 50% glycerol (diluted with Milli-Q H2O; (Sigma-Aldrich)) and stored 
at –80°C. 
Bacterial cultures were centrifuged at 1,780 g for 10 minutes at 4°C. Pelleted bacteria were 
suspended in 250 μL Cell Resuspension Solution and transferred to sterile 1.5 mL microcentrifuge 
tubes. An equal volume of Cell Lysis Solution and 10 μL Alkaline Protease Solution were added 
and mixed by inversion. Cell lysis reactions were incubated at room temperature for 5 minutes 
and neutralised by adding 350 μL Neutralization Solution. Cleared lysates, which were obtained 
by centrifuging each sample at 18,400 g for 10 minutes at room temperature, were transferred 
to Spin Columns within Collection Tubes and centrifuged at 18,400 g for 1 minute to facilitate 
binding of plasmid DNA to the column. Columns containing DNA were washed twice by adding 
750 μL Wash Buffer and centrifuging at 18,400 g for 1 minute. A final centrifuge at 18,400 g for  
1 minute was performed to remove residual buffer. The spin columns were then transferred to 
fresh microcentrifuge tubes, 50 μL DNase-free H2O (pre-warmed to 60°C) was added to each 
column and the columns were centrifuged at 18,400 g for 1 minute to elute the DNA. DNA was 
quantified by nanodrop and stored at –20°C for future use. 
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 MAXIPREPARATION  
Constructs obtained by miniprep (section 2.3.6) were validated by restriction digest analysis 
(section 2.3.2) and sequence analysis. To acquire large preparations of desired constructs, 20 μL 
of the corresponding glycerol stock, prepared as detailed in section 2.3.6, was inoculated into  
200 mL LB broth supplemented with an appropriate antibiotic. Bacterial cultures were then 
incubated under shaking conditions at 37°C overnight. 
Maxipreps were performed using the PureLink® HiPure Plasmid Filter Maxiprep Kit (Thermo 
Fisher Scientific), as per manufacturer’s protocols. The density of transformed E. coli present in 
the overnight cultures was assessed by photospectrometry, measuring the absorbance at  
600 nm. Absorbance values of cultures diluted 1:10 were typically between 0.2 and 0.4 OD600 
units. For each maxiprep, the equivalent of 300 OD600 units of bacteria was used. 
PureLink® HiPure Maxi Columns were equilibrated by adding 30 mL Equilibration Buffer directly 
to the Filtration Cartridge within each column and allowing the solution to elute by gravity. The 
desired quantity of bacteria was pelleted by centrifugation at 1,780 g for 10 minutes at 4°C. 
Pelleted bacteria were suspended in 10 mL Resuspension Buffer supplemented with RNaseA by 
vortex/pipetting until the solution was homogenous. Bacteria were lysed by adding 10 mL Lysis 
Buffer to each cell suspension, mixing by inversion and incubating at room temperature for  
5 minutes. The lysis reaction was neutralised by adding 10 mL Precipitation Buffer to each 
solution. Cell lysates were added to the equilibrated columns and allowed to drain by gravity. 
Once the solution had eluted, the Filtration Cartridge within the column was discarded and the 
column containing the DNA was washed with 50 mL Wash Buffer. The DNA was eluted by adding 
15 mL Elution Buffer to the column and allowing the solution to drain by gravity. 
The 15 mL eluted DNA was mixed with 10.5 mL isopropanol (7:3 DNA:isopropanol v/v ratio; 
Sigma-Aldrich) and centrifuged at 4,025 g for 1 hour at 4°C. Supernatants were discarded and the 
pelleted DNA was washed by suspending in 5 mL 70% ethanol (diluted with Milli-Q H2O; Sigma-
Aldrich) and centrifuged again at 4,025 g for 5 minutes at 4°C. Supernatants were discarded and 
DNA pellets were air-dried before being suspended in 400 μL Tris-EDTA (TE) buffer. DNA was 
quantified by nanodrop and stored at –20°C for future use. 
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 VIRUS PRODUCTION AND CELL TRANSDUCTION 
 RETROVIRAL PARTICLE PRODUCTION FOR TRANSDUCING 
HUMAN CELLS  
To generate a stable retroviral packaging cell line, a two-step protocol was employed, as outlined 
by Parente-Pereira A et al. (Parente-Pereira, Wilkie et al. 2014). H29D cells were transfected with 
the SFG retroviral vector containing the A2 CAR gene (Table 2-3) using a Calcium Phosphate 
Transfection Kit (Sigma-Aldrich), as per manufacturer’s protocols. 
H29D cells (section 2.2.4) were seeded in 6-well plates and transfected when at a confluency of 
80-90%. The culture media of these cells was replaced with 3 mL fresh “DMEM complete cell 
media” (section 2.2.1) without tetracycline 2-3 hours prior to transfection. A solution containing 
of 2.5 M CaCl2, 5 μg SFG_A2-28ζ DNA and DNase-free H2O in a final volume of 60 μL was prepared 
and incubated at room temperature for 5 minutes before being added dropwise to an equal 
volume (60 μL) of 2X HeBS. This mixture was incubated at room temperature for 20 minutes to 
allow for precipitation before being added dropwise to the H29D cells. Media of the H29D cells 
was replaced with fresh “DMEM complete cell media” (section 2.2.1) without tetracycline  
24 hours post-transfection. Viral supernatants from the H29D cells were harvested 3, 4, 5 and  
6 days post-transfection and used to transduce PG13 cells.  
Empty PG13 cells (section 2.2.4) were transduced in 6-well plates when at a confluency of  
20-30%. This was achieved by replacing the PG13 cell media with supernatant from the 
transfected H29D cells containing VSV-G-pseudotyped retroviral particles. PG13 cells were then 
incubated for 72 hours to allow for transduction and generation of a stable retroviral packaging 
cell line. PG13 cells which were transduced using H29D supernatant taken 5 days  
post-transfection were transduced with the highest efficiency (data not shown) thus these PG13 
cells were maintained in culture and used for downstream experiments. These cells were 
maintained in “DMEM complete cell media” (section 2.2.1) and supernatants from these cells was 
used to transduce target cells, as detailed in section 2.4.2. 
 
 RETROVIRAL TRANSDUCTION OF HUMAN CELLS  
Stably transduced PG13 cells (section 2.4.1) consistently generated viable retroviral particles 
containing the SFG vector of interest. In preparation for transducing human T cells, PG13 cells 
were seeded in 6-well plates and expanded until they reached a confluency of 80-90%. The cell  
 
 Construct Construct description Principle open reading frame description Protein name 
SFG_NK1-28ζ RV expression vector CAR specific for NK1 with human CD28-CD3ζ signalling domain NK1 CAR 
SFG_A2-28ζ RV expression vector CAR specific for HLA-A2 with human CD28-CD3ζ signalling domain A2 CAR 
SFG_V8 RV expression vector Non-specific CAR with human CD29-CD3ζ signalling domain V8 CAR 
SFG_P4 RV expression vector CAR specific for PSMA with human CD28-CD3ζ signalling domain P4 CAR 
pLNT/SFFV_eGFP LV expression vector Cytoplasmic eGFP eGFP 
pLNT/SFFV_A2-28ζ-eGFP LV expression vector HLA-A2-specific CAR with human CD28-CD3ζ signalling domain and eGFP fusion A2 CAR-eGFP 
pLNT/SFFV_A2-eGFP LV expression vector HLA-A2-specific CAR with eGFP fusion (no signalling domain)  A2 ΔCAR-eGFP 
pLNT/SFFV_A2-28ζ LV expression vector HLA-A2-specific CAR with human CD28-CD3ζ signalling domain (no eGFP fusion) A2 CAR 
pLNT/SFFV_A2 LV expression vector HLA-A2-specific CAR (no signalling domain or eGFP fusion) A2 ΔCAR 
pCMV-ΔR8.91 LV packaging plasmid HIV-I gag-pol polyprotein N/A 
pCMV-VSV-G LV envelope plasmid VSV-G envelope protein N/A 
pMP71-PRE_Kd-28ζ-eGFP RV expression vector Kd-specific CAR with mouse CD28-CD3ζ signalling domain and eGFP fusion Kd CAR-eGFP 
pMP71-PRE_Kd-eGFP RV expression vector Kd-specific CAR with eGFP fusion (no signalling domain) Kd ΔCAR-eGFP 
pCL-Eco RV packaging plasmid MoMuLV gag-pol-env polyprotein N/A 
    
Table 2-3 | Summary of the constructs used, a description of the open reading frames (ORF) within these constructs and the designated name given to the proteins coded by these 
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culture media of these cells was then replaced with 2 mL fresh “DMEM compete cell media” 
(section 2.2.1) 24 hours prior to transduction. 
RetroNectin®-coated plates were prepared by incubating non-tissue culture treated plates with  
50 µg/mL RetroNectin® diluted in PBS (Clontech/TaKaRa Bio Inc., Kusatsu, Shiga Prefecture, 
Japan) overnight at 4°C. 24-well and 6-well plates were coated with 300 μL and 2 mL 
RetroNectin®, respectively. RetroNectin® was removed and the wells washed twice with PBS prior 
to use. 
Unfractioned T cells, selectively activated using PHA-L from PBMCs, were transduced 72 hours 
post-activation (section 2.2.2) in 6-well RetroNectin®-coated plates. T cells were harvested, 
washed with PBS and suspended at a concentration of 0.5x106 cells/mL in “RPMI-1640 human 
complete media” (section 2.2.1). 1x106 T cells (2 mL) were plated into RetroNectin®-coated wells 
of 6-well plates and mixed with an equal volume of PG13-derived viral supernatant. To aid 
transduction, the cells were then spinoculated at 600 g for 1 hour at room temperature before 
being incubated at 37°C. IL-2 was replenished every 2 days until the time of experiment. 
T cells were used 7-10 days post-transduction at which point the transduction efficiency was 
assessed by flow cytometry. As the CARs expressed in these cells lacked a fluorescent reporter 
(Figure 3-2B), the transduction efficiency was assessed by staining the cells with a fluorescently-
conjugated antibody specific for the cMyc 9E10 epitope (EQKLISEEDL; Figure 3-2B), as detailed in 
section 2.5.1. 
 
 LENTIVIRAL PARTICLE PRODUCTION AND CONCENTRATION  
Lentiviral particles were generated using a 2nd generation packaging system approach. 5.25x106 
HEK293T cells (section 2.2.4) were seeded per T75 flask 18 hours prior to transfection. 24 µg DNA 
consisting of the plasmid of interest (pLNT/SFFV_A2-28ζ-eGFP or pLNT/SFFV_A2-eGFP), a 
packaging plasmid (cytomegalovirus p(CMV)-ΔR8.91) and an envelope plasmid (pCMV-VSV-G) 
were mixed at a 4:3:1 ratio (w/w/w) in 1.5 mL DMEM supplemented with 2 mM L-glutamine only. 
Polyethylenimine (PEI; Sigma-Aldrich) was added to the DNA/DMEM mixture at a PEI:DNA ratio 
of 3:1 (w/w) and the mixture was incubated at room temperature for 15 minutes. The media of 
the HEK293T cells was then replaced with the DNA/DMEM/PEI mixture and fresh “DMEM 
complete cell media” (section 2.2.1) in a final volume of 8 mL and the cells were incubated at 
37°C for 48-56 hours. 
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Transfection of the HEK293T cells was confirmed visually by fluorescence microscopy 48-56 hours 
post-transfection. Viral particles were harvested and concentrated 10-fold using polyethylene 
glycol (PEG)-it™ Virus Precipitation Solution (System Biosciences, Mountain View, California, 
USA), according to manufacturer’s protocols. Briefly, HEK293T cell supernatant containing the 
viral particles was harvested and filtered through a 0.45 μm filter to remove cell debris before 
being mixed with cold PEG-it™ solution (4:1 supernatant:PEG-it™ v/v ratio) and incubated at 4°C 
for 18 hours. The viral particles were then pelleted by centrifugation at 1,500 g for 30 minutes at 
4°C before being re-suspended in a desired cell media and frozen at –80°C for later use. 
 
 LENTIVIRAL TRANSDUCTION  
Target human Tregs or Tconvs were transduced in 24-well RetroNectin®-coated plates  
(section 2.4.2) 72 hours post-activation, unless stated otherwise. Cells were transduced in the 
same media they were originally cultured, in the presence of IL-2 but absence of rapamycin. 
Concentrated viral particles were added to the RetroNectin®-coated wells and mixed with 5x105 
target cells. The final concentration of viral particles was 4-fold that of neat viral supernatant, 
unless stated otherwise. Tregs or Tconvs were then spinoculated at 600 g for 1 hour at room 
temperature before being incubated at 37°C. The cells were given fresh media supplemented 
with IL-2 and rapamycin, where appropriate, 18 hours and 72 hours post-transduction (days 4 
and 6 post-activation; a detailed timeline for IL-2 and rapamycin replenishment provided in Figure 
2-1). 
 
 RETROVIRAL PARTICLE PRODUCTION FOR TRANSDUCING 
MOUSE CELLS  
For transducing mouse T cells and Tregs, retroviral particles were produced using a protocol 
optimised and kindly donated by Dr Angelika Holler and Prof Hans Stauss (Institute of Immunity 
and Transplantation, University College London, UK). 1.5x106 Phoenix-Eco cells (section 2.2.4) 
were seeded in a 10 cm cell culture dish, 24 hours prior to transfection, and the culture media of 
these cells was replaced with 5 mL fresh “IMDM complete cell media” (section 2.2.1)  
30-60 minutes before transfection. 
The Phoenix-Eco cells were co-transfected with the pMP71_Kd-28ζ-eGFP or pMP71_Kd-eGFP 
construct and the pCL-Eco retroviral packaging vector using FuGENE® HD (Promega). The original 
pMP71-PRE constructs were provided by Dr Angelika Holler and Prof Hans Stauss with the express 
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permission of Prof Christopher Baum and Prof Axel Schambach (Hannover Medical School, 
Hannover, Germany). 2 solutions were prepared in isolation: ‘solution A’ which contained 10 μL 
FuGENE® HD and 150 μL Opti-MEM® Reduced Serum Medium (Thermo Fisher Scientific) and 
‘solution B’ which contained 2.6 μg pMP71_Kd-28ζ-eGFP or pMP71_Kd-eGFP and 1.5 μg  
pCL-Eco in a total volume of 50 μL. ‘Solution A’ and ‘solution B’ were gently mixed and incubated 
for 15-20 minutes at room temperature before being added dropwise to the Phoenix-Eco cells. 
After 24 hours, the culture media of the transfected Phoenix-Eco cells was removed, the cells 
were gently washed with PBS and the media was replaced with pre-warmed “RPMI-1640 mouse 
complete cell media” (section 2.2.1). The transfected Phoenix-Eco cells were then incubated for 
a further 24 hours, after which the “RPMI-1640 mouse complete cell media” containing retroviral 
particles was harvested. This viral supernatant was centrifuged at 300 g for 5 minutes to remove 
contaminating cells and cell debris before use. 
 
 RETROVIRAL TRANSDUCTION OF MOUSE CELLS  
Murine cells were activated using different approaches, depending on the cell type being 
transduced. For T cell transductions, spleens were explanted and total splenocytes were liberated 
by passing through a 70 μm nylon cell strainer using “RPMI-1640 mouse complete cell media” 
(section 2.2.1). RBCs in the splenocytes were lysed using ACK buffer, as detailed in section 2.2.9. 
The splenocytes were then activated with 2 μg/mL Concanavalin A (ConA; Sigma-Aldrich) and 
cultured in “RPMI-1640 mouse complete cell media” (section 2.2.1) supplemented and 1 ng/mL 
recombinant human IL-7 (R&D Systems) at a concentration of 1.5x106 cells/mL in 24-well plates 
(2 mL/well). Activated splenocytes were transduced 24 hours post-activation. In contrast, Tregs 
from a previously established cell line (Tsang, Tanriver et al. 2008) were transduced 48 hours 
following stimulation with irradiated BM-DCs (section 2.2.10). 
All murine cells were transduced in 24-well RetroNectin®-coated plates (section 2.4.2) which 
were blocked with 2% BSA for 30 minutes at room temperature and washed twice with PBS prior 
to use. Cells were harvested, washed with RPMI-1640 and suspended in Phoenix-Eco cell-derived 
supernatant containing retroviral particles (section 2.4.5) at a concentration of 4x106 cells/mL 
(supplemented with 10 U/mL recombinant human IL-2 for Treg transductions). 2x106 cells  
(0.5 mL) were added to each well of a 24-well RetroNectin®-coated plate and the cells were 
spinoculated at 450 g for 1.5 hours at room temperature before being incubated at 37°C. 
Transduced splenocytes were given fresh media supplemented with 10 U/mL recombinant 
human IL-2, 24 hours post-transduction (day 2 post-activation) and harvested for analysis and 
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downstream applications 72 hours post-transduction (day 4). Alternatively, transduced Tregs 
were given fresh media supplemented with 10 U/mL recombinant human IL-2, 24 hours (day 3) 
and 48 hours (day 4) post-transduction and were harvested for analysis and downstream 
applications 5 days post-transduction (day 7). 
 
 FLOW CYTOMETRY 
 FLOW CYTOMETRIC ANALYSES 
All cells were stained in fluorescence assisted cell sorting (FACS) buffer (PBS without Ca2+ or Mg2+, 
5 mM EDTA and 1% heat inactivated FCS). Analyses involving human cells were performed using 
5x105 cells/sample whilst analyses of mouse cells were performed using 2x105 cells/sample. For 
standard phenotype analysis, cells were stained in FACS tubes in a total volume of 100 μL. In  
co-culture assays, cells were stained in 50 μL and used for analysis. 
Dead cells were labelled with the LIVE/DEAD® Fixable Near-infra red (IR) Dead Cell Stain Kit, as 
per manufacturer’s protocols, prior to antibody staining. Cells were harvested and washed twice 
with PBS to remove contaminating FCS before being suspended in 0.5 mL PBS containing a 
1:1,000 dilution of the LIVE/DEAD® stock solution (reconstituted in DMSO) and incubated for 30 
minutes at 4°C. Cells were then washed twice with 2 mL FACS buffer prior to antibody staining. 
For mouse cells only, non-specific antibody binding was blocked by incubating the cells with  
5 μg/mL anti-CD16/CD32 (clone 93) for 20 minutes at 4°C. For human cells, no blocking step was 
performed. The cells were then incubated with fluorescently-conjugated antibodies specific for  
antigens of interest (Table 2-4 and Table 2-5) for 20 minutes at 4°C. For antibodies which were 
supplied with stock concentration values, cells were stained with 2-5 μg/mL. Alternatively, 
manufacturer-specified antibody volumes were used. Following staining, cells were washed twice 
with 2 mL FACS buffer. 
For intracellular staining, cells were fixed and permeabilised with Foxp3/Transcription Factor 
Staining Buffer (eBioscience, Santa Clara, California, USA), according to manufacturer’s protocols. 
Cells were incubated in 0.5 mL fixation/permeabilisation for 1 hour at 4°C and washed twice with 
2 mL permeabilisation buffer. Cells were then stained in 100 μL permeabilisation buffer with 
desired fluorescently-conjugated antibodies for 30 minutes at 4°C and washed twice with  
2 mL FACS buffer. 
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Following the final wash, all cells were suspended in 400 μL FACS buffer for acquisition. Data was 
acquired on either a BD FACSCalibur™ or BD LSRFortessa™ (BD Biosciences, Franklin Lakes, New 
Jersey, USA) and analysed using FlowJo 7 (for calculating division indices only) or FlowJo 10 
software (Tree Star, Ashland, Oregon, USA). 
 
 FLUORESCENCE-ASSISTED CELL SORTING 
Transduced cells were harvested, washed twice with 50 mL FACS buffer and suspended at a 
maximum concentration of 20x106 cells/mL. Desired eGFP+ cells were purified using a BD 
Specificity Flourochrome Clone Company 
CD3 APC-H7 SK7 (Leu-4) BD Biosciences 
CD4 PerCP Cy5.5 OKT4 eBioscience 
CD25 Brilliant Violet 605™ 2A3 BD Biosciences 
CD25 PE 4E3 eBioscience 
CD127 PE A019D5 BioLegend 
FOXP3 eFluor® 660 PCH101 eBioscience 
CTLA-4 Brilliant Violet 421™ BNI3 BD Biosciences 
CD39 PE-Cy7 eBioA1 eBioscience 
CCR9 PerCP Cy5.5 L053E8 BioLegend 
CCR4 Brilliant Violet 605™ L291H4 BioLegend 
CCR10 PE 6588-5 BioLegend 
Integrin β7 APC FIB504 BioLegend 
CD62L Brilliant Violet 421™ DREG-56 BioLegend 
CLA PE-Cy7 HECA-452 BioLegend 
CD69 PE-Cy7 H1.2F3 eBioscience 
HLA-A2 PE-Cy7 BB7.2 eBioscience 
HLA-A2/A28 PE-Vio770 REA142 Miltenyi Biotec 
HLA class I APC Tu149 Thermo Fisher Scientific 
HLA-DR Alexa Fluor®647 L243 BioLegend 
cMyc FITC 9E10 Sigma-Aldrich 
cMyc APC 9E10 R&D Systems 
    
Table 2-4 | Summary of the fluorescently-conjugated antibodies used for staining human markers. 
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FACSAria II (BD Biosciences). Human cells were sorted into X-vivo complete cell media (section 
2.2.1) and mouse cells were sorted into 100% FCS. 
 IN VITRO ASSAYS 
 TREG SUPPRESSION ASSAYS 
The suppressive capacity of human and mouse Tregs was measured in vitro by assessing the 
efficacy with which these cells inhibited CD4+ responder T cell (Tresp) proliferation. Tresps were 
activated in either a polyclonal or antigen-dependent manner and co-cultured with the Tregs in 
96-well U-bottom plates, as detailed below. 
 
Specificity Flourochrome Clone Company 
CD4 PE-Cy7 GK1.5 eBioscience 
CD25 PE-Cy7 PC61 BD Biosciences 
FoxP3 APC FJK-16s eBioscience 
CTLA-4 APC UC10-4B9 eBioscience 
CD39 PE 24DMS1 eBioscience 
CD73 PE eBioTY/11.8 eBioscience 
CD11c PerCP-Cy5.5 N418 eBioscience 
CD80 Brilliant Violet 421™ 16-10A1 BioLegend 
CD86 Brilliant Violet 605™ GL-1 BioLegend 
MHC I (Kd) PE SF1-1.1.1 eBioscience 
MHC class I (Kb) APC AF6-88.5.5.3 eBioscience 
MHC class II (I-Ad) FITC 39-10-8 BioLegend 
MHC class II (I-Ab) FITC AF6-120.1 eBioscience 
CD40 PE-Cy7 3/23 BioLegend 
cMyc APC 9E10 R&D Systems 
    
Table 2-5 | Summary of the fluorescently-conjugated antibodies used for staining mouse markers. 
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 Human polyclonal suppression assay 
The suppressive capacity of human Tregs was assessed after 20 days of expansion (Figure 2-1). 
CD4+CD25– Tresps autologous to the Tregs being analysed (section 2.2.3) were thawed in PBS and 
washed 3 times to remove contaminating DMSO and FCS. The Tresps were then labelled with  
2 µM CellTrace Violet (CTV; Thermo Fisher Scientific), according to manufacturer’s protocols. 
Briefly, CD4+CD25– Tresps were suspended at a concentration of 20x106 cells/mL in pre-warmed 
PBS only. A solution of pre-warmed PBS containing 4 µM CTV was prepared and added to the 
Tresps at a 1:1 (v/v) ratio. The cells were incubated for 15 minutes at 37°C after which the CTV 
labelling reaction was quenched by adding an equal volume of cold FCS and incubating the cells 
on ice for 5 minutes. Labelled Tresps were washed twice with “X-vivo complete cell media” 
(section 2.2.1) before being suspended at a concentration of 1x106 cells/mL in “X-vivo complete 
cell media” and incubated on ice until required. 
Human Tregs were harvested and anti-CD3/CD28 beads removed using a magnet. The cells were 
washed twice with PBS and suspended at a concentration of 1x106 cells/mL in “X-vivo complete 
cell media”. Immediately prior to co-culture, fresh anti-human CD3/CD28 beads were added to 
the Tresps at a 1:40 bead:cell ratio. 1x105 Tresps (100 µL) with anti-CD3/CD28 beads were plated 
into a 96-well U-bottom plate with a varying number of Tregs to achieve a desired Tresp:Treg 
ratio in a final volume of 200 µL. 
Co-cultures were incubated at 37°C for 5 days after which Tresp proliferation was measured by 
flow cytometry. Co-cultures were pelleted and supernatants were harvested and frozen for 
cytokine analysis. The cells were washed twice with PBS and dead cells were labelled as detailed 
in section 2.5.1. Cells were then washed twice with FACS buffer and data was acquired by flow 
cytometry (section 2.5.1). Data was analysed with FlowJo 7 software using division indices. A 
summary of the gating strategy is provided in Figure 2-2. 
 
 Human antigen-specific suppression assay 
Human Treg antigen-specific suppression assays were performed using a similar approach to the 
polyclonal suppression assay protocol outlined above (section 2.6.1.1). Tregs and autologous 
Tresps were prepared as previously detailed. However, Tresp were not activated with anti-human 
CD3/CD28 beads but instead with B-LCLs described in section 2.2.6. B-LCLs were harvested, 
washed twice with PBS and suspended at a concentration of 1x106 cells/mL in “X-vivo complete 
cell media” (section 2.2.1). 
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Tregs and Tresps (without anti-CD3/CD28 beads) were plated, as previously detailed, into a  
96-well U-bottom plate with 3x104 B-LCL (30 µL; 3:1 Tresp:B-LCL ratio) in a final volume of  
230 µL. Co-cultures were incubated for 5 days after which Tresp proliferation was analysed, as 
previously detailed (section 2.6.1.1). 
Figure 2-2 │ Gating strategy for suppression assay analysis.  Representative data shown is taken from a 
polyclonal human Treg suppression assay in which human Tregs (untransduced or lentivirally transduced 
to express the A2 CAR-eGFP construct) are co-cultured with 1x105 autologous CellTrace Violet  
(CTV)-labelled CD4+CD25– responder T cells (Tresp) in the presence of anti-human CD3/CD28 beads  
(1:40 bead:Tresp ratio). A: Total cells were gated after which doublets and dead cells were excluded.  
B: Live Tresps were gated based on the presence of CTV and lack of eGFP, where appropriate. C: Gated 
Tresps were analysed for the extent to which they proliferated using division indices in FlowJo 7 software. 
Chapter II │ Materials and methods 
 
69 
 Mouse suppression assay 
Mouse suppression assays were performed by co-culturing Tregs with freshly-isolated APCs 
(section 2.6.1.3.1) and Tresps. For polyclonal suppression assays, B6 Tregs were co-cultured with 
5x104 B6 CD4+ T cells and 1x105 B6 APCs in the presence of 1 μg/mL anti-mouse CD3ε  
(145-2C11 clone; BD Pharmingen™, BD Biosciences). For antigen-specific suppression assays, 
Tregs were co-cultured with Tresps and APCs isolated from specific strains of mice, depending on 
the nature of the experiment being performed, in the absence of anti-mouse CD3ε. For linked 
suppression assays, chicken ovalbumin peptide (OVA323-339; Thermo Fisher Scientific) was added 
to co-cultures at a final concentration of 0.2 μg/mL.  
 
2.6.1.3.1 APC isolation 
Mouse splenocytes depleted of RBCs were acquired as detailed in section 2.4.6 and incubated 
with rat anti-mouse CD8 (YTS-169) and CD4 (YTS-191) antibodies (made in house from 
hybridomas) for 30 minutes at 4°C, under rotation. Splenocytes were then washed to remove 
excess antibodies and incubated with pre-washed magnetic beads coated with polyclonal  
anti-rat IgGs (Dynal® beads, Thermo Fisher Scientific) for a further 30 minutes at 4°C, under 
rotation. Dynal® beads binding contaminating T cells were removed using a magnet, according to 
manufacturer’s protocol. Remaining APCs were washed with RPMI-1640, suspended at a 
concentration of 2x106 cells/mL in “RPMI-1640 mouse complete cell media” and incubated on ice 
until required. A phenotype analysis of these APCs, performed by flow cytometry, demonstrated 
that >90% of these APCs expressed MHC class II (Figure 2-3A). 
 
2.6.1.3.2 CD4+ Tresp isolation 
CD4+ T cells were isolated from mouse splenocytes (section 2.4.6) using a Dynabeads® 
Untouched™ Mouse CD4+ Cells Kit (Thermo Fisher Scientific). Briefly, RBC-free splenocytes were 
suspended at 1x108 leukocytes/mL in Isolation Buffer, labelled with a CD4 negative selection 
‘Antibody Mix’ and contaminating CD4– T cells were removed using a magnet. CD4+-enriched 
splenocytes were suspended at a concentration of 1x106 cells/mL in “RPMI-1640 mouse complete 
cell media” (section 2.2.1) and incubated on ice until required. The purity of these CD4+ Tresps 
was >90% (Figure 2-3B), as confirmed by flow cytometry. 
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2.6.1.3.3 Murine suppression assay setup 
Tregs were harvested and suspended at 1x106 cells/mL in “RPMI-1640 mouse complete cell 
media” (section 2.2.1). Co-cultures consisting of 5x104 CD4+ T cells, 1x105 APCs and 5x104 Tregs 
were plated out by adding 50 μL of each respective cell suspension to appropriate wells of a  
96-well U-bottom plate. A final volume of 200 μL/well was achieved by adding “RPMI-1640 mouse 
complete cell media”, with or without anti-mouse CD3ε. Co-cultures were incubated at 37 °C for 
72 hours, after which Tresp proliferation was assessed. 
CD4+ Tresp proliferation was assessed either by CTV dilution or 3H-thymidine incorporation. For 
CTV-based assays, Tresps were labelled with CTV prior to co-culture and proliferation was 
measured after 3 days using flow cytometry, as detailed in section 2.6.1.1. For 3H-thymidine-
based assays, co-cultures were pulsed with 1 μCi 3H-thymidine/well (Amersham GE Healthcare, 
UK) for the last 18 hours of culture. Cell proliferation was then measured using a beta-plate 
scintillation counter (LKB Wallac 1205 Betaplate® liquid scintillation counter, Austria). Data is 
presented as counts per minute (cpm), representing cells in which 3H-thymidine has been 
incorporated upon division. 
 
 HUMAN TREG ACTIVATION AND PROLIFERATION ASSAYS  
Human Treg activation and proliferation assays were performed by co-culturing Tregs with 
irradiated (120 Gy) K562s (section 2.2.7) or B-LCLs (section 2.2.6) as artificial APCs. Tregs and APCs 
Figure 2-3 │ Purity of APCs and CD4 T cells isolated from mouse spleens. A: Proportion of BALB/c 
splenocytes which expressed I-Ad immediately following an APC-enrichment protocol. Splenocytes were 
depleted of CD4+ and CD8+ T cells by negative selection. Remaining cells were analysed for expression of  
I-Ad by flow cytometry. B: Purity of CD4+ T cells following enrichment. Splenocytes were enriched for CD4+ 
T cells by negative selection. The purity of this protocol was assessed by flow cytometry. Stained cells are 
shown with a blue line with the percentage of cells expressing the antigen of interest (according to the 
gate provided) is provided in the top right corner of each plot. Isotype control stains are shown in solid 
grey. 
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were prepared as detailed in sections 2.6.1.1 and 2.6.1.2, respectively. For activation assays, 
1x105 Tregs were co-cultured with 2.5x104 APCs in a 96-well U-bottom plate. CD69 expression 
was then measured after 18 hours of co-culture by flow cytometry (section 2.5.1). For 
proliferation assays, 5x104 Tregs were co-cultured with 5x104 APCs in “X-vivo complete cell 
media” (section 2.2.1) which was supplemented with 10 U/mL IL-2 in 96-well U-bottom plates. 
Proliferation was measured by 3H-thymidine incorporation after 72 hours, as detailed in  
section 2.6.1.3.3. 
 
 MOUSE T  CELL PROLIFERATION ASSAYS 
Murine proliferation assays were performed by co-culturing transduced splenocytes with  
freshly-isolated APCs. Splenocytes were harvested 3 days post-transduction (section 2.4.6) and 
APCs were prepared as described in section  2.6.1.3.1. 1x105 splenocytes were co-cultured with 
varying numbers of APCs in a final volume of 200 μL “RPMI-1640 mouse complete cell media” in 
96-well U-bottom plates. Proliferation was assessed either by 3H-thymidine incorporation or  
CTV-dilution (section 2.6.1.3.3) thus where appropriate, splenocytes were labelled with 2 μM CTV 
(section 2.6.1.1) prior to co-culture. Proliferation was measured after 72 hours, as previously 
described. 
 
 CO-CULTURE OF HUMAN T  CELLS AND BREAST CANCER CELL 
MONOLAYERS  
The specificity and functionality of the human CARs was assessed by investigating the ability of 
human CAR T cells to kill target cell monolayers expressing the antigen-target of interest, upon 
co-culture. Human PBMCs or CD4+CD25– T cells were isolated, activated and transduced as 
detailed in sections 2.2 and 2.4, respectively. T cells were harvested 7 days post-transduction and 
suspended at a concentration of 1x106 cells/mL in their respective cell culture media. 1x106  
T cells/well were then co-cultured with 90% confluent MCF-7 and T-47D breast cancer epithelial 
cell monolayers (section 2.2.4) in a 24-well plate at 37°C overnight. Following co-culture, the 
viability of the cell monolayers and cytokine production was assessed by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and enzyme-linked immunosorbent assay 
(ELISA), respectively, as detailed below. 
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 MTT assay 
Supernatants were harvested and cell monolayers were gently washed twice with PBS to remove 
contaminating T cells. Remaining monolayer cells were cultured in 500 µL/well “DMEM cell 
culture media” (section 2.2.1) containing 500 μg/mL MTT for 2 hours at 37°C. Viable cells were 
quantified based on their mitochondrial activity which reduced the soluble yellow dye MTT into 
the insoluble purple formazan. After 2 hours, all culture media was removed and 300 μL DMSO 
was added to each well to dissolve the purple formazan. Absorbance was measured at 560 nm. 
Data is presented as “% viability”, relative to the OD560 of cell monolayers cultured alone. 
 
 IL-2/IFNγ/IL-10 ELISA 
IL-2, IFNγ and IL-10 ELISAs were performed using Ready-SET-Go!® ELISA kits (eBioscience), as per 
manufacturer’s protocols. NUNC MaxiSorp® 96-well plates (VWR) were coated with 1X Coating 
Buffer containing a cytokine-specific ‘capture antibody’ overnight at 4°C. Plates were washed for 
1 minute under shaking conditions 3 times with Wash Buffer (PBS containing 0.05% (v/v)  
Tween-20) using an ELISA plate washer (Thermo Scientific) before being blocked by incubating 
with 1X ELISA/ELISPOT Diluent at room temperature for 1 hour. Plates were washed 3 times as 
above and incubated with cell culture supernatants overnight at 4°C. A 2-fold serial dilution 
standard curve containing 9 points was included in each plate and assays were performed with 3 
technical replicates per sample. Where necessary, sample supernatants were diluted up to  
50-fold with 1X ELISA/ELISPOT Diluent to ensure the final OD450 remained within the range of the 
standard curve. Plates were washed 5 times as above and incubated with a cytokine-specific 
biotin-conjugated ‘detection antibody’ for 1 hour at room temperature. Plates were washed a 
further 5 times as above and incubated with Avidin-Horse Radish Peroxidase (HRP) for 30 minutes 
at room temperature. Plates were then washed 7 times (2 minutes/wash) before being incubated 
with 1X tetramethylbenzidine (TMB) substrate solution for 20 minutes at room temperature. 
Reactions were stopped by adding 1 M H3PO4, absorbance was measured at 450 nm and cytokine 
quantities were calculated using the standard curve. 
 
 FLOW CHAMBER ASSAY OF HUMAN TREGS ACROSS HUVEC  
MONOLAYERS  
Experiments involving HUVECs were performed by Dr Dianne Cooper at the William Harvey 
Research Institute (Queen Mary University of London, UK). 
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HUVECs were cultured in HUVEC media (section 2.2.1) supplemented with 15 ng/mL IFNγ (R&D 
Systems) for 72 hours prior to experimentation to upregulate expression of HLA molecules. 
HUVECs were seeded in μ-Slides VI 0.4 (Ibidi, Munich, Germany) pre-coated with 0.5% bovine 
gelatin such that they were confluent 24 hours later at the time of experimentation. 
Tregs were harvested, suspended at 1x107 cells/mL in Dulbecco’s PBS (DPBS) without Ca2+ or Mg2+ 
containing 0.1% BSA and stored on ice until required. Immediately before flowing, the Tregs were 
diluted to 1x106 cells/mL in DPBS with Ca2+ or Mg2+. Tregs were flowed using a shear stress of  
1 dyn/cm2 generated with an automated syringe pump (Harvard Apparatus Ltd, Harvard 
Bioscience Inc., Holliston, Massachusetts, USA). Tregs were flowed for 8 minutes prior to 
recording 10 second frames from 6 random fields of view per condition, observed using a Retiga 
EXi digital video camera (Q-Imaging, Surrey, British Columbia, Canada) and recorded in StreamPix 
capture software (NorPix Inc., Montreal, Quebec, Canada). Sequences were loaded into 
ImagePro-Plus software (Media Cybernetics, Rockville, Maryland, USA), Tregs were manually 
tagged and their migration monitored. 3 measurements were made in the analysis: the total 
number of interacting cells which initially captured during the 10 second frame, those which were 
firmly adherent (remain stationary for the 10 second observation period) and cells which 
transmigrated (migrated through the endothelial monolayer). 
 
 IN VIVO ASSAYS 
 XENO-GVHD 
Immunodeficient Ch1-2hSa mice, 6-7 weeks of age, were injected intravenously (iv) with 1x107 
CD25– PBMCs ± 2x106 autologous Tregs isolated from a HLA-A2– donor. Following cell transfer, 
the mice were monitored every 2-3 days for signs of xeno-GvHD including, but not limited to, 
weight loss, hunching, reduced mobility, ruffled hair or orbital inflammation. End-points were 
defined prior to experimentation but were not reached. 
 
 HUMAN SKIN XENOGRAFT TRANSPLANTATION  
Human skin grafts were transplanted by Dr Lesley Smyth. 
Human skin was obtained from routine surgical procedures, stored in sterile PBS and grafted onto 
mice within 12 hours of initial explantation. Skin was disinfected using PBS containing 100 U/mL 
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penicillin and 100 μg/mL streptomycin and split-thickness skin explants were prepared using a 
dermatome. Skin explants were cut into 1.5 cm2 grafts using a scalpel, kept moist using sterile 
gauze swabs saturated with PBS containing 100 U/mL penicillin and 100 μg/mL streptomycin and 
stored at 4°C until required. 
Skin allografts were transplanted onto recipient BRG mice, 10-11 weeks of age,  as previously 
described (Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). Mice were administered 2 μg 
Vetergesic Multidose analgesia (Alstoe Ltd., Sogeval, Laval, France) by subcutaneous injection and 
put under general anaesthesia using Isoflurane (Merial, Sandringham, UK). Skin on the back of 
the mice was shaved and disinfected using Vetasept povidone-iodine antiseptic solution 
(Animalcare Ltd., York, UK). A square of mouse skin measuring approximately 1.5 cm2 was 
explanted and replaced with the human skin allograft. The allograft was held in place using 
Figure 2-4 │ Summary of human skin xenograft transplant model. Split thickness HLA-A2+ human skin grafts 
measuring approximately 1.5 cm2 were transplanted onto the back of recipient BALB/c  
RAG2–/–γc–/– mice and allowed to engraft for 4-6 weeks. 100 μg anti-mouse Gr-1 was injected 
intraperitoneally every 3-4 days from this point onwards. During this engraftment period, allogeneic Tregs 
and PBMCs were isolated from a HLA-A2– donor. PBMCs were depleted of CD25+ cells and cryopreserved. 
Tregs were transduced and expanded as previously described (Figure 2-1). BRG transplant recipients were 
then injected iv with 5x106 CD25– PBMCs ± 1x106 expanded Tregs. Mice were sacrificed 5-6 weeks following 
PBMC transfer and skin grafts were harvested for histological analyses. 
Chapter II │ Materials and methods 
 
75 
Vetbond™ Tissue Adhesive (3M™, Maplewood, Minnesota, USA) and covered liberally with 
Fucidin® fusidic acid cream (LEO Pharma, Ballerup, Denmark). Two dressings were then applied: 
an OpSite® Spray Dressing (Smith & Nephew plc, London, UK) followed by a Jelonet paraffin gauze 
dressing (Smith & Nephew plc). The graft and dressings were secured by wrapping the mice with 
a Tegaderm™ Transparent Film Dressing (3M™). Mice were administered 100 µg anti-mouse Gr-
1 (BioXCell, West Lebanon, New Hampshire, USA) intraperitoneally (ip) every 3-4 days from this 
point onwards. 
Allografts were allowed to engraft for 5-6 weeks, after which the mice were injected iv with 5x106 
CD25– PBMCs ± expanded 1x106 Tregs (sections 2.2.2 and 2.2.3). Mice were monitored every 2-3 
days for changes in skin allograft morphology and weighed weekly to detect signs of xeno-GvHD. 
Human immune cell engraftment was assessed in the peripheral blood by flow cytometry staining 
for human and mouse CD45+ cells (section 2.5.1). Mice were culled five weeks following 
PBMCs/Tregs transfer at which point the spleen and skin allograft was harvested for measuring 
human CD45+ cell engraftment and histological analysis, respectively. A summary of the 
experimental protocol is provided in Figure 2-4. 
 
 Human skin allograft histological analysis 
Human skin allografts were analysed with the help of Dr Christina Philippeos (Centre for Stem 
Cells & Regenerative Medicine, King’s College London, UK). 
Skin allografts were explanted and frozen in optimum cutting temperature (OCT; Thermo Fisher 
Scientific) over dry ice. Skin sections were cut at a thickness of 8 and 16 µm using a cryostat,  
air-dried and fixed by incubating in 4% paraformaldehyde for 15 minutes at room temperature. 
Specificity Host species Clone Company 
CD3 Rabbit Polyclonal DAKO 
FOXP3 Mouse 259D/C7 BD Pharmingen 
CD45 Mouse HI30 eBioscience 
Ki67 Rabbit Polyclonal Abcam 
Involucrin Mouse CY5 Sigma-Aldrich 
CD31 Rabbit Polyclonal Abcam 
    
Table 2-6 | Primary antibodies used for staining human skin allograft sections. 
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Sections were washed three times (5 minutes each) with PBS and incubated with a blocking 
solution (PBS containing 10% donkey serum, 0.1% fish skin gelatin, 0.1% Triton X-100 and 0.5% 
Tween-20 (all from Sigma-Aldrich)) for 1 hour at room temperature. The sections were then 
stained with the primary antibodies listed in Table 2-6 and incubated at overnight at 4°C. Sections 
were washed twice for 5 minutes and incubated with secondary antibodies detailed in Table 2-7 
with 2 μg/mL 4-6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) for 2 hours at room 
temperature. Sections were then washed 3 times for 5 minutes and mounted with Fluorescence 
Mounting Medium (DAKO, Agilent Technologies, Santa Clara, California, USA). Slides were stored 
at 4°C until analysis. Images were acquired at x20 magnification using a C2+ point scanning 
confocal microscope (Nikon). Maximum intensity projection (MaxIP) images consisting of 10  
z-stacks (1.1 µm apart) were acquired and analysed/quantified with Nikon Instrument Software 
(NIS) Elements and Fiji is just ImageJ (FIJI) imaging software (Leung, Maurer et al. 2013). 
 
 IN VIVO  MOUSE TREG PROLIFERATION ASSAY  
Resting Tregs were harvested 7 days post-stimulation and labelled with CTV, as detailed in  
section 2.6.1.1. Recipient mice were injected iv with 2x106 cells/mouse. Mice were culled 72 
hours post-injection, spleens were explanted and splenocytes were isolated (section 2.4.6). Dead 
cells were labelled as detailed in section 2.5.1 and proliferation was measured by flow cytometry, 
as detailed in section 2.6.1.1. 
 STATISTICAL ANALYSIS 
Data shown is mean ± standard error (SEM) or mean ± standard deviation (SD). Details pertaining 
to the statistical test used in each experiment are provided in the accompanying figure legends. 
In brief, the tests used were either a two-tailed paired Student’s t-test, a two-way analysis of 
variance (ANOVA) or a one-way ANOVA with a Tukey multiple comparison post-hoc test. 
Significance is denoted as follows: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
Specificity Host species Fluorochrome Company 
Mouse Donkey Alexa Fluor®555 Thermo Fisher Scientific 
Rabbit Donkey Alexa Fluor®647 Thermo Fisher Scientific 
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 DESIGNING A CAR 
Over the past 25 years, CARs have evolved in a divergent manner to include elements from an 
ever-increasing number of proteins (section 1.3.1). A prime example of this is how the signalling 
domain of CARs has developed through multiple generations. This has given rise to a range of 
options which are available when designing a CAR with no universally accepted “optimal CAR 
design”. As such, in addition to deciding what antigen to target, one must now consider factors 
such as how this antigen is to be targeted, which transmembrane domain to include, what 
generation of CAR to use or which signalling elements are to be incorporated with no consensus 
currently existing to address these aspects. 
Despite this range of factors, two fundamental and overriding decisions must be made before 
anything else: i) what antigen is to be targeted, and; ii) what generation CAR is to be generated. 
HLA-A2 was selected as a suitable HLA class I molecule to target due to the high prevalence of 
this allele (>40%) in the UK population (Burt, Cryer et al. 2013). This simplified the identification 
of a HLA-A2 targeting moiety (Watkins, Brown et al. 2000) and well as the application of this CAR 
in various downstream experiments which required HLA-A2+ and HLA-A2– donors. To address the 
second decision, a second generation CAR was selected based on the superior function of second 
generation CARs relative to first generation CARs (Finney, Lawson et al. 1998, Maher, Brentjens 
et al. 2002, Savoldo, Ramos et al. 2011). Furthermore, with second generation CARs proving 
adequate in multiple studies and clinical trials (Srivastava and Riddell 2015, Abate-Daga and Davila 
2016), it was difficult to argue the benefits of using a third generation CAR, in this setting. In a 
cancer setting, additional signalling domains may be advantageous (Pule, Straathof et al. 2005, 
Hombach, Heiders et al. 2012, Srivastava and Riddell 2015, Abate-Daga and Davila 2016). 
However, given the results of Hombach et al. which demonstrated that the inclusion of two 
costimulatory domains (CD28 and OX40) abrogated CAR T cell production of the  
anti-inflammatory cytokine IL-10, for the purpose of generating CAR Tregs, a second generation 
CAR may in fact be preferable (Hombach, Heiders et al. 2012). Consequently, bearing in mind the 
importance of CD28 for Treg activation (Hombach, Kofler et al. 2007), a CAR was designed to 
incorporate a CD28-CD3ζ signalling domain. 
Having decided which components to collate into a CAR, the next question to address was how 
this CAR was to be delivered in to human T cells and Tregs. The most prevalent approach which 
has been used in previous studies and CAR-based clinical trials to deliver genes of interest (GOI) 
into target cells is to use retroviruses. 
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 RETROVIRUSES IN RESEARCH AND THE CLINIC  
Retroviruses (Retroviridae) are a special family of virus which are able to integrate proviral DNA 
into the genome of an infected cell. This has made them fundamental tools in biological research 
where they are commonly used to deliver GOIs into target cells. 
The retroviral virion is comprised of three key components: an envelope, various proteins and the 
RNA genome. The envelope is a lipid bilayer casing which is formed when the virus “buds” out of 
the host cell. This contains a protein capsid which houses the RNA genome and fundamental 
proteins such as the enzymes reverse transcriptase and integrase which are discussed below. 
Virions infect target cells through the use of specific glycoproteins which are present on the outer 
surface of the envelope lipid bilayer. These glycoproteins are encoded by specific env genes which 
differ between viral species and dictate which target cells are infected. For example, the viral 
haemagglutinin (HA) present on the surface of most human influenza strains binds the  
N-acetylneuraminic acid-α2,6-galactose (NeuAcα2,6Gal) linkage on sialyloligosaccharides (Rogers 
and Paulson 1983, Rogers, Pritchett et al. 1983), sugar groups which is present at high levels on 
upper respiratory tract epithelial cells (Baum and Paulson 1990, Couceiro, Paulson et al. 1993, 
Gagneux, Cheriyan et al. 2003). Alternatively, the glycoprotein (gp)120 on the surface of the 
human immunodeficiency virus (HIV) preferentially binds the CD4 co-receptor of T cells (Yoon, 
Fridkis-Hareli et al. 2010). This viral specificity, termed “viral tropism”, can be exploited 
experimentally to generate viral particles which preferentially infect certain cell types, a process 
is termed “pseudotyping”.  
Engagement of the virion glycoproteins with cognate cell surface receptors facilitates fusion of 
the lipid bilayer envelope with the plasma membrane of the target cell and release of the 
nucleocapsid (capsid containing RNA) into the cytosol (Nisole and Saib 2004, Grove and Marsh 
2011). The precise mechanisms of the subsequent processes remain a matter of debate, 
particularly with regards to timing and location (Iordanskiy and Bukrinsky 2007, Arhel 2010, 
Campbell and Hope 2015), but the overall outcome is that the protein capsid uncoats to release 
its contents whilst the RNA is reverse transcribed. For the latter, single-stranded RNA molecules, 
which form the genome of the virion, are incorporated into reverse transcription complexes 
(RTC). RTCs utilise the enzyme reverse transcriptase (encoded by pol) to synthesise proviral DNA 
from the RNA template. This DNA combines with other proteins such as the enzyme integrase 
(also encoded by pol) to form pre-integration complexes (PIC) which facilitate entry of the proviral 
DNA into the nucleus (Arhel 2010, Eckwahl, Telesnitsky et al. 2016). 
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Nuclear access of the PIC typically relies on the breakdown of the nuclear membrane which occurs 
during cell division (Campbell and Hope 2015). As such, typical gamma-retroviruses do not 
efficiently integrate genes into the genomes of target cells which are not actively proliferating 
(Yamashita, Perez et al. 2007, Campbell and Hope 2015). However, lentiviruses, a specific genera 
of retrovirus, form PICs which are able to efficiently infect non-dividing cells as these PICs enter 
the nucleus through nuclear pores without disrupting the nuclear membrane (Piller, Caly et al. 
2003, De Rijck, Vandekerckhove et al. 2007). Consequently, to efficiently deliver GOIs into target 
cells which do not rapidly proliferate, a lentiviral approach is typically preferred. 
Once in the nucleus, integrase helps incorporate the proviral DNA into the genomic DNA. 
Consequently, progeny cells derived from the transduced cells contain the GOI which is of 
particular use and great importance when generating a T cell or Treg line that is being expanded 
ex vivo for clinical use. However, despite this advantage, cell therapy using genetically modified 
cells is regarded as a potentially hazardous process as retroviruses integrate their genes into 
genomic DNA is a partially random manner with active regions of the genome being preferred 
integration sites (Schroder, Shinn et al. 2002, Wu, Li et al. 2003, Kvaratskhelia, Sharma et al. 2014, 
LaFave, Varshney et al. 2014). Consequently, there is a potential to inadvertently activate  
proto-oncogenes or disrupt essential regulatory processes in target cells, resulting in the 
generation of cancerous cells. 
In spite of these concerns, the clinical use of retroviral and lentiviral vectors has prevailed. In fact, 
trials using CAR modified T cells have now been performed for >10 years (Kershaw, Westwood et 
al. 2006) with no adverse effects due to insertional mutagenesis being observed during this time. 
However, the aforementioned concerns are not misplaced as serious adverse effects have been 
observed in alternative settings, most notably in X-linked SCID (SCID-X1) patients. These patients 
lack the γc gene thus in these trials, patients were administered autologous CD34+ stem cells 
which were modified using retroviruses to express the γc. Gene insertion was confirmed to 
principally occur in or near genes that were highly expressed in the CD34+ cells (Aiuti, Cassani et 
al. 2007, Deichmann, Hacein-Bey-Abina et al. 2007, Schwarzwaelder, Howe et al. 2007). In the 
first two trials, insertional mutagenesis led to the development of T cell leukaemias in 2/10 
(Hacein-Bey-Abina, Von Kalle et al. 2003) and 4/9 (Hacein-Bey-Abina, von Kalle et al. 2003) 
patients treated, with similarly concerning results being obtained in subsequent trials 
(Deichmann, Hacein-Bey-Abina et al. 2007, Howe, Mansour et al. 2008). 
In the laboratory, various steps have been adopted to improve the safety of in vitro virus 
production, particularly with regards to lentiviral production (Cepko and Pear 2001). A key step 
was to split the fundamental gag, pol and env genes into separate vectors which has given rise to 
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a number of different generations of lentiviral vectors. In current research, vectors of at least the 
second generation are used whereby packaging cells must be transfected with three separate 
plasmids: i) an expression vector containing the GOI; ii) a packaging plasmid containing the gag-
pol polyprotein gene, and; iii) an envelope plasmid containing an env gene. 
 
 AIMS AND OBJECTIVES 
The primary aim of this chapter was to design and generate a second generation CAR which was 
specific for HLA-A2 and comprised a human CD28-CD3ζ signalling domain. The functionality and 
specificity of this CAR was validated through the use of a previously established Tconv assay 
(Parente-Pereira, Wilkie et al. 2014) and different transduction approaches were explored to 
identify an optimal method for delivering the A2 CAR gene into target cells. 
 
 RESULTS 
 DESIGN AND GENERATION OF A HUMAN CAR  SPECIFIC FOR 
HLA-A2 
 Design of a HLA-A2-targeting moiety 
In 2000, Watkins et al. identified a 57 year old female patient who developed post-transfusion 
purpura (PTP) 5 days following a routine blood transfusion (Watkins, Brown et al. 2000). PTP 
manifests as a rash on the skin and is caused by the generation of allospecific antibodies which 
opsonise transferred platelets, leading to thrombocytopenia (Greenway 1991). Subsequent 
investigations performed on the serum of this patient identified the presence of antibodies 
specific for HLA-A2. 
The authors proceeded to use “phage display” to obtain the sequences of novel scFv clones 
specific for HLA-A2. Mononuclear cells were isolated from the patient, total RNA was extracted 
and IgG variable heavy (VH) chain sequences were amplified by PCR. The variable light (VL) chain 
sequences used were obtained from an irrelevant, previously established scFv phage display 
library (Marks, Hoogenboom et al. 1991). These VL chain sequences had previously been cloned 
into pHEN vectors (Sheets, Amersdorfer et al. 1998). As such, scFv open reading frames (ORF) 
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were generated by cloning the patient-derived VH chain sequences into the donated pHEN-VL-rep 
vectors, resulting in an scFv library consisting of 4.7x107 clones. 
Bacteriophage particles displaying the various scFv clones were co-cultured with HLA-A2+ 
platelets for 2 hours, after which the platelets were thoroughly washed. The platelets were then 
incubated with TG1 E. coli. This allowed the phage still bound to the platelets to infect the E. coli. 
Transduced E. coli clones were then stimulated to secrete soluble scFv and the ability of these 
scFvs to bind HLA-A2 was assessed by staining HLA-A2+ platelets or lymphocytes and using flow 
cytometry (termed a platelet/lymphocyte immunofluorescence test (PIFT or LIFT) (von dem 
Borne, Verheugt et al. 1978)). Three similar HLA-A2-specific scFv sequences were identified in this 
process. For this thesis, the published 3PB2 VH chain and DPK1 VL chain sequences were used to 
construct a HLA-A2-specific scFv. The specificity of this scFv was validated using 
immunoprecipitation by Dr Mohammad Ibrahim (Department of Allergy and Clinical Immunology, 
King’s College Hospital, UK; unpublished data). 
A HLA-A2-specific CAR antigen-targeting domain was designed using the aforementioned  
HLA-A2-specific scFv sequence, as shown in Figure 3-1. In this sequence, the VH was linked to the 
downstream VL through a (GGGGS)3 serine/glycine linker. A human CD8α signal peptide sequence 
was added upstream of the scFv sequence to ensure that following expression, the CAR was 
translocated to the cell membrane. Additionally, NcoI and NotI restriction sites were added to the 
5’ and 3’ ends of this antigen-binding domain sequence, respectively, to facilitate cloning. This 
sequence was then gene synthesised by GenScript (Piscataway Township, New Jersey, USA). 
 
 Construction of a human HLA-A2-specific CAR 
Following validation of the nucleotide sequence, the scFv-coding DNA was cloned into the SFG 
retroviral expression vector which was kindly donated by Dr Michel Sadelain (Memorial Sloan 
Kettering Cancer Center, New York, USA). This vector had previously been modified by Dr John 
Maher (Division of Cancer studies, King’s College London, UK) to contain the ORF of a second 
generation CAR (Maher, Brentjens et al. 2002). The extracellular antigen targeting moiety of this 
CAR contained an NK1 sequence (Thayaparan, Maher, unpublished data), a naturally-occurring 
splice variant of the ligand hepatocyte growth factor (Jakubczak, LaRochelle et al. 1998). This was 
followed by a 9E10 cMyc epitope, a human CD28 hinge/transmembrane domain and a human 
CD28-CD3ζ signalling domain. 
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The NK1-targeting moiety of the NK1-28ζ CAR was replaced with the HLA-A2-targeting moiety 
described in Figure 3-1A, using the unique 5’ NcoI and 3’ NotI restriction sites shown in  
Figure 3-2A. This cloning process was performed by GenScript and resulted in the generation of 
an SFG retroviral vector containing the ORF of a HLA-A2-specific CAR comprising a CD28-CD3ζ 
signalling domain, hereon in referred to as “SFG_A2-28ζ”. Upon receipt of this SFG_A2-28ζ vector, 
the results of the gene synthesis and cloning process were validated in house by restriction 
digestion using NcoI and XhoI restriction enzymes. Two fragments of 6.4 and 1.5 kilobases (kbp) 
were expected in order to confirm that the scFv was correctly orientated in the SFG retroviral 
vector. Bands corresponding to DNA fragments of these sizes were identified following the 
digestion (Figure 3-3). 
Figure 3-1 │ Diagram detailing the components of the HLA-A2-targeting moiety used for constructing a HLA-
A2-specific CAR. A: Nucleotide sequence of the HLA-A2-targeting moiety. Flanking 5’ NcoI and 3’ NotI 
restriction sites are underlined. B: Amino acid sequence of the HLA-A2-targeting moiety. The sequence of 
a human CD8α leader (red), scFv VH chain (orange), serine/glycine linker (blue) and scFv VL chain (green) 
are shown in addition to predicted complementarity determining regions (CDR) in bold. 




Figure 3-2 │ Restriction map of the SFG_A2-28ζ plasmid and a schematic diagram of the A2-28ζ CAR.  
A: Restriction map of the SFG retroviral expression vector containing the A2-28ζ CAR gene. The  
HLA-A2-targeting sequence (red) was cloned between NcoI and NotI to yield the sequence of a  
HLA-A2-specific second generation CAR comprising a human CD28 transmembrane domain (orange) and 
a CD28-CD3ζ signalling domain (blue). The complete nucleotide sequence of this vector is provided in the 
Supplementary data, Figure S2. B: Schematic diagram of the A2-28ζ CAR. A preceding human CD8α 
sequence (grey) was added upstream of the HLA-A2-targeting moiety (red) to facilitate trafficking of the 
CAR protein to the cell membrane. The MYPPPY recognition motif in the CD28 extracellular region was 
replaced with a 9E10 cMyc epitope (black), downstream of which was a human CD28 
hinge/transmembrane domain (orange) and CD28-CD3ζ signalling domain (blue). Amp. Res. = ampicillin 
resistance, TM = transmembrane. 
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 FUNCTIONAL VALIDATION OF THE A2  CAR 
The functionality and specificity of the HLA-A2-specific CAR (A2 CAR) was assessed using a 
previously established Tconv functional assay (Parente-Pereira, Wilkie et al. 2014). In this 
experimental procedure, human PBMCs were activated with PHA-L and retrovirally transduced 
to express the A2 CAR. These cells were then co-cultured with tumour cell monolayers which 
were HLA-A2+ or HLA-A2–. It was anticipated that if the A2 CAR was functional, the CAR T cells 
would be activated in the presence of HLA-A2+ tumour monolayers. This would result in the 
elicitation of cytotoxic activity and production of pro-inflammatory cytokines, a response which 
would not be expected in the absence of HLA-A2. 
 
 Retroviral transduction delivered the A2 CAR gene 
into unfractioned human T cells 
As discussed in the chapter introduction, retroviral transduction is a well-established and safe 
approach for delivering genes of interest into target cells (Scholler, Brady et al. 2012). In order to 
deliver the A2 CAR gene into PBMCs, GaLV-pseudotyped retroviral particles containing the 
SFG_A2-28ζ construct were generated using a two-step process (Parente-Pereira, Wilkie et al. 
2014). This two-step process was employed such that a stable cell line could be generated which 
consistently produced desired retroviral particles, eliminating the requirement to transfect fresh 
cells every time viral particles were desired. To generate this line, genomic integration of the A2 
CAR gene was required. As such, it was necessary to transfect one retroviral packaging cell line to 
Figure 3-3 │ Restriction digest of SFG_A2-28ζ plasmid minipreps with NcoI and XhoI. DNA isolated from 3 
minipreps of the SFG_A2-28ζ were restriction digested with NcoI and XhoI. Resultant DNA fragments were 
separated on a 1% agarose gel with a 1 kb DNA ladder. 
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transiently release VSV-G-pseudotyped viral particles which could then be used to transduce a 
second stable retroviral packaging cell line which secreted GaLV-pseudotyped viral particles. 
Initially, the SFG_A2-28ζ construct was transfected into H29D human retroviral packaging cells 
(Ory, Neugeboren et al. 1996) using calcium phosphate (Graham and van der Eb 1973). These 
cells were cultured in the absence of tetracycline to allow VSV-G-pseudotyped retroviral particles 
to be produced (section 2.2.4). Viral supernatant was harvested from these H29D cells 5 days 
post-transfection and used to transduce PG13 cells. PG13 cells were incubated with  
H29D-derived viral supernatant for 72 hours and maintained in culture for at least one week prior 
to analysis. 
In subsequent experiments, two control CARs previously constructed by Dr John Maher were 
used to confirm that recognition of HLA-A2+ target cells was indeed dependent on the CAR 
possessing a HLA-A2-targeting moiety. Both of these CARs contained a CD28-CD3ζ signalling 
domain which matched that present in the A2 CAR. V8 was a control CAR of irrelevant antigen 
specificity which was generated by point-mutating the peptide-based antigen-targeting moiety 
of an integrin αvβ6-specific CAR (Whilding, Parente-Pereira et al. 2016) whilst P4 was a  
prostate-specific membrane antigen (PSMA)-specific CAR (Maher, Brentjens et al. 2002). 
Figure 3-4 │ PG13 retroviral packaging cells are efficiently transduced with VSV-G-pseudotyped retroviral 
particles to express the A2, V8 and P4 CARs. PG13 cells were transduced with VSV-G-pseudotyped retroviral 
particles to express the A2 (A), V8 (B) or P4 (C) CAR. The proportion of PG13 cells which was successfully 
transduced was measured by flow cytometry. Expression of the A2 and V8 CARs was detected by staining 
for the 9E10 cMyc tag epitope whilst expression of the P4 CAR was detected using an  
anti-mouse IgG antibody which reacted with murine elements within the scFv (blue line). Cells stained with 
an isotype control are shown in solid grey. The percentage of cells in which CAR expression was detected, 
determined by the gate provided, is shown in the top right corner of each plot. 
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Expression of the A2, V8 and P4 CARs in transduced PG13 cells was measured by flow cytometry 
(Figure 3-4). A2 and V8 CARs were detected using an antibody specific for the 9E10 cMyc tag 
epitope present in the extracellular domain of these CARs (Figure 3-2B). However, as the P4 CAR 
did not contain a cMyc tag epitope, expression of this CAR was measured using an anti-mouse 
IgG antibody which coincidently recognised the murine scFv domain of the CAR. As shown in 
Figure 3-4, the A2 and irrelevant V8 CARs were expressed in PG13 cells with a high efficiencies of 
96.1% and 99.6%, respectively. However, the proportion of PG13 cells expressing the irrelevant 
P4 CAR was lower (56.3%). 
In order to assess whether GaLV-pseudotyped retroviral particles could deliver a GOI into target 
T cells, unfractioned human T cells from peripheral blood were activated and transduced with 
supernatant derived from the stably transduced PG13 cells. PBMCs were isolated from a HLA-A2– 
donor and cultured with PHA-L (5 μg/mL) and IL-2 (100 U/mL) to selectively activate the T cells. 
The T cells were transduced to express the A2, V8 or P4 CARs after 72 hours by mixing the cells 
in viral supernatant derived from the PG13 cells, spinoculating the cells at 600 g for 1 hour in 
RetroNectin®-coated plates and incubating the cells at 37°C with 5% CO2. Transduced cells were 
expanded for 7-10 days where fresh media and IL-2 was supplied every 2 days. The transduction 
efficiency was then assessed by flow cytometry and functional assays were performed. As shown 
Figure 3-5 │ Unfractioned human T cells are successfully transduced with GaLV-pseudotyped retroviral 
particles to express the A2, V8 and P4 CARs. Human PBMCs were isolated from a HLA-A2– donor, activated 
with PHA-L and retrovirally transduced with PG13-derived GaLV-pseudotyped retroviral particles to 
express the A2 (A), V8 (B) or P4 (C) CARs 72 hours post-activation. The transduction efficiency was 
measured 7-10 days post-transduction by flow cytometry, using antibodies specific for the 9E10 cMyc tag 
epitope (A2 and V8 CAR) or an anti-mouse IgG antibody (P4 CAR). Stained cells are shown with a blue line 
and isotype control staining is shown in solid grey. The percentage of CAR-expressing T cells, as determined 
by the gate shown, is provided in the top right corner of each plot. Data is representative of 4 individual 
experiments. 
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in Figure 3-5, total T cells were successfully transduced to express the CARs with efficiencies of 
approximately 10% (A2 = 9.9 ± 7.6%, V8 = 11.6 ± 15.2% and P4 = 10.8 ± 10.8%; n=4). Overall, 
these results demonstrated that GaLV-pseudotyped retroviral particles delivered CARs into target 
T cells with a sufficient efficiency for downstream experiments to be performed. 
 
 Human T cells expressing the A2 CAR exhibited 
cytotoxicity in a HLA-A2-specific manner 
A literature search was performed to identify adherent target cells which differentially expressed 
HLA-A2. Two breast cancer epithelial cell lines were identified (Carlsson, Forsberg et al. 2007) and 
kindly donated by Dr John Maher. In this study, MCF-7 cells were shown to express HLA-A2+ whilst 
T-47D cells were reported to be HLA-A2–. These findings were confirmed by flow cytometry using 
2 separate antibody clones (BB7.2 and REA142), as shown in Figure 3-6A-B. Furthermore, to 
confirm that the lack of HLA-A2 detection in the T-47D cells was due to these cells being negative 
for the expression of HLA-A2, and not because these cells downregulated HLA class I molecules, 
both cell lines were analysed for expression of total HLA class I (Tu149 clone) and  
HLA-DR (L243 clone). Interestingly, T-47D cells were found to express significantly more total  
HLA class I (mean fluorescence intensity (MFI) = 20,915), compared to the MCF-7 cells  
(MFI = 1,045; Figure 3-6C), whilst both cell lines expressed low levels of HLA-DR (Figure 3-6D). 
Overall, these results confirmed that MCF-7 cells expressed high levels of HLA-A2 whilst T-47D 
cells did not express this molecule, despite expressing high levels of total HLA class I. 
Figure 3-6 │ MCF-7 and T-47D differentially expressed HLA-A2. MCF-7 (blue line) and T-47D (green line) 
breast cancer epithelial cells were stained with fluorophore-conjugated antibodies to measure their 
expression of HLA-A2 (A/B) HLA class I (C) and HLA-DR (D) by flow cytometry. Two separate antibodies 
clones (BB7.2 and REA142) were used to confirm HLA-A2 recognition. Isotype control staining is shown in 
solid grey and MFI values are provided. 
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To assess the functionality and specificity of the A2 CAR, unsorted transduced T cells were  
co-cultured overnight with confluent monolayers of MCF-7 and T-47D cells. Following co-culture, 
supernatants were collected to analyse cytokine production. Cell monolayers were washed gently 
using PBS to remove contaminating T cells and an MTT assay was performed to measure the 
viability of the cell monolayers. 
Cytotoxicity was observed microscopically when T cells expressing the A2 CAR were co-cultured 
with HLA-A2+ MCF-7 cells (Figure 3-7A). In contrast, destruction of the monolayers was not 
observed when the A2 CAR T cells were co-cultured with HLA-A2– T-47D cells, nor when T cells 
Figure 3-7 │ T cells transduced to express the A2 CAR exhibited cytotoxicity in a HLA-A2-dependent manner. 
A: CAR-modified T cells were co-cultured overnight with confluent monolayers of MCF-7 and  
T-47D cells. Images were taken after the co-culture at x10 magnification. Scale bar represents 250 μm.  
B: The viability of the cell monolayers following co-culture was quantified by MTT assay. % viability of  
MCF-7 (blue bars) and T-47D (green bars) cells is shown relative to monolayer cells cultured alone. Data 
represents mean + SEM pooled from 3 individual experiments. Significance was determined using a  
two-tailed paired Student’s t-test where *=p<0.05. ns = not significant. 
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Figure 3-8 │ T cells transduced to express the A2-28ζ CAR 
produce higher levels of IFNγ, IL-2, TNFα, IL-4, IL-17α and 
IL-6 in the presence of HLA-A2+ target cells compared to 
untransduced and V8 CAR T cells. Supernatants from  
co-cultures of CAR-modified T cells and MCF-7 cells were 
analysed preliminarily for production of IFNγ (A), IL-2 (B), 
TNFα (C), IL-4 (D), IL-10 (E) IL-17α (F) and IL-6 (G) by 
cytometric bead array. 
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expressing an irrelevant CAR were co-cultured with either of the cell lines. The viability of the 
MCF-7 cells was significantly lower (p=0.031) than the viability of the T-47D cells following  
co-culture with the A2 CAR T cells (MCF-7 = 27.0 ± 4.9%, T-47D = 103 ± 7.0%, n=3; Figure 3-7B). 
However, these differences in HLA-A2+ and HLA-A2– monolayer viability were not observed 
following co-culture with the untransduced (p=0.40), V8 CAR (p=0.53) or P4 CAR (p=0.74) T cells. 
The efficacy of the A2 CAR T cells was particularly impressive given the fact that approximately 
90% of these cells did not express the CAR construct (Figure 3-5A). Overall, these results 
demonstrated that T cells transduced to express the A2 CAR recognised HLA-A2 on target cells 
which led to elicitation of an effector function, in this case cytotoxicity. 
To confirm these findings, co-culture supernatants were analysed for the presence of cytokines 
which are known to be released by T cells following activation. A preliminary cytometric bead 
array (CBA) analysis was performed to investigate the range of cytokines which were produced. 
This analysis included a measurement of IL-2, IFNγ, TNFα, IL-4, IL-10, IL-17α and IL-6 produced by 
T cells co-cultured with HLA-A2+ MCF-7 cells only (Figure 3-8). From a single, preliminary 
experiment, A2 CAR T cells were shown to produce higher quantity of IL-2, IFNγ, TNFα, IL-4,  
IL-17α and IL-6 than untransduced or V8 CAR T cells. A2 CAR T cells production of IFNγ was  
180-fold higher than untransduced T cells (Figure 3-8A). Similarly, the quantity of IL-2 (Figure 
Figure 3-9 │ T cells transduced to express the A2 CAR produced high levels of IL-2 and IFNγ in the presence 
of HLA-A2+ target cells. Supernatants from co-cultures of CAR-modified T cells and MCF-7 (blue bars) or  
T-47D (green bars) cells were analysed for production of IL-2 (A) and IFNγ (B) by cytokine-specific ELISAs. 
Data represents mean ± SEM pooled from 3 individual experiments. A two-tailed paired Student’s t -test 
was performed but no significant differences were observed. 
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3-8B), TNFα (Figure 3-8C) and IL-17α (Figure 3-8F) produced by the A2 CAR T cells was >9-fold 
more than untransduced T cells. Interestingly, V8 CAR T cells also produced noticeably higher 
levels of IFNγ and TNFα than untransduced T cells. However, this was likely an anomalous result 
as elevated IFNγ production from the V8 CAR T cells was not observed in subsequent experiments 
(measured by ELISA analysis; Figure 3-9). 
IL-2 and IFNγ produced during the co-cultures was further analysed using cytokine-specific ELISAs. 
Using this approach, IL-2 production was only detectable when A2 CAR T cells were co-cultured 
with HLA-A2+ MCF-7 cells (Figure 3-9A). Under the same conditions, these cells also produced 
high levels of IFNγ. A2 CAR T cells produced 212-fold more IFNγ when co-cultured with the  
HLA-A2+ MCF-7 cells (10,341 pg/mL), compared to the HLA-A2– T-47D cells (48.8 pg/mL). This 
result did not reach statistical significance (p=0.11; n=3), likely due to a combination of variability 
in the donors and transduction efficiencies. In these assays, the untransduced, V8 CAR and P4 
CAR T cells all produced low levels of IFNγ in the presence of the HLA-A2+ MCF-7 cells (all <100 
pg/mL). However, these findings clearly affirmed the functionality of the CAR, particularly given 
the fact that only approximately 10% of these cells expressed the CAR. Overall, these results 
demonstrated that T cells modified to express the A2 CAR were capable of functioning in a  
HLA-A2-specific manner, confirming the functionality and specificity of the novel CAR. 
 
 SUB-CLONING OF THE HLA-A2-SPECIFIC CAR  ORF  FROM A 
RETROVIRAL CONSTRUCT INTO A LENTIVIRAL CONSTRUCT 
In order to aid downstream experiments, it was desirable to improve the efficiency with which  
T cells were transduced. As discussed in the introduction (section 3.1.2), lentiviruses are a 
subclass of retrovirus which are capable of transducing target cells in the absence of cell division 
(Cooray, Howe et al. 2012). As such, to investigate whether the T cell transduction efficiency could 
be improved by using a lentiviral approach, the A2 CAR gene was sub-cloned into a 
pLNT/SFFV_eGFP lentiviral vector (kindly provided by Dr Gilbert Fruhwirth; Division of Imaging 
Sciences and Biomedical Engineering, King’s College London, London, UK). 
The pLNT/SFFV second generation lentiviral vector was originally a kind gift provided by  
Prof Adrian Thrasher (Molecular and Cellular Immunology, University College London, UK). This 
vector was modified by Dr Gilbert Fruhwirth who inserted a cassette coding a short, flexible linker 
(GGAGGTGGCGCCACC) followed by the ORF of an enhanced green fluorescent protein (eGFP) 
reporter, resulting in the generation of the pLNT/SFFV_eGFP plasmid (Figure 3-10A). 
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Figure 3-10 │ Restriction map of the pLNT/SFFV_A2 CAR-eGFP plasmid and a schematic diagram of the A2-
28ζ CAR-eGFP and A2 ΔCAR-eGFP constructs. A: Restriction map of the pLNT/SFFV_eGFP lentiviral 
expression vector containing the full-length A2-28ζ CAR-eGFP ORF. The A2-28ζ CAR ORF (red/blue) was 
cloned between BamHI and MluI, immediately upstream of the eGFP ORF (green) to yield a CAR-eGFP 
fusion. The complete nucleotide sequence of this vector is provided in the Supplementary data, Figure S3. 
B: Schematic diagrams of the full-length A2-28ζ CAR-eGFP and truncated A2 ΔCAR-eGFP proteins. The 
complete nucleotide sequence of this vector is provided in the Supplementary data, Figure S1. Amp. Res. = 
ampicillin resistance. 
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The aim of this cloning process was to insert the A2 CAR gene into the LNT/SFFV_eGFP vector 
immediately upstream of the eGFP ORF to generate a A2 CAR-eGFP fusion (Figure 3-10B). To 
assess whether a simple cloning strategy could be employed to achieve this, the flanking 
restriction sites of the A2 CAR gene in the SFG retroviral construct were compared to those 
present in the recipient pLNT/SFFV_eGFP construct but unfortunately, no matching sites were 
identified. Consequently, the cloning strategy shown in Figure 3-11 was employed. 
PCR primers were designed to amplify the A2 CAR gene from the SFG retroviral construct whilst 
concurrently adding a BamHI and MluI restriction site to the 5’ and 3’ ends of the PCR products, 
respectively (Figure 3-12A and Table 3-1). Inserting the A2 CAR gene into the pLNT/SFFV_eGFP 
Figure 3-11 │ Summary of the cloning strategy employed to sub-clone the A2-28ζ CAR gene from the 
resident SFG retroviral construct into a recipient pLNT/SFFV_eGFP lentiviral construct. 
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vector using the BamHI and MluI restriction sites (Figure 3-10A) would have resulted in the 
generation of an A2-28ζ-eGFP fusion ORF. However, as it was unclear whether the presence of a 
C-terminal eGFP fusion would influence the function of the CAR, a second reverse primer was 
designed whereby a TAA stop codon and an extra nucleotide was incorporated to prevent 
transcription of the downstream eGFP gene (Figure 3-12B and Table 3-1). Additionally, as this 
cloning process presented the opportunity to generate a truncated HLA-A2-specific CAR as an 
additional control, similar reverse primers were designed which recognised the A2-28ζ CAR 
Figure 3-12 │ Schematic diagrams of custom PCR primers for amplifying the A2 CAR gene whilst adding a 5’ 
BamHI and 3’ MluI restriction site. Custom PCR primers were designed to amplify the A2-28ζ CAR gene 
whilst concurrently adding restriction sites to facilitate subsequent cloning. A universal primer recognising 
the 5’ end of the start of the CAR was designed to add a BamHI restriction site and 4 reverse primers were 
designed to generate different CAR genes with a 3’ MluI restriction site: a full-length CAR with a C-terminal 
eGFP fusion (A), a full-length CAR with no eGFP fusion (B), a truncated CAR with a C-terminal eGFP  
fusion (C) and a truncated CAR with no eGFP fusion (D). 
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sequence in the CD28 signalling domain, upstream of the first ITAM, ultimately resulting in CARs 
which were capable of binding HLA-A2 but not signalling intracellularly (Figure 3-12C/D). 
The designed PCR primers (Table 3-1) were synthesised by Sigma-Aldrich and used to amplify the 
A2 CAR gene. The forward primer was designed to recognise the first 19 nucleotides of the CD8α 
leader sequence whilst the reverse primers were designed to recognise either the last 19 
nucleotides of the CD3ζ signalling domain (full-length CAR) or a 22 nucleotide region downstream 
of the transmembrane domain (truncated CAR; precise recognition loci are shown in the 
Supplementary data, Figure S1). These PCR primers were used to amplify the A2 CAR ORF from 
the resident SFG retroviral vector. Unidentified nucleic acid contaminants were removed from 
the PCR products using a membrane-based purification system (Figure 3-13A, red boxes) and the 
PCR products were blunt-end ligated into an intermediate pCR™ vector to facilitate an efficient 
downstream BamHI/MluI restriction digestion. Successfully ligated pCR™ vectors containing DNA 
inserts were expanded by transforming DH5α cells and growing these cells in the presence of 
kanamycin which inhibited the growth of E. coli that did not contain a pCR™ vector. DNA was 
isolated from single colonies by miniprep and pCR™ vectors containing a CAR insert in the correct 
orientation were identified by restriction digestion using NotI. Bands of 720 bp (complete CAR) 
and 300 bp (truncated CAR) were indicative of the CAR gene insert being orientated correctly 
(Figure 3-14, highlighted with green boxes) whilst bands of 865 bp (complete CAR) and 900 bp 
(truncated CAR) indicated the CAR gene insert was orientated incorrectly (Figure 3-14, highlighted 
with red boxes). 
The pCR™ vectors containing correctly orientated CAR inserts and the pLNT/SFFV_eGFP lentiviral 
vector were restriction digested with BamHI and MluI to generate DNA fragments with flanking 
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Figure 3-13 │ Purification of CAR gene PCR products using a membrane-based purification system. CAR 
gene PCR products were purified using the membrane-based Wizard® SV Gel and PCR Clean-Up System. 
PCR products before (A) and after (B) purification are shown on a 0.8% agarose gel alongside the 
Hyperladder I. Contaminants are highlighted with red boxes. 
Figure 3-14 │ NotI restriction digest of pCR™ vector containing A2 CAR gene inserts. CAR gene inserts 
generated from a PCR amplification process were blunt-end ligated into the pCR™ vector. DNA ligation 
products were expanded, purified by miniprep and restriction digested with NotI. Digest fragments were 
separated on a 0.8% agarose gel alongside the Hyperladder I. Correctly orientated CAR gene inserts were 
identified by bands of 4,300 and 720 bp (complete (comp.) CAR) or 4,300 and 300 bp (truncated (trunc.) 
CAR), as highlighted with green boxes. Conversely, incorrectly orientated CAR gene inserts resulted in 
fragments of 4,100 and 865 bp (comp. CAR) or 3,700 and 900 bp (trunc. CAR), highlighted with red boxes. 
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Figure 3-15 │ BamHI and MluI restriction digest of pCR™ vectors containing the A2 CAR gene inserts. pCR™ 
vectors containing the A2 CAR gene inserts in the correct orientation were restriction digested with BamHI 
and MluI. CAR gene inserts with 5’ BamHI and 3’ MluI sticky ends were separated on a 0.6% agarose gel 
and visualised using a long wavelength ultraviolet transilluminator to minimise photo-nicking damage 
(green boxes). These bands were cut out and DNA was extracted using the membrane-based Wizard® SV 
Gel and PCR Clean-Up System. 
 
Figure 3-16 │ PvuII restriction digest of pLNT/SFFV_eGFP vectors containing A2 CAR gene inserts. A2 CAR 
gene inserts were ligated into the target pLNT/SFFV_eGFP vector. DNA ligation products were expanded, 
purified by miniprep and restriction digested with PvuII. Digest fragments were separated on a 0.8% 
agarose gel alongside the Hyperladder I. pLNT/SFFV_eGFP vectors containing a CAR insert yielded 
predicted PvuII digest fragments of 3,100, 2,800 and 2,400 bp. 
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BamHI and MluI sticky ends. DNA was separated by agarose gel electrophoresis and bands of 
1,494 bp (complete CAR) and 1,063 (truncated CAR) were extracted and purified using a 
membrane-based purification system (Figure 3-15, extracted bands highlighted with green 
boxes). Complete and truncated CAR DNA inserts were ligated into the pLNT/SFFV_eGFP vector 
using a T4 ligase. Stbl3 cells were then transformed with the ligation products and grown on agar 
plates in the presence of ampicillin to selectively expand successfully transformed E. coli. DNA 
from single colonies was isolated by miniprep and correctly ligated vectors were identified by 
PvuII restriction digest. DNA bands of 3,100, 2,800 and 2,400 bp were expected for vectors 
containing the full-length or truncated CAR genes (Figure 3-16) and were observed in all cases. 
Subsequent sequencing analysis confirmed that this cloning process had successfully been 
performed without the incorporation of a point mutation with the A2-28ζ-eGFP ORF. 
 
 The full-length A2-28ζ CAR remains functional with a 
C-terminal eGFP fusion 
During the sub-cloning process, the C-terminus of the A2 CAR was modified, either by the addition 
of an eGFP fusion or the removal of the CD28-CD3ζ signalling domain. To evaluate the potential 
consequences of these modifications in terms of their functionality, the aforementioned A2 CARs 
were assessed by measuring their ability to activate T cells in the presence of HLA-A2. Hereafter, 
the full-length CARs with and without the eGFP fusions were termed A2 CAR-eGFP and A2 CAR, 
Figure 3-17 │ Fluorescence microscopy images of HEK293T cells transfected to express the 
pLNT/SFFV_CAR-eGFP constructs. HEK293T cells were co-transfected to express a pLNT/SFFV_CAR-eGFP 
plasmid, a pCMV-ΔR8.91 packaging plasmid and a pCMV-VSV-G envelope plasmid, resulting in the 
production of VSV-G-pseudotyped lentiviral particles. HEK293T cells were visualised by fluorescence 
microscopy 24 hours post-transfection. Images were taken at x20 magnification with a scale bar which 
represents 200 μm. Data representative of 3 individual experiments. 
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respectively whilst the truncated CARs which lacked a CD28-CD3ζ signalling domain were termed 
A2 ΔCAR-eGFP and A2 ΔCAR, respectively. 
VSV-G-pseudotyped lentiviral particles containing the various A2 CAR constructs were generated 
by co-transfecting HEK293T cells with a corresponding pLNT/SFFV_CAR-eGFP plasmid, a pCMV-
ΔR8.91 packaging plasmid and a pCMV-VSV-G envelope plasmid. The transfection of these 
HEK293T cells was confirmed by assessing eGFP expression using fluorescence microscopy 
(Figure 3-17). This indicated that the A2 CAR-eGFP and ΔCAR-eGFP fusion proteins were 
successfully expressed. Furthermore, eGFP was not detected in the HEK293T cells which were 
transfected with the A2 CAR and ΔCAR. As the eGFP ORF was still present in these CAR constructs, 
this suggested that there was no “leaky” eGFP expression in this system. 
Viral supernatant was harvested 48-56 hours post-transfection and VSV-G-pseudotyped lentiviral 
particles were concentrated using a precipitation approach. HLA-A2– PBMCs were activated with 
PHA and IL-2, as previously described (section 3.3.2.1), and transduced to express 1 of the 4  
A2 CAR constructs after 72 hours. The transduction efficiency of the T cells was assessed by flow 
cytometry 7 days post-transduction (Figure 3-18) where CAR expression was quantified either by 
measuring eGFP expression for CARs which were fused to eGFP (Figure 3-18C/D), or staining with 
an anti-9E10 cMyc epitope antibody for CARs which lacked an eGFP fusion (Figure 3-18B). CD3+  
T cells were identified using an anti-human CD3 antibody. Using this lentiviral approach, a 
transduction efficiency of 62.4 ± 28.0% was achieved (n=4) which was a vast improvement over 
Figure 3-18 │ Unfractioned human T cells were transduced to express CAR genes with a high efficiency using 
VSV-G-pseudotyped lentiviral particles. Human PBMCs were isolated from a HLA-A2– donor and activated 
with PHA-L and IL-2. Activated T cells were left untransduced (A) or lentivirally transduced  
72 hours post-activation with VSV-G-pseudotyped lentiviral particles to express the A2 CAR (B), the A2 CAR 
with a C-terminal eGFP fusion (A2 CAR-eGFP, C) or the truncated A2 CAR with a C-terminal eGFP fusion 
(A2 ΔCAR-eGFP, D). The transduction efficiency was measured 7 days post-transduction by flow cytometry, 
using antibodies specific for the 9E10 cMyc epitope (B) or eGFP expression (C/D). Data representative of  
2 individual experiments. 
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the 9.9 ± 7.6% that was achieved for the retroviral approach (n=4; Figure 3-5A). It was therefore 
concluded a lentiviral CAR delivery approach was more appropriate for downstream experiments.  
To confirm the functionality of the CARs, A2 CAR-eGFP, CAR and ΔCAR-eGFP T cells were  
co-cultured with confluent monolayers of MCF-7 and T-47D cells, as previously described  
(section 3.3.2.2). As expected, A2 CAR T cells exhibited cytotoxicity towards HLA-A2+ MCF-7 cells 
(Figure 3-19A) and similar findings were observed for A2 CAR-eGFP T cells. In contrast,  
A2 ΔCAR-eGFP T cells did not exhibit cytotoxicity. No significant difference was measured in the 
Figure 3-19 │ T cells expressing the A2 CAR-eGFP fusion exhibited cytotoxicity with a similar potency to  
T cells expressing the A2 CAR. A: CAR-modified T cells were co-cultured overnight with confluent 
monolayers of MCF-7 and T-47D cells. Images were taken after the co-culture at x10 magnification. Scale 
bar = 250 μm. B: The viability of the cell monolayers following co-culture was quantified by MTT assay.  
% viability of MCF-7 (blue bars) and T-47D (green bars) cells is shown relative to monolayer cells cultured 
alone. Data is mean ± SD and is representative of 2 individual experiments. Significance was determined 
using a two-tailed paired Student’s t-test where *=p<0.05. 
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ability of A2 CAR and A2 CAR-eGFP T cells to kill HLA-A2+ MCF-7 cells (MCF-7 viability with A2 CAR 
T cells = 2.8 ± 0.3% and with A2 CAR-eGFP T cells = 1.8 ± 0.1%, p=0.083; representative of  
2 individual experiments; Figure 3-19B). Furthermore, presence of the A2 ΔCAR-eGFP construct 
in T cells did not cause an increase in cytotoxic activity elicited towards HLA-A2+ MCF-7 cells, 
relative to untransduced T cells (MCF-7 viability with untransduced T cells = 84.3 ± 3.5% and with  
A2 ΔCAR-eGFP T cells = 90.9 ± 5.8%, p=0.16). As this A2 ΔCAR-eGFP construct comprised the same  
HLA-A2-targeting moiety as the full-length A2 CARs, this finding suggested that the CARs must 
possess a CD28-CD3ζ signalling domain in order to elicit cytotoxic activity. Overall, these results 
demonstrated that the presence of the eGFP fusion did not influence the functionality of the  
A2 CAR. In contrast, removal of the CD28-CD3ζ signalling domain severely compromised the 
functionality of the CAR. 
Analysis of the cytokines produced during the co-cultures complemented these findings. T cells 
expressing the A2 CAR and A2 CAR-eGFP constructs produced similar levels of IL-2  
(11.9 ± 0.34 ng/mL and 13.3 ± 0.27 ng/mL; Figure 3-20A) and IFNγ (28.6 ± 1.2 ng/mL and 34.7 ± 
0.18 ng/mL; representative of 3 individual experiments; Figure 3-20B) in the presence of HLA-A2+ 
MCF-7 cells with no significant differences in the quantities secreted (IL-2 p=0.49; IFNγ p=0.074). 
Figure 3-20 │ T cells expressing the A2 CAR and A2 CAR-eGFP produce similarly high levels of IL-2 and IFNγ 
in the presence of HLA-A2+ target cells. Supernatants from co-cultures of CAR-modified T cells and MCF-7 
(blue) and T-47D (green) cells were analysed for production of IL-2 (A) and IFNγ (B) by cytokine-specific 
ELISAs. Data is mean ± SD and is representative of 3 individual experiments. Significance was determined 
using a two-tailed paired Student’s t-test where *=p<0.05 and **=p<0.01. 
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No detectable levels of IL-2 were produced in any of the other conditions analysed. The quantity 
of IFNγ produced by the A2 CAR and A2 CAR-eGFP T cells was >100-fold greater than 
untransduced (212.5 ± 7.3 pg/mL; p<0.019) and A2 ΔCAR-eGFP (252.8 ± 19.6 pg/mL; p<0.019)  
T cells. Overall, these results demonstrated that the presence of a C-terminal eGFP fusion did not 
influence the functionality of the A2 CAR. Additionally, removal of the CD28-CD3ζ signalling 
domain from this A2 CAR resulted in the generation of a non-functional HLA-A2-specific CAR 
which was capable of recognising HLA-A2 but was not able to facilitate T cell activation. 
 
 The cytotoxic activity of A2 CAR-eGFP Tconvs is not 
influenced by the presence of a commercial  
HLA-A2-specific blocking antibody 
To further characterise the specificity of the A2 CAR, the previously described cytotoxicity assay 
was performed in the presence and absence of a HLA-A2-specific blocking antibody. Over the past 
40 years, a variety of HLA-A2-specific monoclonal antibodies have been developed. However, the 
use of the majority of these clones has been superseded by the BB7.2 clone to the extent that, to 
our knowledge, this is currently the only HLA-A2-specific antibody clone which is commercially 
available. Confluent monolayers of HLA-A2+ MCF-7 cells were cultured with 20 μg/mL of the BB7.2 
antibody or an IgG2b control for 30 minutes before being co-cultured with 1x106 CD4+CD25– 
Tconvs which were untransduced or engineered to express the A2 CAR-eGFP or A2 ΔCAR-eGFP 
construct. Co-cultures were performed overnight in the presence of 10 μg/mL antibody. The 
viability of the MCF-7 cells was then measured by MTT assay. 
A2 CAR-eGFP Tconvs co-cultured in the presence of the BB7.2 antibody exhibited a similar level 
of cytotoxicity to A2 CAR-eGFP Tconvs which were cultured in the absence of an antibody or 
presence of the IgG2b control antibody (Figure 3-21A). This suggested that recognition of  
HLA-A2 by the A2 CAR was not blocked by the presence of the BB7.2 CAR. This may be explained 
by the locations of the predicted epitopes for the A2 CAR scFv and the BB7.2 antibody, as shown 
in Figure 3-21B. 
 
 DISCUSSION 
In this chapter, a second generation CAR comprising a human-derived HLA-A2-targeting moiety 
and CD28-CD3ζ signalling domain was designed and generated. This A2 CAR was cloned into an 
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SFG retroviral vector and delivered into HLA-A2– T cells with an efficiency of approximately 10%. 
When A2 CAR T cells were co-cultured HLA-A2+ MCF-7 cell monolayers, T cell activation was 
observed whereby cytotoxicity was elicited and pro-inflammatory cytokines were produced, 
suggesting that the A2 CAR was functional and specific for HLA-A2. In an aim to increase the 
efficiency with which target T cells were transduced, the A2 CAR gene was sub-cloned into a 
second generation LNT/SFFV_eGFP lentiviral vector. During this process, an eGFP C-terminal 
fusion was added to the A2 CAR and a second CAR was generated to comprise the same  
HLA-A2-targeting moiety without a CD28-CD3ζ signalling domain (A2 ΔCAR-eGFP). Employing a 
lentiviral transduction approach enabled the A2 CAR to be delivered into PBMCs with an efficiency 
of approximately 60%. Presence of a C-terminal eGFP fusion did not influence the functionality of 
the A2 CAR. However, removal of the CD28-CD3ζ signalling domain was shown to severely 
compromise the ability of this CAR to activate T cells, despite the fact that this CAR was still able 
to engage HLA-A2. 
The expression of mouse-derived sequences in human cells has the potential to trigger undesired 
immune responses in vivo. This is particularly true for proteins which have elements exposed on 
Figure 3-21 │ The cytotoxic activity of A2 CAR-eGFP Tconvs is not blocked by the presence of a  
HLA-A2-specific blocking antibody. A: CD4+CD25– Tconvs expressing the A2 CAR-eGFP construct were  
co-cultured overnight with confluent monolayers of HLA-A2+ MCF-7 cells in the presence of 10 μg/mL of 
an anti-HLA-A2 monoclonal antibody (BB7.2 clone). The viability of the MCF-7 cells was then measured by 
MTT assay. Data represents mean ± SD where % viability is shown relative to monolayer cells. B: Molecular 
graphic of HLA-A2 (PDB: 2AV1) with the predicted A2 CAR scFv epitope (Watkins, Brown et al. 2000) 
highlighted in red (amino acids 142-145 in the α2 chain) and the predicted epitope of the BB7.2 antibody 
clone (amino acids 107 in the α2 chain) highlighted in blue. Image generated using PyMOL software 
(Schrödinger LLC, New York, USA). 
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the cell surface, such as the scFv of a CAR. The severity of this issue has been demonstrated in 
two clinical trials in which CAR T cells containing a murine-derived scFv did not persist long-term 
post-transfer (Kershaw, Westwood et al. 2006, Lamers, Willemsen et al. 2011). Upon further 
investigation, this limited CAR T cell survival was attributed to the in vivo generation of antibodies 
which specifically recognised the CARs. The scFv employed to generate the A2 CAR in this project 
was of human origin (Watkins, Brown et al. 2000). This reduced the immunogenicity of the CAR 
and improved the chances of CAR Tregs surviving long-term post-transfer. In its original 
description, this HLA-A2-specific scFv sequence was shown to cross-react with HLA-A28 and  
HLA-A68. This cross-reactivity has not been confirmed using the A2 CAR but would be 
advantageous in a clinical setting, provided that the recipients lacked expression of all three of 
these HLA class I antigens. In a cancer setting, a CAR specific for one antigen can be used in the 
treatment of many patients. However, in the envisaged transplant setting, it would be necessary 
to generate a library of numerous CARs targeting different HLA class I molecules to accommodate 
the allele variability between different donors and recipients. Using cross-reactive CARs which 
target multiple HLA class I molecules would significantly reduce the number of CARs which would 
need to be developed to adopt CAR Tregs in the clinic. 
Recently, a HLA-A2-specific CAR was generated by MacDonald et al. who demonstrated the ability 
of CAR Tregs to inhibit xeno-GvHD (MacDonald, Hoeppli et al. 2016). These authors used a 
hybridoma-derived scFv sequence from the BB7.2 anti-HLA-A2 antibody clone (section 3.3.3.2) to 
comprise their antigen-targeting moiety. However, the elements downstream of this scFv 
including the cMyc tag, the CD28 transmembrane domain and the CD28-CD3ζ signalling domain 
were identical to the CAR generated in this chapter. This CAR was also delivered by lentiviral 
transduction into target cells and was shown to effectively confer HLA-A2-specificity onto Tconvs. 
This was demonstrated by stimulating A2 CAR-expressing CD4+CD25– T cells with HLA-A2+ 
stimulator cells and measuring the upregulation of several activation markers and the production 
of various cytokines. These findings were similar to the results presented in this chapter. 
In cancer research, control CARs are typically generated by mutating either the ectodomain 
(Kuramitsu, Ohno et al. 2015, Whilding, Parente-Pereira et al. 2016) or the endodomain 
(Bridgeman, Ladell et al. 2014, Kobold, Grassmann et al. 2015) of a functional CAR of interest. 
Mutating the endodomain is typically preferred as this allows the T cells to engage their target 
antigen and preferentially migrate to where this antigen is expressed in vivo. As such, a  
HLA-A2-specific CAR lacking a CD28-CD3ζ signalling domain was generated to investigate whether 
preferential Treg homing to the allograft was sufficient to elicit protection from graft rejection. 
The idea of using a mutated CAR has not previously been performed for CAR Tregs. 
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 SUMMARY  
Overall, the results presented in this chapter demonstrated the specificity and functionality of a 
novel HLA-A2-specific CAR. This CAR was efficiency delivered into human T cells through lentiviral 
transduction. The following chapter will explore whether lentiviral delivery of this CAR into human 
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 TREG ISOLATION FOR CLINICAL USE 
Clinical-grade human Tregs can be isolated by using one of two GMP-compatible approaches: i) 
to FACS sort Tregs using a range of different cell surface markers such as CD4, CD25 and CD127, 
or; ii) to enrich CD8–CD25+ T cells using sequential bead-based negative and positive selection 
protocols. 
Cell sorting is advantageous as it allows Tregs to be isolated with a high purity. Consequently, this 
approach is preferred and currently used for clinical trials outside of the UK. However, current 
GMP guidelines restrict the use of this approach in the UK, due in part to the lack of a suitable 
“closed system” cell sorter. This will likely be resolved in the near future with the development of 
the MACSQuant® Tyto™ cell sorter (Miltenyi Biotec). However, this has impacted previous and 
ongoing UK-based trials which have been restricted to enriching CD8–CD25+ Tregs using 
paramagnetic bead-based negative and positive selection protocols in combination with a 
CliniMACS closed system (Miltenyi Biotec) which inevitably yields a less pure population of Tregs. 
 
 TREG EXPANSION FOR CLINICAL USE 
In transplant-based clinical trials, Tregs are isolated under GMP-compatible conditions and 
expanded ex vivo to yield a therapeutically applicable number of cells. This can be achieved by 
activating the Tregs using one of two approaches, allowing cells to be expanded in a polyclonal or 
antigen-specific manner. For the former, the Tregs are activated with GMP-compatible  
anti-human CD3/CD28 beads. This approach is currently used for generating the cell products 
which are used in The ONE Study and ThRIL trials based at Guy’s Hospital. Alternatively, Tregs 
with direct allospecificity can be preferentially expanded by culturing the cells with allogeneic 
donor-derived APCs which can be in the form of PBMCs (Peters, Hilbrands et al. 2008, Jeffery, 
Braitch et al. 2016), DCs (Sagoo, Ali et al. 2011, Cherai, Hamel et al. 2015) or B cells (Tu, Lau et al. 
2008, Chen, Delgado et al. 2009, Zheng, Liu et al. 2010, Noyan, Lee et al. 2013, Putnam, Safinia 
et al. 2013). 
Following activation, the Tregs are expanded ex vivo in the presence of high levels of IL-2 (>500 
U/mL) although the period of time for which the Tregs are expanded varies between trials. For 
example, the original standard operating procedures (SOP) for The ONE Study and ThRIL at King’s 
College London dictated that the Tregs had to be expanded for 36 days where fresh  
anti-CD3/CD28 beads were provided on days 12 and 24 to re-stimulate the cells. This has since 
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been modified such that if a sufficient number of cells is acquired after 2 simulation procedures 
(24 days), the cells can be cryopreserved at this point in their expansion protocol. Conversely, 
Bluestone et al. recently published data from a clinical trial where autologous Tregs were 
expanded for 14 days with just one stimulation procedure before being transferred back into T1D 
patients (Bluestone, Buckner et al. 2015). Despite this shorter culture period, CD4+CD25+CD127lo 
Tregs in this trial were efficiently expanded with an average fold-increase of 554.7 ± 370.2. 
 
 Tregs and rapamycin 
The translation of Treg therapy into the clinic was hindered for many years due to concerns 
regarding the purity of the Tregs, particularly as the only GMP-compatible approach which was 
available during this time was to enrich Tregs by negative and positive selection. It was realised 
that expanding Tregs in the presence of high levels of IL-2 alone allowed for the concurrent 
expansion of contaminating T cells which could potentially promote graft rejection if adoptively 
transferred. Secondary concerns were also raised regarding the stability of the expanded Tregs 
following transfer. This was based on studies which had demonstrated that Tregs were 
susceptible to converting into Th17 cells when in a pro-inflammatory environment (Koenen, 
Smeets et al. 2008, Yang, Nurieva et al. 2008, Scotta, Esposito et al. 2013), such as that which 
would be expected in an allograft which is undergoing rejection. Again, in this scenario, 
transferred cells would promote graft rejection.    
These issues were subdued by various studies which demonstrated that expanding T cells in the 
presence of rapamycin both allowed for the selective expansion of Tregs and enhanced the 
stability of these cells (Battaglia, Stabilini et al. 2005, Strauss, Whiteside et al. 2007, Basu, 
Golovina et al. 2008, Golovina, Mikheeva et al. 2011, Scotta, Esposito et al. 2013). Rapamycin is 
one of the immunosuppressive drugs used in vivo to reduce solid organ transplant rejection 
(section 1.1.2.1) (Touzot, Soulillou et al. 2012). However, the ability of rapamycin to selectively 
promote the expansion of Treg makes it a useful asset for growing Tregs ex vivo thus it commonly 
features in GMP-compatible Treg expansion protocols where it is usually supplemented into 
culture media at a concentration of 100 nM. Presence of exogenous rapamycin in ex vivo T cell 
cultures favours the expansion of Tregs, allowing these cells to outgrow contaminating Tconvs 
which may exist in an isolated Treg preparation, particularly when these cells have been enriched 
using a bead-based negative and positive selection protocol. Similar preferential expansion of 
Tregs in the presence of rapamycin has also been observed in mouse models (Hester, Schiopu et 
al. 2012) and suggested in renal and liver transplant recipients (Segundo, Ruiz et al. 2006, Noris, 
Casiraghi et al. 2007, Akimova, Kamath et al. 2012). 
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The principle target or rapamycin is mTOR, a serine/threonine kinase which plays an important 
role in many cell processes including cell adhesion, growth, proliferation and survival (Ballou and 
Lin 2008). mTOR regulates these processes as a component of a protein complex. These protein 
complexes exist in different forms and are defined by the additional proteins included in the 
complex. By combining with regulatory-associated protein of mTOR (Raptor), mTOR complex 1 
(mTORC1) is formed whilst combining with rapamycin-insensitive companion of mTOR (Rictor) 
results in the formation of mTOR complex 2 (mTORC2). mTORC1 acts downstream of AKT and 
phosphorylates numerous target proteins to influence a wide variety of cell processes. In 
contrast, mTOCR2 is currently believed to act solely on AKT (Wang, Camirand et al. 2011). 
Although the mechanisms are not fully understood, it is widely reported that rapamycin primarily 
functions by inhibiting mTORC1 (Shimobayashi and Hall 2014). However, studies have suggested 
that rapamycin may also influence mTORC2 (Sarbassov, Ali et al. 2006, Yin, Hua et al. 2016). 
IL-2 signalling, which is of fundamental importance for T cell survival (section 1.1.3.2.1), is 
transmitted intracellularly through two signalling pathways: i) the phosphatidylinositol 3-kinase 
(PI3K)-AKT-mTOR pathway, and; ii) the Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) pathway (Safinia, Scotta et al. 2015). Studies have demonstrated that 
proliferating Tregs are less dependent than Tconvs on signalling through the PI3K-AKT-mTOR 
pathway and instead, Tregs preferentially rely on signalling through STAT5 (Bensinger, Walsh et 
al. 2004, Zeiser, Leveson-Gower et al. 2008), suggesting a mechanism by which rapamycin 
promotes Treg expansion. 
 
 GENETIC MANIPULATION OF HUMAN TREGS 
Although gene-modified Tregs do not feature heavily in clinical trials, various studies have 
demonstrated that genetic manipulation of human Tregs is possible. This has typically been 
performed to generate antigen-specific Tregs by transducing these cells to express specific TCR α 
and β chain genes (Brusko, Koya et al. 2010, Plesa, Zheng et al. 2012, Kim, Zhang et al. 2015) or 
CARs (Hombach, Kofler et al. 2009, MacDonald, Hoeppli et al. 2016). In these studies, there was 
a preference to deliver the GOIs using a lentiviral approach rather than a retroviral approach. 
Furthermore, transduced cells were shown to maintain both their phenotype and function in a 
polyclonal manner, whilst exhibiting a superior suppressive capacity in an antigen-specific 
manner. 
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 AIMS AND OBJECTIVES 
The aim of this chapter was to generate human Tregs which expressed either the A2 CAR-eGFP 
or the A2 ΔCAR-eGFP construct. To enhance the translatability of these findings, the Tregs were 
isolated using protocols which are relatable to those currently employed in the GMP facility at 
Guy’s Hospital, i.e. CD4+CD25+ Tregs were enriched using sequential negative and positive 
selection protocols. A protocol was then optimised to efficiency deliver the A2 CAR-eGFP or  
A2 ΔCAR-eGFP genes into these Tregs, without influencing the phenotype or suppressive ability 
of these cells, as assessed by flow cytometry and investigating the ability of the Tregs to suppress 
autologous CD4+CD25– Tresp proliferation in vitro, respectively. 
 
 RESULTS 
 ISOLATION ,  EXPANSION AND CHARACTERISATION OF HUMAN 
TREGS EXPANDED IN THE PRESENCE OF RAPAMYCIN  
 CD4+CD25+ human Tregs were enriched from 
peripheral blood using a GMP-compatible protocol 
with a high purity 
Human CD4+CD25+ Tregs were enriched from the peripheral blood of healthy donors using a 
previously established GMP-compatible protocol (Afzali, Edozie et al. 2013, Scotta, Esposito et al. 
2013, Safinia, Vaikunthanathan et al. 2016). CD4+ PBMCs were enriched by negative selection, 
specifically depleting cells which expressed CD8, CD16, CD19, CD36, CD56, CD66b and γ/δ TCRs. 
This was followed by a positive selection step in which CD25+ cells were enriched. Using this 
protocol, a CD4+CD25+ purity of approximately 90% (89.5 ± 4.4%, n=16) was achieved (Figure 
4-1A). A detailed phenotypic analysis of these cells (Figure 4-1B/C) demonstrated that a high 
proportion (79.0 ± 14.9%, n=6) of the cells expressed the lineage-determining Treg transcription 
factor FOXP3 (Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003, Fontenot, Rasmussen et al. 
2005) whilst a low proportion (30.1 ± 9.1%) expressed the IL-7 receptor α chain, CD127 (Liu, 
Putnam et al. 2006). CTLA-4 (46.0 ± 14.4%) and CD39 (55.1 ± 12.0%) were not expressed in all of 
the isolated cells, in line with previous studies which have demonstrated that whilst the majority 
of CD4+CD25+ human T cells express these markers, not all of these cells do (Dieckmann, Plottner 
et al. 2001, Jago, Yates et al. 2004, Borsellino, Kleinewietfeld et al. 2007). This result may be 
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partially attributed to the presence of contaminating activated T cells which have downregulated 
CTLA-4 or CD39 expression (Jago, Yates et al. 2004). 
Figure 4-1 │ Purity and phenotype of CD4+CD25+ Tregs freshly isolated from the peripheral blood of healthy 
donors. CD4+ PBMCs were enriched by negative selection after which CD25+ cells were enriched by positive 
selection. The phenotype of these cells was assessed by flow cytometry. A: The purity of freshly isolated 
Tregs was determined by staining the cells with fluorescently-conjugated anti-human CD4 (OKT4 clone) 
and anti-human CD25 (4E3 clone) antibodies. Gate positions were defined on cells stained with isotype 
controls. Data representative of 16 individual experiments. B: An extensive phenotype of the freshly 
isolated Tregs was performed. Dead cells were excluded using a LIVE/DEAD dye and cells were stained with 
fluorescently-conjugated antibodies specific for CD4, CD25, CD127, FOXP3, CTLA-4 and CD39 (blue lines). 
Cells were fixed and permeabilised prior to staining of FOXP3 and CTLA-4. Cells stained with appropriate 
isotype controls are shown in solid grey and were used to define the gate positions shown. The percentage 
of stained cells within the gate shown is provided in the top left corner of each plot. Data representative 
of 6 individual experiments. C: Pooled data of the freshly isolated Treg phenotype. Data shown is mean + 
SD pooled from 6 individual experiments. 
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 Human Tregs cultured in the presence of rapamycin 
were highly suppressive 
As discussed in the chapter introduction, culturing human CD4+CD25+ T cells in the presence of 
rapamycin has previously been demonstrated to selectively promote the expansion of 
CD4+CD25+FOXP3+ Tregs (Battaglia, Stabilini et al. 2006, Scotta, Esposito et al. 2013). To assess 
whether these findings could be replicated using human Tregs which were isolated using the 
aforementioned Treg enrichment protocol, freshly isolated Tregs were expanded for 20 days in 
the presence or absence of 100 nM rapamycin (Figure 2-1). Following expansion, the phenotype 
and polyclonal suppressive capacity of the untreated and rapamycin-treated Tregs was 
compared. 
Tregs cultured in the presence and absence of rapamycin exhibited a similar phenotype  
(Figure 4-2A). However, Tregs cultured in the presence of rapamycin expressed noticeably higher 
levels of Treg markers including FOXP3 (untreated MFI = 15,670; rapamycin-treated  
MFI = 20,293), CTLA-4 (untreated MFI = 1,783; rapamycin-treated MFI = 5,539) and CD39 
(untreated MFI = 1,859; rapamycin-treated MFI = 2,257) although the overall proportion of cells 
expressing these markers was unaltered by the presence of this drug. 
To investigate the suppressive capacity of the Tregs in a polyclonal manner, co-cultures of the 
Tregs and autologous CD4+CD25– Tresps were performed to measure the ability of the Tregs to 
inhibit Tresp proliferation. Tresps were labelled with CTV, activated with a low-dose of  
anti-human CD3/CD28 beads (1:40 bead:Tresp ratio) and co-cultured with Tregs at Treg:Tresp 
ratios ranging from 1:1 to 1:32 for 5 days. Tresp proliferation was then analysed by flow 
cytometry, as determined by CTV dilution and the proliferation of these cells was calculated using 
division indices (FlowJo 7). Tresps cultured in the absence of Tregs typically achieved a division 
index of 0.95 ± 0.35 (n=6). Inhibition of Tresp proliferation was then used as a measure of 
suppression. As shown in Figure 4-2B, Tregs cultured in the presence of rapamycin were 
significantly more suppressive than Tregs cultured alone (p-values ranging from 0.0059 to  
1.3x10–4; representative of 3 individual experiments). At a 1:1 ratio, untreated Tregs inhibited 
Tresps proliferation by 51.0% whilst rapamycin-treated Tregs suppressed 96.6% of the Tresp 
proliferation. Similarly, at a 1:16 Treg:Tresp ratio, no suppression was observed for untreated 
Tregs whilst the rapamycin-treated Tregs remained highly suppressive, inhibiting 61.3% of the 
Tresp proliferation, proving the potency of these cells. 
Overall, expanding human CD4+CD25+ Tregs in the presence of rapamycin resulted in cells which 
expressed higher levels of known Treg markers including FOXP3 and the functional molecules 
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CTLA-4 and CD39. This phenotype may have contributed to the superior suppressive capacity 
these cells exhibited in vitro. 
Figure 4-2 │ Human Tregs cultured in the presence of rapamycin were highly suppressive.  
A: Representative flow cytometry data comparing the expression of typical Tregs markers by untreated 
(blue line) and rapamycin-treated (green line) Tregs. Tregs were expanded in the presence or absence of 
100 nM rapamycin for 20 days prior to analysis. Isotype control staining is shown in solid grey and MFI 
values are provided in the top right corner of each plot. Data representative of 4 individual experiments  
B: Suppressive capacity of untreated (blue bars) and rapamycin-treated (green bars) human Tregs. After 
20 days of expansion in the presence or absence of rapamycin, Tregs were co-cultured with CTV-labelled 
Tresps which were activated in a polyclonal manner using a low-dose of anti-human CD3/CD28 beads 
(1:40 bead:Tresp ratio). Cells were co-cultured at varying ratios for 5 days after which Tresp proliferation 
was measured by CTV dilution using a flow cytometer. % suppression was calculated as the inverse of 
% Tresp proliferation, relative to Tresps cultured alone. Data shown is the mean + SD of 3 technica l 
replicates and is representative of 3 individual experiments. Statistical significance was determined 
using a two-tailed paired Student’s t-test where **=p<0.01 and ***=p<0.001. 
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 Human Tregs were lentivirally transduced to express 
the A2 CAR constructs with a high efficiency 
As lentiviral delivery of the A2 CAR into human T cells was demonstrated to be more efficient 
than retroviral delivery (Chapter III), a similar approach was  adopted to generate human A2 CAR 
Tregs. Human CD4+CD25+ Tregs were enriched from peripheral blood, activated using anti-human 
CD3/CD28 beads and cultured in the presence of 1,000 U/mL IL-2 and 100 nM rapamycin, as 
described above. To transduce Tregs in their optimum culture media, lentiviral particles were 
precipitated and re-suspended in X-vivo complete cell media (section 2.2.1). Furthermore, these 
viral particles were suspended in 1∕10 of their original volume to concentrate the viral particles  
10-fold with the rationale that concentrated lentiviral particles may increase the chances of the 
CAR genes being successfully integrated into the genome of the Tregs, ultimately resulting in a 
better transduction efficiency. 
The optimal viral particle concentration required to efficiently delivered the A2 CAR genes into 
human Tregs was determined by transducing these cells with varying concentrations of virus. 
Freshly-isolated Tregs were activated using anti-human CD3/CD28 beads and transduced after  
72 hours with unconcentrated (1X), 2-fold concentrated (2X) or 4-fold concentrated (4X) viral 
particles, relative to the concentration of viral particles present in the original transfected 
HEK293T supernatant (Figure 4-3A). The efficiency with which the Tregs were transduced was 
measured by flow cytometry 7 days post-transduction whereby the proportion of eGFP+ cells was 
assessed. Tregs which were incubated with 1X, 2X and 4X lentiviral particles were transduced with 
efficiencies of 52.7 ± 12.6%, 67.8 ± 11.2% and 79.5 ± 7.3% (n=4), respectively, demonstrating that 
the Tregs were transduced with higher efficiencies when higher concentrations of viral particles 
were used (Figure 4-3B). As such, a viral concentration of 4X was selected for downstream 
experiments. 
The optimal time-point within the Treg expansion protocol (Figure 2-1) for transducing the Tregs 
was also investigated by transducing a fraction of the cells 72 hours after each stimulation. 
Freshly-isolated Tregs were activated using anti-human CD3/CD28 beads, cultured in the 
presence of rapamycin and re-stimulated with fresh anti-CD3/CD28 beads every 10 days. 72 hours 
after each stimulation, a sample of the activated Tregs was removed and transduced with 4X 
lentiviral particles, as detailed above. Transduced cells were maintained in culture for an 
additional 7 days before their transduction efficiency was assessed by flow cytometry  
(Figure 4-4A). The human Tregs were transduced with the highest efficiency following the first 
stimulation (79.7 ± 7.1%; n=4; Figure 4-4B), compared to the second (49.7 ± 6.8%) and third (59.2 
± 10.1%) stimulations. 
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Figure 4-3 │ Transducing human Tregs with higher concentrations of VSV-G-pseudotyped lentiviral particles 
yielded a higher transduction efficiency. A: VSV-G-pseudotyped lentiviral particles were generated by co-
transfecting HEK293T cells with pLNT/SFFV_CAR-eGFP, pCMV-Δ8.91 and pCMV-VSV-G plasmids. 
Transfected HEK293Ts were incubated for 48-56 hours, after which the supernatant containing viral 
particles was collected. The viral particles were precipitated and re-suspended in X-vivo complete cell 
media in one tenth of the volume that was harvested from the HEK293T cells. Consequently, the viral 
particles were concentrated 10-fold (10X). Human CD4+CD25+ Tregs were enriched from the peripheral 
blood of healthy donors, activated using anti-human CD3/CD28 beads and cultured in the presence of 
1,000 U/mL IL-2 and 100 nM rapamycin. After 72 hours, 5x105 Tregs were transduced with different 
concentrations of lentiviral particles in a 24-well plate. In each well, the cells were mixed with media and 
10X virus such that a final viral concentration of 1X, 2X or 4X was achieved. These cells were maintained 
in culture for 7 days where fresh media, IL-2 and rapamycin was replenished every 2 days. B: The efficiency 
with which the Tregs were transduced was measured after 7 days by flow cytometry based on eGFP 
expression. Data representative of 2 individual experiments. 




Figure 4-4 │ Human Tregs were transduced with VSV-G-pseudotyped lentiviral particles more efficiently at 
an earlier time-point. Human CD4+CD25+ Tregs were enriched from the peripheral blood of healthy donors, 
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Overall, these results demonstrated that lentiviral transduction efficiently delivered the  
A2 CAR-eGFP and A2 ΔCAR-eGFP constructs into human Tregs. Furthermore, the optimal 
conditions for transducing the Tregs in this setting was after the first stimulation using a viral 
concentration of 4X. Both of these criteria were adopted for subsequent experiments. 
 
 PHENOTYPIC AND FUNCTIONAL ASSESSMENT OF 
LENTIVIRALLY TRANSDUCED HUMAN TREGS 
Lentiviral transduction is a safe gene delivery approach which is currently employed clinically to 
deliver CD19-specific CAR genes into target T cells for the treatment of CLL (Kalos, Levine et al. 
2011, Porter, Levine et al. 2011). Lentiviruses have also been routinely used in vitro to genetically 
manipulate Tregs (Wright, Notley et al. 2009, Brusko, Koya et al. 2010, Plesa, Zheng et al. 2012, 
MacDonald, Hoeppli et al. 2016). However, given the nature of these viruses to integrate proviral 
into active regions of a target cells’ genome (Ciuffi 2008), it was possible that transducing the 
Tregs using the protocol optimised above could have undesired effects on these cells. To assess 
this, untransduced and transduced Tregs were compared. 
Human Tregs were isolated, activated in a polyclonal manner using anti-human CD3/CD28 beads 
and expanded in the presence of 1,000 U/mL IL-2 and 100 nM rapamycin. After 72 hours, these 
cells were transduced with 4X-concentrated VSV-G-pseudotyped lentiviral particles to express 
either the A2 CAR-eGFP or A2 ΔCAR-eGFP constructs and expanded for an additional 7 days. The 
average transduction efficiencies for the A2 CAR-eGFP and A2 ΔCAR-eGFP constructs was  
55.1 ± 20.3% and 69.2 ± 16.4%, respectively (n=15). Interestingly, as well as being transduced 
more efficiently, the A2 ΔCAR-eGFP construct was also more highly expressed in the Tregs  
(MFI = 13,463 ± 8,572; n=19) compared to the A2 CAR-eGFP construct (MFI = 5,728 ± 3,772). This 
was likely due to the fact that the A2 ΔCAR-eGFP gene was 29% smaller than the A2 CAR-eGFP 
gene and smaller viral RNA species are more easily packaged and delivered into target cells 
(Cante-Barrett, Mendes et al. 2016). 
activated using anti-human CD3/CD28 beads and cultured in the presence of 1,000 U/mL IL-2 and 100 nM 
rapamycin. Tregs were re-stimulated with fresh anti-CD3/CD28 beads every 10 days. 72 hours after each 
stimulation, a fraction of the cells were transduced with 4X concentrated VSV-G-pseudotyped lentiviral 
particles to express either the A2 CAR-eGFP or A2 ΔCAR-eGFP construct. The efficiency of transduction was 
measured 7 days post-transduction by flow cytometry based on eGFP expression. Data representative of 
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Successfully transduced cells were isolated by cell sorting 7 days post-transduction, gating on 
eGFP+ cells. eGFP expression was shown to be directly correlated with presence of the CAR on 
the cell surface, as detected by 9E10 cMyc tag epitope staining (Figure 4-5). The Tregs were then 
re-simulated with anti-human CD3/CD28 beads and expanded for an additional 10 days in the 
presence of 1,000 U/mL IL-2 and 100 nM rapamycin prior to characterisation. 
 
 The phenotype of human Tregs was unaltered 
following lentiviral transduction 
At the end of the expansion protocol, more than 95% (95.3-97.8 ± 4.7%; n=4) of the transduced 
Tregs were eGFP+, demonstrating that the A2 CAR-eGFP and A2 ΔCAR-eGFP genes were stably 
integrated and expressed in the Tregs. To investigate whether the expression of typical Treg 
markers was influenced by the transduction and cell sorting processes, the expression of CD4, 
CD25, CD127, FOXP3, CTLA-4 and CD39 in these cells was assessed (Figure 4-6). Untransduced, 
A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs all exhibited a similar phenotype; they remained 
Figure 4-5 │ Human Tregs expressing the A2 CAR-eGFP and A2 ΔCAR-eGFP constructs were isolated with a 
high purity by cell sorting based on eGFP expression. Human Tregs cultured in the presence of rapamycin 
were lentivirally transduced with VSV-G-pseudotyped particles 3 days post-activation to express the  
A2 CAR-eGFP or A2 ΔCAR-eGFP constructs. Successfully transduced cells were isolated by cell sorting, 
based on their eGFP expression 7 days post-transduction. A: Transduction efficiency of human Tregs 7 days 
post-transduction, immediately before cell sorting. Cells were stained with a fluorescently-conjugated 
9E10 clone antibody specific for the cMyc tag present in the extracellular domain of each A2 CAR construct 
prior to data acquisition. B: eGFP+ cell purity immediately after cell sorting. Data shown is representative 
of 2 (A) or 15 (B) individual experiments. 
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CD4+CD25+CD127lo with a high expression the transcription factor FOXP3 (94.2-95.8 ± 7.3%; n=4, 
Figure 4-6B). With regards to Treg functional markers, all of the cells expressed CTLA-4 (91.3-95.3 
± 3.1%) with a high proportion also expressing CD39 (72.4-81.7 ± 16.3%). Overall, no significant 
differences were observed in the expression of the Treg markers analysed between the 3 Treg 
cell lines. 
Figure 4-6 │ Human Tregs remain CD4+CD25hiCD127lo with a high expression of FOXP3, CTLA-4 and CD39 
following lentiviral delivery of the A2 CAR-eGFP/ΔCAR-eGFP constructs. Cell sorted eGFP+ Tregs were  
re-stimulated in a polyclonal manner using anti-human CD3/CD28 beads and cultured in the presence of 
rapamycin for 10 days. The expression of crucial human Treg markers was then measured by flow 
cytometry. Dead cells were excluded using a LIVE/DEAD dye and cells were stained with fluorescently-
conjugated antibodies specific for CD4, CD25, CD127, FOXP3, CTLA-4 and CD39. Cells were fixed and 
permeabilised prior to staining of FOXP3 and CTLA-4 A: Representative flow cytometry data comparing 
the expression of the aforementioned Tregs markers and eGFP by untransduced (red line) A2 CAR-eGFP 
(blue line) and A2 ΔCAR-eGFP (green line) Tregs. Isotype control staining is shown in solid grey. B: Pooled 
flow cytometry data comparing the expression of Treg markers by untransduced (red bars), CAR (blue bars) 
and ΔCAR (green bars) Tregs. Data represents mean + SD pooled from 4 individual experiments. A paired 
Student’s t-test was performed to determine statistical significance but no significance was observed.  
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Considering the functional importance of Treg trafficking in vivo, the expression of specific 
homing receptors was also evaluated. No significant differences in the proportion of Tregs 
expressing these markers were observed between the untransduced, A2 CAR-eGFP and  
A2 ΔCAR-eGFP Treg lines (Figure 4-7). All of the Tregs expressed the skin homing molecule CCR4 
Figure 4-7 │ Human Tregs maintain their expression of specific homing receptors following lentiviral 
delivery of the A2 CAR-eGFP/ΔCAR-eGFP constructs. The expression of various homing receptors by the 
human Tregs was measured at the end of the expansion period by flow cytometry. Dead cells were 
excluded using a LIVE/DEAD dye and cells were stained with fluorescently-conjugated antibodies specific 
for the skin homing receptors CCR4, CCR10 and CLA, the gut-homing receptors CCR9 and Integrin β7, and 
the secondary lymphoid organ homing receptor CD62L. A: Representative flow cytometry data comparing 
the expression of the aforementioned homing receptors by untransduced (red line) A2 CAR-eGFP (blue line) 
and A2 ΔCAR-eGFP (green line) Tregs. Isotype control staining is shown in solid grey. B: Pooled flow 
cytometry data comparing the expression of homing receptors by untransduced (red bars), A2 CAR-eGFP 
(blue bars) and A2 ΔCAR-eGFP (green bars) Tregs. Data shown is mean + SD pooled from 4 individual 
experiments. A paired Student’s t-test was performed to determine statistical significance but no 
significance was observed. 
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(96.7-98.8 ±3.2%; n=4, Figure 4-7B) whilst an intermediate proportion expressed CLA  
(48.4-51.0 ± 26.4%) and few cells expressed CCR10 (0.6-1.5 ± 0.7%). Furthermore, a high 
proportion of the Tregs expressed the secondary lymphoid organ homing molecule CD62L  
(93.7-95.6 ± 3.9%). With regards to gut homing, whilst a high proportion of cells expressed 
integrin β7 (91.7-93.2 ± 5.9%), few cells expressed CCR9 (1.1-1.7 ± 1.0%) which is required for 
trafficking to gut-associated lymphoid tissues (Svensson, Marsal et al. 2002). 
Overall, these results demonstrated that the phenotype of the rapamycin-treated Tregs remained 
stable following the transduction process, with a dominance of chemokine receptors favouring 
homing to the skin and lymph nodes, as previously published (Scotta, Esposito et al. 2013). 
 
 Human Tregs remained suppressive following 
lentiviral transduction 
 To investigate whether the lentiviral transduction procedure influenced the suppressive capacity 
of rapamycin-treated Tregs, the suppressive capacity of the A2 CAR-eGFP and A2 ΔCAR-eGFP 
Tregs was compared to untransduced Tregs, as described above. Tresp proliferation was 
Figure 4-8 │ Human Tregs maintained their suppressive capacity following lentiviral delivery of the A2 CAR-
eGFP/ΔCAR-eGFP constructs. The suppressive capacity of the human Tregs was assessed at the end of the 
Treg expansion period. Untransduced (red line), A2 CAR-eGFP (blue line) and A2 ΔCAR-eGFP (green line) 
Tregs were co-cultured with 1x105 autologous CTV-labelled CD4+CD25– Tresps which were activated with 
a low-dose (1:40 bead:cell ratio) of anti-human CD3/CD28 beads. Tresp proliferation was measured after 
5 days of culture. Dead cells were excluded using a LIVE/DEAD dye and CTV dilution was assessed using a 
flow cytometer. Tresp proliferation was calculated as a percentage relative to Tresps cultured in the 
absence of Tregs and the inverse of this % proliferation was used to determine the % suppression. Data 
shown represents mean ± SEM pooled from 5-6 individual experiments. A two-tailed paired Student’s  
t-test was performed to determine statistical significance but no significant differences were observed.  
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measured by CTV dilution and calculated using division indices. At all Treg:Tresp ratios analysed, 
no significant differences were observed in the extent to which the untransduced, A2 CAR-eGFP 
or A2 ΔCAR-eGFP suppressed Tresp proliferation (Figure 4-8). Furthermore, the overall 
suppressive profile of all 3 Treg lines was very similar. At a 1:32 ratio, untransduced Tregs 
inhibited Tresp proliferation by 43.0% ± 4.1% whilst the A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs 
suppressed the proliferation of the Tresps by 44.8% ± 5.4% and 39.4% ± 5.7%, respectively  
(n=5). Overall, these results demonstrated that delivery of the A2 CAR genes into human 
rapamycin-treated Tregs using second-generation VSV-G-pseudotyped lentiviral particles did not 
impede the suppressive ability of these cells. 
 
 DISCUSSION 
In this chapter, a previously established GMP-compatible protocol was employed to enrich 
human CD4+CD25+ Tregs with an efficiency of approximately 90%. The sequential negative and 
positive selection protocol used was directly relatable to what is currently employed in clinical 
trials based at Guy’s Hospital. These cells were activated in a polyclonal manner using anti-human 
CD3/CD28 beads and expanded in the presence of 1,000 U/mL IL-2, with or without 100 nM 
rapamycin. Rapamycin-treated Tregs were shown to express higher levels of FOXP3, CTLA-4 and 
CD39 and suppress autologous CD4+CD25– Tresp proliferation more effectively than untreated 
Tregs, in line with previous studies (Putnam, Brusko et al. 2009, Golovina, Mikheeva et al. 2011, 
Scotta, Esposito et al. 2013). 
Culturing Tregs in the presence of rapamycin also enhances the stability of these cells. Over the 
past few years, there has been a shift in the understanding of CD4+ T cell subsets, moving away 
from the idea of defined lineages and towards a model based on T cell plasticity. This train of 
thought has emerged from studies which have demonstrated that CD4+ T cells which exhibit 
typical characteristics of one subset (including specific transcription factor expression) can 
convert and exhibit characteristics of another subset. This is exemplified by the crosstalk which 
exists between tTregs and Th17 cells; culturing Th17 cells in the presence of TGFβ promotes 
conversion towards a regulatory phenotype (Bettelli, Carrier et al. 2006, Zhou, Lopes et al. 2008, 
Gagliani, Amezcua Vesely et al. 2015) whilst culturing Tregs in the presence of IL-6,  
IL-1β and IL-23 can cause a loss of FOXP3 expression and increased IL-17 production (Koenen, 
Smeets et al. 2008, Yang, Nurieva et al. 2008). However, studies have also demonstrated that 
culturing Tregs in the presence of rapamycin confers a resistance to this conversion (Golovina, 
Mikheeva et al. 2011, Tresoldi, Dell'Albani et al. 2011, Scotta, Esposito et al. 2013). This resistance 
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is believed to be due to changes in the epigenetic profile of the Tregs which promotes the 
expression of FOXP3 (Abele-Ohl, Leis et al. 2010, Golovina, Mikheeva et al. 2011, Rossetti, 
Spreafico et al. 2015). Additional studies have also demonstrated a link between this increased 
Treg stability and TSDR demethylation (Golovina, Mikheeva et al. 2011, Rossetti, Spreafico et al. 
2015). 
The results presented in this chapter proceeded to demonstrate that lentiviral transduction of 
the human Tregs did not influence the phenotype or suppressive ability of these cells. This is in 
line with previous studies which have shown similar findings (Hombach, Kofler et al. 2009, Brusko, 
Koya et al. 2010, Plesa, Zheng et al. 2012, Kim, Zhang et al. 2015, MacDonald, Hoeppli et al. 2016) 
but was important to address given the different laboratory conditions under which this gene 
manipulation was being performed. Previously published Treg transduction protocols transduce 
the cells 48-72 hours following polyclonal activation (Hombach, Kofler et al. 2009, Brusko, Koya 
et al. 2010). In this chapter, Tregs were activated in a polyclonal manner and cultured in the 
absence of IL-2 for 48 hours, allowing time for the rapamycin to act on the Tconvs. This concept 
is currently applied for an extended period of time (>4 days) in the GMP facility at Guy’s Hospital. 
The Treg cultures were then supplemented with 1,000 U/mL IL-2 for 24 hours before being 
transduced with concentrated lentiviral particles 72 hours post-activation, in line with previous 
studies (MacDonald, Hoeppli et al. 2016). Transduction did not influence the expression of 
published Treg markers such as CD4, CD25, CD127, FOXP3, CTLA-4 and CD39, nor the expression 
of various homing receptors including CCR4, CCR10, CLA, CCR9, integrin β7 and CD62L. 
Furthermore, the suppressive capacity of the transduced Tregs was the same as the untransduced 
Tregs.  
The adaptation of gene-modified Tregs in the clinic is somewhat dependent on current clinical 
trials, designed to assess the safety and efficacy of polyclonal Treg therapy. In these trials, 
promising results have been noted to date where Treg doses of up to 10x106 cells/kg have been 
well tolerated in renal transplant recipients at Guy’s Hospital. However, to apply CAR technology 
in this setting, it will be necessary to genetically modify the Tregs, a process which is associated 
with additional risks. Due diligence would dictate that a sequential timeline is employed whereby 
Treg therapy using unmodified cells is deemed safe before trials using gene-modified cells are 
initiated. This may unfortunately hamper the progression of clinical trials which aim to investigate 
the safety and efficacy of CAR Treg therapy.  
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 SUMMARY  
The results presented in this chapter confirmed that culturing human Tregs in the presence of 
rapamycin enhanced the functionality of these cells. Furthermore, these Tregs can be transduced 
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EXPRESSION IN HUMAN TREGS 
Conferring antigen-specificity onto Tregs can influence the functionality of these cells in a variety 
of different ways. The most profound and archetypical effect is the efficacy with which these cells 
elicit a suppressive function in the presence of their target antigen. This is typically assessed using 
an “antigen-specific suppression assay” whereby CD4+CD25– Tresps are activated with allogeneic 
APCs and the ability of the Tregs to inhibit Tresp proliferation is assessed (Thornton and Shevach 
2000, Tang, Henriksen et al. 2004, Zhou, Borojevic et al. 2004, Fujio, Okamoto et al. 2006, Tsang, 
Tanriver et al. 2008, Stephens, Malpass et al. 2009, Tsang, Tanriver et al. 2009, Wright, Notley et 
al. 2009, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). Variations on this type of experiment 
are included in all studies investigating the influence of antigen-specificity on Treg function. 
Trafficking of Tregs is believed to be principally driven by homing receptors, although studies 
investigating antigen-specific Tconvs have demonstrated that this process can be influenced by 
interactions made through the TCR. This is primarily mediated through the TCR engaging  
MHC-peptide complexes which are presented by epithelial cells. In a transplant context, this 
engagement typically leads to the induction of anergy (Marelli-Berg, Weetman et al. 1997). 
However, studies have demonstrated that TCR engagement can also facilitate the egression of  
T cells (Marelli-Berg, Frasca et al. 1999, Greening, Tree et al. 2003, Marelli-Berg, James et al. 2004) 
and Tregs (Fu, Kishore et al. 2014) into specific tissues. TCR engagement may also contribute to 
the retention of antigen-specific T cells in tissues where a cognate antigen is expressed, as has 
been observed in models of MS (Karin, Szafer et al. 1993) and T1D (Lennon, Bettini et al. 2009). 
 
 HUMANISED MOUSE MODELS IN TRANSPLANTATION  
Mouse models have been instrumental in progressing our understanding of the immune system. 
However, treatment options which have been revealed in mice have not always been successfully 
translated to humans due to fundamental differences which exist between these two organisms. 
A prime example relates to non-obese diabetes (NOD) mice which spontaneously develop T1D 
(Makino, Kunimoto et al. 1980). Studies over the past 35 years have attributed this to mutations 
in various genetic loci including the MHC loci (Lund, O'Reilly et al. 1990, Miyazaki, Uno et al. 1990, 
Slattery, Kjer-Nielsen et al. 1990, Hattori, Yamato et al. 1999), the preproinsulin gene (French, 
Allison et al. 1997, Todd and Wicker 2001) and a locus comprising the CD28 and CTLA-4 genes 
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(Hill, Lyons et al. 2000, Lamhamedi-Cherradi, Boulard et al. 2001). Studies performed with these 
mice demonstrated that treatment with rapamycin and IL-2 prevented the spontaneous 
development and recurrence or diabetes after islet transplantation (Rabinovitch, Suarez-Pinzon 
et al. 2002). However, when a similar approach was adopted in a clinical trial, rapamycin and  
IL-2 treatment was found to have the opposite effect in humans, exacerbating β-cell dysfunction 
and overall having a detrimental effect (Long, Rieck et al. 2012). 
The issues surrounding the discordance between different species can be partially circumvented 
through the use of humanised mouse models whereby mice are engrafted with human immune 
cells. In order to achieve engraftment, it is necessary to use immunocompromised mice such that 
transferred human cells are not immediately killed by xeno-immune responses. This was a 
particular issue in early humanised mouse models which relied on mutations in the protein 
kinase, DNA activated, catalytic polypeptide, scid (Prkdcscid) gene, where injection of 
haematopoietic cells or PBMCs commonly resulted in <0.1% engraftment (McCune, Namikawa et 
al. 1988, Mosier, Gulizia et al. 1988, Lapidot, Pflumio et al. 1992). However, this was resolved over 
the forthcoming years with the development of mice with alternative genetic mutations 
(Goldman, Blundell et al. 1998, Mazurier, Fontanellas et al. 1999, Shultz, Lyons et al. 2005). 
Consequently, humanised mice are now utilised to investigate human immune responses in vivo 
in a wide variety of settings, ranging from solid and haematological cancers to autoimmunity and 
transplantation. 
Two strains which are commonly used in modern humanised mouse models are BRG and NSG 
mice. BRG mice lack the RAG2 and the γc gene (section 3.1.2) and as such, do not develop cells 
which rely on rearrangement of the TCR/BCR loci or on detection of IL-2, IL-4, IL-7, IL-9, IL-15 or 
IL-21 (Sugamura, Asao et al. 1996, Shultz, Lyons et al. 2005). Along similar lines, NSG mice 
combine the features of NOD and scid mice with the deficiencies which accompany removal of 
the γc gene. The mutations in both BRG and NSG mice culminate in strains which lack lymphoid 
lineage-derived cells, namely B cells, T cells and NK cells (Cao, Shores et al. 1995, DiSanto, Muller 
et al. 1995, Ohbo, Suda et al. 1996). 
Unlike many of their predecessors, BRG and NSG mice support long-term reconstitution of human 
immune cells, making them versatile tools which can be used in many research settings (Shultz, 
Lyons et al. 2005). However, the range and location of the human cells which are reconstituted is 
dependent on many factors including the nature of the cells transferred, the route of 
administration and the age of the mice. For example, mice which receive human haematopoietic 
stem cells (HSC) are capable of reconstituting a more complete immune system than mice which 
receive PBMCs (Shultz, Lyons et al. 2005, Brehm, Cuthbert et al. 2010, Ali, Flutter et al. 2012). 
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Furthermore, HSC infusion into new-born mice achieves a more efficient engraftment than 
infusion into adult mice (Brehm, Cuthbert et al. 2010).  
Despite advances with humanised mouse models, there are still certain issues which remain to 
be addressed. For example, the T cells which develop in the majority of these models do not 
undergo thymic selection which has important implications when assessing the functionality of  
T cells or Tregs. Recent studies have attempted to address this using different approaches. One 
approach is to reconstitute irradiated immunocompromised mice with human HSCs and allow the 
T cells to develop within the mouse thymic environment (Lepus, Gibson et al. 2009, Brehm, 
Cuthbert et al. 2010). Although this can be accomplished with relative ease, it is important to 
note that the nature with which human T cells engage murine MHC-peptide complexes is not fully 
understood (Halkias, Yen et al. 2015). However, this approach was recently improved by  
Serra-Hassoun et al. who generated mice in which murine MHC presentation was replaced with 
human HLAs, allowing human HSCs to be educated against human HLA complexes (Serra-
Hassoun, Bourgine et al. 2014). An alternative approach to generate humanised mice with 
thymically educated human T cells is to surgically implant adult mice with a human foetal thymus 
and liver under the kidney capsule and then to transfer human HSCs into these mice (Lan, 
Tonomura et al. 2006, Aryee, Shultz et al. 2014). This is known as the BM, liver and thymus (BLT) 
model and achieves both high levels of human cell engraftment and yields T cells which have been 
educated in a human thymus (Safinia, Becker et al. 2016). 
In the transplant field, humanised mouse models have been used to investigate both GvHD and 
solid tissue transplantation. An overview of these applications is provided below. 
 
 Xeno-graft-versus-host disease 
BM transplantation (or more broadly haematopoietic stem cell transplantation (HSCT)) is a 
treatment option which is performed to treat various haematological conditions including 
cancers (leukaemias/myelomas), aplastic anaemia and congenital immunodeficiencies (Safinia, 
Becker et al. 2016). However, the benefits of this treatment option are severely compromised by 
GvHD in which the transferred donor immune cells recognise their recipient surroundings as 
foreign. 
To research GvHD in vivo, humanised mouse models have been developed which rely on a  
xeno-immune response elicited by human immune cells towards murine antigens. In these 
models, human PBMCs are usually transferred into adult recipient mice (Ali, Flutter et al. 2012). 
Over the past 20 years, it has become apparent that higher levels of engraftment are achievable 
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in mice which are more severely immunocompromised, such as NSGs (Ito, Katano et al. 2009) or 
mice which have undergone TBI to kill haematopoietic progenitor cells (Cui, Hisha et al. 2002, van 
Rijn, Simonetti et al. 2003). A recent study performed in collaboration with the host laboratory 
demonstrated that human cell engraftment and GvHD development was faster in NSG mice than 
BRG mice (Ali, Flutter et al. 2012). Studies have also demonstrated that the GvHD symptoms 
induced by the transfer of human PBMCs can be suppressed by the co-transfer of Tregs. This 
suppression is mediated in a dose-dependent manner and has been exploited to both 
demonstrate the efficacy of Treg therapy, and the potential of biological agents which promote 
the activity of Tregs in vivo (Mutis, van Rijn et al. 2006, Becker, Taube et al. 2009, Hahn, Stahl et 
al. 2013, Hahn, Bellinghausen et al. 2015). 
 
 Solid tissue transplantation 
Various healthy human tissues can be transplanted into mice such as vessels (Lorber, Wilson et 
al. 1999, Koh, Wang et al. 2004, Nadig, Wieckiewicz et al. 2010), islets (Jacobson, Heuts et al. 
2010, Wu, Hester et al. 2013, Xiao, Ma et al. 2014) and bronchi (Sommer, Knofel et al. 2015). 
However, the most common human tissue transplanted onto mice is human skin due to the 
relative abundance of this organ and the less invasive nature of the transplant procedure (Issa, 
Hester et al. 2010, Racki, Covassin et al. 2010, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). 
Early human skin xenograft transplant models were performed using C.B-17 scid recipient mice 
and were deemed highly successful as the skin xenografts maintained their tissue architecture 
(Kawamura, Niguma et al. 1992, Alegre, Peterson et al. 1994, Murray, Petzelbauer et al. 1994). 
However, human immune cells did not efficiently engraft in these mice. To address this, a range 
of different strategies were trialled with varying success; some models opted to increase the 
number of cells which were injected into the recipient mice (up to 3x108/mouse) whilst other 
models investigated using TBI or different recipient mouse strains (Alegre, Peterson et al. 1994, 
Murray, Petzelbauer et al. 1994).  
Current models opt to use NSG or BRG mice as human skin xenograft recipients and to mediate 
graft rejection through the transfer of human allogeneic PBMCs (Issa, Hester et al. 2010, Racki, 
Covassin et al. 2010, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). However, the functional 
granulocytes in these mice have been shown to significantly damage the tissue architecture thus 
consistent depletion of these cells achieved through bi-weekly injections of anti-mouse Gr-1 is 
necessary (Racki, Covassin et al. 2010). Transfer of human PBMCs into Gr-1-depleted mice bearing 
well-healed human skin xenografts resulted in alloimmune-mediated graft injury which can be 
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measured by a loss of microvasculature and destruction of the epidermal/dermal skin layers 
(Racki, Covassin et al. 2010, Sagoo, Ali et al. 2011). This damage correlateed with human immune 
cell infiltration and was alleviated by the co-transfer of human Tregs (Sagoo, Ali et al. 2011, 
Putnam, Safinia et al. 2013). Importantly, the latter studies also demonstrated that  
allograft-specific Tregs, generated by expanding Tregs using allogeneic APCs, offered significantly 
more protection from alloimmune-mediated graft injury than polyclonal Tregs, upon adoptive 
transfer. In an islet transplant setting, Treg transfer was demonstrated to delay allograft rejection 
and diabetes onset by inhibiting innate immune cell infiltration and T cell 
differentiation/proliferation (Wu, Hester et al. 2013, Xiao, Ma et al. 2014). 
 
 AIMS AND OBJECTIVES 
The aim of this chapter was to assess how expression of an alloantigen-specific CAR influenced 
the functionality of human Tregs in vitro and in vivo. The functionality of the Tregs was confirmed 
in vitro through the use of an antigen-specific suppression assay with allogeneic HLA-A2+ or  
HLA-A2– B-LCLs as APCs. The trafficking of these cells was then assessed in vitro using a 
transmigration system whereby the Tregs were to be flowed across HLA-A2+ or HLA-A2– 
endothelial HUVEC monolayers. Having confirmed that the A2 CAR-eGFP Tregs were functionally 
superior in vitro, the protective efficacy of these cells was compared to polyclonal and  
A2 ΔCAR-eGFP Tregs in vivo in both a xeno-GvHD model using HLA-A2 transgenic mice and a 
human skin xenograft transplant model. 
 
 RESULTS 
 HUMAN TREGS EXPRESSING THE A2  CAR-EGFP  OR  
A2  ΔCAR-EGFP  SPECIFICALLY RECOGNISED HLA-A2 
In the analyses performed in Chapter IV, it was confirmed that lentiviral delivery of the A2 CAR 
genes into rapamycin-treated Tregs did not influence the phenotype or suppressive capacity of 
these cells following polyclonal stimulation. However, in order to confirm whether CAR 
expression conferred an ability to recognise HLA-A2, transduced Tregs were stained with 
dextramers which presented peptides in the context of HLA-A2 or HLA-B7 (an irrelevant control). 
These dextramers were kindly donated by Dr Marc Martinez-Llordella (Institute of Liver Sciences, 
Chapter V │ Characterising human A2 CAR Tregs 
 
132 
King’s College London, UK). Given the TCR heterogeneity of the polyclonally-expanded cells, no 
polyclonal (untransduced) Tregs were able to recognise the specific HLA-peptide complexes 
presented in these dextramers (Figure 5-1A). In contrast, all eGFP+ Tregs expressing the  
A2 CAR-eGFP (Figure 5-1B) and A2 ΔCAR-eGFP (Figure 5-1C) constructs were able to recognise 
the HLA-A2-based dextramer but not the irrelevant HLA-B7-based dextramer. Furthermore, as 
alluded to above (Figure 4-5), Tregs which expressed more of the CAR constructs (a higher MFI) 
were able to bind a greater amount of the HLA-A2-based dextramer, demonstrating a direct 
correlation between CAR expression and HLA-A2 recognition. Overall, these results confirmed 
that Tregs expressing the A2 CARs specifically recognised intact HLA-A2-peptide complexes. 
To demonstrate the activation of A2 CAR-eGFP Tregs in the presence of HLA-A2, transduced Tregs 
were co-cultured with artificial HLA-A2+ or HLA-A2– APCs for 18 hours after which Treg expression 
of CD69 expression was measured by flow cytometry. Two forms of APC were used: K562 cells 
and EBV-transformed B-Lymphoblastoid cell lines (B-LCL). K562 cells are immortalised 
myelogenous leukaemia cells which do not express MHC molecules (Andersson, Nilsson et al. 
1979). The K562 cell lines used were kindly donated by Dr Marc Martinez-Llordella and were 
either empty (HLA-A2–) or stably transduced to express HLA-A2 (Figure 5-2A). B-LCLs are B cells 
which are derived from HLA-typed donors and immortalised by CMV transduction (Leung, Maurer 
Figure 5-1 │ Lentiviral delivery of the A2 CAR-eGFP/ΔCAR-eGFP constructs into human Tregs confers the 
ability to specifically recognise HLA-A2. The ability of the human Tregs to specifically recognise HLA-A2 was 
determined by dextramer staining at the end of the Treg expansion period. Polyclonal (A), A2 CAR-eGFP 
(B) and A2 ΔCAR-eGFP (C) Tregs were stained with PE-conjugated dextramers which presented peptides in 
the context of HLA-A2 or HLA-B7 (irrelevant dextramer) and dextramer recognition was measured by flow 
cytometry. 
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et al. 2013). The B-LCLs used were SPO (HLA-A2+) or BM21 (HLA-A2–) which both expressed the 
MHC class II molecules HLA-DR11 (Figure 5-2B). Tregs were co-cultured with irradiated (120 Gy) 
APCs at a 4:1 Treg:APC ratio for 18 hours. Total cells were then harvested, stained with 
fluorophore-conjugated antibodies specific for CD4 and CD69 and expression of CD69 was 
measured by flow cytometry. As shown in Figure 5-2, polyclonal and A2 ΔCAR-eGFP Tregs were 
not activated upon co-culture with either the HLA-A2+ or HLA-A2– APCs. In contrast, CD69 was 
upregulated on the A2 CAR-eGFP Tregs following co-culture with the HLA-A2+ APCs only. 
A similar experimental approach was adopted to assess whether proliferation was induced in  
A2 CAR-eGFP Tregs upon co-culture with HLA-A2+ APCs. Tregs were co-cultured at a 1:1 ratio with 
the irradiated artificial APCs described above for 72 hours. 1 μCi 3H-thymidine was added for the 
last 18 hours of culture and proliferation was measured as 3H-thymidine incorporation using a 
beta-plate liquid scintillation counting approach. A2 CAR-eGFP Tregs proliferated significantly 
more in the presence of HLA-A2-transfected K562s than in the presence of HLA-A1-transfected 
K562s (p=0.029; Figure 5-3A, representative of 2 experiments). This difference was not observed 
for the polyclonal (p=0.15) or A2 ΔCAR-eGFP (p=0.58) Tregs. Similar results were obtained when 
Figure 5-2 │ A2 CAR-eGFP Tregs were specifically activated in the presence of HLA-A2. Tregs were  
co-cultured at the end of their expansion period with irradiated (120 Gy) artificial APCs for 18 hours at a 
4:1 Treg:APC ratio after which CD69 expression in the CD4+ Tregs was analysed by flow cytometry. The 
APCs used were K562s (A) or B-LCLs (B). The K562s were either empty (HLA-A2–; green line) or stably 
transfected to express HLA-A2 (blue line). The B-LCLs used were SPO (HLA-A2+; blue line) or BM21  
(HLA-A2–; green line). Tregs cultured without APCs are shown in solid grey. Data representative of 2 
individual experiments. 
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the Tregs were co-cultured with HLA-A2+ (SPO) and HLA-A2– (BM21) B-LCLs whereby  
A2 CAR-eGFP Tregs proliferated more in the presence of HLA-A2 (p=0.0047; Figure 5-3B, 
representative of 2 experiments) whilst polyclonal (p=0.74) and A2 ΔCAR-eGFP (p=0.76) Tregs did 
not.  
Figure 5-3 │ A2 CAR-eGFP Tregs were induced to proliferate in the presence of HLA-A2. Tregs were  
co-cultured at the end of their expansion period with irradiated (120 Gy) artificial APCs for 18 hours at a 
1:1 Treg:APC ratio after which Treg proliferation was measured by 3H-thymidine incorporation. The APCs 
used were either K562s (A) or B-LCLs (B). The K562s were stably transfected to express either HLA-A2 (blue 
bars) or HLA-A1 (green bars). The B-LCLs used were SPO (HLA-A2+; blue bars) or BM21 (HLA-A2–; green 
bars). Data shown is mean + SD of technical triplicates and is representative of 2 individual experiments. 
Statistical significance was determined using a two-tailed paired Student’s t-test where *p<0.05 and 
**p<0.01. ns = not significant. 
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Overall, these results demonstrated that Tregs expressing either of the A2 CARs were able to 
specifically recognise HLA-A2. However, Treg activation following HLA-A2 engagement was 
dependent on the ability of the CAR construct to signal intracellularly as no activation was 
observed for Tregs expressing the A2 ΔCAR-eGFP construct which lacked an intracellular  
CD28-CD3ζ signalling domain. 
 
 ASSESSMENT OF THE EFFICACY OF HUMAN A2  CAR-EGFP  
TREGS IN VITRO 
Having confirmed that human Tregs expressing the A2 CARs were specifically activated in the 
presence of HLA-A2, the next step was to assess whether this conferred a conferred a functional 
advantage to these cells in the presence of HLA-A2. This was accomplished through the use of 
various Treg functional assays which were performed in the presence and absence of HLA-A2. 
 
 Human A2 CAR-eGFP Tregs exhibited a superior 
suppressive capacity in the presence of HLA-A2 
In a typical direct alloimmune response, CD4+ T cells are activated by allogeneic APCs which 
present intact donor HLA-peptide complexes on their surface. To investigate whether  
A2 CAR-eGFP Tregs were more potent than polyclonal Tregs at suppressing Tresp activation and 
proliferation in the presence of HLA-A2+ APCs, an antigen-specific suppression assay was 
performed using the aforementioned B-LCLs as APCs (Figure 5-4). CTV-labelled CD4+CD25‒ Tresps 
were co-cultured with either HLA-A2+ B-LCLs (DBB or SPO) or HLA-A2‒ B-LCLs (MOU or BM21) 
where the HLA-DR molecule expressed by the B-LCLs was the same (HLA-DR7 or HLA-DR11). 
Activation of the Tresp was facilitated by direct allorecognition of the HLA-DR molecules 
presented by the APCs and polyclonal, A2 CAR-eGFP or A2 ΔCAR-eGFP Tregs were added to these 
co-cultures to investigate the efficacy with which they could suppress this Tresp activation. As the 
Tregs were autologous to the Tresps, it was expected Tregs which had direct allospecificity would 
be activated through their TCR, in a similar manner to the Tresps (Veerapathran, Pidala et al. 
2011). Consequently, polyclonal Tregs were expected to have the capacity to suppress Tresp 
activation but the efficacy with which this could be achieved was hypothesised to be greater for 
A2 CAR-eGFP Tregs in the presence of HLA-A2. 
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The suppressive profile of the polyclonal Tregs cultured with HLA-A2+ and HLA-A2‒ B-LCLs was 
identical (Figure 5-5A). This indicated that, as expected, the presence of HLA-A2 did not influence 
the suppressive capacity of these cells. In contrast, A2 CAR-eGFP Tregs inhibited Tresp 
proliferation more effectively (p-values ranging from 0.0082 to 1.1x10‒5; n=5) in the presence of 
HLA-A2+ B-LCLs, compared to HLA-A2‒ B-LCLs, at Treg:Tresp ratios ranging from 1:2 to 1:64  
(Figure 5-5B). At a 1:32 Treg:Tresp ratio, A2 CAR-eGFP Tregs inhibited Tresp proliferation by  
62.8 ± 5.2% in the presence of HLA-A2+ B-LCLs but only 35.8 ± 3.5% in the presence of  
HLA-A2‒ B-LCLs. Similarly, at a 1:64 Treg:Tresp ratio, Tresp proliferation was inhibited in the 
presence of HLA-A2+ B-LCLs by 38.1 ± 3.6% and in the presence of HLA-A2‒ B-LCLs by 16.9 ± 3.4%. 
Overall, these results suggested that at physiologically-relevant Treg:Tresp ratios, A2 CAR-eGFP 
Tregs were twice as potent as polyclonal Tregs at suppressing Tresp proliferation in the presence 
of HLA-A2+ APCs. Interestingly, the suppressive capacity of the A2 ΔCAR-eGFP Tregs was also 
influenced by the presence of HLA-A2 (Figure 5-5C); A2 ΔCAR-eGFP Tregs were significantly more 
Figure 5-4 │ Schematic diagram explaining the setup of the antigen-specific suppression assay.  
Antigen-specific suppression assays were performed by co-culturing CD4+CD25– Tresps (purple) with 
allogeneic B-LCLs as APCs (blue) and Tregs (orange). Tresp activation relied on direct allorecognition of the 
allogeneic HLA-DR molecule which was either HLA-DR7 or HLA-DR11 (green) and proliferation of these 
cells was measured by CTV dilution. Assays were performed in pairs which differed by the B-LCL which was 
included in the co-culture. In each pair, the B-LCLs expressed the same HLA-DR molecule but one B-LCL was 
HLA-A2+ (A) and the other was HLA-A2– (B). Control Tresps were cultured with APCs only without Tregs. 
Polyclonal, A2 CAR-eGFP or A2 ΔCAR-eGFP Tregs were added to the Tresp:APC co-culture at Treg:Tresp 
ratios ranging from 1:2 to 1:128. It was hypothesised that A2 CAR-eGFP Tregs would supress the Tresp 
proliferation more effectively in the presence of HLA-A2 (A) compared to the absence of HLA-A2 (B). In 
contrast, the polyclonal and A2 ΔCAR-eGFP Tregs were expected to exhibit a similar suppressive profile 
irrespective of the presence of HLA-A2. 
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Figure 5-5 │ Human Tregs expressing the A2 CAR-eGFP construct suppressed autologous CD4+CD25– Tresp 
proliferation with a greater potency in the presence of HLA-A2+ antigen presenting cells. The efficacy with 
which human Tregs suppressed autologous Tresp proliferation in the presence HLA-A2+ or HLA-A2– APCs 
was determined at the end of the Treg expansion period. Polyclonal (A), A2 CAR-eGFP (B) and  
A2 ΔCAR-eGFP (C) Tregs were co-cultured with 1x105 autologous CTV-labelled CD4+CD25– Tresps and  
3x104 irradiated (120 Gy) B-LCLs. Assays were performed in parallel where one co-culture contained  
HLA-A2+ B-LCLs (blue line) and the other co-culture contained HLA-A2– B-LCLs (green line). In each assay 
pairing, the B-LCLs used expressed the same HLA-DR molecule (HLA-DR7 or HLA-DR11). Assays were 
performed in duplicate and the data shown represents mean ± SEM pooled from 5 individual experiments. 
Significance was determined using a two-tailed paired Student’s t-test where *=p<0.05, **=p<0.01, 
***=p<0.001 and ****=p0.0001. 
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suppressive in the presence of HLA-A2+ B-LCLs compared to HLA-A2‒ B-LCLs at Treg:Tresp ratios 
of 1:2 (p=0.041) and a 1:32 (p=0.027). This minor increase in suppressive ability may have been 
due to the antigen-targeting moiety of the A2 ΔCAR-eGFP molecule facilitating an interaction 
between the A2 ΔCAR-eGFP Tregs and the HLA-A2+ APCs, bringing the Treg into the vicinity of the  
Tresp:B-LCL interaction. 
 
 A2 CAR-eGFP Tregs did not exert their suppressive 
capacity in a cytotoxic manner 
Studies investigating the mechanisms by which Tregs function have demonstrated that Tregs can 
elicit cytotoxicity towards target cells including tumour cells (Cao, Cai et al. 2007), autologous  
T cells and APCs (Grossman, Verbsky et al. 2004) by secreting granzyme and perforin. This 
mechanism of function was of particular concern as in the envisaged transplant setting, the 
principle cells which expressed the target antigen (HLA-A2) were the allograft cells. If a cytotoxic 
response was directed towards HLA-A2+ cells in vivo, the A2 CAR-eGFP Tregs would inadvertently, 
but specifically, target and destroy the cells which comprised the allograft, thereby contributing 
to allograft rejection instead of preventing it. 
To investigate whether A2 CAR-eGFP Tregs elicited a cytotoxic function in a HLA-A2-specific 
manner, Tregs were co-cultured overnight with MCF-7 (HLA-A2+) and T-47D (HLA-A2‒) cell 
monolayers, as previously described (section 3.3.2.2). CD4+CD25+ Tregs and control  
CD4+CD25– Tconvs, were lentivirally transduced to express the A2 CAR constructs, cell sorted 
based on their eGFP expression, re-stimulated and expanded for an addition 10 days prior to the 
assays being performed. Following co-culture, the viability of the monolayer cells was measured 
by MTT assay and supernatants were collected to measured cytokine production. In a similar 
manner to the A2 CAR-eGFP-expressing unfractioned T cells (Figure 3-19), A2 CAR-eGFP 
CD4+CD25– Tconvs specifically destroyed the HLA-A2+ (MCF-7) cell monolayers (Figure 5-6;  
n=5). In contrast, Tregs expressing this CAR exhibited no detectable level of cytotoxicity towards 
either the MCF-7 or T-47D (HLA-A2–) cell monolayers (n=3). 
Looking at the cytokines which were produced during co-culture, IL-2 was detectable only in the 
supernatants of A2 CAR-eGFP Tconvs which were co-cultured with MCF-7 cells (139 pg/mL;  
Figure 5-7A; n=5). Upon co-culture with MCF-7 cells, A2 CAR-eGFP Tconvs produced significantly 
high levels of the pro-inflammatory cytokine IFNγ (11,210 ± 3,937.0 pg/mL) compared to 
polyclonal (36.2 ± 10.8 pg/mL) or A2 ΔCAR-eGFP Tconvs (83.3 ± 40.4 pg/mL ;p<0.047) and 
compared to co-cultures with T-47D cells (26.1 ± 9.0 pg/mL; p=0.047; Figure 5-7B). A2 CAR-eGFP 
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Tregs also produced significant levels of IFNγ upon co-culture with HLA-A2+ cells  
(323.3 ± 88.6 pg/mL; n=3) although this was 35-fold less than that produced by the A2 CAR-eGFP 
Tconvs (Figure 5-7B). In contrast, the quantity of the immunosuppressive cytokine IL-10 secreted 
A2 CAR-eGFP Tregs was 2.7-fold higher than that secreted by A2 CAR-eGFP Tconvs following 
antigen recognition (Figure 5-7C). Upon culture with MCF-7 cells, A2 CAR-eGFP Tregs produced 
significantly high levels of the IL-10 (1,162 ± 274 pg/µL) compared to polyclonal Tregs (not 
detected) and A2 ΔCAR-eGFP Tregs (11.6 ± 1.5 pg/µL). These results demonstrated that compared 
to CD4+CD25– Tconvs, Tregs expressing the A2 CAR-eGFP construct preferentially secreted low 
quantities of the pro-inflammatory cytokine IFNγ and high quantities of the anti-inflammatory 
cytokine IL-10. 
Taken together, these findings suggested that in vivo, Tregs expressing the A2 CAR-eGFP 
construct would not elicit cytotoxicity towards the allograft cells but instead, would likely be 
activated within the graft and contribute to the establishment of an intragraft 
immunosuppressive milieu. 
Figure 5-6 │ Human Tregs expressing the A2 CAR-eGFP construct did not elicit cytotoxic activity in a  
HLA-A2-specific manner. Human Tconvs and Tregs were harvested at the end of their expansion period 
and co-cultured overnight with confluent monolayers of HLA-A2+ MCF-7 cells and HLA-A2– T-47D cells. The 
viability of the monolayer cells was measured after co-culture by MTT assay. % viability was calculated 
relative to monolayer cells cultured alone. Data is mean + SEM pooled from 3-5 individual experiments. 
Statistical significance was determined using a two-tailed paired Student’s t-test where ****=p<0.0001.  




Figure 5-7 │ Human Tregs 
expressing the A2 CAR-eGFP 
secreted immunosuppressive 
cytokines in the presence of 
HLA-A2+ epithelial cells. Human 
Tconvs and Tregs were 
harvested at the end of their 
culture period (day 20  
post-isolation) and co-cultured 
overnight with confluent 
monolayers of HLA-A2+ MCF-7 
cells and HLA-A2– T-47D cells. 
Supernatants from these  
co-cultures were analysed for 
the presence of human IL-2 (A), 
IFNγ (B) and IL-10 (C) by 
cytokine-specific ELISAs. Data 
shown represents mean + SEM 
pooled from 3-5 individual 
experiments. Statistical 
significance was determined 
using a two-tailed paired 
Student’s t-test where 
*=p<0.05. ND = not detected. 
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 Human Tregs expressing a HLA-A2-specific CAR 
preferentially transmigrated across HLA-A2+ 
endothelial cell monolayers 
One of the key purposes of using a CAR to redirect Tregs towards a donor HLA class I molecule 
was the fact that unlike HLA class II molecules, HLA class I is ubiquitously expressed in allografts. 
As such, in addition to assessing the functionality of A2 CAR-eGFP Tregs in the presence of  
HLA-A2, it was of particular interest to investigate how expression of this CAR influenced the 
ability of the Tregs to migrate into HLA-A2+ tissues. To evaluate this in vitro, a transmigration assay 
was performed to determine whether Tregs expressing the A2 CAR-eGFP construct preferentially 
Figure 5-8 │ Human Tregs expressing a HLA-A2-specific CAR preferentially transmigrated across HLA-A2+ 
endothelial cell monolayers. HLA-A2+ and HLA-A2– HUVEC cell monolayers were pre-treated with IFNγ for 
72 hours prior to the assay in order to upregulate HLA class I expression. Human Tregs were harvested at 
the end of their expansion period and flowed across HUVEC monolayers with a shear stress of 1 dyn/cm2. 
The number of Tregs which transmigrated through the monolayers was measured. Data shown represents 
mean + SEM pooled from 2-6 individual experiments. A: % transmigration was calculated as the number 
of A2 CAR-eGFP (blue) or A2 ΔCAR-eGFP (green) Tregs which transmigrated relative to the number of 
polyclonal Tregs which transmigrated. Statistical significance was determined using a two-way ANOVA 
where *=p<0.05. B: The average number of Tregs which transmigrated through the HLA-A2– (blue) and 
HLA-A2+ (green) HUVEC monolayers within the 10 second analysis frames is shown. Statistical significance 
was determined using a one-tailed unpaired Student’s t-test. ns = not significant. 
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transmigrated across HLA-A2-expressing endothelial (HUVEC) monolayers, compared to  
HLA-A2– HUVEC monolayers.  
Polyclonal, A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs were flowed across HLA-A2+ and  
HLA-A2– HUVEC monolayers. To mimic inflammatory conditions which would be expected in vivo, 
the HUVECs were pre-treated with IFNγ to upregulate HLA class I expression and the Treg lines 
were flowed with a shear stress of 1 dyn/cm2. The Tregs were imaged to measure the rate at 
which they adhered and transmigrated (Hayhoe, Kamal et al. 2006). Relative to polyclonal Tregs, 
the A2 CAR-eGFP and the A2 ΔCAR-eGFP Tregs transmigrated through HLA-A2+ endothelial 
monolayers at a significantly faster rate than HLA-A2– endothelial monolayers (p=0.042;  
Figure 5-8A; n=2-6). However, when this data was analysed independently of the polyclonal Tregs, 
statistical significance was not achieved (Figure 5-8B) although trends were observed for both the 
A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs to transmigrate faster across HLA-A2+ HUVEC monolayers. 
Interestingly, in this latter analysis, the preferential transmigration was more evident for the A2 
ΔCAR-eGFP Tregs than the A2 CAR-eGFP Tregs, possibly due to the higher level of expression of 
the A2 ΔCAR-eGFP construct in the Tregs (eGFP MFI in Figure 4-6A). Overall, these results 
demonstrated that Tregs expressing a HLA-A2-specific CAR preferentially transmigrated through 
HLA-A2+ HUVECs. Furthermore, as Tregs containing the truncated A2 ΔCAR-eGFP construct which 
lacked a CD28-CD3ζ signalling domain were able to transmigrate through the HLA-A2+ HUVEC 
monolayers at a similar rate to Tregs which expressed the full-length A2 CAR-eGFP construct, this 
result also suggested that the transmigration was driven by the CAR:HLA-A2 ligation process and 
did not rely on the activation of signalling cascades within the Treg. Overall, this result 
demonstrated that Tregs expressing a CAR with a HLA-A2-recognition domain preferentially 
transmigrated across HLA-A2+ HUVEC endothelial monolayers. 
 
 INVESTIGATION OF THE EFFICACY OF HUMAN A2  CAR  TREGS 
IN VIVO 
Having demonstrated the functional superiority and enhanced transmigratory capacity of  
A2 CAR-eGFP Tregs in the presence of HLA-A2 in vitro, the next step was to investigate the 
protective capacity of A2 CAR-eGFP Tregs in the presence of HLA-A2 in vivo.  
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 Assessment of the efficacy of A2 CAR-eGFP Tregs 
using a xeno-GvHD model 
The first clinical trials to demonstrate the efficacy of polyclonal Treg therapy were performed in 
recipients of allogeneic HSCT where the principle aim was to reduce the incidence of GvHD 
(Trzonkowski, Bieniaszewska et al. 2009, Brunstein, Miller et al. 2011, Di Ianni, Falzetti et al. 2011, 
Theil, Tuve et al. 2015). This has previously been modelled in humanised mice. One of the most 
common models currently used is to infuse human PBMCs into immunocompromised mice, 
allowing xenogeneic activation of the PBMCs and development of xeno-GvHD (Ali, Flutter et al. 
2012). 
To compare the protective efficacy of A2 CAR-eGFP Tregs and polyclonal Tregs in the presence of 
HLA-A2 in vivo, a xeno-GvHD model was employed using immunodeficient HLA-A2+ transgenic 
Ch1-2hSa mice (Serra-Hassoun, Bourgine et al. 2014). Additional details relating to these mice are 
provided in Table 2-1 but briefly, these are mice which lack the expression of murine MHC 
complexes and instead, present the human HLA complexes HLA-A2 and HLA-DR1. Consequently, 
Figure 5-9 │ Immunodeficient HLA-A2+ Ch1-2hSa transgenic mice did not develop xeno-GvHD following iv 
adoptive transfer of 107 allogeneic CD25-depleted PBMCs. Ch1-2hSa mice were injected iv with saline  
(red line) or 1x107 allogeneic CD25-depleted PBMCs (orange line) ± 2x106 autologous Tregs which were 
untransduced (polyclonal; green line) or engineered to express the A2 CAR-eGFP (blue line) or  
A2 ΔCAR-eGFP construct (purple line). Mice were 6-7 weeks old at the time of injection. Mice were 
monitored for signs of xeno-GvHD including weight loss which was measured every 2-3 days. % weight 
change was calculated relative to the initial weight of the mice on the day of cell transfer (day 0). Data 
shown represents mean ± SD with 3-4 mice per group and is representative of 2 individual experiments. 
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it was expected that A2 CAR-eGFP Tregs would have an enhanced protective capacity in these 
mice which ubiquitously express HLA-A2. Ch1-2hSa mice were injected i.v. with 1x107 allogeneic 
HLA-A2– CD25– PBMCs ± 2x106 autologous Tregs and monitored regularly for signs of GvHD but 
unfortunately, contrary to previous studies (Ali, Flutter et al. 2012), these mice continued to gain 
weight and ultimately, did not develop GvHD (Figure 5-9). An analysis of leukocytes in the 
peripheral blood of these mice was performed 1.5 and 2.5 months post-transfer. RBC-depleted 
leukocytes from the peripheral blood were stained with fluorescently-conjugated antibodies 
specific for human and mouse CD45 and the proportion of cells expressing these markers was 
measured by flow cytometry. The results suggested that no human CD45+ cells were present in 
the mice. This finding was confirmed 3 months post-transfer when the mice were sacrificed and 
an analysis of human CD45+ cells in the spleens was performed (Supplementary data, Figure S6). 
This lack of human CD45+ cell engraftment may be attributed to a variety of different causes 
including an insufficient number of PBMCs transferred, the absence of pre-irradiation of the mice 
or simply the mouse strain which was used. Overall, due to a lack of human cell engraftment in 
the HLA-A2+ transgenic mice, no meaningful data was obtained from this model. 
 
 A2 CAR-eGFP-mediated Treg allorecognition 
conferred a functional advantage in reducing human 
skin allograft rejection 
Due to the unsuccessful establishment of the xeno-GvHD model described above (section 
5.3.3.1), the efficacy of the A2 CAR-eGFP Tregs was investigated in vivo using a previously 
established human skin xenograft transplant model (Racki, Covassin et al. 2010, Sagoo, Ali et al. 
2011, Putnam, Safinia et al. 2013). This model was previously employed by the host laboratory to 
demonstrate that human Tregs with direct allospecificity were superior to polyclonal Tregs at 
inhibiting alloimmune injury. In these studies, Tregs were generated ex vivo by expanding 
polyclonal Tregs against allogeneic DCs (Sagoo, Ali et al. 2011) or B cell (Putnam, Safinia et al. 
2013). An extensive description of this model is provided in section 2.7.2 and Figure 2-4. Briefly, 
human skin explants were transplanted onto immunodeficient recipient mice (NSG or BRG) and 
allowed to engraft for 5-6 weeks. Mice were then injected iv with 5x106 human PBMCs ±  
1x106 Tregs. After an additional 5-6 weeks, the skin grafts were harvested and analysed 
histologically for various indicators of damage. Transfer of allogeneic PBMCs alone was shown to 
cause significant levels of damage to the skin grafts whilst co-transfer of Tregs alleviated this 
response. However, Tregs which had direct allospecificity were shown to protect the skin grafts 
more effectively than polyclonal Tregs (Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). 
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To investigate whether A2 CAR-eGFP Tregs elicited a similar protective role and prevented 
alloimmune mediated skin graft injury more effectively than polyclonal Tregs, the same model 
was employed. Human skin was obtained from healthy donors following routine abdominal 
angioplasty surgery and HLA-A2 expression was determined by flow cytometry using  
HLA-A2-specific antibodies to stain cells obtained from collagenase-treated skin explants  
(Figure 5-10). Immunodeficient BRG mice were transplanted with human HLA-A2+ skin allografts 
which were allowed to engraft for 5-6 weeks. The mice were then injected iv with 5x106 allogeneic 
HLA-A2‒ CD25– PBMCs ± 1x106 autologous Tregs which were either unmodified or engineered to 
express the A2 CAR-eGFP or A2 ΔCAR-eGFP constructs. 
Skin grafts were explanted 5 weeks following PBMC transfer and analysed histologically for 
changes in the skin morphology and immune cell infiltration, indicative of graft rejection (Racki, 
Covassin et al. 2010, Sagoo, Ali et al. 2011, Putnam, Safinia et al. 2013). The skin grafts were 
Figure 5-10 │ Skin donor HLA-A2 typing was performed by flow cytometry. Healthy human skin was 
acquired in an anonymised manner from routine abdominal angioplasty procedures and split-thickness 
(approximately 500 μm) skin sections were generated using a dermatome. To determine whether the skin 
donor was HLA-A2+ or HLA-A2–, a skin section measuring 0.5 cm2 was diced as small as possible using 
scalpels and incubated with 0.5 mg/mL collagenase IV and 0.1 U/mL DNase for 1 hour at 37°C. Cells 
resulting from this process were passed through a 70 μm cell strainer, washed with FACS buffer  
(section 2.5.1) and stained with fluorophore-conjugated antibodies specific for HLA-A2. Antibody staining 
was then assessed by flow cytometry, gating on cell singlets. Two separate antibody clones  
(BB7.2 represented with blue line and REA142 represented with green line) were used to ensure a false 
positive result was not acquired from the antibodies cross-reacting with different HLA-A molecules. Control 
cells were stained with an isotype control (solid grey). 
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cryosectioned, fixed and stained using haemotoxalin and eosin (H&E) or antigen-specific 
antibodies to look for the following indicators of skin damage: increased presence of proliferating 
Ki67+ keratinocytes, destruction of CD31+ endothelial cells and loss of involucrin, a late stage 
keratinocyte differentiation marker (Green, Easley et al. 2003). Immune cell infiltration was also 
assessed by staining sections for the presence of human CD45+, CD3+ and FOXP3+ cells. 
A microscopic, non-quantified analysis of the allografts by H&E staining demonstrated that there 
was dramatically more cell infiltration and damage in the skin graft explants of mice which 
received PBMCs compared to skin grafts taken from mice which received saline alone  
(Figure 5-11). Visually, this infiltration and damage appeared to be reduced by the co-transfer of  
1x106 Tregs. In the grafts of mice treated with PBMCs, there was a loss of definition between the 
epidermal and dermal skin layers. This definition was restored by the transfer of Tregs although 
the thickness of the epidermal layer suggested that general inflammation remained an issue and 
Treg transfer did not offer complete protection from alloimmune-mediated graft damage. 
Immunofluorescence analysis was performed on the allografts to assess the extent of 
alloimmune-mediated damage in greater detail. Compared to allografts from mice which were 
injected with saline, significant alloimmune damage was observed in the human skin grafts 
explanted from mice that received PBMCs only, as demonstrated by a high number of Ki67+ 
keratinocytes (Figure 5-12A), a loss of CD31+ endothelial cell integrity and loss of the  
involucrin-expressing epidermal layer (Figure 5-13A). In the skin grafts of mice treated with 
PBMCs and Tregs, the number of Ki67+ keratinocytes was reduced (Figure 5-12A), CD31+ 
endothelial cells were protected and an intact involucrin layer was observed (Figure 5-13A). 
Quantification of these observations was performed and confirmed that whilst treatment with 
Tregs significantly reduced the number of Ki67+ keratinocytes in the allografts (all p<0.0005),  
A2 CAR-eGFP Tregs achieved this significantly more effectively than polyclonal Tregs (p=0.042) 
where complete protection was offered by the A2 CAR-eGFP Treg treatment (number of Ki67+ 
keratinocytes/field: saline = 10.9 ± 1.9, PBMC + A2 CAR-eGFP Treg = 10.5 ± 1.3; Figure 5-12B). 
Interestingly, the A2 ΔCAR-eGFP Tregs also exerted greater protection than the polyclonal Tregs 
although the extent to which this was achieved did not reach statistical significance (p=0.11). 
Unfortunately, however, the magnitude of these findings was not replicated when the CD31+ 
blood vessel integrity was analysed as a measure of skin graft damage. In this analysis, no 
statistical differences were observed between the three Treg lines. However, a trend was 
observed for the A2 CAR-eGFP Tregs (CD31+ cluster size = 88.9 ± 8.5) to protect the grafts more 
effectively than the polyclonal (73.3 ± 8.7) or A2 ΔCAR-eGFP (70.9 ± 10.1) Tregs (Figure 5-13B). 
Overall, these results demonstrated that A2 CAR-eGFP Tregs were more effective than polyclonal 
Tregs at protecting human skin grafts in vivo. 
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Figure 5-11 │ High levels of cellular infiltration were observed in HLA-A2+ human skin allografts of mice 
which received 5x106 allogeneic PBMCs. Immunodeficient BRG mice were transplanted with HLA-A2+ 
human skin allografts which were allowed to engraft for 6 weeks. Mice were then injected with 5x106 
allogeneic CD25-depleted PBMCs ± 1x106 autologous Tregs which were untransduced (polyclonal) or 
engineered to express the A2 CAR-eGFP or A2 ΔCAR-eGFP construct. The mice were sacrificed 6 weeks 
post-transfer at which point the allografts were harvested and cryopreserved. 8 μm cryosections were 
stained with H&E and analysed by microscopy. Images shown are representative of 2-3 mice per group in 
an experiment which is representative of 2 individual experiments. Scale bars indicate 250 μm. 
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Figure 5-12 │ HLA-A2+ human skin allografts of 
mice which were injected with allogeneic 
PBMCs contained significantly fewer Ki67+ 
keratinocytes when A2 CAR-eGFP Tregs were 
adoptively transferred compared to when 
polyclonal Tregs were transferred. BRG mice 
which received HLA-A2+ human skin allografts 
were injected with 5x106 PBMCs ± 1x106 
Tregs. Control mice received saline only. 
Human skin allografts were removed 6 weeks 
post-injection. A: Cryopreserved sections were 
fixed and stained for human CD45 (red), Ki67 
(green) and DAPI (blue). Images were acquired 
using a confocal microscope at x20 
magnification where multiple frames were 
stitched together using NIS imaging software. Scale bar represents 200 μm. B: The number of Ki67+ 
proliferating keratinocytes per field was quantified. Explanted grafts were cut into multiple sections and 
imaged individually by confocal microscopy. 4-6 fields of a fixed size were randomly positioned along the 
epithelial layer of each confocal acquired image and the total number of Ki67+ cells in each field was 
counted. Data is pooled from 2-3 mice per group where the contributing points from each mouse are 
shown in different colours. Data is mean ± SEM and represents 1 of 2 individual experiments. Statistical 
significance was determined using a one-way ANOVA with a Tukey multiple comparison post-hoc test 
where *=p<0.05, ***=p<0.001 and ****=p<0.0001. ns = not significant. 
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Figure 5-13 │ The integrity of CD31+ blood 
vessels in HLA-A2+ human skin allografts was 
protected from alloimmune-mediated graft 
injury more effectively by the adoptive transfer 
of A2 CAR-eGFP Tregs compared to the 
transfer of polyclonal Tregs. BRG mice which 
received HLA-A2+ human skin allografts were 
injected with 5x106 PBMCs ±  
1x106 Tregs. Control mice received saline only. 
Human skin allografts were removed 6 weeks 
post-injection. A: Cryopreserved sections were 
fixed and stained for Involucrin (red), CD31 
(green) and DAPI (blue). Images were acquired 
using a confocal microscope at x20 
magnification where multiple frames were 
stitched together using NIS imaging software. Scale bar represents 200 μm. B: The average size of the 
CD31+ blood vessels per field was quantified. Explanted grafts were cut into multiple sections and imaged 
individually by confocal microscopy. 4 fields of a fixed size were randomly positioned in the dermal layer 
of each confocal acquired image and the average size of the blood vessels in each field was calculated 
using NIS imaging software. Data is pooled from 2-3 mice per group where the contributing points from 
each mouse are shown in different colours. Data is mean ± SEM and represents 1 of 2 individual 
experiments. Statistical significance was determined using a one-way ANOVA with a Tukey multiple 
comparison post-hoc test where *=p<0.05 and ****=p<0.0001. ns = not significant. 
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Figure 5-14 │ HLA-A2+ human skin allografts of 
mice which received A2 CAR-eGFP or  
A2 ΔCAR-eGFP Tregs contained a higher 
proportion of FOXP3+ cells than allografts of 
mice injected with polyclonal Tregs. BRG  
mice which received HLA-A2+ human skin 
allografts were injected with 5x106 PBMCs ± 
1x106 Tregs. Control mice received saline only. 
Human skin allografts were removed 5 weeks 
post-injection. A: Cryopreserved sections were 
fixed and stained for FOXP3 (red), CD3 (green) 
and DAPI (blue). Images were acquired using a 
confocal microscope at x20 magnification 
where multiple frames were stitched together 
using NIS imaging software. Scale bar 
represents 200 μm. B: The number of CD3+FOXP3– and CD3+FOXP3+ cells per field was quantified.  
Explanted grafts were cut into multiple sections and imaged individually by confocal microscopy. 4-6 fields 
of a fixed size were randomly positioned in the dermal layer of each confocal acquired image and the 
number of CD3+FOXP3– and CD3+FOXP3+ cells in each field was counted. The number of CD3+FOXP3+ cells 
was divided by the number of CD3+FOXP3– cells to calculate the FOXP3:CD3 ratio in each field. Data is 
pooled from 2-3 mice per group where the contributing points from each mouse are shown in different 
colours. Data is mean ± SEM and represents 1 of 2 individual experiments. Statistical significance was 
determined using a one-way ANOVA with a Tukey multiple comparison post-hoc test where *=p<0.05, 
***=p<0.001 and ****=p<0.0001. ns = not significant. 
Chapter V │ Characterising human A2 CAR Tregs 
 
151 
An analysis of the immune cell infiltration into the grafted tissue demonstrated that mice which 
received PBMCs in combination with Tregs had a significantly greater FOXP3:CD3 ratio than mice 
which received PBMCs alone (Figure 5-14B). This difference in FOXP3:CD3 ratio was more 
statistically significant when A2 CAR-eGFP (p<0.0001) or A2 ΔCAR-eGFP (p<0.0001) Tregs were 
transferred, compared to when polyclonal Tregs (p=0.019) were transferred. Furthermore, a 
trend was observed for the FOXP3:CD3 ratio to be higher in the grafts of mice which received  
A2 CAR-eGFP or A2 ΔCAR-eGFP Tregs, compared to polyclonal Tregs. Importantly however, no 
statistically significant differences were observed when the three Treg treatment conditions were 
directly compared. These findings suggested that the A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs were 
present at a higher proportion in the HLA-A2+ grafts than the polyclonal Tregs, insinuating a 
preferential migration into HLA-A2+ tissues (correlating with the findings described in section 
5.3.2.3) and/or a preferential retention of these cells in the HLA-A2+ grafts. 
In summary, Tregs engineered to express the A2 CAR-eGFP construct inhibited alloimmune 
mediated injury against HLA-A2+ human skin allografts more effectively than polyclonal or  
A2 ΔCAR-eGFP Tregs. These results demonstrated the increased potency of A2 CAR-eGFP Tregs 
compared to polyclonal Tregs in vivo and the requirement for the activation of intracellular Treg 
signalling cascades in order to elicit this response. 
 
 DISCUSSION 
In this chapter, A2 CAR-eGFP Tregs were shown to be specifically activated in the presence of 
HLA-A2, a response which was not replicated by polyclonal or A2 ΔCAR-eGFP Tregs. A2 CAR-eGFP 
Tregs suppressed autologous CD4+CD25– Tresp proliferation significantly more effectively in the 
presence of HLA-A2+ APCs compared to HLA-A2– APCs which was also not observed for polyclonal 
or A2 ΔCAR-eGFP Tregs. Furthermore, in the presence of HLA-A2+ target cells, A2 CAR-eGFP Tregs 
did not exhibit cytotoxicity, unlike their CD4+CD25– A2 CAR-eGFP Tconv counterparts. Instead, 
these A2 CAR-eGFP Tregs secreted high levels of the immunoregulatory cytokine IL-10 in the 
presence of HLA-A2+ target cells. With regards to trafficking, A2 CAR-eGFP Tregs were shown to 
preferentially transmigrate across HLA-A2+ HUVEC cell monolayers. Interestingly, a similar 
transmigratory profile was observed for A2 ΔCAR-eGFP Tregs, demonstrating that this process 
relied on the engagement of HLA-A2 and not on the ability of the CAR to deliver intracellular 
activatory signals. Using a human skin xenograft transplant model, A2 CAR-eGFP Tregs were 
shown to protect HLA-A2+ skin allografts from alloimmune-mediated injury more effectively than 
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polyclonal or A2 ΔCAR-eGFP Tregs, demonstrating the superior protective capacity of these cells 
in vivo. 
All previous studies which have investigated the protective capacity of CAR-expressing Tregs have 
demonstrated the ability of these cells to suppress Tresp proliferation more effectively than 
polyclonal Tregs when in the presence of their target antigen (Elinav, Waks et al. 2008, Elinav, 
Adam et al. 2009, Blat, Zigmond et al. 2014, MacDonald, Hoeppli et al. 2016). This was most 
recently achieved by MacDonald et al. who investigated the efficacy of human CAR Tregs which 
were also redirected towards HLA-A2 (MacDonald, Hoeppli et al. 2016). The A2 CAR generated 
by these authors incorporated a hybridoma-derived HLA-A2 scFv (BB7.2 clone) which was 
coupled to a cMyc tag-containing CD28 hinge/transmembrane domain and an intracellular CD28-
CD3ζ signalling domain. As such, the composition of this CAR was very similar to that which was 
generated in Chapter III and only differed in the antigen-targeting ectodomain. 
To assess the functionality of their A2 CAR in vitro, MacDonald et al. performed an  
antigen-specific suppression assay in which CD8+ T cells were used as Tresps and HLA-A2+ 
monocyte-derived DCs were used as APC. Their results demonstrated that the A2 CAR Tregs were 
able to inhibit CD8+ Tresp proliferation but this was achieved with a relatively low efficacy. Their 
A2 CAR Tregs suppressed Tresp proliferation significantly more effectively than irrelevant CAR 
Tregs at a 1:5 Treg:Tresp but when lower ratios of 1:10 or 1:20 were analysed, statistical 
significance was not reached. In contrast, the experiments performed in this chapter used CD4+ 
T cells as Tresps and demonstrated that the A2 CAR-eGFP Tregs were significantly more 
suppressive in the presence of HLA-A2+ APCs at Treg:Tresp ratios as low as 1:64, although 
signalling through the TCR was shown to contribute to this result as polyclonal Tregs also 
exhibited suppression. Overall, this implied that either the full potential of the A2 CAR Tregs was 
not demonstrated in the experiments performed by MacDonald et al., or that the HLA-A2-specific 
CAR Tregs generated in this thesis (Chapters III and IV) were more efficacious than those 
generated by MacDonald et al. These authors proceeded to demonstrate that A2 CAR Tregs did 
not elicit cytotoxicity towards HLA-A2+ K562s, mirroring results described in this chapter. 
In cancer research, CAR T cells have been shown to be particularly effective at treating 
haematological conditions (Davila, Riviere et al. 2014, Maude, Frey et al. 2014). However, these 
successes have not been translated to the treatment of solid tumours (Dai, Wang et al. 2016). 
This has been partially attributed to the fact that tumours have an abnormal vasculature (Herman, 
Savage et al. 2011) which complicates the trafficking of CAR T cells into the tumour. Consequently, 
various studies in cancer research are investigating strategies which may be employed to improve 
the trafficking of CAR T cells into the tumour site (Newick, Moon et al. 2016, Newick, O'Brien et 
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al. 2016). With regards to CAR Tregs, although studies have demonstrated that these cells are 
present in tissues where their cognate antigen is expressed, (Fransson, Piras et al. 2012, Elinav, 
Waks et al. 2008, Blat, Zigmond et al. 2014) (discussed in section 1.3.4), no study has specifically 
investigated the migratory capacity of CAR Tregs in vitro or in vivo. The results in this chapter 
demonstrated that A2 CAR-eGFP Tregs preferentially transmigrated through endothelial HUVEC 
monolayers which expressed HLA-A2. Furthermore, this favoured transmigration was primarily 
mediated in a Treg activation-independent manner as Tregs expressing the A2 ΔCAR-eGFP 
construct which lacked an intracellular CD28-CD3ζ signalling domain migrated at a similar rate to 
Tregs expressing the A2 CAR-eGFP construct. However, the applicability of this finding to cancer 
research is limited as contrary to transplanted organs and previously mentioned, tumours have 
an abnormal vasculature and can manipulate local endothelial cells to up/downregulate specific 
molecules as a mechanism of immune recognition evasion (Buckanovich, Facciabene et al. 2008, 
Young 2012). 
The first approach which was employed to compare the efficacy of polyclonal and A2 CAR-eGFP 
Tregs in vivo in this chapter was a xeno-GvHD model. However, these experiments were 
unsuccessful as the transferred human cells failed to engraft in the HLA-A2 transgenic mice. The 
Ch1-2hSa mice used for this model were particularly complicated in their genetic composition in 
that they not only expressed human HLA genes (HLA-A2 and HLA-DR1), but they also lacked 
specific genes required for the presentation of murine MHC complexes. This lack of mouse MHC 
presentation may have severely compromised the engraftment of these mice, as a previous study 
has demonstrated that human PBMC engraftment is significantly decreased in NSG mice when 
the β2-microglobulin or I-Aβb genes are removed (King, Covassin et al. 2009). Although this study 
did not proceed to investigate the effects of knocking out both genes together, as was done when 
generating the Ch1-2hSa mice, one may assume that the cumulative effect would be even more 
detrimental for the engraftment of these cells. It was hypothesised that the presence of the 
human HLA genes would circumvent this issue and provide a more translationally-applicable 
result but unfortunately, this was not the case, potentially due to the lower immunogenicity of 
the allo-response compared to the xeno-response. It should also be noted that no previous study 
has attempted to induce xeno-GvHD in Ch1-2hSa mice and that they have only ever been used to 
investigate the concept of generating humanised mice with human T cells which are educated 
against human HLA complexes (Serra-Hassoun, Bourgine et al. 2014). It was possible that the 
engraftment issues with the Ch1-2hSa mice could have solved by irradiating the mice (van Rijn, 
Simonetti et al. 2003) or transferring more cells (Ito, Katano et al. 2009). For example, in the study 
performed by MacDonald et al., recipient NSG mice, which have a proven track record in  
xeno-GvHD models (Ali, Flutter et al. 2012), were irradiated prior to cell transfer although the 
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number of PBMCs transferred (1x107) was the same as the experiment performed in this chapter 
(MacDonald, Hoeppli et al. 2016). In this study, xeno-GvHD onset was evident from 10 days  
post-transfer with severe weight loss amongst other factors being observed. 
CAR Tregs have been shown to be superior to polyclonal Tregs at protecting various tissues which 
express a target cognate antigen including the colon (Elinav, Waks et al. 2008, Elinav, Adam et al. 
2009, Blat, Zigmond et al. 2014) and CNS (Fransson, Piras et al. 2012). As such, it was reasonable 
to hypothesise that A2 CAR-eGFP Tregs would protect HLA-A2+ human skin grafts more effectively 
than polyclonal Tregs. The results acquired from these experiments proved this hypothesis and 
were comparable to the results of Sagoo et al. and Putnam/Safinia et al. who demonstrated the 
superior efficacy of Tregs with direct allospecificity over polyclonal Tregs (Sagoo, Ali et al. 2011, 
Putnam, Safinia et al. 2013). In these studies, graft-specific Tregs were generated by stimulating 
polyclonal Tregs with allogeneic DCs or B cells, respectively. The results in this chapter suggested 
that the A2 CAR-eGFP Tregs protected human skin grafts with a similar efficacy to the direct 
allospecific Tregs generated in these studies. A2 CAR-eGFP Tregs were significantly more effective 
than polyclonal Tregs at reducing the proliferation of keratinocytes (Figure 5-12) in a similar 
manner to the results of both Sagoo et al. and Putnam/Safinia et al. Additionally, there was a 
trend for the A2 CAR-eGFP Tregs and Tregs with direct allospecificity generated by Sagoo et al. to 
protect the integrity of CD31+ blood vessels (Figure 5-13), although this protection was not 
statistically significant in either case. 
The analysis of immune cell infiltration into the HLA-A2+ skin grafts demonstrated that the 
FOXP3:CD3 ratio in the grafts of mice which received A2 CAR-eGFP or A2 ΔCAR-eGFP Tregs was 
similar. This finding echoed the results of Putnam/Safinia et al. and confirmed the 
aforementioned Treg trafficking results which suggested that Tregs expressing a HLA-A2-specific 
CAR favoured homing to a HLA-A2+ graft. This favoured homing may have facilitated the  
A2 ΔCAR-eGFP Tregs to protect the HLA-A2+ skin grafts more effectively than the polyclonal Tregs 
(keratinocyte Ki67 expression; Figure 5-12), although this protection was not as great as that 
which was provided by the A2 CAR-eGFP Tregs (CD31+ blood vessel integrity; Figure 5-13). 
Together, these results suggested that Tregs expressing the A2 ΔCAR-eGFP which lacked an 
intracellular signalling domain favoured migration into the HLA-A2+ skin grafts. However, more 
effective protection was offered by Tregs which expressed the full-length A2 CAR-eGFP construct. 
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 SUMMARY  
Overall, the results presented in this chapter demonstrated that A2 CAR-eGFP Tregs were 
specifically activated and more suppressive than polyclonal or A2 ΔCAR-eGFP Tregs in the 
presence of HLA-A2+ APCs and that this suppression did not rely on the elicitation of cytotoxicity. 
A2 CAR-eGFP and A2 ΔCAR-eGFP Tregs preferentially transmigrated across HLA-A2+ HUVEC 
endothelial monolayers in vitro and appeared to preferentially localise in HLA-A2+ skin grafts in 
vivo, compared to polyclonal Tregs. This may have contributed to the superior efficacy with which 
the A2 CAR-eGFP Tregs protected the HLA-A2+ skin grafts from alloimmune-mediated injury 
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 MOUSE VERSUS HUMANISED MOUSE MODELS IN 
TRANSPLANTATION  
The translational aspect of humanised mouse models provides a distinct advantage over mouse 
models for clinically related studies. However, for certain research questions, meaningful data 
are more simply acquired when the latter is adopted. A prime example is when comparing the 
efficacy of Tregs with different allospecificities at limiting transplant rejection. 
In a transplant context, Tregs with two different allospecificities are of particular interest: those 
which recognise intact donor MHC-peptide complexes (direct allospecificity) and those which 
recognise allopeptides presented in the context of self-MHC molecules (indirect allospecificity). 
As previously discussed (section 1.1.1.1), Tregs with direct allospecificity exist in mice and humans 
at a disproportionately high precursor frequency. Approximately 1-10% of the cell in a standard 
T cell pool have direct allospecificity which is orders of magnitude greater than the ~0.01% of  
T cells with indirect allospecificity (Veerapathran, Pidala et al. 2011). As such, various studies have 
successfully isolated and expanded Tregs with direct allospecificity and demonstrated that these 
cells are more potent than polyclonal Tregs at reducing graft rejection (Sagoo, Ali et al. 2011, 
Putnam, Safinia et al. 2013). Regarding the human skin xenograft transplant models employed in 
these studies, it should be noted that only Tregs with direct allospecificity were able to be 
assessed as the lack of human APC engraftment (including B cells) prevented the priming of 
human T cells or Tregs with indirect allospecificity. 
Studies investigating Tregs with indirect allospecificity have also shown  that these cells are more 
effective than polyclonal Tregs at promoting transplant tolerance (Golshayan, Jiang et al. 2007). 
However, generating Tregs with indirect allospecificity is difficult as a low number of these cells 
exist in a recipient, prior to a transplant procedure (Veerapathran, Pidala et al. 2011). 
Furthermore, once isolated, expanding these cells is difficult as autologous APCs must be 
effectively and efficiently pulsed with an allopeptide in such a way as to displace the naturally 
presented self-peptide. Failure to achieve this would result in the expansion of Tregs with  
self-specificity. A previous study has demonstrated that it is possible to preferentially expand 
human Tregs with indirect allospecificity ex vivo but this was achieved with limited success (Jiang, 
Tsang et al. 2006). DCs were cultured in the presence of GM-CSF for 5-6 days before being pulsed 
with a HLA-A2-based peptide and used to stimulate freshly-isolated autologous Tregs. After a 
week of expansion, only 9% of the Tregs had indirect allospecificity, as determined by tetramer 
staining (Jiang, Tsang et al. 2006). More promising results were obtained when a similar approach 
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was employed in a mouse setting (Golshayan, Jiang et al. 2007) although this was subsequently 
superseded by an approach which involved transducing polyclonal Tregs to express specific TCR 
α and β chain genes (Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009). In these studies, B6 
Tregs were transduced to express the Vα11.2 and Vβ13 TCR chain genes which allowed for the 
recognition of BALB/c MHC class I (Kd)-peptide presented in the context of B6 MHC class II (I-Ab). 
Combined with the fact that these Tregs could be maintained in culture long-term, this allowed 
Tregs with indirect allospecificity to be enriched by over 95% in the mouse setting (Tsang, Tanriver 
et al. 2008). 
In addition to comparing the efficacy of Tregs with self-specificity, direct allospecificity and 
indirect allospecificity, studies performed in a mouse setting have also explored the potential of 
Tregs with dual direct and indirect allospecificity. These Tregs were generated by expanding B6 
Tregs using allogeneic BALB/c DCs to enrich Tregs with direct allospecificity which were then 
transduced with the aforementioned TCR α and β chain genes to confer indirect allospecificity. 
The efficacy of these cells to protect against transplant rejection was assess in two different 
models: i) a skin transplant model where tail skin from B6.Kd mice was transplanted onto B6 mice, 
and; ii) a fully-mismatched heart transplant model where hearts were transplanted from BALB/c 
into B6 mice. In both cases, Tregs with direct allospecificity alone were found to be insufficient at 
protecting the allografts whilst Tregs with dual specificity prolonged the survival of the skin 
allografts and protected heart allografts from chronic vasculopathy long-term (Tsang, Tanriver et 
al. 2008). Similar findings were also published by Joffre et al. who used similar transplant models 
although the authors of this publication did not comprehensively demonstrate that their Tregs 
indeed possessed both direct and indirect allospecificity (Joffre, Santolaria et al. 2008). 
 
 PHOENIX ECO TRANSDUCTION SYSTEM 
To generate the aforementioned murine Tregs with indirect allospecificity, polyclonal Tregs were 
transduced with specific TCR α and β chain genes using the Phoenix Eco transduction system. This 
is a widely used system originally developed by Nolan et al. (Stanford University, California, USA). 
As discussed in Chapter III (section 3.1.2), the envelope glycoproteins present on the surface of 
retroviral virions dictate which target cells are infected. In the laboratory, these glycoproteins can 
be exploited to not only direct the virion towards specific cell types, but also cells of a specific 
species (Hamilton, Whittaker et al. 2012, Nomaguchi, Fujita et al. 2012). For example, as 
discussed previously, HAs from most human influenza viruses target α2,6 sialic acid linkages. 
However, avian-adapted HAs preferentially bind to α2,3 sialic acid linkages (Couceiro, Paulson et 
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al. 1993, Gagneux, Cheriyan et al. 2003, Hamilton, Whittaker et al. 2012). This species preference 
was exploited by Nolan et al. to develop two Phoenix virus packaging systems: i) an amphotropic 
system which yields viral particles capable of infecting dividing cells from most mammalian 
species, and; ii) an ecotropic system which generates viral particles that can only deliver genes 
into dividing murine or rat cells (Cepko and Pear 2001). 
 
 AIMS AND OBJECTIVES 
The aim of this chapter was to generate a B6 Treg line expressing a functional CAR specific for Kd. 
The rationale behind this was to ultimately compare the efficacy with which self-, direct allo-, 
indirect allo-, dual- and CAR-based allo-MHC class I-specific Tregs protected from graft rejection. 
This was of particular interest as the former four Treg lines mentioned are all MHC class II-
restricted thus primarily activated by professional APCs such as DCs. In contrast, the CAR Tregs 
would be redirect to recognise donor MHC class I, an alloantigen which is ubiquitously expressed 
on tissue parenchyma throughout an allograft rather than solely on APCs. 
To accomplish this, a second generation CAR was generated which incorporated an  
scFv-based Kd-targeting moiety and a mouse CD28-CD3ζ signalling domain. This CAR was 
delivered into B6 T cells and Tregs using the Phoenix Eco system previously employed by Tsang 
et al. (Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009). The functionality and specificity of 
this CAR was then assessed in vitro using Tconv and Treg functional assays. 
 
 RESULTS 
 DESIGN AND GENERATION OF A CAR  SPECIFIC FOR Kd 
 Design and construction of a Kd-specific CAR  
To generate a mouse-based CAR specific for BALB/c MHC class I (Kd), it was necessary to obtain 
the sequence of a Kd-specific scFv. Unfortunately, following a literature search, no sequence was 
identified. As such, a Kd-specific hybridoma cell line (SF1-1.1.10 clone) was purchased from the 
ATCC® and sequenced by GenScript. 
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The specificity of this antibody clone was confirmed by flow cytometry. Splenocytes from B6 (Kb) 
and BALB/c (Kd) mice were stained with antibody purified from the hybridoma followed by a 
secondary fluorescently-conjugated anti-mouse IgG2a antibody. Antibody produced by the  
Kd-specific hybridoma cell line specifically bound to BALB/c splenocytes but not B6 splenocytes, 
demonstrating its specificity (Figure 6-1A). 
Figure 6-1 │ VH and VL chains extracted from the SF1-1.1.10 hybridoma combined to generate a Kd-specific 
targeting moiety. A: An immortalised hybridoma cell line which generated antibody molecules specific for 
Kd (SF1-1.1.10 clone) was purchased from the ATCC®. Antibody from this hybridoma was used to stain total 
splenocytes acquired from B6 (blue line) or BALB/c (green line) mice. The binding of this antibody to CD8+ 
T cells, selected using a fluorescently-conjugated CD8-speicific antibody, is shown. CD8+ T cells stained with 
the secondary antibody only shown in solid grey. B: The SF1-1.1.10 hybridoma cell line was sequenced by 
GenScript. Extracted VH and VL chain sequences were used to construct a Fab fragment which was used to 
stained total B6 and BALB/c splenocytes. Binding of the Fab fragment and the original hybridoma-derived 
antibody (turquoise/orange) is shown, relative to unstained splenocytes (dotted line). MFI values of each 
sample are provided in the top right corner of each plot. 
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Cells from this hybridoma were sent to GenScript for antibody sequencing. Total RNA was 
extracted from the hybridoma cells and cDNA was synthesised. cDNA corresponding to the VH 
and VL chain genes was then amplified by PCR, cloned into standard vectors and sequenced. 
Overall, this process provided the genetic sequences of the antibody VH and VL chain genes. These 
extracted sequences were then used by GenScript to design a Fab fragment which was generated 
in TG1 E. coli and purified using an affinity chromatography column approach. The ability of this 
Fab to bind Kd was then confirmed by GenScript who used a similar flow cytometry approach to 
that described above whereby B6 and BALB/c splenocytes were stained. The Fab was shown to 
bind BALB/c splenocytes in a similar manner to the original hybridoma-derived antibody but not 
Figure 6-2 │ Diagram detailing the components of the Kd-targeting moiety used for constructing the  
Kd-specific CAR. A: Nucleotide sequence of the Kd-targeting moiety. Flanking 5’ NotI/BamHI and 3’ BclI 
restriction sites are underlined. B: Amino acid sequence of the Kd-targeting moiety. The sequence of a 
mouse CD8α leader (red), variable heavy scFv chain (orange), serine/glycine linker (blue) and variable light 
scFv chain (green) are shown in addition to predicted CDRs in bold. 




Figure 6-3 │ Schematic diagram of a murine Kd-specific second generation CAR and restriction map of the 
pMP71-PRE_Kd-28ζ-eGFP retroviral expression vector. A: A Kd-specific scFv sequence was designed using 
the VH and VL chain sequences extracted by GenScript (red). A mouse CD8α leader peptide sequence was 
added upstream of the scFv (grey). The scFv sequence was proceeded by sequences of a mouse CD28 
hinge/TM domain (orange) in which the MYPPPY recognition motif was replaced with the 9E10 cMyc 
epitope (black). Immediately downstream of the CD28 TM domain was either the sequence of a mouse 
CD28-CD3ζ signalling domain (blue) followed by a direct eGFP fusion (green; Kd-28ζ CAR-eGFP) or the eGFP 
ORF without the signalling domain present (Kd ΔCAR-eGFP). The complete nucleotide sequence of the  
Kd CAR-eGFP construct is provided in the Supplementary data, Figure S5. B: Restriction map of the  
Kd-28ζ-eGFP CAR nucleotide sequence in the pMP71-PRE retroviral expression vector. The CAR gene was 
gene synthesised by Biomatik and cloned into this vector using the 5’ NotI and 3’ AccI restriction sites. The 
complete nucleotide sequence of this vector is provided in the Supplementary data, Figure S6.  
Amp. Res. = ampicillin resistance gene. 
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the B6 splenocytes, confirming that the DNA sequences coded for the VH and VL chain sequences 
of a Kd-specific antibody (Figure 6-1B). 
The VH and VL chain sequences provided by GenScript were used to design a Kd-specific scFv. This 
was accomplished by linking the VH chain sequence to the downstream VL chain sequence via a 
(GGGGS)3 serine/glycine linker, as shown in Figure 6-2. The rest of the Kd-specific CAR gene was 
then designed around this scFv sequence whereby a mouse CD8α leader peptide sequence was 
added upstream of the scFv sequence to facilitate translocation of the CAR protein to the cell 
membrane whilst sequences of a murine CD28 transmembrane and CD28-CD3ζ signalling domain 
were added downstream of the scFv antigen-targeting moiety. Furthermore, to aid downstream 
analyses, an eGFP ORF was added immediately downstream of the CD28-CD3ζ signalling domain, 
resulting in the generation of a Kd CAR-eGFP fusion. A schematic of this in silico designed gene is 
provided in Figure 6-3A. 
This Kd-28ζ-eGFP CAR nucleotide sequence was gene synthesised by Biomatik (Wilmington, 
Delaware, USA) and cloned into the pMP71-PRE retroviral vector (kindly provided by Dr Angelika 
Holler and Prof Hans Stauss; Institute of Immunity and Transplantation, University College 
London, UK) using the 5’ NotI and 3’ AccI restriction sites shown in Figure 6-3B. The resulting 
retroviral expression vector which contained the Kd CAR-eGFP ORF was termed the  
pMP71-PRE_Kd-28ζ-eGFP construct. 
 
 Generation of a Kd-specific CAR lacking an 
intracellular signalling domain 
As the Kd-28ζ-eGFP was custom synthesised, it was possible to tailor the gene to incorporate 
multiple restriction sites where desired. To aid the generation of a truncated Kd CAR lacking a 
CD28-CD3ζ signalling domain, a ClaI restriction site was incorporated immediately upstream of 
the first ITAM in the CD28 signalling domain and a BstBI restriction site was added between the 
end of the CAR ORF, before the eGFP ORF (Figure 6-3B). 
A summary of the cloning strategy employed to generate the truncated Kd-specific CAR  
(Kd ΔCAR-eGFP) is provided in Figure 6-4A. The pMP71-PRE_Kd-28ζ-eGFP vector was digested with 
ClaI and BstBI to remove the DNA coding for the CD28-CD3ζ signalling domain. Vector DNA 
containing the truncated CAR gene sequence in a linear form was separated using a 0.6% agarose 
gel and purified using a membrane-based purification system. Purified DNA was then quantified 
by running DNA volumes of 1, 3 and 5 μL on a 0.8% agarose gel alongside 5 μL of Hyperladder I. 
The Hyperladder I bands contained a known concentration of DNA thus the intensity of these 
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bands could be used to estimate the concentration of purified DNA (Figure 6-5A). The linear DNA 
of the digested pMP71-PRE vector containing the truncated CAR gene sequence was estimated 
to have a concentration of 7-8 μg/mL. 
As shown in Figure 6-4B, ClaI and BstBI recognise different DNA sequences. However, the sticky 
ends which remain when these enzymes cleave DNA are the same – both enzymes leave a 5’ CG 
Figure 6-4 │ Cloning strategy for generating a truncated Kd ΔCAR-eGFP construct lacking an intracellular 
CD28-CD3ζ signalling domain. A: Summary of the cloning strategy employed to remove the CD28-CD3ζ 
signalling domain sequence from the pMP71-PRE_Kd-28ζ-eGFP vector. B: The restriction enzymes ClaI 
(blue) and BstBI (red) recognise different sequences but both cleave DNA to leave a 5’ CG overhang. 
Consequently, it was possible to re-ligate the DNA products from these digests without an insert. This 
process abolished the original ClaI and BstBI restriction sites. X = irrelevant nucleotide. 
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overhang. As such, it was possible to re-ligate the pMP71-PRE_Kd-eGFP vector directly, negating 
the requirement to fill in the sticky ends and perform a blunt end ligation. The vector was  
re-ligated using a T4 ligase which resulted in the generation of a pMP71-PRE vector containing a 
truncated Kd-eGFP CAR gene (pMP71-PRE_Kd-eGFP or Kd ΔCAR-eGFP). 
Products from the ligation were transformed into Stbl3 cells and grown in the presence of 
ampicillin. Bacterial colonies were harvested, expanded and minipreps were performed to purify 
DNA. A BamHI restriction digestion was then performed on the isolated DNA to validate the 
cloning process. This digestion correctly revealed bands of 0.28, 2.4 and 4.5 kbp for the truncated 
CAR preparations and 0.28, 2.9 and 4.5 kbp for the full-length CAR (Figure 6-5B). Results of this 
process were confirmed by sequencing prior to downstream application of this construct. 
Figure 6-5 │ A truncated Kd-specific CAR was generated by removing the intracellular CD28-CD3ζ signalling 
domain from the full-length CAR gene sequence. A: Quantification of the digested pMP71-PRE vector 
containing the truncated Kd CAR-eGFP sequence. Desired DNA was isolated on a 0.6% agarose gel and 
purified using a membrane-based purification system. DNA resulting from this purification was quantified 
by running 1, 3 and 5 μL of the DNA on a 0.8% agarose gel alongside the 5 μL Hyperladder I. The 
Hyperladder I bands contained a known quantity of DNA (shown), allowing one to estimate the 
concentration of a DNA in a sample. This DNA sample was estimated to have a concentration of 7-8 μg/mL. 
B: BamHI digestion of pMP71-PRE_Kd-eGFP vector minipreps (trunc. CAR) and the  
pMP71-PRE_Kd-28ζ-eGFP vector (comp. CAR). Resultant fragments were separated on a 0.8% agarose gel 
which is shown. Expected bands for the full-length CAR digest were 4,600, 2,900 and 300 bp whilst 
expected bands for the truncated CAR digest were 4,600, 2,400 and 300 bp. 
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 CHARACTERISATION OF THE Kd-SPECIFIC CAR  USING 
SPLENOCYTES  
 Splenocyte-derived T cells were retrovirally 
transduced to express the Kd CAR-eGFP construct 
with a high efficiency 
The functionality of the novel Kd-specific CAR was initially assessed using murine T cells, employing 
previously published transduction protocols kindly provided by Dr Angelika Holler and Prof Hans 
Stauss (Wright, Notley et al. 2009). Retroviral particles containing the pMP71-PRE_Kd-28ζ-eGFP 
(Kd CAR-eGFP) or pMP71-PRE_Kd-eGFP (Kd ΔCAR-eGFP) vector were generated by transfecting 
Phoenix Eco cells with the pMP71-PRE vector of interest and a pCL-eco packaging plasmid. High 
transfection efficiencies with bright eGFP expression were observed in the Phoenix Eco cells by 
fluorescence microscopy (Figure 6-6). The media of these transfected cells was replaced 24 hours 
post-transfection such that retroviral particles were released into RPMI-1640 mouse complete 
cell media (section 2.2.1). This retroviral supernatant was harvested after a further 24 hours and 
used to transduce splenocytes which had been isolated from B6 mice, activated 24 hours earlier 
with the mitogen ConA (2μg/mL) and cultured in the presence of 1 ng/mL recombinant human 
IL-7. Transduced splenocytes were expanded for an additional 3 days prior to analysis and 
experimentation. 
Figure 6-6 │ Fluorescence microscopy images of Phoenix Eco cells transfected to express the Kd CAR-eGFP 
and Kd ΔCAR-EGFP constructs. Phoenix Eco cells were co-transfected to express the  
pMP71-PRE_Kd-28ζ-eGFP or pMP71-PRE_Kd-eGFP vector and the pCL-eco plasmid, resulting in the 
generation of retroviral particles. Phoenix Eco cells were visualised by fluorescence microscopy 48 hours 
post-transfection. Images were taken at 10x magnification. Scale bar represents 200 μm. 
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Using this protocol, splenocytes were transduced, as measured by eGFP expression, with an 
average efficiency of 29.4 ± 17.2% (Figure 6-7; n=6). To detect whether the Kd CAR-eGFP construct 
was present on the cell surface of transduced splenocytes, the cells were stained with a 
fluorescently-conjugated antibody which was specific for the 9E10 cMyc tag epitope present in 
the extracellular domain of the CARs (Figure 6-3A). As the eGFP reporter protein was directly 
fused to the C-terminus of the CARs, the eGFP MFI was directly proportional to the level of CAR 
expression in these cells. However, despite a high level of eGFP expression in these splenocytes, 
presence of cMyc tag staining was not detected (Figure 6-7). This suggested that either i) the CAR 
was not successfully trafficked to the cell surface following synthesis, or; ii) the globular nature of 
the scFv domain blocked the cMyc tag epitope, preventing binding of the antibody. Overall, this 
data demonstrated that B6 splenocytes could be transduced to express either the Kd CAR-eGFP 
and Kd ΔCAR-eGFP constructs. 
 
 The Kd CAR-eGFP construct appeared to be 
successfully translocated to the cell surface 
To investigate whether the Kd CAR-eGFP protein was successfully trafficked to the cell surface 
following synthesis, Phoenix Eco cells were seeded onto glass coverslips and transfected to 
express the Kd CAR-eGFP construct. Cells transfected with the human A2 CAR-eGFP construct 
Figure 6-7 │ B6 splenocytes were transduced to express the Kd CAR-eGFP and Kd ΔCAR-eGFP constructs with 
a high efficiency. Total B6 splenocytes were activated with 2 μg/mL ConA and either left untransduced or 
transduced after 24 hours to express the Kd CAR-eGFP or Kd ΔCAR-eGFP constructs. Cells were expanded 
for an additional 3 days before being stained with a fluorescently-conjugated antibody specific for the 
cMyc tag 9E10 epitope. The efficiency of transduction was assessed by flow cytometry, based on eGFP 
expression. Presence of the CAR on the surface of these cells was determined by  
cMyc tag staining. Data representative of 4 individual experiments. The percentage of events in each gate 
is provided. 
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were used as a positive control. After 24 hours, these cells were stained with  
fluorescently-conjugated phalloidin (without cell permeabilisation) to label the surface of these 
cells prior to analysis by confocal microscopy. A comparison of the eGFP localisation in Phoenix 
Eco cells transfected with the Kd CAR-eGFP construct and the A2 CAR-eGFP construct correlated 
(Figure 6-8) suggesting that the Kd CAR-eGFP protein may have localised to the cell surface, 
although this finding was by no means definitive. 
 
 Splenocytes expressing the Kd CAR-eGFP construct 
proliferated more when activated by Kd-expressing 
APCs compared to APCs which did not express Kd 
To investigate whether total B6 splenocytes expressing the Kd CAR-eGFP construct preferentially 
proliferated in the presence of Kd, these cells were co-cultured with APCs isolated from B6, B6.Kd 
and BALB/c mice. Proliferation was measured after 72 hours of co-culture using two approaches; 
3H-thymidine incorporation and CTV dilution. For the former, 1 μCi 3H-thymidine was added to 
Figure 6-8 │ The Kd CAR-eGFP protein appeared to localise to the cell membrane of Phoenix Eco cells in a 
similar manner to the A2 CAR-eGFP protein. Phoenix Eco cells were seeded onto glass coverslips and 
transfected to express either the Kd CAR-eGFP protein or the A2 CAR-eGFP protein (green). 24 hours  
post-transfection, the cells were harvested and stained (in the absence of permeabilisation) with 
fluorescently-conjugated phalloidin (red), a peptide typically used to label F-actin in cells following 
permeabilization. This phalloidin staining was performed to distinguish the surface of these cells. The cells 
were also stained with DAPI (blue) to label the nuclei. 3-4 images per condition were acquired at x60 
magnification and data is representative of 2 individual experiments. Scale bar represents 50 μm. 
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the cells for the last 18 hours of culture. Alternatively, T cells were labelled with CTV prior to  
co-culture and the dilution of this dye was used as a measure of proliferation. 
Figure 6-9 │ B6 splenocytes expressing the Kd CAR-eGFP construct preferentially proliferated in the 
presence of Kd-expressing APCs. B6 splenocytes were untransduced or engineered to express the  
Kd CAR-eGFP or Kd ΔCAR-eGFP construct. These cells were co-cultured with APCs isolated from B6 (blue), 
B6.Kd (green) or BALB/c (red) mice for 72 hours. Splenocyte proliferation was then measured by  
3H-thymidine incorporation (A) or CTV dilution (B). For the 3H-thymidine incorporation (A), co-cultures were 
pulsed with 1 μCi 3H-thymidine for the last 18 hours of culture and proliferation was quantified using a 
beta liquid scintillation counting approach. Data is mean + SD of technical triplicates and is representative 
of 2 individual experiments. Significance was determined using a two-tailed paired Student’s t-test where 
*=p<0.05 and **=p<0.01. cpm = counts per minute. For the CTV-dilution (B), splenocytes were labelled 
with 2 μM CTV prior to co-culture. Proliferation of only eGFP+ cells was measured, where appropriate and 
the percentage of cells which divided, as defined by the gate shown, is provided in the top left corner of 
each plot. Data is mean values only, representing a single preliminary experiment. ns = not significant. 
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When proliferation was measured by 3H-thymidine incorporation, expression of Kd by the APC 
induced a 2.6-fold increase in proliferation of the untransduced T cells, suggesting a high level of 
background proliferation (p=0.069; Figure 6-9A). This may have been due in part to the activation 
of CD8+ T cells with direct allospecificity against the Kd molecule. The involvement of the direct 
pathway in activating the T cells was further confirmed when BALB/c APCs were used as 
stimulators, as the presentation of allogeneic MHC class I (Kd) and MHC class II (I-Ad) by these cells 
facilitated the activation of both CD8+ and CD4+ T cells with direct allospecificity. 
In the same analysis, Kd CAR-eGFP T cells proliferated 4.2-fold more in the presence of B6.Kd APCs, 
relative to B6 APCs (p=0.0049; Figure 6-9A). Given the fact that this was a greater fold-increase 
than was observed for the untransduced T cells, this suggested that expression of the  
Kd CAR-eGFP was influencing the proliferation of the T cells. However, the modesty of this 
difference and the fact that the T cells proliferated 9.3-fold more in the presence of BALB/c APCs 
draws attention to the low potency of the Kd CAR-eGFP’s effect and may even suggest that the 
CAR was not functioning properly. Interestingly, similar results were also observed for T cells 
expressing the truncated Kd ΔCAR-eGFP (p=0.026), perhaps due to the Kd ΔCAR-eGFP bringing the 
T cell into the vicinity of the APC, thus promoting the activation of T cells with a low level of direct 
allospecificity. 
Looking solely at the proliferation of the three T cell lines in the presence of B6.Kd APCs  
(Figure 6-9A), T cells expressing the Kd CAR-eGFP construct proliferated more than the 
untransduced or Kd ΔCAR-eGFP T cells. However, these differences were very minor and did not 
reach statistical significance (untransduced versus Kd CAR-eGFP = 1.9-fold increase in 
proliferation, p=0.053; Kd CAR-eGFP versus Kd ΔCAR-eGFP = 1.5-fold increase in proliferation, 
p=0.061), again calling into question the potency of the CAR. 
Similar results were obtained when proliferation was analysed in a preliminary experiment by CTV 
dilution (Figure 6-9B). In this analysis, only proliferation of the eGFP+ cells was assessed, where 
appropriate. These results demonstrated that the Kd CAR-eGFP T cells proliferated 5.8-fold more 
than the untransduced T cells and 2-fold more than the Kd ΔCAR-eGFP T cells in the presence of 
B6.Kd APCs. However, this result was again much more modest than expected as the eGFP gating 
strategy meant that in theory, 100% of the Kd CAR-eGFP T cells had the potential to be activated 
in the presence of the B6.Kd APCs. In contrast, TCR-mediated activation through direct 
allorecognition, achieved by co-culture with BALB/c APCs, would typically be expected to 
stimulate approximately ~10% of the T cells (Boardman, Jacob et al. 2016). However, dramatically 
more proliferation (approximately 60%) was observed as a consequence of direct allorecognition 
than Kd CAR-eGFP engagement (21.1%), suggesting that the CAR did not potently activate the T 
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cells. Overall, these results suggested that expression of the Kd CAR-eGFP construct did influence 
the T cells in the presence of Kd but this effect was much more modest than expected, calling into 
question the potency of this CAR and potentially suggesting that it was not fully functional. 
 
 MAINTENANCE AND TRANSDUCTION OF MURINE TREGS 
 Characterisation of a previously established Treg line 
As discussed above, previous studies performed by the host laboratory have used the Phoenix 
Eco transduction system to generate B6 Treg lines with indirect allospecificity (Tsang, Tanriver et 
al. 2008, Tsang, Tanriver et al. 2009) and to generate B6 Tregs which expressed the human 
sodium-iodide symporter (NIS) for use in an in vivo imaging context (Sharif-Paghaleh, Sunassee et 
al. 2011). In both cases, there was a preference to establish a Treg line by stimulating  
freshly-isolated CD4+CD25+ Tregs with DCs for a minimum of 6 consecutive weeks before 
attempting to transduce these cells. As such, for this thesis, Tregs were used from a cell line 
previously established by Dr Julia Tsang (MRC Centre for Transplantation, King’s College London, 
UK). This cell line was originally generated by enriching CD4+CD25+ T cells from the secondary 
lymphoid organs of B6 mice using a bead-based negative and positive selection protocol. To 
generate a B6 Treg cell line with self-specificity, these cells were then stimulated with irradiated 
B6 BM-DCs. The Tregs were re-stimulated once a week and cultured in the presence of 10 U/mL 
recombinant human IL-2. These cells were then cryopreserved after 6 weeks of expansion. 
Figure 6-10 │ Phenotype of BM-DCs 6 days post-isolation. DC progenitors were enriched from the BM of 
B6 mice by negative selection, depleting cells which expressed CD4, CD8, B220 and MHC class II. Isolated 
cells were grown in the presence of GM-CSF for 6 days. The phenotype of these cells was assessed by flow 
cytometry, using fluorescently-conjugated antibodies which were specific for CD11c, CD80, CD86,  
MHC class I (Kb), MHC class II (I-Ab) and CD40 (blue lines). Cells stained with isotype controls are shown in 
solid grey. Data representative of 2 individual experiments. 
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Tregs from this previously established self-specific cell line were thawed and stimulated with B6 
BM-DCs. These DCs had been enriched as progenitors from the BM of B6 mice and grown in the 
presence of GM-CSF for 6 days, prior to use. A phenotypic analysis of these BM-DCs was 
performed by flow cytometry. This demonstrated that the cells expressed the DC marker CD11c 
as well as I-Ab (MHC class II), CD80 and CD86 which were essential for efficiently activating the 
CD4+ Tregs (Figure 6-10). 
The suppressive capacity of the Treg line was confirmed prior to transduction. This was 
accomplished by co-culturing the Tregs at a 1:1 ratio with 5x104 CD4+ Tresps in the presence of 
1x105 B6 APCs and 1 μg/mL anti-mouse CD3ε (145-2C11 clone) (Golshayan, Jiang et al. 2007, 
Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009). The cells were co-cultured for 72 hours 
after which Tresp proliferation was measured by 3H-thymidine incorporation. Proliferation of the 
polyclonally-activated Tresps, measured as cpm, was reduced 23-fold when cultured in the 
presence of Tregs (1:1 Treg:Tresp ratio; p=0.0023; Figure 6-11). This demonstrated the potent 
suppressive capacity of these cells in vitro. 
Figure 6-11 │ CD4+CD25+ Tregs from a previously established cell line efficiently suppressed CD4+ Tresp 
proliferation. Resting CD4+CD25+ Tregs from a previously established cell line were co-cultured at a 1:1 
ratio with 5x104 B6 CD4+ Tresps which were activated by the presence of 1x105 B6 APCs and 1 μg/mL  
anti-mouse CD3ε (145-2C11 clone). Co-cultures were performed for 72 hours where 1 μCi 3H-thymidine 
was added for the last 18 hours of culture. Total cell proliferation was measured using beta liquid 
scintillation counting approach. Significance was determined using a paired two-tailed Student’s t-test 
where *=p<0.05 and **=p<0.01. cpm = counts per minute, ● = 5x104 Tresps, ●● = 1x105 Tresps. 
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The Tregs were transduced 2 weeks after they were thawed (8 weeks post-isolation). To achieve 
this, the Tregs were re-stimulated with irradiated B6-derived BM-DCs and cultured in the 
presence of 10 U/mL IL-2. These cells were then harvested 48 hours post-stimulation and 
suspended in fresh Phoenix Eco-derived supernatant containing retroviral particles. The Tregs 
were maintained in culture for 5 days post-transduction where IL-2 was supplemented every  
2 days. The efficiency of transduction was then assessed by flow cytometry, based on eGFP 
expression. Unfortunately, as the aforementioned studies performed in the host laboratory had 
previously demonstrated, Tregs from the established cell line were transduced with a low 
efficiency (0.55 ± 0.48%; n=4; Figure 6-12A). As such, it was necessary to expand these cells for 
approximately 2 months to obtain a usable number of Tregs. Successfully transduced Tregs were 
then isolated by cell sorting, based on their eGFP expression, and expanded for an additional 2 
Figure 6-12 │ CD4+CD25+ Tregs from a previously established cell line were retrovirally transduced to 
express the Kd CAR-eGFP and Kd ΔCAR-eGFP constructs with a low efficiency. A: Transduction efficiency of 
Tregs from a previously established cell line. CD4+CD25+ Tregs were stimulated with irradiated B6  
BM-DCs and cultured in the presence of 10 U/mL recombinant human IL-2. 48 hours post-stimulation, 
these Tregs were either left untransduced or retrovirally transduced to express the Kd CAR-eGFP or  
Kd ΔCAR-eGFP construct. The cells were expanded for an additional 5 days after which the efficiency of 
transduction was assessed by flow cytometry, based on eGFP expression. B: Transduced cells were 
expanded for 2 months with repeated stimulations on a weekly basis with irradiated B6 BM-DCs.  
eGFP+ cells were then enriched by cell sorting. The purity of the end cell product was compromised to 
ensure a sufficient number of cells was acquired to continue expanding in vitro. These cells were expanded 
for an additional 2 months after which the proportion of eGFP+ cells was assessed by flow cytometry, as 
shown. The percentage of events in each gate is provided. 
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months to obtain enough cells for downstream applications. Following this 4 month expansion 
period, the proportion of eGFP+ cells in each Treg line was >50% (Figure 6-12B). 
Taken together, these results demonstrated that it was possible to generate a Kd CAR-eGFP Treg 
line by transducing Tregs from a previously established cell line. However, these cells were 
transduced with a low efficiency thus multi rounds of expansion were required in order to obtain 
a practical number of cells for downstream applications. 
 
Figure 6-13 │ CD4+CD25+ Tregs maintained their phenotype following retroviral transduction, cell sorting 
and a prolonged expansion period. A: The presence of the Kd CAR-eGFP and Kd ΔCAR-eGFP proteins on the 
surface of the sorted Tregs was assessed by flow cytometry using a fluorescently-conjugated antibody 
specific for the 9E10 cMyc tag epitope present in the extracellular domains of these CARs (Figure 6-3A). 
The percentage of events in each gate is provided. B: Sorted Tregs were stained with  
fluorescently-conjugated antibodies specific for the following Treg markers: CD4, CD25, FoxP3, CTLA-4, 
CD39 and CD73. The expression of these markers by the untransduced (red lines), Kd CAR-eGFP (blue lines) 
and Kd ΔCAR-eGFP (green lines) Tregs was measured by flow cytometry. MFI values for each of the samples 
is provided in the top right corner of each plot. Data representative of 2-3 individual experiments. 
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 Retroviral transduction and cell sorting did not 
influence the phenotype or suppressive capacity of 
murine CD4+CD25+ Tregs 
As previously mentioned, all of the Tregs lines were expanded for approximately 4 months in 
order to obtain a sufficient number of Kd CAR-eGFP and Kd ΔCAR-eGFP cells. This prolonged 
expansion period coupled with the genetic manipulation process had the potential to influence 
the phenotype or suppressive capacity of these cells. Therefore, in order to confirm that the Tregs 
maintained their expression of Treg markers and preserved their suppressive capacity, the 
phenotype and ability of the cells to inhibit CD4+ Tresp proliferation was assessed in vitro, as 
previously described. 
Tregs were harvested 7 days post-stimulation and stained with various fluorescently-conjugated 
antibodies to measure expression of the CAR (cMyc tag) and typical Treg markers. As previously 
demonstrated with transduced splenocytes (Figure 6-7), there was no detectable cMyc tag on 
Figure 6-14 │ CD4+CD25+ Tregs maintained their suppressive capacity in a polyclonal manner following 
retroviral transduction, cell sorting and a prolonged expansion period. 5x104 B6 CD4+ Tresps were 
stimulated with 1x105 B6 APCs and 1 μg/mL anti-mouse CD3ε (145-2C11 clone). Resting CD4+CD25+ Tregs 
which were untransduced (red bars), or engineered to express the Kd CAR-eGFP (blue bars) or  
Kd ΔCAR-eGFP (green bars) construct were added to the co-culture at various ratios. Co-cultures were 
performed for 72 hours where 1 μCi 3H-thymidine was added for the last 18 hours of culture. Total cell 
proliferation was measured using beta liquid scintillation counting approach. A two-tailed paired Student’s 
t-test was performed but no significant differences were observed. Data representative of 2 individual 
experiments. cpm = counts per minute, ns = not significant, ● = 5x104 Tresps, ●● = 1x105 cells.  
Chapter VI │ Generating murine Kd CAR Tregs 
 
176 
the surface of the eGFP+ Tregs when assessed using a fluorescently-conjugated cMyc tag-specific 
antibody (Figure 6-13A). Fortunately, the transduction and sorting processes were found to have 
not influenced the phenotype of the Tregs as the untransduced and Kd CAR-eGFP Tregs expressed 
similar levels of CD4, CD25, FoxP3, CTLA-4, CD39 and CD73 (Figure 6-13B). However, the  
Kd ΔCAR-eGFP Tregs did express lower levels various markers compared to the other two Treg 
lines including CD25 (MFI = 5,121 compared to >9,000), FoxP3 (MFI = 1,535 compared to >2,000) 
and CD39 (1,888 compared to >3,400), suggesting that the prolonged expansion period may have 
begun to influence the phenotype of this cell line. 
To compare the suppressive capacity of the 3 Treg lines, a polyclonal suppression assay was 
performed where the Tregs were co-cultured with Tresps at various ratios with Tresps and B6 
APCs in the presence of 1 μg/mL anti-mouse CD3ε, as previously described. Proliferation was 
measured after 72 hours of culture by 3H-thymidine incorporation. Overall, the transduced Tregs 
exhibited a similar suppressive capacity to the untransduced Tregs, demonstrating that the 
transduction and subsequent cell sorting processes had not influenced the functionality of these 
cells (Figure 6-14). However, relative to the suppressive capacity these cells exhibited prior to the 
transduction and expansion processes (Figure 6-11), each line appeared to be less potent. 
Previously, at a 1:1 Treg:Tresp ratio, the Tregs inhibited Tresp proliferation (measured as cpm) by 
23-fold prior to the expansion. However, the same (untransduced) Tregs co-cultured at the same 
ratio only inhibited Tresp proliferation by 4.1-fold following expansion. 
Taken together, these results demonstrated that retroviral transduction of murine CD4+CD25+ 
Tregs did not influence the phenotype or suppressive capacity of these cells. The subsequent 
prolonged expansion period which was necessary to acquire a practical number of cells may have 
influenced the functionality of these cells, independently of the transduction process. 
 
 FUNCTIONAL ASSESSMENT OF THE Kd-SPECIFIC CAR  
EXPRESSED BY TREGS 
 Kd CAR-eGFP Tregs preferentially proliferated in the 
presence of the Kd target antigen 
In a previous study published by the host laboratory, Tregs with indirect allospecificity were 
shown to proliferate in vivo when injected into transgenic B6.Kd mice but not in B6 mice (Tsang, 
Tanriver et al. 2008). To investigate whether Kd CAR-eGFP Tregs responded in a similar manner, 
B6 and B6.Kd mice were injected i.v. with 2x106 CTV-labelled Tregs. The mice were sacrificed after 
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72 hours and the proliferation of the transferred Tregs present in the spleens was assessed by 
flow cytometry, as determined by CTV dilution. 
Transferred Tregs were identified in the total splenocytes by their expression of CD4 and CTV 
label. A minimal level of proliferation was recorded for both the untransduced and Kd CAR-eGFP 
Tregs when injected into B6 mice (Figure 6-15A and Table 6-1). In contrast, a noticeable level of 
proliferation was observed when these cells were transferred into B6.Kd mice (Figure 6-15B and 
Table 6-1). Untransduced Tregs proliferated 4-fold more in the B6.Kd mice compared to B6 mice,  
demonstrating a high level of background proliferation. Kd CAR-eGFP Tregs improved on this 
difference, proliferating 8.5-fold more in the B6.Kd mice compared to the B6 mice suggesting that 
expression of the Kd CAR-eGFP construct did confer an advantage. However, given the high level 
of background proliferation in this assay and very minor increase in Kd CAR-eGFP Treg 
proliferation that was observed in the B6.Kd mice, relative to this background, it was clear that 
the Kd CAR-eGFP construct was not having the desired potent effect one would have expected. 
Overall, these results suggested that Tregs expressing the Kd CAR-eGFP construct preferentially 
Figure 6-15 │ Kd CAR-eGFP Tregs preferentially proliferate upon transfer into B6.Kd mice, compared to B6 
mice. 2x106 untransduced or Kd CAR-eGFP Tregs were adoptively transferred into wt B6 or B6.Kd mice by 
iv injection. Mice were scarified after 72 hours and spleens were harvested to measure Treg proliferation. 
Total splenocytes were stained with a fluorescently-conjugated anti-mouse CD4 and Treg proliferation was 
assessed using a flow cytometer. Transferred Tregs were identified by their expression of CD4 and CTV 
label (gate shown). % proliferation of these cells was calculated as the proportion of divided Tregs (shaded 
region of the gate) relative to the total number of transferred cells (entire gate). % proliferation values are 
provided in the bottom right corner of each plot. Data shown is representative of 2 mice per group in a 
preliminary experiment which was performed once. Total data is summarised in Table 6-1.  
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expanded in the presence of Kd in vivo, but this was not achieved at an extent which unequivocally 
demonstrated the functionality of the Kd CAR-eGFP construct. 
 
 Kd CAR-eGFP Tregs were not more suppressive than 
polyclonal Tregs in the presence of Kd-expressing 
APCs 
As Kd CAR-eGFP Tregs preferentially proliferated in the presence of Kd, this suggested that the 
CAR was functional. To confirm this, a linked antigen-specific suppression assay was performed. 
The ability of untransduced, Kd CAR-eGFP and Kd ΔCAR-eGFP Tregs to suppress antigen-specific 
CD4+ Tresp proliferation in the presence of Kd was compared. In this assay, CD4+ Tresps were 
isolated from transgenic OT-II mice, a B6 mouse strain which expresses a transgenic TCR that is 
specific for the chicken ovalbumin peptide (OVA323-339) presented in the context of I-Ab. OT-II 
Tresps were stimulated with B6.Kd APCs which were pulsed with 0.2 μg/mL OVA323-339 peptide. 
Tregs were then added to the co-culture at various Treg:Tresp ratios to assess whether the  
Kd CAR-eGFP Tregs inhibited OVA-specific Tresp proliferation more effectively than the 
untransduced Tregs in the presence of Kd.  
When Tresp proliferation was measured by 3H-thymidine incorporation, all three of the Treg lines 
exhibited a minimal level of suppression (Figure 6-16). However, a high cpm count was observed 
in wells that did not contain Tresps, suggesting that the suppressive ability of the Tregs was being 
masked by their own proliferation. This was confirmed when the proliferation of the Tresps was 
measured by CTV dilution (Figure 6-17). In this setting, all of the Tregs were shown to efficiently 
inhibit Tresp proliferation, affirming their suppressive capacity. However, no statistically 
significant differences were observed in the level of suppression exhibited by the three Treg lines, 
Recipient Mouse Treg line injected 
% Treg proliferation 
Mouse 1 Mouse 2 Average 
wt B6 
Untransduced 1.77 N/A 1.77 
Kd CAR-eGFP 1.56 1.92 1.74 
B6.Kd 
Untransduced 7.99 7.23 7.61 
Kd CAR-eGFP 16.5 13.0 14.75 
     
Table 6-1 | Summary of the % of Treg proliferation upon adoptive transfer into B6 and B6.Kd 
mice (Figure 6-15). 
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at any of the Treg:Tresp ratios analysed. At a 1:4 Treg:Tresp ratio, the % suppression exhibited by 
the untransduced, Kd CAR-eGFP and Kd ΔCAR-eGFP Tregs was 38.3 ± 3.1%, 30.3 ± 1.0% and  
32.1 ± 6.9%, respectively. Taken together with the overall suppressive profile of the three Treg 
lines, these results suggested that the Kd CAR-eGFP Tregs did not possess a superior suppressive 
capacity over untransduced Tregs in the presence of Kd. In this assay, the TCR-dependent  
self-specificity of the Tregs likely contributed to “background suppression”. However, it was 
expected that expression of the Kd CAR-eGFP construct would contribute in a cumulative manner 
to this self-specificity, providing the Kd CAR-eGFP Tregs with an added advantage, but this was 
not observed. Overall, these results demonstrated that in the presence of B6.Kd APCs, Tregs 
expressing the Kd CAR-eGFP were unable to suppress CD4+ Tresp proliferation more effectively 




Figure 6-16 │ Kd CAR-eGFP Tregs did not suppress CD4+ Tresp proliferation more effectively than 
untransduced Tregs in the presence of Kd-expressing APCs. A linked suppression assay was performed 
where 5x104 CD4+ Tresps from OT-II mice were co-cultured with 1x105 B6.Kd APCs pulsed with 0.2 μg/mL 
OVA323-339. Untransduced (red bars), Kd CAR-eGFP (blue bars) and Kd ΔCAR-eGFP (green bars) Tregs were 
added to the co-culture at various Treg:Tresp ratios. Co-cultures were performed for 72 hours where 1 μCi 
3H-thymidine was added for the last 18 hours of culture. Total cell proliferation was measured using a beta 
liquid scintillation approach. Data represents mean + SD of a single preliminary experiment. cpm = counts 
per minute. 




Figure 6-17 │ Kd CAR-eGFP Tregs did not suppress CD4+ Tresp proliferation more effectively than 
untransduced Tregs in the presence of Kd-expressing APCs. A linked suppression assay was performed 
where 5x104 CTV-labelled CD4+ Tresps from OT-II mice were co-cultured with 1x105 B6.Kd APCs pulsed with 
0.2 μg/mL OVA323-339. Untransduced (red), Kd CAR-eGFP (blue) and Kd ΔCAR-eGFP (green) Tregs were added 
to the co-culture at various Treg:Tresp ratios. Co-cultures were performed for 72 hours and Tresp 
proliferation was measured using CTV dilution by flow cytometry (A). B: Data from technical replicates was 
pooled. % Tresp proliferation was calculated using division indices, relative to Tresps cultured alone.  
% suppression was then calculated as the inverse of % Tresp proliferation. Data represents mean ± SD of 
a single preliminary experiment. No statistical differences were observed at any Treg:Tresp ratio analysed 
(paired two-tailed Student’s t-test). 




In this chapter, a novel second generation CAR specific for Kd was constructed with the aim of 
generating a mouse MHC class I-allospecific Treg cell line. The rationale behind this was to 
compare the efficacy with which CAR Tregs and Tregs with alternative allospecificities protected 
against graft rejection. The antigen-targeting moiety of this CAR incorporated the VH and VL chain 
sequences of a well characterised Kd-specific antibody clone (SF1-1.1.10). This scFv sequence was 
linked to an intracellular murine CD28-CD3ζ signalling domain with a C-terminal eGFP fusion 
reporter gene (Kd CAR-eGFP). A second truncated Kd-specific CAR which lacked the capacity to 
signal intracellularly was generated by removing the CD28-CD3ζ coding sequence from the 
original CAR ORF (Kd ΔCAR-eGFP). 
Total splenocytes were efficiently transduced to express both of these constructs (29.4 ± 17.2%). 
Upon co-culture with B6.Kd APCs, Kd CAR-eGFP T cells proliferated more than untransduced or  
Kd ΔCAR-eGFP T cells, suggesting that the Kd CAR-eGFP was functional but given the minor 
difference which was observed, it was evident that the Kd CAR-eGFP construct was not potent. 
CD4+CD25+ Tregs from a previously established cell line were then transduced to express the Kd 
CAR constructs with a low efficiency (0.55 ± 0.48%). This process did not influence the phenotype 
or suppressive capacity of the Tregs. Kd CAR-eGFP Tregs were shown to preferentially proliferate 
in the presence of Kd when adoptively transferred into B6.Kd mice, although the increase in 
proliferation achieved was minimal compared to the high levels of background proliferation 
which were also observed. Unfortunately, proceeding results demonstrated that Kd CAR-eGFP 
Tregs did not inhibit CD4+CD25– Tresp proliferation more effectively than untransduced  
self-specific or Kd ΔCAR-eGFP Tregs in the presence of B6.Kd APCs. These findings demonstrated 
that expression of the Kd CAR-eGFP construct did not confer a biologically-relevant specificity for 
Kd and suggested that this CAR possessed a very low potency. 
One issue which was not categorically resolved in this chapter was the fact that cMyc tag staining 
was not detectable on transduced Kd CAR-eGFP-expressing T cells or Tregs. The concept of 
exploiting a cMyc tag to detect CAR expression was successfully demonstrated in Chapters III  
and IV and has previously been shown by Maher et al. (unpublished data) and MacDonald et al. 
(MacDonald, Hoeppli et al. 2016). However, despite the 9E10 epitope being incorporated into the 
Kd CAR-eGFP construct, cMyc tag staining was not detectable in cells which expressed this 
construct. This suggested that either the Kd CAR-eGFP construct was not trafficked to the cell 
surface or that steric hindrance of the scFv was blocking the 9E10 epitope. Experiments using 
confocal microscopy suggested that the Kd CAR-eGFP construct was trafficked to the cell 
membrane, thus blocking of the 9E10 epitope was to blame for a lack of cMyc tag detection. 
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However, this could have more simply been resolved by staining transduced cells with a Kd-based 
tetramer. Positive staining would have confirmed that the CAR was present on the cell surface 
and that it facilitated the recognition of Kd. However, this approach was not possible due to a lack 
of a Kd-based tetramer.  
Many of the assays described in this chapter were plagued by a high level of background 
responses. The first approach which was employed to assess the functionality of the Kd CAR-eGFP 
construct was to investigate whether Kd CAR-eGFP T cells preferentially proliferated in the 
presence of B6.Kd APCs, compared to B6 APCs. However, high levels of background proliferation 
were observed in these experiments, particularly when control T cells were co-cultured with B6.Kd 
and BALB/c APCs. This could be attributed to TCR-mediated stimulation of approximately 10% of 
the T cells which possessed direct allospecificity (Boardman, Jacob et al. 2016). To circumvent this 
issue, a similar experimental setup could be applied to investigate the proliferation of CD4+ T cells 
which are co-cultured with MHC class II-deficient Kd-expressing APCs. The depletion of CD8+  
T cells would prevent background proliferation of cells stimulated by the Kd molecule whilst the 
absence of MHC class II would limit TCR-mediated stimulation of the remaining CD4+ T cells. 
Experiments using CD4+CD25– T cells were performed but unfortunately, no differences were 
observed in the proliferation induced by stimulation with B6 or B6.Kd APCs. Taken together with 
the subsequent results which implied that the Kd CAR-eGFP construct was functional, this 
suggested that to obtain optimal results in this setup, MHC class II-deficient Kd-expressing APCs 
were required. However, MHC class II-deficient mice were unfortunately not available. 
Experiments assessing the suppressive efficacy of the Kd CAR-eGFP Tregs in the presence of  
Kd-expressing APCs were also complicated by a high level of background responses. In this setup, 
CD4+ Tresps from OT-II mice were stimulated with OVA peptide-pulsed B6.Kd APCs. B6 Tregs which 
were either untransduced or modified to express a Kd-specific CAR were co-cultured the Tresps 
and APCs to investigate the efficacy with which these cells inhibited Tresp proliferation. However, 
these Tregs were likely to express TCRs with a high specificity for self-I-Ab, due to being stimulated 
with B6 DCs. As such, the Kd CAR-eGFP Tregs could have been activated by the B6.Kd APCs in a 
CAR-independent manner. Tsang et al. resolved this issue by using CD4+ Tresps and APCs from 
alternative transgenic mice (Tsang, Tanriver et al. 2008). DO11.10 mice are BALB/c mice which 
are transgenic for the same OVA-specific TCR genes which are possessed by OT-II mice 
(Robertson, Jensen et al. 2000). Tsang et al. performed a suppression assay in which DO11.10 
CD4+ Tresps were stimulated with OVA323-339 peptide-pulsed BALB/c APCs. Consequently, in the 
absence of B6 I-Ab-expressing APCs, only Tregs with direct allospecificity were stimulated through 
their TCR, limiting the background suppression which was observed. This approach was not 
possible due to the lack of DO11.10 mice available but is a fundamental experiment which should 
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be performed in the future to assess whether expression of the Kd CAR-eGFP does indeed confer 
a functional advantage in the presence of Kd. 
An additional concern raised from the experiments performed in this chapter surrounded the 
efficacy of the Kd CAR-eGFP construct. Results from the aforementioned T cell proliferation assays 
suggested that the Kd CAR-eGFP construct may have been functional, but the low level of 
proliferation which was observed in these experiments called into question the efficacy of the 
CAR. This was particularly true given the fact that significantly more proliferation was induced 
through direct allorecognition in <10% of the cells (co-culture with BALB/c APCs) than through 
the CAR in ~30% of the cells (co-culture with B6.Kd APCs). 
In 2010, Kochenderfer et al. generated and published the sequence of a murine CD19-specific 
CAR which incorporated a CD28-CD3ζ signalling domain (Kochenderfer, Yu et al. 2010). A 
comparison of this sequence to the Kd CAR-eGFP sequence demonstrated that the hinge, 
transmembrane and signalling domains of these CARs were 99% identical. This suggested that 
the low efficacy of the Kd CAR-eGFP could be attributed either to a sub-optimal antigen 
recognition domain or the two amino acid residues which differed between the CD19-specific 
CAR and the Kd CAR-eGFP construct. Both of these options are discussed below. 
The simplest explanation to account for the low efficacy of the Kd CAR-eGFP construct was that 
the CAR did not efficiently bind Kd. The length of the hinge domain can influence this process, 
particularly when a target epitope is close to the cell membrane (discussed in section 1.3.1.2) 
(Guest, Hawkins et al. 2005). Consequently, when targeting an MHC class I molecule, the ideal 
MHC subunits to target are the α1 and α2 subunits as these are the subunits which are most 
exposed and accessible. Indeed, the A2 CARs constructed in Chapter III and by MacDonald et al. 
both targeted different epitopes of the HLA-A2 α2 subunit (shown in Figure 3-21B). However, the 
SF1-1.1.10 scFv clone used to generate the Kd CAR-eGFP construct recognised an epitope in the 
α3 subunit of the Kd molecule (Abastado, Ojcius et al. 1993, Noun, Reboul et al. 1996, Noun, 
Reboul et al. 1998). Consequently, it is a distinct possibility that the hinge domain incorporated 
into the Kd CAR-eGFP construct was not of a sufficient length to allow for optimal engagement of 
the SF1-1.1.10 epitope in the Kd molecule. This is a fundamental point to address in the future 
which cannot be resolved through tetramer staining. 
An alternative explanation for the low efficacy of the Kd CAR-eGFP is that the scFv domain itself 
did not efficiently engage Kd. Indeed, this antigen recognition domain was designed and 
generated de novo using VH and VL chain sequences which were obtained from a Kd-specific 
antibody. It is well established that the tertiary structure adopted by these chains can differ when 
they are incorporated into an scFv or a complete antibody (Argos 1990, Smallshaw, Georges et 
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al. 1999). As such, a loss of specificity can be potentiated when these sequences are linked in an 
scFv format. Furthermore, previous studies have demonstrated a clear link between the affinity 
with which a CAR engages its target antigen and the response elicited (Liu, Jiang et al. 2015). 
A third explanation for the low efficacy of the Kd CAR-eGFP construct related to work which was 
published by Nguyen et al. in 2003 (Nguyen, Moisini et al. 2003). This study set out to investigate 
whether CARs could be used to specifically target and destroy CD8+ T cells with direct 
allospecificity in a transplant context. To achieve this, a murine CAR was constructed which 
presented elements of a Kb complex. Specifically, this CAR incorporated the extracellular and 
transmembrane domains of the Kb molecule (Geiger, Nguyen et al. 2001) which were linked to an 
intracellular CD28-CD3ζ signalling domain. The rationale behind this was that in a transplant 
setting, CAR-expressing T cells would specifically engage and destroy CD8+ T cells with direct 
allospecificity. In this study, CAR T cells which were pulsed with OVA257-264 peptide were shown to 
specifically kill OT-I T cells (TCR specific for Kb-OVA) in vitro and in vivo. However, these findings 
were shadowed by the discovery of a noncanonical dileucine internalisation motif which was 
present in the CD28 portion of their CAR. These authors demonstrated that mutating this LL motif 
into a GG motif increased detection of their CAR on the cell surface by up to 4-fold. When 
designing the Kd CAR-eGFP construct, this LL motif was not mutated and as such, was 
incorporated into the end product. Rapid internalisation of the Kd CAR-eGFP protein would 
account for both the limited efficacy of this CAR and the lack of cMyc tag staining which was 
discussed above. The effects of this motif can be determined in the future by generating a  
Kd CAR-eGFP construct with point mutations in this LL motif. 
 
 SUMMARY  
The work presented in this chapter aimed to generate a murine Kd-specific CAR with the rationale 
of comparing the efficacy with which MHC class I-allospecific CAR Tregs and Tregs with alternative 
allospecificies inhibited transplant rejection. A CAR was generated for this purpose but the 
functionality of this CAR in the presence of Kd-expressing cells was unconvincing. Kd CAR-eGFP 
Tregs proliferated marginally more in the presence of Kd but no definitive functional advantage 
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 GENERAL DISCUSSION 
The safety and efficacy of Treg therapy is currently being assessed clinically as a means of 
promoting transplant tolerance in kidney and liver transplant recipients (Table 1-1). For this 
purpose, the successful generation and expansion of graft-specific Tregs is desirable as these cells 
promote transplant tolerance more effectively than polyclonal Tregs (Sagoo, Lombardi et al. 
2008, Tsang, Tanriver et al. 2008, Tsang, Tanriver et al. 2009, Putnam, Safinia et al. 2013). 
Allospecific Tregs can be generated using GMP-compatible protocols by stimulating Tregs with 
allogeneic APCs (Peters, Hilbrands et al. 2008, Tu, Lau et al. 2008, Chen, Delgado et al. 2009, 
Zheng, Liu et al. 2010, Sagoo, Ali et al. 2011, Noyan, Lee et al. 2013, Putnam, Safinia et al. 2013, 
Cherai, Hamel et al. 2015, Jeffery, Braitch et al. 2016). However, the Tregs resulting from this 
process are restricted to recognising allogeneic peptides presented in the context of allo-MHC 
class II molecules. This thesis explored a novel approach which may be employed to confer 
peptide-independent donor MHC class I-allospecificity onto Tregs using CAR technology. 
Novel CARs were used to direct the specificity of human and mouse Tregs towards the allogeneic 
MHC class I molecules HLA-A2 and Kd, respectively. For the human Tregs, CAR delivery was 
achieved through lentiviral transduction which was shown to not influence the phenotype or 
suppressive ability of these cells in vitro. A2 CAR-eGFP Tregs were shown to suppress autologous 
CD4+CD25– Tresp proliferation more effectively than polyclonal or A2 ΔCAR-eGFP Tregs in the 
presence of HLA-A2+ APCs, without eliciting cytotoxicity. Furthermore, Tregs expressing a  
HLA-A2-specific CAR were found to favour transmigration into HLA-A2+ tissues in manner which 
was independent of CAR signalling and Treg activation. This observation was supplemented by 
the finding that these cells were also retained in HLA-A2+ skin allografts in vivo. Most importantly, 
A2 CAR-eGFP Tregs were shown to protect human HLA-A2+ skin grafts more effectively than 
polyclonal Tregs, making the argument for the adaptation of CAR Tregs in the clinic. 
Work with the murine Kd CAR-eGFP Tregs is still ongoing but results thus far have demonstrated 
that this CAR can be delivered into murine Tregs without influencing the phenotype or 
suppressive capacity of these cells. Unfractioned T cells expressing the Kd CAR-eGFP construct 
appeared to proliferate more in the presence of B6.Kd APCs than B6 APCs in vitro although this 
increase in proliferation was minimal and difficult to decipher over the high level of background 
proliferation which was observed in these assays. Similarly, Kd CAR-eGFP Tregs may have 
proliferated more when adoptively transferred into B6.Kd mice, compared to B6 mice, although 
this increase was also minor and obscured by a high level of background proliferation. However, 
the superior suppressive capacity of Kd CAR-eGFP Tregs compared to self-specific Tregs in the 
presence of B6.Kd APCs remained to be demonstrated. 
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The concept of redirecting Tregs towards MHC class I molecules has previously been explored 
using TCRs. Brusko et al. and Plesa et al. both demonstrated that functional HLA-A2-restricted 
CD4+ Tregs could be generated by lentivirally transducing Tregs to express specific CD8+  
T cell-derived TCR α and β chain genes (Brusko, Koya et al. 2010, Plesa, Zheng et al. 2012). These 
studies demonstrated that it was possible to lentivirally transduce human Tregs to confer antigen-
specificity without influencing the phenotype or suppressive capacity of these cells, as was 
confirmed in Chapter IV. Tregs expressing these MHC class I-specific TCRs were shown to 
efficiently suppress the activation and proliferation of Tconvs with the same specificity both in 
vitro and in vivo. More importantly however, these studies highlighted the concept of redirecting 
Tregs towards MHC class I antigens which are prevalently presented in target tissues, as opposed 
to the MHC class II antigens which are typically targeted by Tregs. However, this approach was 
compromised as only specific TCRs which bound the target MHCs with a very high affinity could 
be used, due to the lack of CD8 stabilisation in the TCR:MHC interaction (Plesa, Zheng et al. 2012). 
Furthermore, these cells were still restricted to recognising peptides presented in the context of 
MHC molecules. In contrast, CARs can incorporate antibody-derived antigen recognition domains 
which engage donor MHC molecules in a peptide-independent manner. Consequently, conferring 
specificity through the use of CAR technology is the more prudent choice for generating graft-
specific Tregs as these cells do not rely on the presentation of specific peptides in order to engage 
their target antigen, unlike TCR-manipulated Tregs. 
A widely reported limitation of CAR technology is the fact that these proteins are restricted to 
recognising extracellular target antigens (Morris and Stauss 2016). In contrast, TCRs can recognise 
peptides derived from intracellular antigens. This is a particular limitation in cancer research 
where tumour associated antigens (TAA) may not be presented extracellularly, allowing 
cancerous cells to evade immune recognition. Conversely, in a transplantation context, donor 
MHC class I molecules are ubiquitously expressed in allografts as well as on donor-derived APCs 
and cross-dressed APCs (section 1.1.1.3.1). As such, the availability of the target antigen is not an 
issue. However, this consistent antigen availability may be a double-edged sword as Tregs are 
indeed activated within the graft but consistent activation may potentially lead to  
activation-induced cell death (AICD). In cancer research, T cells expressing hyperactive CARs have 
been shown to be highly susceptible to AICD as a consequence of high FasL expression (Lanitis, 
Poussin et al. 2013, Kunkele, Johnson et al. 2015). Although it has been suggested that Tregs are 
less susceptible to AICD than Tconvs (Yolcu, Ash et al. 2008), this remains a caveat of CAR 
technology which warrants further investigation in Tregs. 
The data presented in Chapter V suggested that AICD of CAR Tregs was not a pressing issue and 
that these cells indeed survived long-term in the investigated setting. HLA-A2+ skin grafts of mice 
Chapter VII │ General discussion 
 
188 
which received PBMCs with A2 CAR-eGFP Tregs contained more CD3+FOXP3+ cells than the grafts 
of mice which received PBMCs with polyclonal Tregs, suggesting that the transferred Tregs 
survived long-term (more than 6 weeks; Figure 5-14). However, a future analysis to measure the 
presence of the cMyc tag or eGFP is required to confirm this. The long-term Treg survival achieved 
was contrary to the results of MacDonald et al. who investigated the capacity of A2 CAR Tregs to 
inhibit xeno-GvHD (MacDonald, Hoeppli et al. 2016). In their setting, A2 CAR Tregs were not 
detected in circulation 2 weeks following adoptive transfer which was attributed to a lack of IL-2 
in the in vivo system. Indeed, this dependence on IL-2 for Treg survival is currently being 
addressed clinically where trials are investigating the use of low-dose IL-2 therapy to promote  
in vivo Treg expansion for treating transplant rejection and autoimmunity (Koreth, Matsuoka et 
al. 2011, Saadoun, Rosenzwajg et al. 2011, von Spee-Mayer, Siegert et al. 2016).  
MacDonald et al. proceeded to demonstrate that STAT5, a downstream target of IL-2, was not 
phosphorylated in response to CAR stimulation (MacDonald, Hoeppli et al. 2016). STAT5 
phosphorylation is fundamental for the function and survival of Tregs (Passerini, Allan et al. 2008, 
Wuest, Willette-Brown et al. 2008, Vogtenhuber, Bucher et al. 2010, Bailey-Bucktrout, Martinez-
Llordella et al. 2013, Mahmud, Manlove et al. 2013). However, this was not an issue in the 
experiments performed in Chapter V. This difference between systems may be explained by the 
possibility that in the xeno-GvHD setting, protection may have been mediated through the 
inhibition of Tconv engraftment thus these cells were not available to produce IL-2. In contrast, 
in the experiments performed in chapter V, the presence of the allogeneic skin graft facilitated 
the activation of Tconvs which produced IL-2, aiding Treg survival. Treg dependence on IL-2 could 
be circumvented by co-transducing these cells to express a chimeric cytokine receptor which 
delivers intracellular IL-2R signals upon recognition of a prevalent antigen or alternative cytokine 
(Wilkie, Burbridge et al. 2010, Leen, Sukumaran et al. 2014). 
Another mechanism which has been shown to reduce the longevity of CAR-expressing T cells is 
xenogeneic recognition of the exposed antigen targeting moiety of the CAR. This issue has 
previously undermined two clinical trials in which transferred T cells expressing a CAR that 
contained a murine-derived scFv did not persist long-term post-transfer (Kershaw, Westwood et 
al. 2006, Lamers, Willemsen et al. 2011). This was attributed to the in vivo generation of 
antibodies which specifically recognised the CARs. The A2 CAR-eGFP construct designed in 
Chapter III incorporated an scFv which was derived from human origins (Watkins, Brown et al. 
2000). This reduced the immunogenicity of the CAR and improved the chances of the CAR Tregs 
surviving long-term post-transfer. However, it is imperative to note that the immunogenicity of 
this CAR was not addressed in the experiments performed in Chapter V and in humans, the 
generation of anti-A2 CAR antibodies remains a potential problem. Indeed, CAR Tregs were 
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shown to survive long-term in the BRG mice which were injected with human PBMCs but a severe 
limitation of this system is that B cells do not engraft thus it was not possible for anti-A2 CAR 
antibodies to be generated (Ali, Flutter et al. 2012). This lack of B cells, or any other APCs for that 
matter, also had important implications for investigating the responses of T cells and Tregs with 
indirect allospecificity as these cells are unable to be stimulated in these mice. Consequently, a 
different model would be required to compare the protective efficacy of Tregs with different 
allospecificities. The anticipated mouse-based experiments described in Chapter VI had the 
potential to address these issues but were unfortunately not performed due to complications in 
generating a potent Kd-specific CAR. 
 
 FUTURE WORK 
In this thesis, the expression of a donor MHC class I-specific CAR was shown to confer a functional 
advantage to polyclonal Tregs in a transplant context. However, there are still some major 
obstacles which must be addressed before this approach is adopted in the clinic. The most 
pressing of these is whether this approach is the most prudent choice for generating graft-specific 
Tregs. Indeed, A2 CAR-eGFP Tregs were shown to inhibit alloimmune-mediated injury of HLA-A2+ 
skin grafts more effectively than polyclonal Tregs, but it remains unclear how these cells compare 
to Tregs with direct or indirect allospecificity. The work of Chapter VI set out to address this but 
unfortunately, ambiguity in the functionality of the Kd CAR-eGFP construct meant that this was 
not achieved. 
The safety and efficacy of Tregs with direct allospecificity at reducing kidney and liver transplant 
rejection is currently being assessed outside of the UK (Table 1-1). In contrast, evidence for the 
efficacy of CAR Tregs is only just emerging in pre-clinical studies. As such, it is clear that pre-clinical 
studies must first compare the efficacy of these cells before the idea of CAR Tregs is entertained 
in transplantation-based clinical trials. Furthermore, CAR Tregs must be shown to protect 
allografts dramatically more effectively than Tregs with direct allospecificity, as CAR Tregs are 
associated with additional genetic manipulation-based risks. To this end, the efficacy of CAR Tregs 
may be improved by employing approaches which are currently being investigated in cancer 
research. As discussed in section 1.3.3, TRUCK and Armoured CAR T cells have been developed to 
express additional genes which are delivered concurrently with the CAR (Chmielewski, Hombach 
et al. 2014, Yeku and Brentjens 2016). The concept of the inducible IL-12 cassette is of particular 
interest as this facilitated CAR T cells to secrete high levels of IL-12 following CAR engagement. 
This idea could be adapted to CAR Tregs such that they secrete high levels of IL-10 or alternative 
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anti-inflammatory cytokines when activated. Additional manipulations to enhance the stability 
and/or functionality of these cells may also be considered. This could be achieved by  
co-transducing the Tregs to express exogenous FOXP3 (Fransson, Piras et al. 2012), or functional 
molecules such as Nrp-1 (Sarris, Andersen et al. 2008) or LAG3 (Liang, Workman et al. 2008) in 
addition to the CAR although the number of accompanying genes which can be added is restricted 
by the size of the delivery vector (Cante-Barrett, Mendes et al. 2016). 
Although adoptive Treg therapy is known to alleviate graft rejection, the exact mechanisms as to 
how this is achieved are not fully understood. This particularly relates to the location at which 
Tregs inhibit alloimmune responses. Various studies have demonstrated that Tregs suppress the 
activation of alloreactive T cells in draining lymph nodes associated with the allograft (Lee, Moore 
et al. 2006, Zhang, Schroppel et al. 2009) and that the ability to interact with DCs is of particular 
importance (Tadokoro, Shakhar et al. 2006, Tang, Adams et al. 2006, Koutrolos, Berer et al. 2014). 
However, this is contrary to the data shown in Chapter V and studies which have shown that  
re-transplanted allografts are not rejected when they are derived from tolerised mice (Hall, 
Jelbart et al. 1984, Graca, Cobbold et al. 2002). If alloresponses are principally inhibited in the 
draining lymph nodes, this would counter the argument that donor MHC class I-specific CAR Tregs 
facilitate the generation of an intragraft immunoregulatory milieu. Instead, this would suggest 
that the CAR Tregs mediated their protective capacity by engaging donor-derived and  
cross-dressed DCs, as was suggested for Tregs with direct allospecificity by Sagoo et al. (Sagoo, 
Ali et al. 2011). Through this mechanism, CAR Tregs may potentially inhibit both the activation of 
T cells with direct and indirect allospecificities, whereby the latter is achieved through linked 
suppression. Longitudinal imaging studies of transferred Tregs would resolve this conundrum and 
help address whether CAR Tregs alleviated graft rejection by suppressing Tconvs within the graft, 
or whether this was achieved by inhibiting T cell activation via the direct/semi-direct pathways in 
the lymph nodes (Sharif-Paghaleh, Sunassee et al. 2011). Indeed, similar studies performed by 
Parente-Pereira et al. in a cancer setting suggested that the majority of CAR T cells do not migrate 
to the tumour and instead, these cells remain in the liver, spleen and lymph nodes (Parente-
Pereira, Burnet et al. 2011). Current work performed by Dr Nia Emami-Shahri and Dr Sophie Papa 
(Division of Cancer Studies, King’s College London) aims to expand on these findings but in light 
of these results, the exogenous expression of specific homing receptors to promote preferential 
migration to the tumour site may be worthwhile (Kershaw, Wang et al. 2002, Di Stasi, De Angelis 
et al. 2009). 
The principle of CAR Tregs can also be applied to treat various autoimmune diseases, particularly 
in light on ongoing clinical trials which are investigating the safety and efficacy of polyclonal Treg 
therapy in for the treatment of T1D (NCT01210664) (Bluestone, Buckner et al. 2015), lupus 
Chapter VII │ General discussion 
 
191 
erythematosus (NCT02428309) and uveitis (NCT02494492). This concept has already been 
exploited for the treatment of colitis (Elinav, Waks et al. 2008, Elinav, Adam et al. 2009, Blat, 
Zigmond et al. 2014) and MS (Fransson, Piras et al. 2012), where CAR Tregs were shown to inhibit 
undesired immune responses in specific tissues. As such, one may speculate that the concept of 
CAR Tregs can be applied for treating various autoimmune conditions where known autoantigens 
are presented. Investigating the efficacy of CARs that incorporated sequences from autoreactive 
antibodies would be of particular interest. Potential targets include glutamic acid decarboxylase 
(GAD)65, acetylcholine receptor and citrullinated proteins which are typically targeted by 
autoreactive antibodies in T1D, myasthenia gravis and RA patients, respectively (Lindstrom, 
Seybold et al. 1976, Vossenaar and van Venrooij 2004, Towns and Pietropaolo 2011, Kasagi, Zhang 
et al. 2014, Sinmaz, Nguyen et al. 2016). Research has also been conducted to investigate whether 
transplant rejection and autoimmunity can be reduced using CAR Tconvs. Specifically, these 
studies have used adaptations of CARs to redirect Tconvs towards lymphocytes which are 
responsible for eliciting undesired immune responses. In a transplant context, CAR T cells were 
generated which specifically killed CD8+ T cells with direct allospecificity (Nguyen, Moisini et al. 
2003). This was achieved by using a CAR that presented allogeneic MHC class I components. More 
recently, a similar approach was employed to generate CAR T cells which targeted autoreactive  
B cells. In this study, the CAAR presented elements of an autoantigen (Dsg-3) which, when 
naturally targeted by autoreactive antibodies, leads to the rare autoimmune blistering disease 
pemphigus vulgaris (Ellebrecht, Bhoj et al. 2016). B cells which engaged these Dsg3-derived 
elements through their BCR were subject to the cytotoxicity of the CAR T cell. As such, it is clear 
that CARs are versatile tools which can be used outside of their traditional cancer setting to treat 
transplant rejection and a variety of autoimmune conditions using a range of different 
approaches. 
 
 CONSIDERATIONS FOR APPLYING CAR  TREGS IN THE CLINIC  
The fact that both Treg therapy and CAR technology are currently being investigated clinically 
suggest that the concept of CAR Tregs can be efficiently translated to the clinic. However, in 
addition to the issues discussed above, there are three key factors which must be considered 
before attempting this. The first of these is the fact that Tregs will need to be isolated with a high 
purity. The isolation of GMP-grade Tregs with a high purity is possible through the use of cell 
sorting outside of the UK and is currently employed in trials which are investigating the safety and 
efficacy of Treg therapy using Tregs with direct allospecificity (Table 1-1). This purity is of 
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importance as Tconvs with donor-MHC class I specificity would have a particularly deleterious 
effect following transfer. 
The second consideration is the fact that it will be necessary to generate a library of CARs which 
recognise different HLA class I molecules. This would be a substantial undertaking and would be 
complicated by the CAR immunogenicity issues described above. The use of antigen-recognition 
domains which cross-react with various HLA subtypes, such as that which was used to generate 
the A2 CAR (Chapter III), would help limit the number of CARs which would need to be generated.  
The final consideration which must be addressed before CAR Tregs can be applied in the clinic is 
the safety concerns which surround the use of genetically modified cells. As previously alluded 
to, these concerns exist due to the fact that retroviruses integrate their proviral DNA into the 
genome in a partially random manner which has the potential to activate oncogenes and cause 
the development of cancerous cell (section 1.3). Various strategies such as zinc-finger nucleases 
and TALENs have been investigated as potential strategies for inserting exogenous genes at 
specific genomic loci. One such approach which has gained popularity over the past two years is 
the clustered regulatory interspaced short palindromic repeats (CRISPR)/Cas9 system. Using 
approaches which insert exogenous genes into genomic DNA in a regulated and specific manner 
would negate many of the safety concerns which surround genetic modification of cell therapy 
products. 
The CRISPR/Cas9 system relies on two key molecules: i) a guide RNA, and; ii) the CRISPR associated 
protein (Cas)9 endonuclease. In isolation, this system utilises the guide RNA, which is typically 
∼20 nucleotides long, to direct the Cas9 endonuclease to a specific region of the genome which 
is complementary to the guide RNA. When this region is recognised, the Cas9 enzyme performs 
a double strand break of the DNA. Usually, this results in the host DNA repair system being 
activated whereby the DNA is re-ligated through non-homologous end joining (NHEJ), typically an 
imperfect process which yields nucleotide mutations such as insertions or deletions (indel) in this 
region of the genome. However, if a desired “DNA repair template” with flanking homology to 
this region of the genome is supplied, such as a desired GOI, this DNA fragment will be ligated 
into the broken DNA as part of the homology directed repair (HDR) system, resulting in insertion 
of the desired GOI into this specific region of the host DNA. Given the fact that the CRISPR/Cas9 
gene delivery approach remains in its infancy, the efficiency with which target cells are 
successfully manipulated currently remains low (<10%). However, with this approach being 
adopted by numerous research groups over the past two years, improvements will doubtlessly 
occur rapidly. As such, it is likely that the CRISPR/Cas9 system will play an important role in future 
clinical trials which feature genetic modification. 




Polyclonal Treg therapy is currently being investigated clinically as a means of limiting graft 
rejection and reducing the requirement of life-long drug-based immunosuppression. However, 
to avoid the risk of pan-immunosuppression and provide a tailored therapy, the successful 
generation and expansion of alloantigen-specific Tregs is required. The results presented in this 
thesis demonstrated that clinically-applicable CAR technology may be used to generate donor 
MHC class I-specific Tregs which suppress alloimmune responses more effectively than polyclonal 
Tregs. Certain issues remain to be addressed including whether CAR Tregs are superior to Tregs 
with direct/indirect allospecificity at alleviating graft rejection but taken together, this thesis 
suggests a future direction for Treg therapy and has important implications in the pursuit of 
tolerance in transplantation and autoimmunity. 
  
REFERENCES 
Abastado, J. P., D. M. Ojcius, A. Casrouge, P. Yeh, T. N. Schumacher, H. L. Ploegh and P. Kourilsky 
(1993). "A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire 
indistinguishable from that of cell-surface-associated Kd." Eur J Immunol 23(8): 1776-1783. 
Abate-Daga, D. and M. L. Davila (2016). "CAR models: next-generation CAR modifications for 
enhanced T-cell function." Mol Ther Oncolytics 3: 16014. 
Abbas, A. K., C. Benoist, J. A. Bluestone, D. J. Campbell, S. Ghosh, S. Hori, S. Jiang, V. K. Kuchroo, 
D. Mathis, M. G. Roncarolo, A. Rudensky, S. Sakaguchi, E. M. Shevach, D. A. Vignali and S. F. Ziegler 
(2013). "Regulatory T cells: recommendations to simplify the nomenclature." Nat Immunol 14(4): 
307-308. 
Abele-Ohl, S., M. Leis, S. Mahmoudian, M. Weyand, T. Stamminger and S. M. Ensminger (2010). 
"Rag2-/- gamma-chain-/- mice as hosts for human vessel transplantation and allogeneic human 
leukocyte reconstitution." Transpl Immunol 23(1-2): 59-64. 
Acuto, O. and F. Michel (2003). "CD28-mediated co-stimulation: a quantitative support for TCR 
signalling." Nat Rev Immunol 3(12): 939-951. 
Afzali, B., F. C. Edozie, H. Fazekasova, C. Scotta, P. J. Mitchell, J. B. Canavan, S. Y. Kordasti, P. S. 
Chana, R. Ellis, G. M. Lord, S. John, R. Hilton, R. I. Lechler and G. Lombardi (2013). "Comparison of 
regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in 
transplantation." Clin J Am Soc Nephrol 8(8): 1396-1405. 
Ahmed, N., V. S. Brawley, M. Hegde, C. Robertson, A. Ghazi, C. Gerken, E. Liu, O. Dakhova, A. 
Ashoori, A. Corder, T. Gray, M. F. Wu, H. Liu, J. Hicks, N. Rainusso, G. Dotti, Z. Mei, B. Grilley, A. 
Gee, C. M. Rooney, M. K. Brenner, H. E. Heslop, W. S. Wels, L. L. Wang, P. Anderson and S. 
Gottschalk (2015). "Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric 
Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma." J Clin 
Oncol 33(15): 1688-1696. 
Aiuti, A., B. Cassani, G. Andolfi, M. Mirolo, L. Biasco, A. Recchia, F. Urbinati, C. Valacca, S. 
Scaramuzza, M. Aker, S. Slavin, M. Cazzola, D. Sartori, A. Ambrosi, C. Di Serio, M. G. Roncarolo, F. 
Mavilio and C. Bordignon (2007). "Multilineage hematopoietic reconstitution without clonal 




Akane, K., S. Kojima, T. W. Mak, H. Shiku and H. Suzuki (2016). "CD8+CD122+CD49dlow regulatory 
T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity." 
Proc Natl Acad Sci U S A 113(9): 2460-2465. 
Akimova, T., B. M. Kamath, J. W. Goebel, K. E. Meyers, E. B. Rand, A. Hawkins, M. H. Levine, J. C. 
Bucuvalas and W. W. Hancock (2012). "Differing effects of rapamycin or calcineurin inhibitor on 
T-regulatory cells in pediatric liver and kidney transplant recipients." Am J Transplant 12(12): 
3449-3461. 
Alegre, M. L., L. J. Peterson, D. R. Jeyarajah, M. Weiser, J. A. Bluestone and J. R. Thistlethwaite 
(1994). "Severe combined immunodeficient mice engrafted with human splenocytes have 
functional human T cells and reject human allografts." J Immunol 153(6): 2738-2749. 
Ali, N., B. Flutter, R. Sanchez Rodriguez, E. Sharif-Paghaleh, L. D. Barber, G. Lombardi and F. O. 
Nestle (2012). "Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a 
T-effector memory phenotype." PLoS One 7(8): e44219. 
Andersson, L. C., K. Nilsson and C. G. Gahmberg (1979). "K562--a human erythroleukemic cell 
line." Int J Cancer 23(2): 143-147. 
Anghel, D., R. Tanasescu, A. Campeanu, I. Lupescu, G. Podda and O. Bajenaru (2013). 
"Neurotoxicity of immunosuppressive therapies in organ transplantation." Maedica (Buchar) 8(2): 
170-175. 
Antonioli, L., P. Pacher, E. S. Vizi and G. Hasko (2013). "CD39 and CD73 in immunity and 
inflammation." Trends Mol Med 19(6): 355-367. 
Argos, P. (1990). "An investigation of oligopeptides linking domains in protein tertiary structures 
and possible candidates for general gene fusion." J Mol Biol 211(4): 943-958. 
Arhel, N. (2010). "Revisiting HIV-1 uncoating." Retrovirology 7: 96. 
Aryee, K. E., L. D. Shultz and M. A. Brehm (2014). "Immunodeficient mouse model for human 
hematopoietic stem cell engraftment and immune system development." Methods Mol Biol 
1185: 267-278. 
Auchincloss, H., Jr., R. Lee, S. Shea, J. S. Markowitz, M. J. Grusby and L. H. Glimcher (1993). "The 
role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility 
complex class II-deficient mice." Proc Natl Acad Sci U S A 90(8): 3373-3377. 
  
196 
Baan, C. C., B. J. van der Mast, M. Klepper, W. M. Mol, A. M. Peeters, S. S. Korevaar, A. H. Balk and 
W. Weimar (2005). "Differential effect of calcineurin inhibitors, anti-CD25 antibodies and 
rapamycin on the induction of FOXP3 in human T cells." Transplantation 80(1): 110-117. 
Baecher-Allan, C., J. A. Brown, G. J. Freeman and D. A. Hafler (2003). "CD4+CD25+ regulatory cells 
from human peripheral blood express very high levels of CD25 ex vivo." Novartis Found Symp 
252: 67-88; discussion 88-91, 106-114. 
Baecher-Allan, C., E. Wolf and D. A. Hafler (2006). "MHC class II expression identifies functionally 
distinct human regulatory T cells." J Immunol 176(8): 4622-4631. 
Bailey-Bucktrout, S. L., M. Martinez-Llordella, X. Zhou, B. Anthony, W. Rosenthal, H. Luche, H. J. 
Fehling and J. A. Bluestone (2013). "Self-antigen-driven activation induces instability of regulatory 
T cells during an inflammatory autoimmune response." Immunity 39(5): 949-962. 
Bain, B., M. R. Vas and L. Lowenstein (1964). "The Development of Large Immature Mononuclear 
Cells in Mixed Leukocyte Cultures." Blood 23: 108-116. 
Ballou, L. M. and R. Z. Lin (2008). "Rapamycin and mTOR kinase inhibitors." J Chem Biol 1(1-4): 
27-36. 
Barker, C. F. and J. F. Markmann (2013). "Historical overview of transplantation." Cold Spring Harb 
Perspect Med 3(4): a014977. 
Barnes, P. J. (2006). "Corticosteroids: the drugs to beat." Eur J Pharmacol 533(1-3): 2-14. 
Barnes, P. J. (2006). "How corticosteroids control inflammation: Quintiles Prize Lecture 2005." Br 
J Pharmacol 148(3): 245-254. 
Basu, S., T. Golovina, T. Mikheeva, C. H. June and J. L. Riley (2008). "Cutting edge: Foxp3-mediated 
induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin." J 
Immunol 180(9): 5794-5798. 
Battaglia, M., A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper and M. G. Roncarolo (2006). 
"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both 
healthy subjects and type 1 diabetic patients." J Immunol 177(12): 8338-8347. 
Battaglia, M., A. Stabilini and M. G. Roncarolo (2005). "Rapamycin selectively expands 
CD4+CD25+FoxP3+ regulatory T cells." Blood 105(12): 4743-4748. 
  
197 
Baughman, E. J., J. P. Mendoza, S. B. Ortega, C. L. Ayers, B. M. Greenberg, E. M. Frohman and N. 
J. Karandikar (2011). "Neuroantigen-specific CD8+ regulatory T-cell function is deficient during 
acute exacerbation of multiple sclerosis." J Autoimmun 36(2): 115-124. 
Baum, L. G. and J. C. Paulson (1990). "Sialyloligosaccharides of the respiratory epithelium in the 
selection of human influenza virus receptor specificity." Acta Histochem Suppl 40: 35-38. 
Becker, C., C. Taube, T. Bopp, C. Becker, K. Michel, J. Kubach, S. Reuter, N. Dehzad, M. F. Neurath, 
K. Reifenberg, F. J. Schneider, E. Schmitt and H. Jonuleit (2009). "Protection from graft-versus-
host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ 
regulatory T cells." Blood 114(6): 1263-1269. 
Belmonte, N., J. Gertner-Dardenne and A. Foussat (2016). "162 - Regulatory T Cell Engineered 
with Chimeric Antigen Receptor (CAR-Treg) for Inflammatory and Autoimmune Diseases." 
Cytotherapy 18(6_Supplement): S95. 
Bendle, G. M., C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. 
Pouw, R. Debets, E. Kieback, W. Uckert, J. Y. Song, J. B. Haanen and T. N. Schumacher (2010). 
"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy." Nat Med 
16(5): 565-570, 561p following 570. 
Benham, A. M., G. J. Sawyer and J. W. Fabre (1995). "Indirect T cell allorecognition of donor 
antigens contributes to the rejection of vascularized kidney allografts." Transplantation 59(7): 
1028-1032. 
Benichou, G., P. A. Takizawa, C. A. Olson, M. McMillan and E. E. Sercarz (1992). "Donor major 
histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during 
graft rejection." J Exp Med 175(1): 305-308. 
Benichou, G., Y. Yamada, S. H. Yun, C. Lin, M. Fray and G. Tocco (2011). "Immune recognition and 
rejection of allogeneic skin grafts." Immunotherapy 3(6): 757-770. 
Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. 
Saulsbury, P. F. Chance and H. D. Ochs (2001). "The immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3." Nat Genet 27(1): 20-
21. 
Bensinger, S. J., P. T. Walsh, J. Zhang, M. Carroll, R. Parsons, J. C. Rathmell, C. B. Thompson, M. A. 
Burchill, M. A. Farrar and L. A. Turka (2004). "Distinct IL-2 receptor signaling pattern in CD4+CD25+ 
regulatory T cells." J Immunol 172(9): 5287-5296. 
  
198 
Berdien, B., U. Mock, D. Atanackovic and B. Fehse (2014). "TALEN-mediated editing of 
endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral 
gene transfer." Gene Ther 21(6): 539-548. 
Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner and V. K. Kuchroo 
(2006). "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and 
regulatory T cells." Nature 441(7090): 235-238. 
Bevan, M. J. (1976). "Cross-priming for a secondary cytotoxic response to minor H antigens with 
H-2 congenic cells which do not cross-react in the cytotoxic assay." J Exp Med 143(5): 1283-1288. 
Bevan, M. J. (1984). "High determinant density may explain the phenomenon of alloreactivity." 
Immunol Today 5(5): 128-130. 
Bevan, M. J. (2006). "Cross-priming." Nat Immunol 7(4): 363-365. 
Bezie, S., E. Picarda, J. Ossart, L. Tesson, C. Usal, K. Renaudin, I. Anegon and C. Guillonneau (2015). 
"IL-34 is a Treg-specific cytokine and mediates transplant tolerance." J Clin Invest 125(10): 3952-
3964. 
Blat, D., E. Zigmond, Z. Alteber, T. Waks and Z. Eshhar (2014). "Suppression of murine colitis and 
its associated cancer by carcinoembryonic antigen-specific regulatory T cells." Mol Ther 22(5): 
1018-1028. 
Bluestone, J. A. (2005). "Regulatory T-cell therapy: is it ready for the clinic?" Nat Rev Immunol 
5(4): 343-349. 
Bluestone, J. A., J. H. Buckner, M. Fitch, S. E. Gitelman, S. Gupta, M. K. Hellerstein, K. C. Herold, A. 
Lares, M. R. Lee, K. Li, W. Liu, S. A. Long, L. M. Masiello, V. Nguyen, A. L. Putnam, M. Rieck, P. H. 
Sayre and Q. Tang (2015). "Type 1 diabetes immunotherapy using polyclonal regulatory T cells." 
Sci Transl Med 7(315): 315ra189. 
Boardman, D., J. Maher, R. Lechler, L. Smyth and G. Lombardi (2016). "Antigen-specificity using 
chimeric antigen receptors: the future of regulatory T-cell therapy?" Biochem Soc Trans 44(2): 
342-348. 
Boardman, D. A., J. Jacob, L. A. Smyth, G. Lombardi and R. I. Lechler (2016). "What Is Direct 
Allorecognition?" Curr Transplant Rep doi:10.1007/s40472-016-0115-8. 
  
199 
Booth, A. J., S. Grabauskiene, S. C. Wood, G. Lu, B. E. Burrell and D. K. Bishop (2011). "IL-6 
promotes cardiac graft rejection mediated by CD4+ cells." J Immunol 187(11): 5764-5771. 
Bopp, T., C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib, M. Becker, J. 
Kubach, S. Schmitt, S. Stoll, H. Schild, M. S. Staege, M. Stassen, H. Jonuleit and E. Schmitt (2007). 
"Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated 
suppression." J Exp Med 204(6): 1303-1310. 
Borsellino, G., M. Kleinewietfeld, D. Di Mitri, A. Sternjak, A. Diamantini, R. Giometto, S. Hopner, 
D. Centonze, G. Bernardi, M. L. Dell'Acqua, P. M. Rossini, L. Battistini, O. Rotzschke and K. Falk 
(2007). "Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP 
and immune suppression." Blood 110(4): 1225-1232. 
Bowen, K. M., L. Andrus and K. J. Lafferty (1980). "Successful allotransplantation of mouse 
pancreatic islets to nonimmunosuppressed recipients." Diabetes 29 Suppl 1: 98-104. 
Brehm, M. A., A. Cuthbert, C. Yang, D. M. Miller, P. DiIorio, J. Laning, L. Burzenski, B. Gott, O. 
Foreman, A. Kavirayani, M. Herlihy, A. A. Rossini, L. D. Shultz and D. L. Greiner (2010). "Parameters 
for establishing humanized mouse models to study human immunity: analysis of human 
hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the 
IL2rgamma(null) mutation." Clin Immunol 135(1): 84-98. 
Brennan, D. C., J. A. Daller, K. D. Lake, D. Cibrik, D. Del Castillo and G. Thymoglobulin Induction 
Study (2006). "Rabbit antithymocyte globulin versus basiliximab in renal transplantation." N Engl 
J Med 355(19): 1967-1977. 
Brentjens, R. J., M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. 
Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu, T. Wasielewska, Q. He, Y. Bernal, I. V. Rijo, C. 
Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini and M. 
Sadelain (2013). "CD19-targeted T cells rapidly induce molecular remissions in adults with 
chemotherapy-refractory acute lymphoblastic leukemia." Sci Transl Med 5(177): 177ra138. 
Bridgeman, J. S., R. E. Hawkins, S. Bagley, M. Blaylock, M. Holland and D. E. Gilham (2010). "The 
optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane 
domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 
complex." J Immunol 184(12): 6938-6949. 
Bridgeman, J. S., K. Ladell, V. E. Sheard, K. Miners, R. E. Hawkins, D. A. Price and D. E. Gilham 
(2014). "CD3zeta-based chimeric antigen receptors mediate T cell activation via cis- and trans-
  
200 
signalling mechanisms: implications for optimization of receptor structure for adoptive cell 
therapy." Clin Exp Immunol 175(2): 258-267. 
Brimnes, J., M. Allez, I. Dotan, L. Shao, A. Nakazawa and L. Mayer (2005). "Defects in CD8+ 
regulatory T cells in the lamina propria of patients with inflammatory bowel disease." J Immunol 
174(9): 5814-5822. 
Brown, C. E., B. Badie, M. E. Barish, L. Weng, J. R. Ostberg, W. C. Chang, A. Naranjo, R. Starr, J. 
Wagner, C. Wright, Y. Zhai, J. R. Bading, J. A. Ressler, J. Portnow, M. D'Apuzzo, S. J. Forman and 
M. C. Jensen (2015). "Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor 
CD8+ T Cells in Patients with Recurrent Glioblastoma." Clin Cancer Res 21(18): 4062-4072. 
Brown, K., A. K. Nowocin, L. Meader, L. A. Edwards, R. A. Smith and W. Wong (2016). 
"Immunotoxin Against a Donor MHC Class II Molecule Induces Indefinite Survival of Murine 
Kidney Allografts." Am J Transplant 16(4): 1129-1138. 
Brown, K., S. H. Sacks and W. Wong (2011). "Coexpression of donor peptide/recipient MHC 
complex and intact donor MHC: evidence for a link between the direct and indirect pathways." 
Am J Transplant 11(4): 826-831. 
Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. E. Wilkinson, D. 
Galas, S. F. Ziegler and F. Ramsdell (2001). "Disruption of a new forkhead/winged-helix protein, 
scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse." Nat Genet 27(1): 
68-73. 
Brunstein, C. G., J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. 
Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar and J. E. Wagner (2011). "Infusion of 
ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile 
and detection kinetics." Blood 117(3): 1061-1070. 
Brusko, T. M., R. C. Koya, S. Zhu, M. R. Lee, A. L. Putnam, S. A. McClymont, M. I. Nishimura, S. Han, 
L. J. Chang, M. A. Atkinson, A. Ribas and J. A. Bluestone (2010). "Human antigen-specific regulatory 
T cells generated by T cell receptor gene transfer." PLoS One 5(7): e11726. 
Bubenik, J. (2003). "Tumour MHC class I downregulation and immunotherapy (Review)." Oncol 
Rep 10(6): 2005-2008. 




Buckanovich, R. J., A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, K. Balint, D. Katsaros, A. O'Brien-
Jenkins, P. A. Gimotty and G. Coukos (2008). "Endothelin B receptor mediates the endothelial 
barrier to T cell homing to tumors and disables immune therapy." Nat Med 14(1): 28-36. 
Burgos, D., M. Gonzalez-Molina, P. Ruiz-Esteban, C. Gutierrez, M. A. Rodriguez, L. Fuentes, L. 
Blanca and D. Hernandez (2012). "Rate of long-term graft loss has fallen among kidney transplants 
from cadaveric donors." Transplant Proc 44(9): 2558-2560. 
Burt, C., C. Cryer, S. Fuggle, A. M. Little and P. Dyer (2013). "HLA-A, -B, -DR allele group frequencies 
in 7007 kidney transplant list patients in 27 UK centres." Int J Immunogenet 40(3): 209-215. 
Bustami, R. T., A. O. Ojo, R. A. Wolfe, R. M. Merion, W. M. Bennett, S. V. McDiarmid, A. B. 
Leichtman, P. J. Held and F. K. Port (2004). "Immunosuppression and the risk of post-transplant 
malignancy among cadaveric first kidney transplant recipients." Am J Transplant 4(1): 87-93. 
Cai, S. F., X. Cao, A. Hassan, T. A. Fehniger and T. J. Ley (2010). "Granzyme B is not required for 
regulatory T cell-mediated suppression of graft-versus-host disease." Blood 115(9): 1669-1677. 
Calne, R. Y., K. Rolles, D. J. White, S. Thiru, D. B. Evans, P. McMaster, D. C. Dunn, G. N. Craddock, 
R. G. Henderson, S. Aziz and P. Lewis (1979). "Cyclosporin A initially as the only 
immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers." 
Lancet 2(8151): 1033-1036. 
Campbell, D. J. and M. A. Koch (2011). "Phenotypical and functional specialization of FOXP3+ 
regulatory T cells." Nat Rev Immunol 11(2): 119-130. 
Campbell, E. M. and T. J. Hope (2015). "HIV-1 capsid: the multifaceted key player in HIV-1 
infection." Nat Rev Microbiol 13(8): 471-483. 
Cante-Barrett, K., R. D. Mendes, W. K. Smits, Y. M. van Helsdingen-van Wijk, R. Pieters and J. P. 
Meijerink (2016). "Lentiviral gene transfer into human and murine hematopoietic stem cells: size 
matters." BMC Res Notes 9: 312. 
Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms and T. J. Ley (2007). 
"Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor 
clearance." Immunity 27(4): 635-646. 
Cao, X., E. W. Shores, J. Hu-Li, M. R. Anver, B. L. Kelsall, S. M. Russell, J. Drago, M. Noguchi, A. 
Grinberg, E. T. Bloom and et al. (1995). "Defective lymphoid development in mice lacking 
expression of the common cytokine receptor gamma chain." Immunity 2(3): 223-238. 
  
202 
Carlsson, B., O. Forsberg, M. Bengtsson, T. H. Totterman and M. Essand (2007). "Characterization 
of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy." 
Prostate 67(4): 389-395. 
Cepko, C. and W. Pear (2001). "Overview of the retrovirus transduction system." Curr Protoc Mol 
Biol Chapter 9: Unit9 9. 
Chen, L. C., J. C. Delgado, P. E. Jensen and X. Chen (2009). "Direct expansion of human allospecific 
FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application." J Immunol 
183(6): 4094-4102. 
Chen, Q., Y. C. Kim, A. Laurence, G. A. Punkosdy and E. M. Shevach (2011). "IL-2 controls the 
stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo." J Immunol 186(11): 
6329-6337. 
Chen, X., J. J. Oppenheim, R. T. Winkler-Pickett, J. R. Ortaldo and O. M. Howard (2006). 
"Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T 
regulatory cells in vivo and enhances their capacity to suppress EAE." Eur J Immunol 36(8): 2139-
2149. 
Chen, Y., V. K. Kuchroo, J. Inobe, D. A. Hafler and H. L. Weiner (1994). "Regulatory T cell clones 
induced by oral tolerance: suppression of autoimmune encephalomyelitis." Science 265(5176): 
1237-1240. 
Cherai, M., Y. Hamel, C. Baillou, S. Touil, M. Guillot-Delost, F. Charlotte, L. Kossir, G. Simonin, S. 
Maury, J. L. Cohen and F. M. Lemoine (2015). "Generation of Human Alloantigen-Specific 
Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy." 
Cell Transplant 24(12): 2527-2540. 
Chmielewski, M. and H. Abken (2015). "TRUCKs: the fourth generation of CARs." Expert Opin Biol 
Ther 15(8): 1145-1154. 
Chmielewski, M., A. A. Hombach and H. Abken (2013). "Antigen-Specific T-Cell Activation 
Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells." Front Immunol 4: 371. 
Chmielewski, M., A. A. Hombach and H. Abken (2014). "Of CARs and TRUCKs: chimeric antigen 
receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma." 
Immunol Rev 257(1): 83-90. 
  
203 
Chmielewski, M., C. Kopecky, A. A. Hombach and H. Abken (2011). "IL-12 release by engineered 
T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent 
macrophage response on tumor cells that have shut down tumor antigen expression." Cancer Res 
71(17): 5697-5706. 
Churlaud, G., F. Pitoiset, F. Jebbawi, R. Lorenzon, B. Bellier, M. Rosenzwajg and D. Klatzmann 
(2015). "Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during 
Interleukin-2 Therapy." Front Immunol 6: 171. 
Ciuffi, A. (2008). "Mechanisms governing lentivirus integration site selection." Curr Gene Ther 
8(6): 419-429. 
Clayton, P. A., S. P. McDonald, J. R. Chapman and S. J. Chadban (2012). "Mycophenolate versus 
azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial." 
Transplantation 94(2): 152-158. 
Cohen, C. J., Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg and R. A. Morgan (2007). 
"Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second 
disulfide bond." Cancer Res 67(8): 3898-3903. 
Cooray, S., S. J. Howe and A. J. Thrasher (2012). "Retrovirus and lentivirus vector design and 
methods of cell conditioning." Methods Enzymol 507: 29-57. 
Corthay, A. (2009). "How do regulatory T cells work?" Scand J Immunol 70(4): 326-336. 
Couceiro, J. N., J. C. Paulson and L. G. Baum (1993). "Influenza virus strains selectively recognize 
sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of 
hemagglutinin receptor specificity." Virus Res 29(2): 155-165. 
Courme, C. (2016). TxCell appoints its global Scientific Advisory Board (“SAB”) led by Professor 
Zelig Eshhar as Chairman. SAB contains world-leading experts in immunology, T-cell biology and 
chimeric antigen receptors. Valbonne, France. 
Courme, C. and G. Gardini (2016). TxCell and Ospedale San Raffaele launch collaboration for the 
development of CAR-Tregs in Lupus Nephritis. Collaboration agreement between TxCell and 
Ospedale San Raffaele also includes dedicated research program on CAR-Treg biology. Valbonne, 
France and Milan, Italy. 
  
204 
Cui, Y. Z., H. Hisha, G. X. Yang, T. X. Fan, T. Jin, Q. Li, Z. Lian and S. Ikehara (2002). "Optimal protocol 
for total body irradiation for allogeneic bone marrow transplantation in mice." Bone Marrow 
Transplant 30(12): 843-849. 
Dai, H., Y. Wang, X. Lu and W. Han (2016). "Chimeric Antigen Receptors Modified T-Cells for 
Cancer Therapy." J Natl Cancer Inst 108(7). 
Davila, M. L., I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-
Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. 
Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D. C. Bouhassira, M. E. Arcila, M. Gonen, G. J. 
Roboz, P. Maslak, D. Douer, M. G. Frattini, S. Giralt, M. Sadelain and R. Brentjens (2014). "Efficacy 
and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia." 
Sci Transl Med 6(224): 224ra225. 
de la Rosa, M., S. Rutz, H. Dorninger and A. Scheffold (2004). "Interleukin-2 is essential for 
CD4+CD25+ regulatory T cell function." Eur J Immunol 34(9): 2480-2488. 
De Rijck, J., L. Vandekerckhove, F. Christ and Z. Debyser (2007). "Lentiviral nuclear import: a 
complex interplay between virus and host." Bioessays 29(5): 441-451. 
Deichmann, A., S. Hacein-Bey-Abina, M. Schmidt, A. Garrigue, M. H. Brugman, J. Hu, H. Glimm, G. 
Gyapay, B. Prum, C. C. Fraser, N. Fischer, K. Schwarzwaelder, M. L. Siegler, D. de Ridder, K. Pike-
Overzet, S. J. Howe, A. J. Thrasher, G. Wagemaker, U. Abel, F. J. Staal, E. Delabesse, J. L. Villeval, 
B. Aronow, C. Hue, C. Prinz, M. Wissler, C. Klanke, J. Weissenbach, I. Alexander, A. Fischer, C. von 
Kalle and M. Cavazzana-Calvo (2007). "Vector integration is nonrandom and clustered and 
influences the fate of lymphopoiesis in SCID-X1 gene therapy." J Clin Invest 117(8): 2225-2232. 
Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti and S. Romagnani (1993). 
"Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and 
inhibits their antigen-specific proliferation and cytokine production." J Immunol 150(2): 353-360. 
Desreumaux, P., A. Foussat, M. Allez, L. Beaugerie, X. Hebuterne, Y. Bouhnik, M. Nachury, V. Brun, 
H. Bastian, N. Belmonte, M. Ticchioni, A. Duchange, P. Morel-Mandrino, V. Neveu, N. Clerget-
Chossat, M. Forte and J. F. Colombel (2012). "Safety and efficacy of antigen-specific regulatory T-
cell therapy for patients with refractory Crohn's disease." Gastroenterology 143(5): 1207-1217 
e1201-1202. 
Dhein, J., H. Walczak, C. Baumler, K. M. Debatin and P. H. Krammer (1995). "Autocrine T-cell 
suicide mediated by APO-1/(Fas/CD95)." Nature 373(6513): 438-441. 
  
205 
Di Ianni, M., F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. 
Ostini, D. Cecchini, T. Aloisi, K. Perruccio, L. Ruggeri, C. Balucani, A. Pierini, P. Sportoletti, C. Aristei, 
B. Falini, Y. Reisner, A. Velardi, F. Aversa and M. F. Martelli (2011). "Tregs prevent GVHD and 
promote immune reconstitution in HLA-haploidentical transplantation." Blood 117(14): 3921-
3928. 
Di Stasi, A., B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. Foster, H. E. Heslop, M. 
K. Brenner, G. Dotti and B. Savoldo (2009). "T lymphocytes coexpressing CCR4 and a chimeric 
antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin 
tumor model." Blood 113(25): 6392-6402. 
Dieckmann, D., H. Plottner, S. Berchtold, T. Berger and G. Schuler (2001). "Ex vivo isolation and 
characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood." J Exp 
Med 193(11): 1303-1310. 
DiPaolo, R. J., C. Brinster, T. S. Davidson, J. Andersson, D. Glass and E. M. Shevach (2007). 
"Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by 
inhibiting dendritic cells from activating autoreactive T cells." J Immunol 179(7): 4685-4693. 
DiSanto, J. P., W. Muller, D. Guy-Grand, A. Fischer and K. Rajewsky (1995). "Lymphoid 
development in mice with a targeted deletion of the interleukin 2 receptor gamma chain." Proc 
Natl Acad Sci U S A 92(2): 377-381. 
Dostert, A. and T. Heinzel (2004). "Negative glucocorticoid receptor response elements and their 
role in glucocorticoid action." Curr Pharm Des 10(23): 2807-2816. 
Driessens, G., J. Kline and T. F. Gajewski (2009). "Costimulatory and coinhibitory receptors in anti-
tumor immunity." Immunol Rev 229(1): 126-144. 
DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller and M. P. Calos (1987). "Analysis of 
mutation in human cells by using an Epstein-Barr virus shuttle system." Mol Cell Biol 7(1): 379-
387. 
Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. 
Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, 
L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White and S. A. Rosenberg (2002). 
"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor 
lymphocytes." Science 298(5594): 850-854. 
  
206 
Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, 
D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. 
Klapper, K. Morton, C. Laurencot, D. E. White and S. A. Rosenberg (2008). "Adoptive cell therapy 
for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation 
preparative regimens." J Clin Oncol 26(32): 5233-5239. 
Duhen, T., R. Duhen, A. Lanzavecchia, F. Sallusto and D. J. Campbell (2012). "Functionally distinct 
subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells." Blood 119(19): 
4430-4440. 
Eckels, D. D., J. Gorski, J. Rothbard and J. R. Lamb (1988). "Peptide-mediated modulation of T-cell 
allorecognition." Proc Natl Acad Sci U S A 85(21): 8191-8195. 
Eckwahl, M. J., A. Telesnitsky and S. L. Wolin (2016). "Host RNA Packaging by Retroviruses: A 
Newly Synthesized Story." MBio 7(1): e02025-02015. 
Elinav, E., N. Adam, T. Waks and Z. Eshhar (2009). "Amelioration of colitis by genetically 
engineered murine regulatory T cells redirected by antigen-specific chimeric receptor." 
Gastroenterology 136(5): 1721-1731. 
Elinav, E., T. Waks and Z. Eshhar (2008). "Redirection of regulatory T cells with predetermined 
specificity for the treatment of experimental colitis in mice." Gastroenterology 134(7): 2014-
2024. 
Elkord, E. (2016). "Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. 
Commentary: Helios(+) and Helios(-) Cells Coexist within the Natural FOXP3(+) T Regulatory Cell 
Subset in Humans." Front Immunol 7: 276. 
Ellebrecht, C. T., V. G. Bhoj, A. Nace, E. J. Choi, X. Mao, M. J. Cho, G. Di Zenzo, A. Lanzavecchia, J. 
T. Seykora, G. Cotsarelis, M. C. Milone and A. S. Payne (2016). "Reengineering chimeric antigen 
receptor T cells for targeted therapy of autoimmune disease." Science 353(6295): 179-184. 
Engelhardt, B. (2006). "Molecular mechanisms involved in T cell migration across the blood-brain 
barrier." J Neural Transm (Vienna) 113(4): 477-485. 
Eshhar, Z., T. Waks, G. Gross and D. G. Schindler (1993). "Specific activation and targeting of 
cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and 
the gamma or zeta subunits of the immunoglobulin and T-cell receptors." Proc Natl Acad Sci U S 
A 90(2): 720-724. 
  
207 
Evans, W. H. and P. E. Martin (2002). "Gap junctions: structure and function (Review)." Mol 
Membr Biol 19(2): 121-136. 
Fallarino, F., U. Grohmann, K. W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M. L. Belladonna, M. 
C. Fioretti, M. L. Alegre and P. Puccetti (2003). "Modulation of tryptophan catabolism by 
regulatory T cells." Nat Immunol 4(12): 1206-1212. 
Fangmann, J., R. Dalchau and J. W. Fabre (1992). "Rejection of skin allografts by indirect 
allorecognition of donor class I major histocompatibility complex peptides." J Exp Med 175(6): 
1521-1529. 
Filaci, G., S. Bacilieri, M. Fravega, M. Monetti, P. Contini, M. Ghio, M. Setti, F. Puppo and F. Indiveri 
(2001). "Impairment of CD8+ T suppressor cell function in patients with active systemic lupus 
erythematosus." J Immunol 166(10): 6452-6457. 
Finney, H. M., A. D. Lawson, C. R. Bebbington and A. N. Weir (1998). "Chimeric receptors providing 
both primary and costimulatory signaling in T cells from a single gene product." J Immunol 161(6): 
2791-2797. 
Fioretto, P., B. Najafian, D. E. Sutherland and M. Mauer (2011). "Tacrolimus and cyclosporine 
nephrotoxicity in native kidneys of pancreas transplant recipients." Clin J Am Soc Nephrol 6(1): 
101-106. 
Fontenot, J. D., M. A. Gavin and A. Y. Rudensky (2003). "Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4): 330-336. 
Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr and A. Y. Rudensky (2005). 
"Regulatory T cell lineage specification by the forkhead transcription factor foxp3." Immunity 
22(3): 329-341. 
Francisco, L. M., P. T. Sage and A. H. Sharpe (2010). "The PD-1 pathway in tolerance and 
autoimmunity." Immunol Rev 236: 219-242. 
Fransson, M., E. Piras, J. Burman, B. Nilsson, M. Essand, B. Lu, R. A. Harris, P. U. Magnusson, E. 
Brittebo and A. S. Loskog (2012). "CAR/FoxP3-engineered T regulatory cells target the CNS and 
suppress EAE upon intranasal delivery." J Neuroinflammation 9: 112. 
French, M. B., J. Allison, D. S. Cram, H. E. Thomas, M. Dempsey-Collier, A. Silva, H. M. Georgiou, 
T. W. Kay, L. C. Harrison and A. M. Lew (1997). "Transgenic expression of mouse proinsulin II 
prevents diabetes in nonobese diabetic mice." Diabetes 46(1): 34-39. 
  
208 
Frisullo, G., V. Nociti, R. Iorio, D. Plantone, A. K. Patanella, P. A. Tonali and A. P. Batocchi (2010). 
"CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients." 
Hum Immunol 71(5): 437-441. 
Fu, H., M. Kishore, B. Gittens, G. Wang, D. Coe, I. Komarowska, E. Infante, A. J. Ridley, D. Cooper, 
M. Perretti and F. M. Marelli-Berg (2014). "Self-recognition of the endothelium enables regulatory 
T-cell trafficking and defines the kinetics of immune regulation." Nat Commun 5: 3436. 
Fu, R., M. J. Lyle, X. Wang and C. H. Miao (2016). "Factor VIII-specific CAR regulatory T cells 
modulate murine anti-factor VIII immune responses." J Immunol 196(1_Supplement): 126.113. 
Fujio, K., A. Okamoto, Y. Araki, H. Shoda, H. Tahara, N. H. Tsuno, K. Takahashi, T. Kitamura and K. 
Yamamoto (2006). "Gene therapy of arthritis with TCR isolated from the inflamed paw." J 
Immunol 177(11): 8140-8147. 
Fulton, B. and A. Markham (1996). "Mycophenolate mofetil. A review of its pharmacodynamic 
and pharmacokinetic properties and clinical efficacy in renal transplantation." Drugs 51(2): 278-
298. 
Gagliani, N., M. C. Amezcua Vesely, A. Iseppon, L. Brockmann, H. Xu, N. W. Palm, M. R. de Zoete, 
P. Licona-Limon, R. S. Paiva, T. Ching, C. Weaver, X. Zi, X. Pan, R. Fan, L. X. Garmire, M. J. Cotton, 
Y. Drier, B. Bernstein, J. Geginat, B. Stockinger, E. Esplugues, S. Huber and R. A. Flavell (2015). 
"Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation." Nature 
523(7559): 221-225. 
Gagneux, P., M. Cheriyan, N. Hurtado-Ziola, E. C. van der Linden, D. Anderson, H. McClure, A. 
Varki and N. M. Varki (2003). "Human-specific regulation of alpha 2-6-linked sialic acids." J Biol 
Chem 278(48): 48245-48250. 
Gallardo, H. F., C. Tan, D. Ory and M. Sadelain (1997). "Recombinant retroviruses pseudotyped 
with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and 
pseudotransduction in human peripheral blood lymphocytes." Blood 90(3): 952-957. 
Game, D. S. and R. I. Lechler (2002). "Pathways of allorecognition: implications for transplantation 
tolerance." Transpl Immunol 10(2-3): 101-108. 
Garin, M. I., C. C. Chu, D. Golshayan, E. Cernuda-Morollon, R. Wait and R. I. Lechler (2007). 




Geiger, T. L., P. Nguyen, D. Leitenberg and R. A. Flavell (2001). "Integrated src kinase and 
costimulatory activity enhances signal transduction through single-chain chimeric receptors in T 
lymphocytes." Blood 98(8): 2364-2371. 
Giannoukakis, N., B. Phillips, D. Finegold, J. Harnaha and M. Trucco (2011). "Phase I (safety) study 
of autologous tolerogenic dendritic cells in type 1 diabetic patients." Diabetes Care 34(9): 2026-
2032. 
Ginzler, E. M., M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, 
D. J. Wallace, M. H. Weisman and G. B. Appel (2005). "Mycophenolate mofetil or intravenous 
cyclophosphamide for lupus nephritis." N Engl J Med 353(21): 2219-2228. 
Goldfarb-Rumyantzev, A. S., L. Smith, F. S. Shihab, B. C. Baird, A. N. Habib, S. J. Lin and L. L. 
Barenbaum (2006). "Role of maintenance immunosuppressive regimen in kidney transplant 
outcome." Clin J Am Soc Nephrol 1(3): 563-574. 
Goldman, J. P., M. P. Blundell, L. Lopes, C. Kinnon, J. P. Di Santo and A. J. Thrasher (1998). 
"Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor 
gamma chain." Br J Haematol 103(2): 335-342. 
Golovina, T. N., T. Mikheeva, T. M. Brusko, B. R. Blazar, J. A. Bluestone and J. L. Riley (2011). 
"Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo 
expansion of natural human T regulatory cells." PLoS One 6(1): e15868. 
Golshayan, D., S. Jiang, J. Tsang, M. I. Garin, C. Mottet and R. I. Lechler (2007). "In vitro-expanded 
donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation 
tolerance." Blood 109(2): 827-835. 
Gossen, M. and H. Bujard (1992). "Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters." Proc Natl Acad Sci U S A 89(12): 5547-5551. 
Graca, L., S. P. Cobbold and H. Waldmann (2002). "Identification of regulatory T cells in tolerated 
allografts." J Exp Med 195(12): 1641-1646. 
Graham, F. L., J. Smiley, W. C. Russell and R. Nairn (1977). "Characteristics of a human cell line 
transformed by DNA from human adenovirus type 5." J Gen Virol 36(1): 59-74. 
Graham, F. L. and A. J. van der Eb (1973). "A new technique for the assay of infectivity of human 
adenovirus 5 DNA." Virology 52(2): 456-467. 
  
210 
Green, H., K. Easley and S. Iuchi (2003). "Marker succession during the development of 
keratinocytes from cultured human embryonic stem cells." Proc Natl Acad Sci U S A 100(26): 
15625-15630. 
Greening, J. E., T. I. Tree, K. T. Kotowicz, A. G. van Halteren, B. O. Roep, N. J. Klein and M. Peakman 
(2003). "Processing and presentation of the islet autoantigen GAD by vascular endothelial cells 
promotes transmigration of autoreactive T-cells." Diabetes 52(3): 717-725. 
Greenway, J. (1991). "Post-transfusion purpura." J Am Board Fam Pract 4(6): 477. 
Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. 
Belladonna, R. Bianchi, M. C. Fioretti and P. Puccetti (2002). "CTLA-4-Ig regulates tryptophan 
catabolism in vivo." Nat Immunol 3(11): 1097-1101. 
Gross, G., G. Gorochov, T. Waks and Z. Eshhar (1989). "Generation of effector T cells expressing 
chimeric T cell receptor with antibody type-specificity." Transplant Proc 21(1 Pt 1): 127-130. 
Gross, G., T. Waks and Z. Eshhar (1989). "Expression of immunoglobulin-T-cell receptor chimeric 
molecules as functional receptors with antibody-type specificity." Proc Natl Acad Sci U S A 86(24): 
10024-10028. 
Grossman, W. J., J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson and T. J. Ley (2004). "Human 
T regulatory cells can use the perforin pathway to cause autologous target cell death." Immunity 
21(4): 589-601. 
Grossman, W. J., J. W. Verbsky, B. L. Tollefsen, C. Kemper, J. P. Atkinson and T. J. Ley (2004). 
"Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T 
regulatory cells." Blood 104(9): 2840-2848. 
Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries and M. G. Roncarolo 
(1997). "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis." 
Nature 389(6652): 737-742. 
Grove, J. and M. Marsh (2011). "The cell biology of receptor-mediated virus entry." J Cell Biol 
195(7): 1071-1082. 
Gruessner, R. W. and A. C. Gruessner (2013). "The current state of pancreas transplantation." Nat 
Rev Endocrinol 9(9): 555-562. 
  
211 
Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, 
B. Hauck, J. F. Wright, M. C. Milone, B. L. Levine and C. H. June (2013). "Chimeric Antigen 
Receptor-Modified T Cells for Acute Lymphoid Leukemia." N Engl J Med. 
Guest, R. D., R. E. Hawkins, N. Kirillova, E. J. Cheadle, J. Arnold, A. O'Neill, J. Irlam, K. A. Chester, J. 
T. Kemshead, D. M. Shaw, M. J. Embleton, P. L. Stern and D. E. Gilham (2005). "The role of 
extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of 
four different scFvs and antigens." J Immunother 28(3): 203-211. 
Guo, J. and X. Zhou (2015). "Regulatory T cells turn pathogenic." Cell Mol Immunol 12(5): 525-
532. 
Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J. 
L. Villeval, C. C. Fraser, M. Cavazzana-Calvo and A. Fischer (2003). "A serious adverse event after 
successful gene therapy for X-linked severe combined immunodeficiency." N Engl J Med 348(3): 
255-256. 
Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. 
Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de 
Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. 
Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. 
Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer and M. Cavazzana-Calvo (2003). "LMO2-
associated clonal T cell proliferation in two patients after gene therapy for SCID-X1." Science 
302(5644): 415-419. 
Hahn, S. A., I. Bellinghausen, B. Trinschek and C. Becker (2015). "Translating Treg Therapy in 
Humanized Mice." Front Immunol 6: 623. 
Hahn, S. A., H. F. Stahl, C. Becker, A. Correll, F. J. Schneider, A. Tuettenberg and H. Jonuleit (2013). 
"Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4(+) T 
cells." Blood 122(7): 1182-1191. 
Halkias, J., B. Yen, K. T. Taylor, O. Reinhartz, A. Winoto, E. A. Robey and H. J. Melichar (2015). 
"Conserved and divergent aspects of human T-cell development and migration in humanized 
mice." Immunol Cell Biol 93(8): 716-726. 
Hall, B. M., I. de Saxe and S. E. Dorsch (1983). "The cellular basis of allograft rejection in vivo. III. 
Restoration of first-set rejection of heart grafts by T helper cells in irradiated rats." 
Transplantation 36(6): 700-705. 
  
212 
Hall, B. M., S. Dorsch and B. Roser (1978). "The cellular basis of allograft rejection in vivo. I. The 
cellular requirements for first-set rejection of heart grafts." J Exp Med 148(4): 878-889. 
Hall, B. M., S. Dorsch and B. Roser (1978). "The cellular basis of allograft rejection in vivo. II. The 
nature of memory cells mediating second set heart graft rejection." J Exp Med 148(4): 890-902. 
Hall, B. M., M. E. Jelbart and S. E. Dorsch (1984). "Suppressor T cells in rats with prolonged cardiac 
allograft survival after treatment with cyclosporine." Transplantation 37(6): 595-600. 
Hamawy, M. M. (2003). "Molecular actions of calcineurin inhibitors." Drug News Perspect 16(5): 
277-282. 
Hamilton, B. S., G. R. Whittaker and S. Daniel (2012). "Influenza virus-mediated membrane fusion: 
determinants of hemagglutinin fusogenic activity and experimental approaches for assessing 
virus fusion." Viruses 4(7): 1144-1168. 
Harper, S. J., J. M. Ali, E. Wlodek, M. C. Negus, I. G. Harper, M. Chhabra, M. S. Qureshi, M. Mallik, 
E. Bolton, J. A. Bradley and G. J. Pettigrew (2015). "CD8 T-cell recognition of acquired alloantigen 
promotes acute allograft rejection." Proc Natl Acad Sci U S A 112(41): 12788-12793. 
Hartemann, A., G. Bensimon, C. A. Payan, S. Jacqueminet, O. Bourron, N. Nicolas, M. Fonfrede, 
M. Rosenzwajg, C. Bernard and D. Klatzmann (2013). "Low-dose interleukin 2 in patients with type 
1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial." Lancet Diabetes 
Endocrinol 1(4): 295-305. 
Hattori, M., E. Yamato, N. Itoh, H. Senpuku, T. Fujisawa, M. Yoshino, M. Fukuda, E. Matsumoto, T. 
Toyonaga, I. Nakagawa, M. Petruzzelli, A. McMurray, H. Weiner, T. Sagai, K. Moriwaki, T. Shiroishi, 
R. Maron and T. Lund (1999). "Cutting edge: homologous recombination of the MHC class I K 
region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice." J 
Immunol 163(4): 1721-1724. 
Hayhoe, R. P., A. M. Kamal, E. Solito, R. J. Flower, D. Cooper and M. Perretti (2006). "Annexin 1 
and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of 
distinct receptor involvement." Blood 107(5): 2123-2130. 
Heath, W. R., K. P. Kane, M. F. Mescher and L. A. Sherman (1991). "Alloreactive T cells discriminate 
among a diverse set of endogenous peptides." Proc Natl Acad Sci U S A 88(12): 5101-5105. 
Herman, A. B., V. M. Savage and G. B. West (2011). "A quantitative theory of solid tumor growth, 
metabolic rate and vascularization." PLoS One 6(9): e22973. 
  
213 
Herrera, O. B., D. Golshayan, R. Tibbott, F. Salcido Ochoa, M. J. James, F. M. Marelli-Berg and R. I. 
Lechler (2004). "A novel pathway of alloantigen presentation by dendritic cells." J Immunol 
173(8): 4828-4837. 
Heslop, H. E. (2010). "Safer CARS." Mol Ther 18(4): 661-662. 
Hester, J., A. Schiopu, S. N. Nadig and K. J. Wood (2012). "Low-dose rapamycin treatment 
increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo." Am 
J Transplant 12(8): 2008-2016. 
Hill, N. J., P. A. Lyons, N. Armitage, J. A. Todd, L. S. Wicker and L. B. Peterson (2000). "NOD Idd5 
locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 
loci in humans." Diabetes 49(10): 1744-1747. 
Hoffmann, P., R. Eder, T. J. Boeld, K. Doser, B. Piseshka, R. Andreesen and M. Edinger (2006). "Only 
the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell 
lines upon in vitro expansion." Blood 108(13): 4260-4267. 
Hogan, P. G., L. Chen, J. Nardone and A. Rao (2003). "Transcriptional regulation by calcium, 
calcineurin, and NFAT." Genes Dev 17(18): 2205-2232. 
Hombach, A. A., J. Heiders, M. Foppe, M. Chmielewski and H. Abken (2012). "OX40 costimulation 
by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected 
CD4(+) T cells." Oncoimmunology 1(4): 458-466. 
Hombach, A. A., D. Kofler, A. Hombach, G. Rappl and H. Abken (2007). "Effective proliferation of 
human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted 
by IL-2." J Immunol 179(11): 7924-7931. 
Hombach, A. A., D. Kofler, G. Rappl and H. Abken (2009). "Redirecting human CD4+CD25+ 
regulatory T cells from the peripheral blood with pre-defined target specificity." Gene Ther 16(9): 
1088-1096. 
Hooijberg, E., A. Q. Bakker, J. J. Ruizendaal and H. Spits (2000). "NFAT-controlled expression of 
GFP permits visualization and isolation of antigen-stimulated primary human T cells." Blood 96(2): 
459-466. 
Hori, S., T. Nomura and S. Sakaguchi (2003). "Control of regulatory T cell development by the 
transcription factor Foxp3." Science 299(5609): 1057-1061. 
  
214 
Hornick, P. and R. Lechler (1997). "Direct and indirect pathways of alloantigen recognition: 
relevance to acute and chronic allograft rejection." Nephrol Dial Transplant 12(9): 1806-1810. 
Howe, S. J., M. R. Mansour, K. Schwarzwaelder, C. Bartholomae, M. Hubank, H. Kempski, M. H. 
Brugman, K. Pike-Overzet, S. J. Chatters, D. de Ridder, K. C. Gilmour, S. Adams, S. I. Thornhill, K. L. 
Parsley, F. J. Staal, R. E. Gale, D. C. Linch, J. Bayford, L. Brown, M. Quaye, C. Kinnon, P. Ancliff, D. 
K. Webb, M. Schmidt, C. von Kalle, H. B. Gaspar and A. J. Thrasher (2008). "Insertional mutagenesis 
combined with acquired somatic mutations causes leukemogenesis following gene therapy of 
SCID-X1 patients." J Clin Invest 118(9): 3143-3150. 
Hu, D., K. Ikizawa, L. Lu, M. E. Sanchirico, M. L. Shinohara and H. Cantor (2004). "Analysis of 
regulatory CD8 T cells in Qa-1-deficient mice." Nat Immunol 5(5): 516-523. 
Hudecek, M., D. Sommermeyer, P. L. Kosasih, A. Silva-Benedict, L. Liu, C. Rader, M. C. Jensen and 
S. R. Riddell (2015). "The nonsignaling extracellular spacer domain of chimeric antigen receptors 
is decisive for in vivo antitumor activity." Cancer Immunol Res 3(2): 125-135. 
Humrich, J. Y., C. von Spee-Mayer, E. Siegert, T. Alexander, F. Hiepe, A. Radbruch, G. R. Burmester 
and G. Riemekasten (2015). "Rapid induction of clinical remission by low-dose interleukin-2 in a 
patient with refractory SLE." Ann Rheum Dis 74(4): 791-792. 
Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, 
J. A. Thompson and C. Yee (2008). "Treatment of metastatic melanoma with autologous CD4+ T 
cells against NY-ESO-1." N Engl J Med 358(25): 2698-2703. 
Huseby, E. S., J. White, F. Crawford, T. Vass, D. Becker, C. Pinilla, P. Marrack and J. W. Kappler 
(2005). "How the T cell repertoire becomes peptide and MHC specific." Cell 122(2): 247-260. 
Iordanskiy, S. and M. Bukrinsky (2007). "Reverse transcription complex: the key player of the early 
phase of HIV replication." Future Virol 2(1): 49-64. 
Irving, B. A. and A. Weiss (1991). "The cytoplasmic domain of the T cell receptor zeta chain is 
sufficient to couple to receptor-associated signal transduction pathways." Cell 64(5): 891-901. 
Issa, F., J. Hester, R. Goto, S. N. Nadig, T. E. Goodacre and K. Wood (2010). "Ex vivo-expanded 
human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model." 
Transplantation 90(12): 1321-1327. 
  
215 
Ito, R., I. Katano, K. Kawai, H. Hirata, T. Ogura, T. Kamisako, T. Eto and M. Ito (2009). "Highly 
sensitive model for xenogenic GVHD using severe immunodeficient NOG mice." Transplantation 
87(11): 1654-1658. 
Jacobson, S., F. Heuts, J. Juarez, M. Hultcrantz, O. Korsgren, M. Svensson, M. Rottenberg and M. 
Flodstrom-Tullberg (2010). "Alloreactivity but failure to reject human islet transplants by 
humanized Balb/c/Rag2gc mice." Scand J Immunol 71(2): 83-90. 
Jaffe, E. A., R. L. Nachman, C. G. Becker and C. R. Minick (1973). "Culture of human endothelial 
cells derived from umbilical veins. Identification by morphologic and immunologic criteria." J Clin 
Invest 52(11): 2745-2756. 
Jago, C. B., J. Yates, N. O. Camara, R. I. Lechler and G. Lombardi (2004). "Differential expression of 
CTLA-4 among T cell subsets." Clin Exp Immunol 136(3): 463-471. 
Jakubczak, J. L., W. J. LaRochelle and G. Merlino (1998). "NK1, a natural splice variant of 
hepatocyte growth factor/scatter factor, is a partial agonist in vivo." Mol Cell Biol 18(3): 1275-
1283. 
Jeffery, H. C., M. K. Braitch, S. Brown and Y. H. Oo (2016). "Clinical Potential of Regulatory T Cell 
Therapy in Liver Diseases: An Overview and Current Perspectives." Front Immunol 7: 334. 
Jena, B., G. Dotti and L. J. Cooper (2010). "Redirecting T-cell specificity by introducing a tumor-
specific chimeric antigen receptor." Blood 116(7): 1035-1044. 
Jethwa, H., A. A. Adami and J. Maher (2014). "Use of gene-modified regulatory T-cells to control 
autoimmune and alloimmune pathology: is now the right time?" Clin Immunol 150(1): 51-63. 
Jiang, S., O. Herrera and R. I. Lechler (2004). "New spectrum of allorecognition pathways: 
implications for graft rejection and transplantation tolerance." Curr Opin Immunol 16(5): 550-
557. 
Jiang, S., J. Tsang, D. S. Game, S. Stevenson, G. Lombardi and R. I. Lechler (2006). "Generation and 
expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents 
to promote donor-specific transplantation tolerance." Transplantation 82(12): 1738-1743. 
Joffre, O., T. Santolaria, D. Calise, T. Al Saati, D. Hudrisier, P. Romagnoli and J. P. van Meerwijk 
(2008). "Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T 
lymphocytes." Nat Med 14(1): 88-92. 
  
216 
Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins 
and S. A. Rosenberg (2006). "Gene transfer of tumor-reactive TCR confers both high avidity and 
tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating 
lymphocytes." J Immunol 177(9): 6548-6559. 
Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. 
E. Royal, R. M. Sherry, J. R. Wunderlich, C. C. Lee, N. P. Restifo, S. L. Schwarz, A. P. Cogdill, R. J. 
Bishop, H. Kim, C. C. Brewer, S. F. Rudy, C. VanWaes, J. L. Davis, A. Mathur, R. T. Ripley, D. A. 
Nathan, C. M. Laurencot and S. A. Rosenberg (2009). "Gene therapy with human and mouse T-
cell receptors mediates cancer regression and targets normal tissues expressing cognate 
antigen." Blood 114(3): 535-546. 
Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg and C. H. June (2011). "T cells with 
chimeric antigen receptors have potent antitumor effects and can establish memory in patients 
with advanced leukemia." Sci Transl Med 3(95): 95ra73. 
Kanamori, M., H. Nakatsukasa, M. Okada, Q. Lu and A. Yoshimura (2016). "Induced Regulatory T 
Cells: Their Development, Stability, and Applications." Trends Immunol. 
Karin, N., F. Szafer, D. Mitchell, D. P. Gold and L. Steinman (1993). "Selective and nonselective 
stages in homing of T lymphocytes to the central nervous system during experimental allergic 
encephalomyelitis." J Immunol 150(9): 4116-4124. 
Kasagi, S., P. Zhang, L. Che, B. Abbatiello, T. Maruyama, H. Nakatsukasa, P. Zanvit, W. Jin, J. E. 
Konkel and W. Chen (2014). "In vivo-generated antigen-specific regulatory T cells treat 
autoimmunity without compromising antibacterial immune response." Sci Transl Med 6(241): 
241ra278. 
Kawamura, T., T. Niguma, J. H. Fechner, Jr., R. Wolber, M. A. Beeskau, D. A. Hullett, H. W. Sollinger 
and W. J. Burlingham (1992). "Chronic human skin graft rejection in severe combined 
immunodeficient mice engrafted with human PBL from an HLA-presensitized donor." 
Transplantation 53(3): 659-665. 
Kennedy-Nasser, A. A., S. Ku, P. Castillo-Caro, Y. Hazrat, M. F. Wu, H. Liu, J. Melenhorst, A. J. 
Barrett, S. Ito, A. Foster, B. Savoldo, E. Yvon, G. Carrum, C. A. Ramos, R. A. Krance, K. Leung, H. E. 
Heslop, M. K. Brenner and C. M. Bollard (2014). "Ultra low-dose IL-2 for GVHD prophylaxis after 
allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells 
without diminishing antiviral and antileukemic activity." Clin Cancer Res 20(8): 2215-2225. 
  
217 
Kershaw, M. H., G. Wang, J. A. Westwood, R. K. Pachynski, H. L. Tiffany, F. M. Marincola, E. Wang, 
H. A. Young, P. M. Murphy and P. Hwu (2002). "Redirecting migration of T cells to chemokine 
secreted from tumors by genetic modification with CXCR2." Hum Gene Ther 13(16): 1971-1980. 
Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, 
J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg and P. Hwu 
(2006). "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian 
cancer." Clin Cancer Res 12(20 Pt 1): 6106-6115. 
Keydar, I., L. Chen, S. Karby, F. R. Weiss, J. Delarea, M. Radu, S. Chaitcik and H. J. Brenner (1979). 
"Establishment and characterization of a cell line of human breast carcinoma origin." Eur J Cancer 
15(5): 659-670. 
Khattri, R., T. Cox, S. A. Yasayko and F. Ramsdell (2003). "An essential role for Scurfin in 
CD4+CD25+ T regulatory cells." Nat Immunol 4(4): 337-342. 
Kim, J., K. Lahl, S. Hori, C. Loddenkemper, A. Chaudhry, P. deRoos, A. Rudensky and T. Sparwasser 
(2009). "Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific 
ablation of regulatory T cells in genetically targeted mice." J Immunol 183(12): 7631-7634. 
Kim, M. G., T. Y. Koo, J. J. Yan, E. Lee, K. H. Han, J. C. Jeong, H. Ro, B. S. Kim, S. K. Jo, K. H. Oh, C. D. 
Surh, C. Ahn and J. Yang (2013). "IL-2/anti-IL-2 complex attenuates renal ischemia-reperfusion 
injury through expansion of regulatory T cells." J Am Soc Nephrol 24(10): 1529-1536. 
Kim, Y. C., A. H. Zhang, Y. Su, S. A. Rieder, R. J. Rossi, R. A. Ettinger, K. P. Pratt, E. M. Shevach and 
D. W. Scott (2015). "Engineered antigen-specific human regulatory T cells: immunosuppression 
of FVIII-specific T- and B-cell responses." Blood 125(7): 1107-1115. 
King, M. A., L. Covassin, M. A. Brehm, W. Racki, T. Pearson, J. Leif, J. Laning, W. Fodor, O. Foreman, 
L. Burzenski, T. H. Chase, B. Gott, A. A. Rossini, R. Bortell, L. D. Shultz and D. L. Greiner (2009). 
"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency 
interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like 
disease and the role of host major histocompatibility complex." Clin Exp Immunol 157(1): 104-
118. 
Kingsley, C. I., M. Karim, A. R. Bushell and K. J. Wood (2002). "CD25+CD4+ regulatory T cells 
prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses." J 
Immunol 168(3): 1080-1086. 
Kirk, A. D. (2006). "Induction immunosuppression." Transplantation 82(5): 593-602. 
  
218 
Klawitter, J., B. Nashan and U. Christians (2015). "Everolimus and sirolimus in transplantation-
related but different." Expert Opin Drug Saf 14(7): 1055-1070. 
Kobold, S., S. Grassmann, M. Chaloupka, C. Lampert, S. Wenk, F. Kraus, M. Rapp, P. Duwell, Y. 
Zeng, J. C. Schmollinger, M. Schnurr, S. Endres and S. Rothenfusser (2015). "Impact of a New 
Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy." J Natl 
Cancer Inst 107(8). 
Kochenderfer, J. N., W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. 
Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, R. A. Morgan and S. A. Rosenberg (2010). "Eradication 
of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells 
genetically engineered to recognize CD19." Blood 116(20): 4099-4102. 
Kochenderfer, J. N., Z. Yu, D. Frasheri, N. P. Restifo and S. A. Rosenberg (2010). "Adoptive transfer 
of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 
can eradicate lymphoma and normal B cells." Blood 116(19): 3875-3886. 
Koenen, H. J., E. Fasse and I. Joosten (2005). "CD27/CFSE-based ex vivo selection of highly 
suppressive alloantigen-specific human regulatory T cells." J Immunol 174(12): 7573-7583. 
Koenen, H. J., R. L. Smeets, P. M. Vink, E. van Rijssen, A. M. Boots and I. Joosten (2008). "Human 
CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells." Blood 112(6): 
2340-2352. 
Koga, H., D. Tsuruta, B. Ohyama, N. Ishii, T. Hamada, C. Ohata, M. Furumura and T. Hashimoto 
(2013). "Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus 
vulgaris." Expert Opin Ther Targets 17(3): 293-306. 
Koh, K. P., Y. Wang, T. Yi, S. L. Shiao, M. I. Lorber, W. C. Sessa, G. Tellides and J. S. Pober (2004). 
"T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation 
of NO synthase." J Clin Invest 114(6): 846-856. 
Kohm, A. P., P. A. Carpentier, H. A. Anger and S. D. Miller (2002). "Cutting edge: CD4+CD25+ 
regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous 
system inflammation during active experimental autoimmune encephalomyelitis." J Immunol 
169(9): 4712-4716. 
Kohn, D. B., G. Dotti, R. Brentjens, B. Savoldo, M. Jensen, L. J. Cooper, C. H. June, S. Rosenberg, 
M. Sadelain and H. E. Heslop (2011). "CARs on track in the clinic." Mol Ther 19(3): 432-438. 
  
219 
Koreth, J., K. Matsuoka, H. T. Kim, S. M. McDonough, B. Bindra, E. P. Alyea, 3rd, P. Armand, C. 
Cutler, V. T. Ho, N. S. Treister, D. C. Bienfang, S. Prasad, D. Tzachanis, R. M. Joyce, D. E. Avigan, J. 
H. Antin, J. Ritz and R. J. Soiffer (2011). "Interleukin-2 and regulatory T cells in graft-versus-host 
disease." N Engl J Med 365(22): 2055-2066. 
Koutrolos, M., K. Berer, N. Kawakami, H. Wekerle and G. Krishnamoorthy (2014). "Treg cells 
mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS." 
Acta Neuropathol Commun 2: 163. 
Krieger, N. R., D. P. Yin and C. G. Fathman (1996). "CD4+ but not CD8+ cells are essential for 
allorejection." J Exp Med 184(5): 2013-2018. 
Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler and P. D. Greenberg (2007). 
"Facilitating matched pairing and expression of TCR chains introduced into human T cells." Blood 
109(6): 2331-2338. 
Kunkele, A., A. J. Johnson, L. S. Rolczynski, C. A. Chang, V. Hoglund, K. S. Kelly-Spratt and M. C. 
Jensen (2015). "Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL 
Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD." Cancer Immunol Res 
3(4): 368-379. 
Kuramitsu, S., M. Ohno, F. Ohka, S. Shiina, A. Yamamichi, A. Kato, K. Tanahashi, K. Motomura, G. 
Kondo, M. Kurimoto, T. Senga, T. Wakabayashi and A. Natsume (2015). "Lenalidomide enhances 
the function of chimeric antigen receptor T cells against the epidermal growth factor receptor 
variant III by enhancing immune synapses." Cancer Gene Ther 22(10): 487-495. 
Kuss, R., M. Legrain, G. Mathe, R. Nedey and M. Camey (1962). "Homologous human kidney 
transplantation. Experience with six patients." Postgrad Med J 38: 528-531. 
Kvaratskhelia, M., A. Sharma, R. C. Larue, E. Serrao and A. Engelman (2014). "Molecular 
mechanisms of retroviral integration site selection." Nucleic Acids Res 42(16): 10209-10225. 
LaFave, M. C., G. K. Varshney, D. E. Gildea, T. G. Wolfsberg, A. D. Baxevanis and S. M. Burgess 
(2014). "MLV integration site selection is driven by strong enhancers and active promoters." 
Nucleic Acids Res 42(7): 4257-4269. 
Lamers, C. H., R. Willemsen, P. van Elzakker, S. van Steenbergen-Langeveld, M. Broertjes, J. 
Oosterwijk-Wakka, E. Oosterwijk, S. Sleijfer, R. Debets and J. W. Gratama (2011). "Immune 
responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells." 
Blood 117(1): 72-82. 
  
220 
Lamhamedi-Cherradi, S. E., O. Boulard, C. Gonzalez, N. Kassis, D. Damotte, L. Eloy, G. Fluteau, M. 
Levi-Strauss and H. J. Garchon (2001). "Further mapping of the Idd5.1 locus for autoimmune 
diabetes in NOD mice." Diabetes 50(12): 2874-2878. 
Lan, P., N. Tonomura, A. Shimizu, S. Wang and Y. G. Yang (2006). "Reconstitution of a functional 
human immune system in immunodeficient mice through combined human fetal thymus/liver 
and CD34+ cell transplantation." Blood 108(2): 487-492. 
Lanitis, E., M. Poussin, A. W. Klattenhoff, D. Song, R. Sandaltzopoulos, C. H. June and D. J. Powell, 
Jr. (2013). "Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused 
antitumor activity with reduced potential for toxicity in vivo." Cancer Immunol Res 1(1): 43-53. 
Lapidot, T., F. Pflumio, M. Doedens, B. Murdoch, D. E. Williams and J. E. Dick (1992). "Cytokine 
stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice." 
Science 255(5048): 1137-1141. 
Lechler, R. I. and J. R. Batchelor (1982). "Immunogenicity of retransplanted rat kidney allografts. 
Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression 
of the second recipient." J Exp Med 156(6): 1835-1841. 
Lechler, R. I. and J. R. Batchelor (1982). "Restoration of immunogenicity to passenger cell-
depleted kidney allografts by the addition of donor strain dendritic cells." J Exp Med 155(1): 31-
41. 
Lee, J. C., E. Hayman, H. J. Pegram, E. Santos, G. Heller, M. Sadelain and R. Brentjens (2011). "In 
vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a 
xenotransplant murine model of B cell malignancy." Cancer Res 71(8): 2871-2881. 
Lee, M. K. t., D. J. Moore, M. Chiaccio, M. M. Lian, S. Deng, M. Mohiuddin, X. Huang, B. Koeberlein, 
A. Zakheim, P. M. Porrett, C. F. Barker, A. J. Caton and J. F. Markmann (2006). "T-reg mediated 
suppression of the allograft response in the draining lymph node." Transplantation 81(7): 1063-
1066. 
Lee, R. S., M. J. Grusby, L. H. Glimcher, H. J. Winn and H. Auchincloss, Jr. (1994). "Indirect 
recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo." J Exp Med 
179(3): 865-872. 
Lee, R. S., M. J. Grusby, T. M. Laufer, R. Colvin, L. H. Glimcher and H. Auchincloss, Jr. (1997). "CD8+ 
effector cells responding to residual class I antigens, with help from CD4+ cells stimulated 
  
221 
indirectly, cause rejection of "major histocompatibility complex-deficient" skin grafts." 
Transplantation 63(8): 1123-1133. 
Lee, S. K., J. Y. Kim, B. W. Jang, S. E. Hur, B. J. Na, M. Lee, A. Fukui, A. Gilman-Sachs and J. Kwak-
Kim (2011). "Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and 
natural killer cells in peripheral blood." Hum Immunol 72(8): 621-626. 
Lee, Y. H., Y. Ishida, M. Rifa'i, Z. Shi, K. Isobe and H. Suzuki (2008). "Essential role of CD8+CD122+ 
regulatory T cells in the recovery from experimental autoimmune encephalomyelitis." J Immunol 
180(2): 825-832. 
Leen, A. M., S. Sukumaran, N. Watanabe, S. Mohammed, J. Keirnan, R. Yanagisawa, U. 
Anurathapan, D. Rendon, H. E. Heslop, C. M. Rooney, M. K. Brenner and J. F. Vera (2014). 
"Reversal of tumor immune inhibition using a chimeric cytokine receptor." Mol Ther 22(6): 1211-
1220. 
Lennon, G. P., M. Bettini, A. R. Burton, E. Vincent, P. Y. Arnold, P. Santamaria and D. A. Vignali 
(2009). "T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event." 
Immunity 31(4): 643-653. 
Lepus, C. M., T. F. Gibson, S. A. Gerber, I. Kawikova, M. Szczepanik, J. Hossain, V. Ablamunits, N. 
Kirkiles-Smith, K. C. Herold, R. O. Donis, A. L. Bothwell, J. S. Pober and M. J. Harding (2009). 
"Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell 
engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg 
immunodeficient mice." Hum Immunol 70(10): 790-802. 
Leung, C. S., M. A. Maurer, S. Meixlsperger, A. Lippmann, C. Cheong, J. Zuo, T. A. Haigh, G. S. Taylor 
and C. Munz (2013). "Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after 
antigen targeting to DEC-205." Blood 121(9): 1584-1594. 
Levings, M. K., R. Bacchetta, U. Schulz and M. G. Roncarolo (2002). "The role of IL-10 and TGF-
beta in the differentiation and effector function of T regulatory cells." Int Arch Allergy Immunol 
129(4): 263-276. 
Li, Z., L. Chen and Z. Qin (2009). "Paradoxical roles of IL-4 in tumor immunity." Cell Mol Immunol 
6(6): 415-422. 
Liang, B., C. Workman, J. Lee, C. Chew, B. M. Dale, L. Colonna, M. Flores, N. Li, E. Schweighoffer, 
S. Greenberg, V. Tybulewicz, D. Vignali and R. Clynes (2008). "Regulatory T cells inhibit dendritic 
cells by lymphocyte activation gene-3 engagement of MHC class II." J Immunol 180(9): 5916-5926. 
  
222 
Lindstrom, J. M., M. E. Seybold, V. A. Lennon, S. Whittingham and D. D. Duane (1976). "Antibody 
to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic 
value." Neurology 26(11): 1054-1059. 
Liu, W., A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. 
Gingeras, B. Fazekas de St Groth, C. Clayberger, D. M. Soper, S. F. Ziegler and J. A. Bluestone 
(2006). "CD127 expression inversely correlates with FoxP3 and suppressive function of human 
CD4+ T reg cells." J Exp Med 203(7): 1701-1711. 
Liu, X., S. Jiang, C. Fang, S. Yang, D. Olalere, E. C. Pequignot, A. P. Cogdill, N. Li, M. Ramones, B. 
Granda, L. Zhou, A. Loew, R. M. Young, C. H. June and Y. Zhao (2015). "Affinity-Tuned ErbB2 or 
EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in 
Mice." Cancer Res 75(17): 3596-3607. 
Liu, Z., Y. K. Sun, Y. P. Xi, A. Maffei, E. Reed, P. Harris and N. Suciu-Foca (1993). "Contribution of 
direct and indirect recognition pathways to T cell alloreactivity." J Exp Med 177(6): 1643-1650. 
Lombardi, G., K. Arnold, J. Uren, F. Marelli-Berg, R. Hargreaves, N. Imami, A. Weetman and R. 
Lechler (1997). "Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits 
interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells." Eur J Immunol 
27(1): 62-71. 
Lombardi, G., L. Barber, S. Sidhu, J. R. Batchelor and R. I. Lechler (1991). "The specificity of 
alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and 
which influence peptide binding." Int Immunol 3(8): 769-775. 
Lombardi, G., S. Sidhu, J. R. Batchelor and R. I. Lechler (1989). "Allorecognition of DR1 by T cells 
from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides." Proc 
Natl Acad Sci U S A 86(11): 4190-4194. 
Lombardi, G., S. Sidhu, M. Daly, J. R. Batchelor, W. Makgoba and R. I. Lechler (1990). "Are primary 
alloresponses truly primary?" Int Immunol 2(1): 9-13. 
Long, S. A., M. Rieck, S. Sanda, J. B. Bollyky, P. L. Samuels, R. Goland, A. Ahmann, A. Rabinovitch, 
S. Aggarwal, D. Phippard, L. A. Turka, M. R. Ehlers, P. J. Bianchine, K. D. Boyle, S. A. Adah, J. A. 
Bluestone, J. H. Buckner, C. J. Greenbaum, T. Diabetes and N. the Immune Tolerance (2012). 
"Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet 
transiently impairs beta-cell function." Diabetes 61(9): 2340-2348. 
  
223 
Lopez, M., M. R. Clarkson, M. Albin, M. H. Sayegh and N. Najafian (2006). "A novel mechanism of 
action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells." J Am Soc 
Nephrol 17(10): 2844-2853. 
Lorber, M. I., J. H. Wilson, M. E. Robert, J. S. Schechner, N. Kirkiles, H. Y. Qian, P. W. Askenase, G. 
Tellides and J. S. Pober (1999). "Human allogeneic vascular rejection after arterial transplantation 
and peripheral lymphoid reconstitution in severe combined immunodeficient mice." 
Transplantation 67(6): 897-903. 
Louis, C. U., B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, H. V. Russell, O. Diouf, 
E. Liu, H. Liu, M. F. Wu, A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop and M. K. Brenner (2011). 
"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients 
with neuroblastoma." Blood 118(23): 6050-6056. 
Louis, S., C. Braudeau, M. Giral, A. Dupont, F. Moizant, N. Robillard, A. Moreau, J. P. Soulillou and 
S. Brouard (2006). "Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and 
operational drug-free tolerance." Transplantation 81(3): 398-407. 
Lu, L., X. F. Qian, J. H. Rao, X. H. Wang, S. G. Zheng and F. Zhang (2010). "Rapamycin promotes the 
expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation." Transplant Proc 42(5): 
1755-1757. 
Lund, T., L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. Chandler, J. Dyson, J. K. 
Picard, A. Edwards and et al. (1990). "Prevention of insulin-dependent diabetes mellitus in non-
obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain." 
Nature 345(6277): 727-729. 
MacDonald, K. G., R. E. Hoeppli, Q. Huang, J. Gillies, D. S. Luciani, P. C. Orban, R. Broady and M. K. 
Levings (2016). "Alloantigen-specific regulatory T cells generated with a chimeric antigen 
receptor." J Clin Invest. 
MacDonald, K. G., R. E. Hoeppli, Q. Huang, J. Gillies, D. S. Luciani, P. C. Orban, R. Broady and M. K. 
Levings (2016). "Alloantigen-specific regulatory T cells generated with a chimeric antigen 
receptor." J Clin Invest 126(4): 1413-1424. 
Mackensen, A., N. Meidenbauer, S. Vogl, M. Laumer, J. Berger and R. Andreesen (2006). "Phase I 
study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients 
with metastatic melanoma." J Clin Oncol 24(31): 5060-5069. 
  
224 
Maher, J. (2012). "Immunotherapy of malignant disease using chimeric antigen receptor 
engrafted T cells." ISRN Oncol 2012: 278093. 
Maher, J., R. J. Brentjens, G. Gunset, I. Riviere and M. Sadelain (2002). "Human T-lymphocyte 
cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor." Nat 
Biotechnol 20(1): 70-75. 
Mahmud, S. A., L. S. Manlove and M. A. Farrar (2013). "Interleukin-2 and STAT5 in regulatory T 
cell development and function." JAKSTAT 2(1): e23154. 
Mahr, B., L. Unger, K. Hock, N. Pilat, U. Baranyi, C. Schwarz, S. Maschke, A. M. Farkas and T. 
Wekerle (2016). "IL-2/alpha-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive 
Transfer of Regulatory T cells to Promote Bone Marrow Engraftment." PLoS One 11(1): e0146245. 
Main, J. M. and R. T. Prehn (1955). "Successful skin homografts after the administration of high 
dosage X radiation and homologous bone marrow." J Natl Cancer Inst 15(4): 1023-1029. 
Makino, S., K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri and Y. Tochino (1980). "Breeding 
of a non-obese, diabetic strain of mice." Jikken Dobutsu 29(1): 1-13. 
Maltzman, J. S. and G. A. Koretzky (2003). "Azathioprine: old drug, new actions." J Clin Invest 
111(8): 1122-1124. 
Marek-Trzonkowska, N., M. Mysliwiec, A. Dobyszuk, M. Grabowska, I. Derkowska, J. Juscinska, R. 
Owczuk, A. Szadkowska, P. Witkowski, W. Mlynarski, P. Jarosz-Chobot, A. Bossowski, J. Siebert 
and P. Trzonkowski (2014). "Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory 
T cells prolongs survival of pancreatic islets - results of one year follow-up." Clin Immunol 153(1): 
23-30. 
Marelli-Berg, F. M., L. Frasca, L. Weng, G. Lombardi and R. I. Lechler (1999). "Antigen recognition 
influences transendothelial migration of CD4+ T cells." J Immunol 162(2): 696-703. 
Marelli-Berg, F. M., M. J. James, J. Dangerfield, J. Dyson, M. Millrain, D. Scott, E. Simpson, S. 
Nourshargh and R. I. Lechler (2004). "Cognate recognition of the endothelium induces HY-specific 
CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo." Blood 103(8): 3111-3116. 
Marelli-Berg, F. M. and R. I. Lechler (1999). "Antigen presentation by parenchymal cells: a route 
to peripheral tolerance?" Immunol Rev 172: 297-314. 
  
225 
Marelli-Berg, F. M., A. Weetman, L. Frasca, S. J. Deacock, N. Imami, G. Lombardi and R. I. Lechler 
(1997). "Antigen presentation by epithelial cells induces anergic immunoregulatory CD45RO+ T 
cells and deletion of CD45RA+ T cells." J Immunol 159(12): 5853-5861. 
Marks, A. R. (1996). "Cellular functions of immunophilins." Physiol Rev 76(3): 631-649. 
Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths and G. Winter (1991). 
"By-passing immunization. Human antibodies from V-gene libraries displayed on phage." J Mol 
Biol 222(3): 581-597. 
Marrack, P. and J. Kappler (2004). "Control of T cell viability." Annu Rev Immunol 22: 765-787. 
Martinez, F., P. Nos, M. Pastor, V. Garrigues and J. Ponce (2001). "Adverse effects of azathioprine 
in the treatment of inflammatory bowel disease." Rev Esp Enferm Dig 93(12): 769-778. 
Matzinger, P. and M. J. Bevan (1977). "Hypothesis: why do so many lymphocytes respond to major 
histocompatibility antigens?" Cell Immunol 29(1): 1-5. 
Maude, S. L., N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. 
Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. 
Levine, C. H. June, D. L. Porter and S. A. Grupp (2014). "Chimeric antigen receptor T cells for 
sustained remissions in leukemia." N Engl J Med 371(16): 1507-1517. 
Mazurier, F., A. Fontanellas, S. Salesse, L. Taine, S. Landriau, F. Moreau-Gaudry, J. Reiffers, B. 
Peault, J. P. Di Santo and H. de Verneuil (1999). "A novel immunodeficient mouse model--RAG2 x 
common cytokine receptor gamma chain double mutants--requiring exogenous cytokine 
administration for human hematopoietic stem cell engraftment." J Interferon Cytokine Res 19(5): 
533-541. 
McCune, J. M., R. Namikawa, H. Kaneshima, L. D. Shultz, M. Lieberman and I. L. Weissman (1988). 
"The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation 
and function." Science 241(4873): 1632-1639. 
Meier-Kriesche, H. U., J. A. Morris, A. H. Chu, B. J. Steffen, V. P. Gotz, R. D. Gordon and B. Kaplan 
(2004). "Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant 
patients." Nephrol Dial Transplant 19(11): 2864-2869. 
Mellor, A. L. and D. H. Munn (2004). "IDO expression by dendritic cells: tolerance and tryptophan 
catabolism." Nat Rev Immunol 4(10): 762-774. 
  
226 
Menager-Marcq, I., C. Pomie, P. Romagnoli and J. P. van Meerwijk (2006). "CD8+CD28- regulatory 
T lymphocytes prevent experimental inflammatory bowel disease in mice." Gastroenterology 
131(6): 1775-1785. 
Merkenschlager, M., H. Ikeda, D. Wilkinson, P. C. Beverly, J. Trowsdale, A. G. Fisher and D. M. 
Altmann (1991). "Allorecognition of HLA-DR and -DQ transfectants by human CD45RA and 
CD45R0 CD4 T cells: repertoire analysis and activation requirements." Eur J Immunol 21(1): 79-
88. 
Miller, A. D., J. V. Garcia, N. von Suhr, C. M. Lynch, C. Wilson and M. V. Eiden (1991). "Construction 
and properties of retrovirus packaging cells based on gibbon ape leukemia virus." J Virol 65(5): 
2220-2224. 
Miller, J. F. (1961). "Immunological function of the thymus." Lancet 2(7205): 748-749. 
Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. 
Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura, G. Gorochov and 
S. Sakaguchi (2009). "Functional delineation and differentiation dynamics of human CD4+ T cells 
expressing the FoxP3 transcription factor." Immunity 30(6): 899-911. 
Miyazaki, T., M. Uno, M. Uehira, H. Kikutani, T. Kishimoto, M. Kimoto, H. Nishimoto, J. Miyazaki 
and K. Yamamura (1990). "Direct evidence for the contribution of the unique I-ANOD to the 
development of insulitis in non-obese diabetic mice." Nature 345(6277): 722-724. 
Morgan, M. E., R. Flierman, L. M. van Duivenvoorde, H. J. Witteveen, W. van Ewijk, J. M. van Laar, 
R. R. de Vries and R. E. Toes (2005). "Effective treatment of collagen-induced arthritis by adoptive 
transfer of CD25+ regulatory T cells." Arthritis Rheum 52(7): 2212-2221. 
Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. 
Feldman, J. C. Yang, R. M. Sherry, G. Q. Phan, M. S. Hughes, U. S. Kammula, A. D. Miller, C. J. 
Hessman, A. A. Stewart, N. P. Restifo, M. M. Quezado, M. Alimchandani, A. Z. Rosenberg, A. Nath, 
T. Wang, B. Bielekova, S. C. Wuest, N. Akula, F. J. McMahon, S. Wilde, B. Mosetter, D. J. Schendel, 
C. M. Laurencot and S. A. Rosenberg (2013). "Cancer regression and neurological toxicity 
following anti-MAGE-A3 TCR gene therapy." J Immunother 36(2): 133-151. 
Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, 
S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, 
S. A. Mavroukakis and S. A. Rosenberg (2006). "Cancer regression in patients after transfer of 
genetically engineered lymphocytes." Science 314(5796): 126-129. 
  
227 
Morris, E. C. and H. J. Stauss (2016). "Optimizing T-cell receptor gene therapy for hematologic 
malignancies." Blood 127(26): 3305-3311. 
Morrison, C. (2014). "Developers seek to finetune toxicity of T-cell therapies." Nat Biotechnol 
32(12): 1171-1172. 
Mosier, D. E., R. J. Gulizia, S. M. Baird and D. B. Wilson (1988). "Transfer of a functional human 
immune system to mice with severe combined immunodeficiency." Nature 335(6187): 256-259. 
Mottet, C., H. H. Uhlig and F. Powrie (2003). "Cutting edge: cure of colitis by CD4+CD25+ 
regulatory T cells." J Immunol 170(8): 3939-3943. 
Mueller, D. L. (2010). "Mechanisms maintaining peripheral tolerance." Nat Immunol 11(1): 21-27. 
Murphy, J. B. (1914). "Factors of Resistance to Heteroplastic Tissue-Grafting : Studies in Tissue 
Specificity. Iii." J Exp Med 19(5): 513-522. 
Murphy, J. B. (1914). "Heteroplasic tissue grafting effected through Roentgen-ray lymphoid 
destruction." JAMA LXII(19): 1459. 
Murray, A. G., P. Petzelbauer, C. C. Hughes, J. Costa, P. Askenase and J. S. Pober (1994). "Human 
T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined 
immunodeficient mouse." Proc Natl Acad Sci U S A 91(19): 9146-9150. 
Murray, J. E., J. P. Merrill, J. H. Harrison, R. E. Wilson and G. J. Dammin (1963). "Prolonged survival 
of human-kidney homografts by immunosuppressive drug therapy." N Engl J Med 268: 1315-
1323. 
Mutis, T., R. S. van Rijn, E. R. Simonetti, T. Aarts-Riemens, M. E. Emmelot, L. van Bloois, A. Martens, 
L. F. Verdonck and S. B. Ebeling (2006). "Human regulatory T cells control xenogeneic graft-versus-
host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice." Clin 
Cancer Res 12(18): 5520-5525. 
Nadig, S. N., J. Wieckiewicz, D. C. Wu, G. Warnecke, W. Zhang, S. Luo, A. Schiopu, D. P. Taggart 
and K. J. Wood (2010). "In vivo prevention of transplant arteriosclerosis by ex vivo-expanded 
human regulatory T cells." Nat Med 16(7): 809-813. 
Najafian, N., T. Chitnis, A. D. Salama, B. Zhu, C. Benou, X. Yuan, M. R. Clarkson, M. H. Sayegh and 
S. J. Khoury (2003). "Regulatory functions of CD8+CD28- T cells in an autoimmune disease model." 
J Clin Invest 112(7): 1037-1048. 
  
228 
Naumann, A., Y. Kim, C. Königs and D. W. Scott (2014). "Generation and Characterization of FVIII-
Specific CAR-Transduced Regulatory T Cells." Blood 124(21): 236. 
Newick, K., E. Moon and S. M. Albelda (2016). "Chimeric antigen receptor T-cell therapy for solid 
tumors." Mol Ther Oncolytics 3: 16006. 
Newick, K., S. O'Brien, J. Sun, V. Kapoor, S. Maceyko, A. Lo, E. Pure, E. Moon and S. M. Albelda 
(2016). "Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase 
A Localization." Cancer Immunol Res 4(6): 541-551. 
Ng, W. F., R. J. Baker, M. Hernandez-Fuentes, A. Chaudhry and R. I. Lechler (2001). "The role of T-
cell anergy in the maintenance of donor-specific hyporesponsiveness in renal transplant 
recipients." Transplant Proc 33(1-2): 154-155. 
Ng, W. F., P. J. Duggan, F. Ponchel, G. Matarese, G. Lombardi, A. D. Edwards, J. D. Isaacs and R. I. 
Lechler (2001). "Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T 
cells." Blood 98(9): 2736-2744. 
Nguyen, P., I. Moisini and T. L. Geiger (2003). "Identification of a murine CD28 dileucine motif that 
suppresses single-chain chimeric T-cell receptor expression and function." Blood 102(13): 4320-
4325. 
Niethammer, D., J. Kummerle-Deschner and G. E. Dannecker (1999). "Side-effects of long-term 
immunosuppression versus morbidity in autologous stem cell rescue: striking the balance." 
Rheumatology (Oxford) 38(8): 747-750. 
Nishizuka, Y. and T. Sakakura (1969). "Thymus and reproduction: sex-linked dysgenesia of the 
gonad after neonatal thymectomy in mice." Science 166(3906): 753-755. 
Nisole, S. and A. Saib (2004). "Early steps of retrovirus replicative cycle." Retrovirology 1: 9. 
Nomaguchi, M., M. Fujita, Y. Miyazaki and A. Adachi (2012). "Viral tropism." Front Microbiol 3: 
281. 
Noris, M., F. Casiraghi, M. Todeschini, P. Cravedi, D. Cugini, G. Monteferrante, S. Aiello, L. Cassis, 
E. Gotti, F. Gaspari, D. Cattaneo, N. Perico and G. Remuzzi (2007). "Regulatory T cells and T cell 
depletion: role of immunosuppressive drugs." J Am Soc Nephrol 18(3): 1007-1018. 
  
229 
Noun, G., M. Reboul, J. P. Abastado, C. Jaulin, P. Kourilsky and M. Pla (1996). "Alloreactive 
monoclonal antibodies select Kd molecules with different peptide profiles." J Immunol 157(6): 
2455-2461. 
Noun, G., M. Reboul, J. P. Abastado, P. Kourilsky, F. Sigaux and M. Pla (1998). "Strong 
alloantigenicity of the alpha-helices residues of the MHC class I molecule." J Immunol 161(1): 148-
153. 
Noyan, F., Y. S. Lee, M. Hardtke-Wolenski, A. K. Knoefel, R. Taubert, U. Baron, M. P. Manns and E. 
Jaeckel (2013). "Donor-specific regulatory T cells generated on donor B cells are superior to 
CD4+CD25high cells in controlling alloimmune responses in humanized mice." Transplant Proc 
45(5): 1832-1837. 
Oberbarnscheidt, M. H. and F. G. Lakkis (2014). "Innate allorecognition." Immunol Rev 258(1): 
145-149. 
Ochi, T., H. Fujiwara, S. Okamoto, J. An, K. Nagai, T. Shirakata, J. Mineno, K. Kuzushima, H. Shiku 
and M. Yasukawa (2011). "Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector 
encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety." Blood 
118(6): 1495-1503. 
Ohbo, K., T. Suda, M. Hashiyama, A. Mantani, M. Ikebe, K. Miyakawa, M. Moriyama, M. Nakamura, 
M. Katsuki, K. Takahashi, K. Yamamura and K. Sugamura (1996). "Modulation of hematopoiesis in 
mice with a truncated mutant of the interleukin-2 receptor gamma chain." Blood 87(3): 956-967. 
Ojo, A. O., P. J. Held, F. K. Port, R. A. Wolfe, A. B. Leichtman, E. W. Young, J. Arndorfer, L. 
Christensen and R. M. Merion (2003). "Chronic renal failure after transplantation of a nonrenal 
organ." N Engl J Med 349(10): 931-940. 
Okoye, I. S., S. M. Coomes, V. S. Pelly, S. Czieso, V. Papayannopoulos, T. Tolmachova, M. C. Seabra 
and M. S. Wilson (2014). "MicroRNA-containing T-regulatory-cell-derived exosomes suppress 
pathogenic T helper 1 cells." Immunity 41(1): 89-103. 
Ory, D. S., B. A. Neugeboren and R. C. Mulligan (1996). "A stable human-derived packaging cell 
line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes." Proc Natl 
Acad Sci U S A 93(21): 11400-11406. 
Ostraat, O., Z. Qi, M. Olausson, G. Tufveson and H. Ekberg (1997). "Mycophenolate mofetil, 
azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac 
transplantation." Scand J Immunol 45(4): 343-348. 
  
230 
Parente-Pereira, A. C., J. Burnet, D. Ellison, J. Foster, D. M. Davies, S. van der Stegen, S. Burbridge, 
L. Chiapero-Stanke, S. Wilkie, S. Mather and J. Maher (2011). "Trafficking of CAR-engineered 
human T cells following regional or systemic adoptive transfer in SCID beige mice." J Clin Immunol 
31(4): 710-718. 
Parente-Pereira, A. C., S. Wilkie, S. J. van der Stegen, D. M. Davies and J. Maher (2014). "Use of 
retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in 
human T-cells." J Biol Methods 1(2): e7. doi: 10.14440/jbm.12014.14430. 
Park, J. R., D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. Meechoovet, C. 
Bautista, W. C. Chang, J. R. Ostberg and M. C. Jensen (2007). "Adoptive transfer of chimeric 
antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma." Mol 
Ther 15(4): 825-833. 
Pasquet, L., J. Y. Douet, T. Sparwasser, P. Romagnoli and J. P. van Meerwijk (2013). "Long-term 
prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-
expressing T cells." Blood 121(21): 4303-4310. 
Passerini, L., S. E. Allan, M. Battaglia, S. Di Nunzio, A. N. Alstad, M. K. Levings, M. G. Roncarolo and 
R. Bacchetta (2008). "STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ 
regulatory T cells and CD4+CD25- effector T cells." Int Immunol 20(3): 421-431. 
Pegram, H. J., J. H. Park and R. J. Brentjens (2014). "CD28z CARs and armored CARs." Cancer J 
20(2): 127-133. 
Peters, J. H., L. B. Hilbrands, H. J. Koenen and I. Joosten (2008). "Ex vivo generation of human 
alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy." PLoS 
One 3(5): e2233. 
Pietra, B. A., A. Wiseman, A. Bolwerk, M. Rizeq and R. G. Gill (2000). "CD4 T cell-mediated cardiac 
allograft rejection requires donor but not host MHC class II." J Clin Invest 106(8): 1003-1010. 
Piller, S. C., L. Caly and D. A. Jans (2003). "Nuclear import of the pre-integration complex (PIC): 
the Achilles heel of HIV?" Curr Drug Targets 4(5): 409-429. 
Plesa, G., L. Zheng, A. Medvec, C. B. Wilson, C. Robles-Oteiza, N. Liddy, A. D. Bennett, J. Gavarret, 
A. Vuidepot, Y. Zhao, B. R. Blazar, B. K. Jakobsen and J. L. Riley (2012). "TCR affinity and specificity 
requirements for human regulatory T-cell function." Blood 119(15): 3420-3430. 
  
231 
Pomie, C., I. Menager-Marcq and J. P. van Meerwijk (2008). "Murine CD8+ regulatory T 
lymphocytes: the new era." Hum Immunol 69(11): 708-714. 
Porter, D. L., W. T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, A. Bagg, K. T. Marcucci, 
A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. 
Melenhorst and C. H. June (2015). "Chimeric antigen receptor T cells persist and induce sustained 
remissions in relapsed refractory chronic lymphocytic leukemia." Sci Transl Med 7(303): 
303ra139. 
Porter, D. L., B. L. Levine, M. Kalos, A. Bagg and C. H. June (2011). "Chimeric antigen receptor-
modified T cells in chronic lymphoid leukemia." N Engl J Med 365(8): 725-733. 
Provasi, E., P. Genovese, A. Lombardo, Z. Magnani, P. Q. Liu, A. Reik, V. Chu, D. E. Paschon, L. 
Zhang, J. Kuball, B. Camisa, A. Bondanza, G. Casorati, M. Ponzoni, F. Ciceri, C. Bordignon, P. D. 
Greenberg, M. C. Holmes, P. D. Gregory, L. Naldini and C. Bonini (2012). "Editing T cell specificity 
towards leukemia by zinc finger nucleases and lentiviral gene transfer." Nat Med 18(5): 807-815. 
Pule, M. A., B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. Huls, E. Liu, A. P. Gee, 
Z. Mei, E. Yvon, H. L. Weiss, H. Liu, C. M. Rooney, H. E. Heslop and M. K. Brenner (2008). "Virus-
specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor 
activity in individuals with neuroblastoma." Nat Med 14(11): 1264-1270. 
Pule, M. A., K. C. Straathof, G. Dotti, H. E. Heslop, C. M. Rooney and M. K. Brenner (2005). "A 
chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of 
primary human T cells." Mol Ther 12(5): 933-941. 
Putnam, A. L., T. M. Brusko, M. R. Lee, W. Liu, G. L. Szot, T. Ghosh, M. A. Atkinson and J. A. 
Bluestone (2009). "Expansion of human regulatory T-cells from patients with type 1 diabetes." 
Diabetes 58(3): 652-662. 
Putnam, A. L., N. Safinia, A. Medvec, M. Laszkowska, M. Wray, M. A. Mintz, E. Trotta, G. L. Szot, 
W. Liu, A. Lares, K. Lee, A. Laing, R. I. Lechler, J. L. Riley, J. A. Bluestone, G. Lombardi and Q. Tang 
(2013). "Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in 
transplantation." Am J Transplant 13(11): 3010-3020. 
Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, 
S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. Walker and D. M. Sansom (2011). 
"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-
4." Science 332(6029): 600-603. 
  
232 
Rabinovitch, A., W. L. Suarez-Pinzon, A. M. Shapiro, R. V. Rajotte and R. Power (2002). 
"Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent 
autoimmune diabetes in NOD mice." Diabetes 51(3): 638-645. 
Racki, W. J., L. Covassin, M. Brehm, S. Pino, R. Ignotz, R. Dunn, J. Laning, S. K. Graves, A. A. Rossini, 
L. D. Shultz and D. L. Greiner (2010). "NOD-scid IL2rgamma(null) mouse model of human skin 
transplantation and allograft rejection." Transplantation 89(5): 527-536. 
Ramsdell, F. and S. F. Ziegler (2014). "FOXP3 and scurfy: how it all began." Nat Rev Immunol 14(5): 
343-349. 
Ring, S., S. Karakhanova, T. Johnson, A. H. Enk and K. Mahnke (2010). "Gap junctions between 
regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells." J Allergy Clin Immunol 
125(1): 237-246 e231-237. 
Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, 
A. V. Nahvi, L. J. Helman, C. L. Mackall, U. S. Kammula, M. S. Hughes, N. P. Restifo, M. Raffeld, C. 
C. Lee, C. L. Levy, Y. F. Li, M. El-Gamil, S. L. Schwarz, C. Laurencot and S. A. Rosenberg (2011). 
"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using 
genetically engineered lymphocytes reactive with NY-ESO-1." J Clin Oncol 29(7): 917-924. 
Robertson, J. M., P. E. Jensen and B. D. Evavold (2000). "DO11.10 and OT-II T cells recognize a C-
terminal ovalbumin 323-339 epitope." J Immunol 164(9): 4706-4712. 
Rogers, G. N. and J. C. Paulson (1983). "Receptor determinants of human and animal influenza 
virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of 
origin." Virology 127(2): 361-373. 
Rogers, G. N., T. J. Pritchett, J. L. Lane and J. C. Paulson (1983). "Differential sensitivity of human, 
avian, and equine influenza A viruses to a glycoprotein inhibitor of infection: selection of receptor 
specific variants." Virology 131(2): 394-408. 
Rogers, N. J. and R. I. Lechler (2001). "Allorecognition." Am J Transplant 1(2): 97-102. 
Roncarolo, M. G., R. Bacchetta, C. Bordignon, S. Narula and M. K. Levings (2001). "Type 1 T 
regulatory cells." Immunol Rev 182: 68-79. 
Rosenberg, A. S. and A. Singer (1992). "Cellular basis of skin allograft rejection: an in vivo model 
of immune-mediated tissue destruction." Annu Rev Immunol 10: 333-358. 
  
233 
Rosenberg, P. B., A. E. Vriesendorp, M. H. Drazner, D. L. Dries, P. A. Kaiser, L. S. Hynan, J. M. 
Dimaio, D. Meyer, W. S. Ring and C. W. Yancy (2005). "Induction therapy with basiliximab allows 
delayed initiation of cyclosporine and preserves renal function after cardiac transplantation." J 
Heart Lung Transplant 24(9): 1327-1331. 
Rosenzwajg, M., G. Churlaud, R. Mallone, A. Six, N. Derian, W. Chaara, R. Lorenzon, S. A. Long, J. 
H. Buckner, G. Afonso, H. P. Pham, A. Hartemann, A. Yu, A. Pugliese, T. R. Malek and D. Klatzmann 
(2015). "Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D 
patients." J Autoimmun 58: 48-58. 
Rossetti, M., R. Spreafico, S. Saidin, C. Chua, M. Moshref, J. Y. Leong, Y. K. Tan, J. Thumboo, J. van 
Loosdregt and S. Albani (2015). "Ex vivo-expanded but not in vitro-induced human regulatory T 
cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of 
the FOXP3 regulatory T cell-specific demethylated region." J Immunol 194(1): 113-124. 
Saadoun, D., M. Rosenzwajg, F. Joly, A. Six, F. Carrat, V. Thibault, D. Sene, P. Cacoub and D. 
Klatzmann (2011). "Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced 
vasculitis." N Engl J Med 365(22): 2067-2077. 
Sadelain, M., R. Brentjens and I. Riviere (2009). "The promise and potential pitfalls of chimeric 
antigen receptors." Curr Opin Immunol 21(2): 215-223. 
Safinia, N., P. D. Becker, T. Vaikunthanathan, F. Xiao, R. Lechler and G. Lombardi (2016). 
"Humanized Mice as Preclinical Models in Transplantation." Methods Mol Biol 1371: 177-196. 
Safinia, N., J. Leech, M. Hernandez-Fuentes, R. Lechler and G. Lombardi (2013). "Promoting 
transplantation tolerance; adoptive regulatory T cell therapy." Clin Exp Immunol 172(2): 158-168. 
Safinia, N., C. Scotta, T. Vaikunthanathan, R. I. Lechler and G. Lombardi (2015). "Regulatory T Cells: 
Serious Contenders in the Promise for Immunological Tolerance in Transplantation." Front 
Immunol 6: 438. 
Safinia, N., T. Vaikunthanathan, H. Fraser, S. Thirkell, K. Lowe, L. Blackmore, G. Whitehouse, M. 
Martinez-Llordella, W. Jassem, A. Sanchez-Fueyo, R. I. Lechler and G. Lombardi (2016). 
"Successful expansion of functional and stable regulatory T cells for immunotherapy in liver 
transplantation." Oncotarget. 
Sagoo, P., N. Ali, G. Garg, F. O. Nestle, R. I. Lechler and G. Lombardi (2011). "Human regulatory T 
cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than 
polyclonal regulatory T cells." Sci Transl Med 3(83): 83ra42. 
  
234 
Sagoo, P., G. Lombardi and R. I. Lechler (2008). "Regulatory T cells as therapeutic cells." Curr Opin 
Organ Transplant 13(6): 645-653. 
Sagoo, P., G. Lombardi and R. I. Lechler (2012). "Relevance of regulatory T cell promotion of 
donor-specific tolerance in solid organ transplantation." Front Immunol 3: 184. 
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh and M. Toda (1995). "Immunologic self-tolerance 
maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a 
single mechanism of self-tolerance causes various autoimmune diseases." J Immunol 155(3): 
1151-1164. 
Sakaguchi, S., K. Wing, Y. Onishi, P. Prieto-Martin and T. Yamaguchi (2009). "Regulatory T cells: 
how do they suppress immune responses?" Int Immunol 21(10): 1105-1111. 
Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard and D. 
M. Sabatini (2006). "Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB." 
Mol Cell 22(2): 159-168. 
Sarris, M., K. G. Andersen, F. Randow, L. Mayr and A. G. Betz (2008). "Neuropilin-1 expression on 
regulatory T cells enhances their interactions with dendritic cells during antigen recognition." 
Immunity 28(3): 402-413. 
Savoldo, B., C. A. Ramos, E. Liu, M. P. Mims, M. J. Keating, G. Carrum, R. T. Kamble, C. M. Bollard, 
A. P. Gee, Z. Mei, H. Liu, B. Grilley, C. M. Rooney, H. E. Heslop, M. K. Brenner and G. Dotti (2011). 
"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified 
T cells in lymphoma patients." J Clin Invest 121(5): 1822-1826. 
Scholler, J., T. L. Brady, G. Binder-Scholl, W. T. Hwang, G. Plesa, K. M. Hege, A. N. Vogel, M. Kalos, 
J. L. Riley, S. G. Deeks, R. T. Mitsuyasu, W. B. Bernstein, N. E. Aronson, B. L. Levine, F. D. Bushman 
and C. H. June (2012). "Decade-long safety and function of retroviral-modified chimeric antigen 
receptor T cells." Sci Transl Med 4(132): 132ra153. 
Schroder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker and F. Bushman (2002). "HIV-1 integration 
in the human genome favors active genes and local hotspots." Cell 110(4): 521-529. 
Schwartz, R. and W. Dameshek (1960). "The effects of 6-mercaptopurine on homograft 
reactions." J Clin Invest 39: 952-958. 
Schwarzwaelder, K., S. J. Howe, M. Schmidt, M. H. Brugman, A. Deichmann, H. Glimm, S. Schmidt, 
C. Prinz, M. Wissler, D. J. King, F. Zhang, K. L. Parsley, K. C. Gilmour, J. Sinclair, J. Bayford, R. Peraj, 
  
235 
K. Pike-Overzet, F. J. Staal, D. de Ridder, C. Kinnon, U. Abel, G. Wagemaker, H. B. Gaspar, A. J. 
Thrasher and C. von Kalle (2007). "Gammaretrovirus-mediated correction of SCID-X1 is associated 
with skewed vector integration site distribution in vivo." J Clin Invest 117(8): 2241-2249. 
Scotta, C., M. Esposito, H. Fazekasova, G. Fanelli, F. C. Edozie, N. Ali, F. Xiao, M. Peakman, B. Afzali, 
P. Sagoo, R. I. Lechler and G. Lombardi (2013). "Differential effects of rapamycin and retinoic acid 
on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory 
cell subpopulations." Haematologica 98(8): 1291-1299. 
Scotta, C., G. Fanelli, S. J. Hoong, M. Romano, E. N. Lamperti, M. Sukthankar, G. Guggino, H. 
Fazekasova, K. Ratnasothy, P. D. Becker, B. Afzali, R. I. Lechler and G. Lombardi (2016). "Impact of 
immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T 
cells." Haematologica 101(1): 91-100. 
Segundo, D. S., J. C. Ruiz, M. Izquierdo, G. Fernandez-Fresnedo, C. Gomez-Alamillo, R. Merino, M. 
J. Benito, E. Cacho, E. Rodrigo, R. Palomar, M. Lopez-Hoyos and M. Arias (2006). "Calcineurin 
inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in 
renal transplant recipients." Transplantation 82(4): 550-557. 
Serra-Hassoun, M., M. Bourgine, M. Boniotto, J. Berges, F. Langa, M. L. Michel, A. A. Freitas and 
S. Garcia (2014). "Human hematopoietic reconstitution and HLA-restricted responses in 
nonpermissive alymphoid mice." J Immunol 193(3): 1504-1511. 
Sharif-Paghaleh, E., K. Sunassee, R. Tavare, K. Ratnasothy, A. Koers, N. Ali, R. Alhabbab, P. J. 
Blower, R. I. Lechler, L. A. Smyth, G. E. Mullen and G. Lombardi (2011). "In vivo SPECT reporter 
gene imaging of regulatory T cells." PLoS One 6(10): e25857. 
Sheets, M. D., P. Amersdorfer, R. Finnern, P. Sargent, E. Lindquist, R. Schier, G. Hemingsen, C. 
Wong, J. C. Gerhart and J. D. Marks (1998). "Efficient construction of a large nonimmune phage 
antibody library: the production of high-affinity human single-chain antibodies to protein 
antigens." Proc Natl Acad Sci U S A 95(11): 6157-6162. 
Sherman, L. A. and S. Chattopadhyay (1993). "The molecular basis of allorecognition." Annu Rev 
Immunol 11: 385-402. 
Shevach, E. M. (2009). "Mechanisms of foxp3+ T regulatory cell-mediated suppression." Immunity 
30(5): 636-645. 
Shevach, E. M. and A. M. Thornton (2014). "tTregs, pTregs, and iTregs: similarities and 
differences." Immunol Rev 259(1): 88-102. 
  
236 
Shimobayashi, M. and M. N. Hall (2014). "Making new contacts: the mTOR network in metabolism 
and signalling crosstalk." Nat Rev Mol Cell Biol 15(3): 155-162. 
Shultz, L. D., B. L. Lyons, L. M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. Kotb, S. D. Gillies, M. King, 
J. Mangada, D. L. Greiner and R. Handgretinger (2005). "Human lymphoid and myeloid cell 
development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human 
hemopoietic stem cells." J Immunol 174(10): 6477-6489. 
Singer, B. D., L. S. King and F. R. D'Alessio (2014). "Regulatory T cells as immunotherapy." Front 
Immunol 5: 46. 
Singh, A. K., K. A. Horvath and M. M. Mohiuddin (2009). "Rapamycin promotes the enrichment of 
CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naive CD4(+) T cells of baboon that suppress 
antiporcine xenogenic response in vitro." Transplant Proc 41(1): 418-421. 
Singh, K., M. Hjort, L. Thorvaldson and S. Sandler (2015). "Concomitant analysis of Helios and 
Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice." Sci Rep 5: 
7767. 
Sinmaz, N., T. Nguyen, F. Tea, R. C. Dale and F. Brilot (2016). "Mapping autoantigen epitopes: 
molecular insights into autoantibody-associated disorders of the nervous system." J 
Neuroinflammation 13(1): 219. 
Sivaganesh, S., S. J. Harper, T. M. Conlon, C. J. Callaghan, K. Saeb-Parsy, M. C. Negus, R. 
Motallebzadeh, E. M. Bolton, J. A. Bradley and G. J. Pettigrew (2013). "Copresentation of intact 
and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to 
alloreactive CD8 T cells by indirect-pathway CD4 T cells." J Immunol 190(11): 5829-5838. 
Skuljec, J., M. Chmielewski, C. Happle, M. Busse, H. Abken and G. Hansen (2014). "Adoptive 
transfer of chimeric antigen receptor-T regulatory cells as an effective therapy for allergic 
asthma." Eur Respir J 44(Suppl 58). 
Slattery, R. M., L. Kjer-Nielsen, J. Allison, B. Charlton, T. E. Mandel and J. F. Miller (1990). 
"Prevention of diabetes in non-obese diabetic I-Ak transgenic mice." Nature 345(6277): 724-726. 
Smallshaw, J. E., F. Georges, J. S. Lee and E. B. Waygood (1999). "Synthesis, cloning and expression 
of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of 
binding constants with wild-type and mutant HPrs." Protein Eng 12(7): 623-630. 
  
237 
Smyth, L. A., N. Harker, W. Turnbull, H. El-Doueik, L. Klavinskis, D. Kioussis, G. Lombardi and R. 
Lechler (2008). "The relative efficiency of acquisition of MHC:peptide complexes and cross-
presentation depends on dendritic cell type." J Immunol 181(5): 3212-3220. 
Smyth, L. A., R. I. Lechler and G. Lombardi (2016). "Continuous acquisition of MHC:peptide 
complexes by recipient cells contributes to the generation of anti-graft CD8+ T cell immunity." 
Am J Transplant. 
Smyth, L. A., K. Ratnasothy, J. Y. Tsang, D. Boardman, A. Warley, R. Lechler and G. Lombardi 
(2013). "CD73 expression on extracellular vesicles derived from CD4 CD25 Foxp3 T cells 
contributes to their regulatory function." Eur J Immunol. 
Sojka, D. K., Y. H. Huang and D. J. Fowell (2008). "Mechanisms of regulatory T-cell suppression - a 
diverse arsenal for a moving target." Immunology 124(1): 13-22. 
Sommer, S. (2005). "The importance of immune gene variability (MHC) in evolutionary ecology 
and conservation." Front Zool 2: 16. 
Sommer, W., A. K. Knofel, N. Madrahimov, M. Avsar, D. Jonigk, J. Salman, K. Dreckmann, K. 
Jansson, G. Salguero, U. A. Maus, T. Welte, A. Haverich and G. Warnecke (2015). "Allogeneic 
CD4+CD25high T cells regulate obliterative bronchiolitis of heterotopic bronchus allografts in 
both porcinized and humanized mouse models." Transplantation 99(3): 482-491. 
Soule, H. D., J. Vazguez, A. Long, S. Albert and M. Brennan (1973). "A human cell line from a pleural 
effusion derived from a breast carcinoma." J Natl Cancer Inst 51(5): 1409-1416. 
Srivastava, S. and S. R. Riddell (2015). "Engineering CAR-T cells: Design concepts." Trends Immunol 
36(8): 494-502. 
Starzl, T. E., R. Weil, 3rd, S. Iwatsuki, G. Klintmalm, G. P. Schroter, L. J. Koep, Y. Iwaki, P. I. Terasaki 
and K. A. Porter (1980). "The use of cyclosporin A and prednisone in cadaver kidney 
transplantation." Surg Gynecol Obstet 151(1): 17-26. 
Stephens, L. A., K. H. Malpass and S. M. Anderton (2009). "Curing CNS autoimmune disease with 
myelin-reactive Foxp3+ Treg." Eur J Immunol 39(4): 1108-1117. 
Stolk, J. N., A. M. Boerbooms, R. A. de Abreu, D. G. de Koning, H. J. van Beusekom, W. H. Muller 
and L. B. van de Putte (1998). "Reduced thiopurine methyltransferase activity and development 




Strauss, L., T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth and A. Zippelius (2007). "Selective 
survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with 
rapamycin." J Immunol 178(1): 320-329. 
Sugamura, K., H. Asao, M. Kondo, N. Tanaka, N. Ishii, K. Ohbo, M. Nakamura and T. Takeshita 
(1996). "The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor 
complexes and T cell development in XSCID." Annu Rev Immunol 14: 179-205. 
Suri-Payer, E., A. Z. Amar, A. M. Thornton and E. M. Shevach (1998). "CD4+CD25+ T cells inhibit 
both the induction and effector function of autoreactive T cells and represent a unique lineage of 
immunoregulatory cells." J Immunol 160(3): 1212-1218. 
Suzuki, Y. and Y. Suzuki (2011). Chapter 14: Gene Regulatable Lentiviral Vector System. Viral Gene 
Therapy, InTech. 
Svensson, M., J. Marsal, A. Ericsson, L. Carramolino, T. Broden, G. Marquez and W. W. Agace 
(2002). "CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to 
the small-intestinal mucosa." J Clin Invest 110(8): 1113-1121. 
Taams, L. S., J. Smith, M. H. Rustin, M. Salmon, L. W. Poulter and A. N. Akbar (2001). "Human 
anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone 
population." Eur J Immunol 31(4): 1122-1131. 
Taams, L. S., M. Vukmanovic-Stejic, J. Smith, P. J. Dunne, J. M. Fletcher, F. J. Plunkett, S. B. Ebeling, 
G. Lombardi, M. H. Rustin, J. W. Bijlsma, F. P. Lafeber, M. Salmon and A. N. Akbar (2002). "Antigen-
specific T cell suppression by human CD4+CD25+ regulatory T cells." Eur J Immunol 32(6): 1621-
1630. 
Tadokoro, C. E., G. Shakhar, S. Shen, Y. Ding, A. C. Lino, A. Maraver, J. J. Lafaille and M. L. Dustin 
(2006). "Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo." 
J Exp Med 203(3): 505-511. 
Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda and S. Nagata (1994). 
"Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand." 
Cell 76(6): 969-976. 
Talmage, D. W., G. Dart, J. Radovich and K. J. Lafferty (1976). "Activation of transplant immunity: 
effect of donor leukocytes on thyroid allograft rejection." Science 191(4225): 385-388. 
  
239 
Tang, Q., J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria, R. M. Locksley, M. F. 
Krummel and J. A. Bluestone (2006). "Visualizing regulatory T cell control of autoimmune 
responses in nonobese diabetic mice." Nat Immunol 7(1): 83-92. 
Tang, Q. and J. A. Bluestone (2013). "Regulatory T-cell therapy in transplantation: moving to the 
clinic." Cold Spring Harb Perspect Med 3(11). 
Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi 
and J. A. Bluestone (2004). "In vitro-expanded antigen-specific regulatory T cells suppress 
autoimmune diabetes." J Exp Med 199(11): 1455-1465. 
Tarbell, K. V., L. Petit, X. Zuo, P. Toy, X. Luo, A. Mqadmi, H. Yang, M. Suthanthiran, S. Mojsov and 
R. M. Steinman (2007). "Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T 
cells restore normoglycemia in diabetic NOD mice." J Exp Med 204(1): 191-201. 
Taylor, P. A., C. J. Lees and B. R. Blazar (2002). "The infusion of ex vivo activated and expanded 
CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality." Blood 99(10): 
3493-3499. 
Terness, P., T. M. Bauer, L. Rose, C. Dufter, A. Watzlik, H. Simon and G. Opelz (2002). "Inhibition 
of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: 
mediation of suppression by tryptophan metabolites." J Exp Med 196(4): 447-457. 
Testa, G. and M. Siegler (2014). "Increasing the supply of kidneys for transplantation by making 
living donors the preferred source of donor kidneys." Medicine (Baltimore) 93(29): e318. 
Theil, A., S. Tuve, U. Oelschlagel, A. Maiwald, D. Dohler, D. Ossmann, A. Zenkel, C. Wilhelm, J. M. 
Middeke, N. Shayegi, K. Trautmann-Grill, M. von Bonin, U. Platzbecker, G. Ehninger, E. Bonifacio 
and M. Bornhauser (2015). "Adoptive transfer of allogeneic regulatory T cells into patients with 
chronic graft-versus-host disease." Cytotherapy 17(4): 473-486. 
Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. 
Van Glabbeke, A. T. van Oosterom, M. C. Christian and S. G. Gwyther (2000). "New guidelines to 
evaluate the response to treatment in solid tumors. European Organization for Research and 
Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of 
Canada." J Natl Cancer Inst 92(3): 205-216. 
Thomas, S., S. A. Xue, M. Cesco-Gaspere, E. San Jose, D. P. Hart, V. Wong, R. Debets, B. Alarcon, 
E. Morris and H. J. Stauss (2007). "Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR 
  
240 
variants improve tetramer binding but not the function of gene modified human T cells." J 
Immunol 179(9): 5803-5810. 
Thornton, A. M., P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray, Y. Belkaid and E. M. Shevach 
(2010). "Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-
derived from peripherally induced Foxp3+ T regulatory cells." J Immunol 184(7): 3433-3441. 
Thornton, A. M. and E. M. Shevach (2000). "Suppressor effector function of CD4+CD25+ 
immunoregulatory T cells is antigen nonspecific." J Immunol 164(1): 183-190. 
Till, B. G., M. C. Jensen, J. Wang, X. Qian, A. K. Gopal, D. G. Maloney, C. G. Lindgren, Y. Lin, J. M. 
Pagel, L. E. Budde, A. Raubitschek, S. J. Forman, P. D. Greenberg, S. R. Riddell and O. W. Press 
(2012). "CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor 
with both CD28 and 4-1BB domains: pilot clinical trial results." Blood 119(17): 3940-3950. 
Todd, J. A. and L. S. Wicker (2001). "Genetic protection from the inflammatory disease type 1 
diabetes in humans and animal models." Immunity 15(3): 387-395. 
Touzot, M., J. P. Soulillou and J. Dantal (2012). "Mechanistic target of rapamycin inhibitors in solid 
organ transplantation: from benchside to clinical use." Curr Opin Organ Transplant 17(6): 626-
633. 
Towns, R. and M. Pietropaolo (2011). "GAD65 autoantibodies and its role as biomarker of Type 1 
diabetes and Latent Autoimmune Diabetes in Adults (LADA)." Drugs Future 36(11): 847. 
Trenado, A., M. Sudres, Q. Tang, S. Maury, F. Charlotte, S. Gregoire, M. Bonyhadi, D. Klatzmann, 
B. L. Salomon and J. L. Cohen (2006). "Ex vivo-expanded CD4+CD25+ immunoregulatory T cells 
prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells." J 
Immunol 176(2): 1266-1273. 
Tresoldi, E., I. Dell'Albani, A. Stabilini, T. Jofra, A. Valle, N. Gagliani, A. Bondanza, M. G. Roncarolo 
and M. Battaglia (2011). "Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells." 
Haematologica 96(9): 1357-1365. 
Trzonkowski, P., M. Bieniaszewska, J. Juscinska, A. Dobyszuk, A. Krzystyniak, N. Marek, J. 
Mysliwska and A. Hellmann (2009). "First-in-man clinical results of the treatment of patients with 
graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells." 
Clin Immunol 133(1): 22-26. 
  
241 
Tsang, J. Y., Y. Tanriver, S. Jiang, E. Leung, K. Ratnasothy, G. Lombardi and R. Lechler (2009). 
"Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T 
cells with indirect allospecificity and short term immunosuppression." Transpl Immunol 21(4): 
203-209. 
Tsang, J. Y., Y. Tanriver, S. Jiang, S. A. Xue, K. Ratnasothy, D. Chen, H. J. Stauss, R. P. Bucy, G. 
Lombardi and R. Lechler (2008). "Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR 
gene transfer favors transplantation tolerance in mice." J Clin Invest 118(11): 3619-3628. 
Tu, W., Y. L. Lau, J. Zheng, Y. Liu, P. L. Chan, H. Mao, K. Dionis, P. Schneider and D. B. Lewis (2008). 
"Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors 
by CD40-activated B cells." Blood 112(6): 2554-2562. 
Tulunay, A., S. Yavuz, H. Direskeneli and E. Eksioglu-Demiralp (2008). "CD8+CD28-, suppressive T 
cells in systemic lupus erythematosus." Lupus 17(7): 630-637. 
Turner, A. P. and S. J. Knechtle (2013). "Induction immunosuppression in liver transplantation: a 
review." Transpl Int 26(7): 673-683. 
Valujskikh, A., O. Lantz, S. Celli, P. Matzinger and P. S. Heeger (2002). "Cross-primed CD8(+) T cells 
mediate graft rejection via a distinct effector pathway." Nat Immunol 3(9): 844-851. 
Valujskikh, A., Q. Zhang and P. S. Heeger (2006). "CD8 T cells specific for a donor-derived, self-
restricted transplant antigen are nonpathogenic bystanders after vascularized heart 
transplantation in mice." J Immunol 176(4): 2190-2196. 
van der Stegen, S. J., M. Hamieh and M. Sadelain (2015). "The pharmacology of second-
generation chimeric antigen receptors." Nat Rev Drug Discov 14(7): 499-509. 
van Hooff, J. P., M. H. Christiaans and E. M. van Duijnhoven (2004). "Evaluating mechanisms of 
post-transplant diabetes mellitus." Nephrol Dial Transplant 19 Suppl 6: vi8-vi12. 
van Rijn, R. S., E. R. Simonetti, A. Hagenbeek, M. C. Hogenes, R. A. de Weger, M. R. Canninga-van 
Dijk, K. Weijer, H. Spits, G. Storm, L. van Bloois, G. Rijkers, A. C. Martens and S. B. Ebeling (2003). 
"A new xenograft model for graft-versus-host disease by intravenous transfer of human 
peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice." Blood 102(7): 
2522-2531. 
Veerapathran, A., J. Pidala, F. Beato, X. Z. Yu and C. Anasetti (2011). "Ex vivo expansion of human 
Tregs specific for alloantigens presented directly or indirectly." Blood 118(20): 5671-5680. 
  
242 
Vignali, D. A., L. W. Collison and C. J. Workman (2008). "How regulatory T cells work." Nat Rev 
Immunol 8(7): 523-532. 
Villadangos, J. A., B. Galocha and J. A. Lopez de Castro (1994). "Unusual topology of an HLA-B27 
allospecific T cell epitope lacking peptide specificity." J Immunol 152(5): 2317-2323. 
Viola, A. and A. Lanzavecchia (1996). "T cell activation determined by T cell receptor number and 
tunable thresholds." Science 273(5271): 104-106. 
Vogtenhuber, C., C. Bucher, S. L. Highfill, L. K. Koch, E. Goren, A. Panoskaltsis-Mortari, P. A. Taylor, 
M. A. Farrar and B. R. Blazar (2010). "Constitutively active Stat5b in CD4+ T cells inhibits graft-
versus-host disease lethality associated with increased regulatory T-cell potency and decreased T 
effector cell responses." Blood 116(3): 466-474. 
von dem Borne, A. E., F. W. Verheugt, F. Oosterhof, E. von Riesz, A. B. de la Riviere and C. P. 
Engelfriet (1978). "A simple immunofluorescence test for the detection of platelet antibodies." 
Br J Haematol 39(2): 195-207. 
von Spee-Mayer, C., E. Siegert, D. Abdirama, A. Rose, A. Klaus, T. Alexander, P. Enghard, B. 
Sawitzki, F. Hiepe, A. Radbruch, G. R. Burmester, G. Riemekasten and J. Y. Humrich (2016). "Low-
dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus 
erythematosus." Ann Rheum Dis 75(7): 1407-1415. 
Vossenaar, E. R. and W. J. van Venrooij (2004). "Citrullinated proteins: sparks that may ignite the 
fire in rheumatoid arthritis." Arthritis Res Ther 6(3): 107-111. 
Walunas, T. L., C. Y. Bakker and J. A. Bluestone (1996). "CTLA-4 ligation blocks CD28-dependent T 
cell activation." J Exp Med 183(6): 2541-2550. 
Wang, W., S. Man, P. H. Gulden, D. F. Hunt and V. H. Engelhard (1998). "Class I-restricted 
alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated 
peptides." J Immunol 160(3): 1091-1097. 
Wang, Y., G. Camirand, Y. Lin, M. Froicu, S. Deng, W. D. Shlomchik, F. G. Lakkis and D. M. Rothstein 
(2011). "Regulatory T cells require mammalian target of rapamycin signaling to maintain both 




Wang, Z., B. Shi, H. Jin, L. Xiao, Y. Chen and Y. Qian (2009). "Low-dose of tacrolimus favors the 
induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation." 
Int Immunopharmacol 9(5): 564-569. 
Waring, P. and A. Mullbacher (1999). "Cell death induced by the Fas/Fas ligand pathway and its 
role in pathology." Immunol Cell Biol 77(4): 312-317. 
Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins and S. Nagata (1992). 
"Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates 
apoptosis." Nature 356(6367): 314-317. 
Watkins, N. A., C. Brown, C. Hurd, C. Navarrete and W. H. Ouwehand (2000). "The isolation and 
characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display 
library." Tissue Antigens 55(3): 219-228. 
Watson, C. J. and J. H. Dark (2012). "Organ transplantation: historical perspective and current 
practice." Br J Anaesth 108 Suppl 1: i29-42. 
Webster, K. E., S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey and J. Sprent 
(2009). "In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE 
and long-term acceptance of islet allografts without immunosuppression." J Exp Med 206(4): 751-
760. 
Wei, C. M., M. Gibson, P. G. Spear and E. M. Scolnick (1981). "Construction and isolation of a 
transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the 
thymidine kinase gene of herpes simplex virus type 1." J Virol 39(3): 935-944. 
Weiner, H. L. (2001). "Induction and mechanism of action of transforming growth factor-beta-
secreting Th3 regulatory cells." Immunol Rev 182: 207-214. 
Whilding, L. M., A. C. Parente-Pereira, T. Zabinski, D. M. Davies, R. Petrovic, S. Violette, S. Ghaem-
Maghami, S. Vallath, J. Marshall and J. Maher (2016). Chimeric antigen receptor T-cells targeting 
the αvβ6 integrin demonstrate potent antitumor activity in multiple solid tumors [abstract]. 
Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy 
Conference: Translating Science into Survival. New York, NY. 4. 
Wilkie, S., S. E. Burbridge, L. Chiapero-Stanke, A. C. Pereira, S. Cleary, S. J. van der Stegen, J. F. 
Spicer, D. M. Davies and J. Maher (2010). "Selective expansion of chimeric antigen receptor-




Wright, G. P., C. A. Notley, S. A. Xue, G. M. Bendle, A. Holler, T. N. Schumacher, M. R. Ehrenstein 
and H. J. Stauss (2009). "Adoptive therapy with redirected primary regulatory T cells results in 
antigen-specific suppression of arthritis." Proc Natl Acad Sci U S A 106(45): 19078-19083. 
Wu, D. C., J. Hester, S. N. Nadig, W. Zhang, P. Trzonkowski, D. Gray, S. Hughes, P. Johnson and K. 
J. Wood (2013). "Ex vivo expanded human regulatory T cells can prolong survival of a human islet 
allograft in a humanized mouse model." Transplantation 96(8): 707-716. 
Wu, X., Y. Li, B. Crise and S. M. Burgess (2003). "Transcription start regions in the human genome 
are favored targets for MLV integration." Science 300(5626): 1749-1751. 
Wuest, T. Y., J. Willette-Brown, S. K. Durum and A. A. Hurwitz (2008). "The influence of IL-2 family 
cytokines on activation and function of naturally occurring regulatory T cells." J Leukoc Biol 84(4): 
973-980. 
Xiao, F., L. Ma, M. Zhao, G. Huang, V. Mirenda, A. Dorling, R. Lechler and G. Lombardi (2014). "Ex 
vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived 
monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid 
IL2rgammanull mice." PLoS One 9(3): e90387. 
Xing, Y. and K. A. Hogquist (2012). "T-cell tolerance: central and peripheral." Cold Spring Harb 
Perspect Biol 4(6). 
Xystrakis, E., A. S. Dejean, I. Bernard, P. Druet, R. Liblau, D. Gonzalez-Dunia and A. Saoudi (2004). 
"Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of 
regulation." Blood 104(10): 3294-3301. 
Yadav, M., C. Louvet, D. Davini, J. M. Gardner, M. Martinez-Llordella, S. Bailey-Bucktrout, B. A. 
Anthony, F. M. Sverdrup, R. Head, D. J. Kuster, P. Ruminski, D. Weiss, D. Von Schack and J. A. 
Bluestone (2012). "Neuropilin-1 distinguishes natural and inducible regulatory T cells among 
regulatory T cell subsets in vivo." J Exp Med 209(10): 1713-1722, S1711-1719. 
Yamashita, M., M. Katsumata, M. Iwashima, M. Kimura, C. Shimizu, T. Kamata, T. Shin, N. Seki, S. 
Suzuki, M. Taniguchi and T. Nakayama (2000). "T cell receptor-induced calcineurin activation 
regulates T helper type 2 cell development by modifying the interleukin 4 receptor signaling 
complex." J Exp Med 191(11): 1869-1879. 
Yamashita, M., O. Perez, T. J. Hope and M. Emerman (2007). "Evidence for direct involvement of 
the capsid protein in HIV infection of nondividing cells." PLoS Pathog 3(10): 1502-1510. 
  
245 
Yang, X. O., R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. 
Schluns, S. S. Watowich, X. H. Feng, A. M. Jetten and C. Dong (2008). "Molecular antagonism and 
plasticity of regulatory and inflammatory T cell programs." Immunity 29(1): 44-56. 
Yegutkin, G. G. (2008). "Nucleotide- and nucleoside-converting ectoenzymes: Important 
modulators of purinergic signalling cascade." Biochim Biophys Acta 1783(5): 673-694. 
Yeku, O. O. and R. J. Brentjens (2016). "Armored CAR T-cells: utilizing cytokines and pro-
inflammatory ligands to enhance CAR T-cell anti-tumour efficacy." Biochem Soc Trans 44(2): 412-
418. 
Yin, Y., H. Hua, M. Li, S. Liu, Q. Kong, T. Shao, J. Wang, Y. Luo, Q. Wang, T. Luo and Y. Jiang (2016). 
"mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation 
through the tyrosine kinase activity of mTOR." Cell Res 26(1): 46-65. 
Yolcu, E. S., S. Ash, A. Kaminitz, Y. Sagiv, N. Askenasy and S. Yarkoni (2008). "Apoptosis as a 
mechanism of T-regulatory cell homeostasis and suppression." Immunol Cell Biol 86(8): 650-658. 
Yoon, V., M. Fridkis-Hareli, S. Munisamy, J. Lee, D. Anastasiades and L. Stevceva (2010). "The 
GP120 molecule of HIV-1 and its interaction with T cells." Curr Med Chem 17(8): 741-749. 
Yoshimura, A. and G. Muto (2011). "TGF-beta function in immune suppression." Curr Top 
Microbiol Immunol 350: 127-147. 
Young, M. R. (2012). "Endothelial cells in the eyes of an immunologist." Cancer Immunol 
Immunother 61(10): 1609-1616. 
Yu, G., X. Xu, M. D. Vu, E. D. Kilpatrick and X. C. Li (2006). "NK cells promote transplant tolerance 
by killing donor antigen-presenting cells." J Exp Med 203(8): 1851-1858. 
Zeiser, R., D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J. Z. Hou and R. 
S. Negrin (2008). "Differential impact of mammalian target of rapamycin inhibition on 
CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells." Blood 111(1): 
453-462. 
Zeiser, R., V. H. Nguyen, A. Beilhack, M. Buess, S. Schulz, J. Baker, C. H. Contag and R. S. Negrin 
(2006). "Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-
2 production." Blood 108(1): 390-399. 
  
246 
Zhang, J., X. Xu and Y. Liu (2004). "Activation-induced cell death in T cells and autoimmunity." Cell 
Mol Immunol 1(3): 186-192. 
Zhang, N., B. Schroppel, G. Lal, C. Jakubzick, X. Mao, D. Chen, N. Yin, R. Jessberger, J. C. Ochando, 
Y. Ding and J. S. Bromberg (2009). "Regulatory T cells sequentially migrate from inflamed tissues 
to draining lymph nodes to suppress the alloimmune response." Immunity 30(3): 458-469. 
Zhao, Y., Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong, M. Sadelain, Z. Eshhar, S. A. 
Rosenberg and R. A. Morgan (2009). "A herceptin-based chimeric antigen receptor with modified 
signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor 
activity." J Immunol 183(9): 5563-5574. 
Zheng, J., Y. Liu, Y. L. Lau and W. Tu (2010). "CD40-activated B cells are more potent than 
immature dendritic cells to induce and expand CD4(+) regulatory T cells." Cell Mol Immunol 7(1): 
44-50. 
Zheng, S. G., J. H. Wang, M. N. Koss, F. Quismorio, Jr., J. D. Gray and D. A. Horwitz (2004). "CD4+ 
and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-
versus-host disease with a lupus-like syndrome." J Immunol 172(3): 1531-1539. 
Zhou, L., J. E. Lopes, M. M. Chong, Ivanov, II, R. Min, G. D. Victora, Y. Shen, J. Du, Y. P. Rubtsov, A. 
Y. Rudensky, S. F. Ziegler and D. R. Littman (2008). "TGF-beta-induced Foxp3 inhibits T(H)17 cell 
differentiation by antagonizing RORgammat function." Nature 453(7192): 236-240. 
Zhou, P., R. Borojevic, C. Streutker, D. Snider, H. Liang and K. Croitoru (2004). "Expression of dual 
TCR on DO11.10 T cells allows for ovalbumin-induced oral tolerance to prevent T cell-mediated 
colitis directed against unrelated enteric bacterial antigens." J Immunol 172(3): 1515-1523. 
Zikherman, J. and A. Weiss (2008). "Alternative splicing of CD45: the tip of the iceberg." Immunity 
29(6): 839-841. 
Zinkernagel, R. M. and P. C. Doherty (1974). "Restriction of in vitro T cell-mediated cytotoxicity in 
lymphocytic choriomeningitis within a syngeneic or semiallogeneic system." Nature 248(5450): 
701-702. 
Zong, L., Y. Zhu, R. Liang and H. B. Zhao (2016). "Gap junction mediated miRNA intercellular 
transfer and gene regulation: A novel mechanism for intercellular genetic communication." Sci 



































Human αCD8 leader sequence  anti-HLA-A2 scFv sequence 
9e10 epitope    hCD28-derived sequences 
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Figure S1 │ Nucleotide sequence of A2 CAR-eGFP gene with elements highlighted. 
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Mouse αCD8 leader sequence  anti-Kd scFv sequence 
9e10 epitope    mCD28-derived sequences 
mCD3-derived sequences   eGFP ORF 
 
   Figure S4 │ Nucleotide sequence of Kd CAR-eGFP gene with elements highlighted. 
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Kd CAR-eGFP sequence   eGFP ORF 
PRE sequence    Ampicillin resistance 
    
   Figure S5 │ Nucleotide sequence of pMP71-PRE retroviral vector with Kd CAR, eGFP and ampicillin 





Figure S6 │ Engraftment of Ch1-2hSa mice. The proportion of human cells present in the spleens of  
Ch1-2hSa mice was measured 100 days following transfer of 5x106 PBMC ± 1x106 Tregs iv. 5x105 
splenocytes were stained with fluorescently conjugated antibodies specific for mouse and human CD45 
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Abstract
Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expanded ex vivo is a promising therapeutic
approach which is currently being investigated clinically as a means of treating various autoimmune diseases
and transplant rejection. Despite this, early results have highlighted the need for potent Tregs to yield a
substantial clinical advantage. One way to achieve this is to create antigen-speciﬁc Tregs which have
been shown in pre-clinical animal models to have an increased potency at suppressing undesired immune
responses, compared to polyclonal Tregs. This mini review outlines where Treg therapy currently stands and
discusses the approaches which may be taken to generate antigen-speciﬁc Tregs, including the potential
use of chimeric antigen receptors (CARs), for future clinical trials.
Regulatory T-cells
Regulatory T-cells (Treg) are a subpopulation of T-cells
which play a critical role in the maintenance of tolerance
in vivo [1,2]. The idea of regulatory immune cells was first
proposed by Gershon and Kondo in 1970 [3], at which time
they were termed ‘suppressor T-cells’. However, in the face
of scepticism [4], research on these cells diminished until
1995 when Sakaguchi et al. [5] published a seminal paper
describing a population of CD4+ CD25+ T-cells which were
capable of inhibiting autoimmunity upon adoptive transfer
(described below). This was followed by a series of papers
which went on to demonstrate that murine CD4+ CD25+ T-
cells were a unique lineage of T-cells [6] which were capable
of suppressing undesired immune responses in a plethora
of different contexts ranging from organ transplantation [7–
12], where a clear correlation between the Treg numbers in a
graft and allograft survival has been made [13,14], to various
autoimmune diseases [15–19].
Key words: adoptive cell therapy, antigen-speciﬁc, autoimmune disease, chimeric antigen
receptor, regulatory T-cell, transplantation.
Abbreviations: APC, antigen presenting cell; BMT, bone marrow transplantation; CAR, chimeric
antigen receptor; CEA, carcinoembryonic antigen; CTLA, cytotoxic T-lymphocyte antigen; EAE,
experimental autoimmune encephalomyelitis; FACS, ﬂuorescence-assisted cell sorting; FOXP3,
forkhead-box protein 3; GITR, glucocorticoid-induced tumour-necrosis factor-receptor-related
protein; GMP, good manufacturing practice; GvHD, graft-versus-host disease; HLA, human
leucocyte antigen; IL, interleukin; IPEX, immune dysregulation polyendocrinopathy enteropathy
X-linked syndrome; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MS,
multiple sclerosis; OVA, ovalbumin; PBMC, peripheral blood mononuclear cell; pTreg, periphery-
derived regulatory T-cell; RA, rheumatoid arthritis; scFv, single-chain variable fragment; T1D,
Type I diabetes; TALEN, transcription activator-like effector nuclease; TCR, T-cell receptor; Teff,
effector T-cell; TGF, transforming growth factor; Th3, T helper 3 cell; TM, transmembrane; TNBS,
2,4,6-trinitrobenzene sulfonic acid; TNF, tumour necrosis factor; TNP, 2,4,6-trinitrophenol; Tr1,
Type-I regulatory T-cell; Treg, regulatory T-cell; tTreg, thymus-derived regulatory T-cell.
1 Correspondence may be addressed to either of these authors (email giovanna.
lombardi@kcl.ac.uk or lesley.smyth@kcl.ac.uk).
2 Co-last author.
It is now well-established that many types of Treg exist.
The best characterized are the naturally occurring Tregs
which develop in the thymus (tTreg). tTregs constitute
approximately 5–10 % of all peripheral CD4+ T-cells
[9,15] and are characterized by a high expression of the
fundamental transcription factor forkhead-box protein 3
(FOXP3) [1]. Mutations in the FoxP3 gene have been
directly linked with the severe autoimmune disease immune
dysregulation polyendocrinopathy enteropathy X-linked
syndrome (IPEX), accentuating the critical role of FOXP3+
Tregs in vivo [1]. tTregs are also characterized in humans
by a high expression of CD4, the interleukin (IL)-2
receptor α-chain, CD25, and a low expression of the IL-
7 receptor α-chain, CD127 [14]. However, other markers
may be used to characterize human tTregs including
CD62L, CD27, CD45RA, human leucocyte antigen (HLA)-
DR, glucocorticoid-induced tumour-necrosis factor (TNF)-
receptor-related protein (GITR), CD73, CD39 and cytotoxic
T-lymphocyte antigen (CTLA)-4 [14]. In the periphery,
Tregs are capable of suppressing a wide range of target
cells including CD4+ and CD8+ effector T-cells (Teff),
B-cells, natural killer cells and antigen presenting cells
(APCs) [2]. To accomplish this, Tregs employ a range
of contact-dependent and contact-independent mechanisms
[2,15] such as the CTLA-4-facilitated removal of co-
stimulatory molecules from APCs [20] or the secretion of
inhibitory factors including exosomes [21] and inhibitory
cytokines [2].
Another Treg population of interest is the induced
Tregs which are derived in the periphery following antigen
exposure (pTreg) [22]. Although not as well characterized
as tTregs, pTregs have been implicated with the induction
and maintenance of tolerance in vivo, mostly through the
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secretion of immunosuppressive cytokines. It is believed that
at least two types of pTregs exist, namely Type-I regulatory
T-cells (Tr1) and T helper 3 cells (Th3) which secrete high
levels of IL-10 and transforming growth factor (TGF)-β,
respectively [23]. A feature of particular interest is the fact
that pTregs may be generated from naı¨ve T-cells in vitro, a
phenomenon which has been applied to generate Tr1 cells for
clinical application in Crohn’s disease [24] (detailed below).
Regulatory T-cell therapy – current
applications
Due to their ability to regulate immune responses, the
adoptive transfer of ex vivo-expanded Tregs has emerged,
clinically, as an exciting therapeutic strategy for suppress-
ing undesired immune responses, both in the context
of transplantation and autoimmunity. Unlike drug-based
immunosuppressive regimens which have detrimental effects
on the patient’s wellbeing [25] and do not offer a complete
treatment option [14,23], Treg therapy has the potential to
be a highly personalized technique which allows for the
manipulation of a patient’s immune system in order to
promote immunological tolerance. The essence of what
Treg therapy entails can be split into three key steps: cell
isolation, ex vivo expansion and subsequent re-infusion of
Tregs (Figure 1A).
The potential for Treg therapy using CD4+ CD25+ tTregs
was initially demonstrated by Sakaguchi et al. in 1995 [5] in a
study which showed that the onset of autoimmune diseases in
nude mice injected with CD4+ CD25- T-cells was hindered
by the co-injection of CD4+ CD25+ T-cells. Furthermore,
they showed prolonged survival of skin allografts following
adoptive transfer of CD4+ CD25+ T-cells. Following on
from this seminal paper, various groups demonstrated the
potential for CD4+ CD25+ Treg therapy in a variety of
animal models including graft-versus-host disease (GvHD)
[26], organ transplantation [7], multiple sclerosis (MS) [16],
colitis [17], lupus erythematosus [18], Type I diabetes (T1D)
[15] and rheumatoid arthritis (RA) [19].
The success of these animal-based studies led to an interest
in utilizing Tregs as a potential therapy in humans. As
such, various groups developed protocols for isolating and
expanding autologous human Tregs [14,23,27]. However, the
lack of a definitive human Treg marker and the requirement
for compliance with good manufacturing practice (GMP)
has meant that Treg therapy is only now moving from the
bench to the clinic [14,23,27]. To date, a handful of clinical
trials have demonstrated that Treg therapy, using autologous
Tregs specific for self-antigens (self-specific) and expanded in
a polyclonal manner using anti-CD3/CD28 beads, is safe and
potentially efficacious with some T1D patients being insulin-
independent for at least one year following Treg infusion
[28,29]. However, in the context of GvHD following bone
marrow transplantation (BMT) [30–33], early results question
the efficacy of these cells as a therapeutic option. In some
cases, patients with GvHD were successfully withdrawn from
immunosuppression without evidence of recurrence [32].
However, approximately half of all patients with GvHD did
not survive, despite Treg treatment [30,33]. As such, it is clear
that further research to increase the potency or specificity of
these cells is required.
Currently, several clinical trials, listed on www.
clinicaltrials.gov, are investigating the safety and/or
efficacy of polyclonal Tregs in the contexts of kidney
transplantation (The ONE Study: NCT02129881/
NCT02371434/NCT02091232, TASK: NCT02088931,
NCT02145325 and NCT01446484), liver transplantation
(ThRIL: NCT02166177 and NCT01624077), GvHD follow-
ing BMT (TREGeneration: NCT02385019, NCT01903473,
NCT01937468, NCT01911039, NCT00602693 and
NCT02526329), T1D (NCT01210664), lupus erythematosus
(NCT02428309) and uveitis (NCT02494492).
As alluded to above, one possible way to improve the
efficacy of Treg therapy is to use Tregs with a defined antigen-
specificity. This is supported by a substantial number of
studies conducted in pre-clinical animal models which have
demonstrated that Tregs specific for a desired antigen are
functionally superior to polyclonal Tregs [9–12,15,26,34]. In
2004, Tang et al. [15] demonstrated that development of T1D
induced by the transfer of 25x106 diabetogenic cells could be
blocked by the transfer of 2x106 Tregs specific for islet β-
cell antigens, but not as efficiently blocked by the transfer
of 8x106 self-specific Tregs, suggesting that the antigen-
specific Tregs were over four times more potent at preventing
disease manifestation. Furthermore, these antigen-specific
Tregs could not only prevent the development of T1D but
were also able to reverse diabetes following disease onset,
further accentuating the potency of these cells for clinical use.
Approaches to generate regulatory T-cells
with antigen-speciﬁcity
Preferential expansion using antigen presenting
cells
To date, we are aware of only one clinical trial
(NCT02327221) which has investigated the potential use
of antigen-specific Tregs for therapy in the context of
Crohn’s disease [24]. In this trial, ovalbumin (OVA)-specific
Tr1 cells were generated ex vivo by expanding peripheral
blood mononuclear cells (PBMC) using modified Drosophila
Schneider 2 feeder cells as artificial APCs, thus preferentially
selecting cells which expressed a T-cell receptor (TCR) α and
β chain with OVA-specificity (Figure 1B). Adoptive transfer
of these Tr1 cells resulted in 8 out of 20 patients showing
significant signs of remission, as defined by a reduction in
Crohn’s Disease Activity Index.
Another context in which the potential for antigen-
specific Tregs is currently being assessed clinically is in
the field of transplantation as a means of limiting graft
rejection. Graft rejection is primarily driven by alloreactive
T-cells which recognize donor antigens via three distinct
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Figure 1 Schematic diagrams outlining the process of Treg therapy and the antigen-targeting moieties which may be used to redirect
the speciﬁcity of Tregs
(A) To acquire an autologous population of Tregs which may be applied in a Treg therapy protocol, peripheral blood is drawn
from the patient and Tregs are isolated either through the use of GMP-compatible ﬂuorescence-assisted cell sorting (FACS)
or in vitro negative and positive selection protocols using magnetic beads (red). The Tregs are then activated, usually in a
polyclonal manner using anti-CD3/CD28 beads, and undergo a single or multiple rounds of stimulation in order to expand
the number of Tregs ex vivo (yellow). This expanded population of Tregs is then infused back into the patient, typically
as part of a combination therapy protocol (blue). (B) The antigen-speciﬁcity of Tregs is naturally determined by the α
and β TCR genes which are expressed (blue). In vitro, Tregs can be genetically manipulated to express speciﬁc α and β
TCR genes which are capable of signalling through the use of endogenous CD3 signalling chains (red), thereby conferring
speciﬁcity towards a desired MHC-peptide complex. (C) Tregs may be artiﬁcially redirected towards an antigen of interest
through the transduction and expression of a chimeric antigen receptor (CAR). CARs utilize an extracellular antigen-targeting
domain (blue) which is typically derived from an antigen-speciﬁc antibody. As such, CARs are capable of binding their target
antigen in an MHC-independent manner. Engagement of the antigen is translated into the activation of tailored intracellular
T-cell signalling cascades via customisable intracellular TCR and co-stimulatory signalling domains (red). Ag: antigen, TM:
transmembrane.
pathways of allorecognition. In the direct pathway, recipient
T-cells recognize allopeptides presented in the context of
allogeneic major histocompatibility complexes (MHC) by
donor-derived APCs (Figure 2A). In the indirect pathway,
recipient T-cells recognize allopeptides presented in the
context of self-MHC by recipient APCs (Figure 2B).
More recently, the semi-direct pathway was described in
which recipient-derived APCs acquire and present intact
donor MHC-peptide complexes. As such, these APCs are
capable of presenting not only allopeptides in the context
of recipient MHC (indirect pathway), but also intact donor
MHC-peptide complexes (direct pathway) contributing to
the activation of T-cells with either direct or indirect
allospecificity (Figure 2C).
It has been demonstrated in various animal models that
Tregs which possess the same allospecificity as the T-cells
which drive graft rejection are far more effective at protecting
from graft rejection than polyclonal Tregs. Murine Tregs with
direct allospecificity have successfully been preferentially
expanded by us [9,10] and others [34] using allogeneic APCs
and have demonstrated a superior efficacy at protecting from
allograft rejection in vivo compared to self-specific Tregs.
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Figure 2 Schematic diagram detailing the three distinct pathways of allorecognition
(A) In the direct pathway of allorecognition, donor-derived antigen presenting cells (APCs) migrate from the transplanted
allograft to secondary lymphoid organs where they present donor antigen in the context of donor MHC molecules.
Recipient-derived CD4+ T-cells binding antigen presented by MHC class II are then capable of facilitating the activation of
recipient-derived CD8+ T-cells recognizing antigen presented by MHC class I. (B) In the indirect pathway of allorecognition,
recipient-derived APCs inﬁltrate the transplanted allograft where they acquire donor antigen. These APCs then migrate to
secondary lymphoid organs where they present this donor antigen in the context of recipient MHC class II to recipient-derived
CD4+ T-cells which can facilitate the activation of recipient B-cells. (C) In the semi-direct pathway of allorecognition,
recipient-derived APCs inﬁltrate the transplanted allograft and uptake intact donor class I and class II MHC/peptide complexes.
In addition, these APCs also uptake, process and present peptides derived from donor MHC molecules in the context of
recipient MHC class II. Therefore, in the secondary lymphoid organs, recipient-derived APCs are capable of presenting donor
antigen in the context of recipient MHC class II to recipient-derived CD4+ T-cells and in the context of donor MHC class I to
recipient-derived CD8+ T-cells, enabling the CD4+ T-cells to facilitate in the activation of the CD8+ T-cells.
More recently, we confirmed these results using human
allospecific Tregs expanded using allogeneic dendritic cells
[12] and B-cells [11] as APCs. Employing a human skin
xenograft transplant model, we demonstrated that allospecific
Tregs were more potent than polyclonal Tregs at protecting
skin allografts from injury induced by the transfer of
allogeneic PBMCs. Following on from these promising
results, the efficacy of direct allospecific Tregs at promoting
transplant tolerance is due to be assessed in kidney (DART as
part of The ONE study: NCT02244801) and liver transplant
recipients (deLTa: NCT02188719 and NCT01624077).
In spite of the promising results detailed above, the
expansion of Tregs with indirect allospecificity has proved
more challenging due to the low frequency of these cells
naturally present in the periphery. A solution to this issue
is to genetically manipulate Tregs with self-specificity to
express one of two antigen-targeting moieties: either a
specific TCR complex or a chimeric antigen receptor (CAR),
both options of which are discussed below (Figure 1 and
Table 1).
T-cell receptors – a traditional approach to
confer antigen-speciﬁcity
Antigen-specificity can be conferred on to Tregs through the
expression of defined TCR α and β chain genes (Figure 1B).
In animal models, this can be accomplished either by
transducing self-specific Tregs to express exogenous α and
β TCR genes which are specific for a desired antigen or by
isolating Tregs from transgenic mice which express these TCR
transgenes in place of rearranged α and β genes (Table 1).
However, translating the successes of TCR gene modification
into the clinic is hampered by the fact that Tregs inherently
contain their own endogenous TCR genes. As such, both the
endogenous and introduced α and β chains are co-expressed
in the same cell with no preference as to whichα andβ chain is
partnered together. As half of the TCR complexes on the cell
surface will inevitably consist of a mixture of endogenous and
transduced α and β chains, these receptors will not be specific
for the antigen of interest.
Various strategies have been explored to reduce this
issue. One such solution is to target Tregs with α and β
TCR chains structurally modified in the constant region,
such that they pair with endogenous chains with a low
efficiency [35]. Alternatively, strategies to decrease the
expression of endogenous α and β chain TCR genes
have also been explored using either RNA-interference to
knockdown endogenous TCR expression [36] or genome
editing techniques such as transcription activator-like effector
nucleases (TALENs) to partially knockout endogenous TCR
genes [37]. With an ever-increasing number of solutions
to this endogenous/exogenous TCR dimerization problem
coming to light, research into the use of TCR genes to
redirect the specificity of Tregs has prevailed. As such, the
superior efficacy of TCR-modified antigen-specific Tregs,
as compared to self-specific Tregs, has been demonstrated
in mouse models for the treatment of colitis [38], MS [39],
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Table 1 A non-exhaustive selection of studies in which antigen-speciﬁc Tregs have been isolated or generated and demonstrated to be
efﬁcacious in vivo
Setting Targeting moiety Speciﬁcity Reference
Colitis CAR TNP/CEA [47–49]
Multiple sclerosis CAR MOG [50]
Autoimmune gastritis TCR H+ /K+ ATPase proton pump [40]
Colitis TCR OVA peptide presented by BALB/c MHC II [38]
Multiple sclerosis TCR MBP [39]
Rheumatoid arthritis TCR Type II collagen or OVA peptide presented by C57BL/7 MHC II [41,42]
Type I diabetes TCR Unidentiﬁed islet β-cell antigen [15,43]
GvHD following BMT TCR Direct allospeciﬁcity [26,44]
Transplantation TCR Direct allospeciﬁcity [8,11,12]
Transplantation TCR Indirect and dual allospeciﬁcity [9,10,34]
autoimmune gastritis [40], RA [41,42], T1D [15,43], GvHD
[26,44] and organ transplantation [8–12].
One of the first studies to compare the efficacy of antigen-
specific and self-specific Tregs upon adoptive transfer in vivo
was conducted by Taylor et al. [26] in the context of GvHD.
In addition to being one of the first papers to explore the
potential for Treg therapy using ex vivo-expanded Tregs,
this study also demonstrated that murine Tregs preferentially
expanded using allogeneic splenocytes were more effective at
protecting from GvHD than Tregs expanded using anti-CD3,
upon adoptive transfer.
In a transplant setting, although Tregs with direct
allospecificity (Figure 2A) can be isolated through pref-
erential expansion, as outlined above, acquiring Tregs
with indirect allospecificity (Figure 2B), recognizing donor
peptide presented in the context of recipient MHC molecules,
is more complex due to the low frequency of these cells in
recipients, prior to the transplant procedure. However,
in 2008, we demonstrated in a mouse setting that Tregs with
indirect allospecificity could be generated by transducing self-
specific Tregs with specific TCR genes [10]. Furthermore, we
[9] and others [34] have demonstrated that Tregs with dual
direct and indirect allospecificity can prolong graft survival
more effectively than any population of Tregs found naturally,
highlighting the potential for gene-modified cell therapy in
the clinic.
Chimeric antigen receptors – a novel approach
to confer antigen-speciﬁcity
An approach which has been explored extensively in cancer
research for generating antigen-specific T-cells is to transduce
polyclonal T-cells with CARs [45] (Figure 1C). Adoptive
transfer of effector T-cells expressing CARs specific for a
wide range of antigens such as ErbB receptors or CD19 has
successfully led to the treatment of various cancers in murine
models [45]. These studies paved the way for several clinical
trials which are designed to demonstrate the advantageous
clinical applications of CAR-transduced T-cells for treating
various cancers in humans, such as chronic lymphocytic
leukaemia, non-Hodgkin’s lymphoma and B-cell lymphoma
(extensively reviewed by Maher [45]).
CARs contain an extracellular antigen-binding domain
which typically comprises a single-chain variable fragment
(scFv) capable of binding a specific antigen with high
affinity in an MHC-independent manner (Figure 1C). This
is linked via a transmembrane (TM) domain to a series of
customised intracellular TCR and co-stimulatory signalling
domains, allowing the CAR to signal in a similar manner
to a TCR complex. The concept of using CARs to redirect
the specificity of T-cells was first suggested by Eshhar
and colleagues over 25 years ago [46]. The resultant first
generation CARs which were developed at this time were
engineered to mimic endogenous TCRs, thus contained a
CD3ζ signalling domain. However, these CARs were found
to have a low efficacy attributed to the lack of co-stimulatory
domains. Therefore, second generation CARs were designed
to incorporate a single co-stimulatory domain and third
generation CARs were developed to incorporate multiple co-
stimulatory domains from different sources, such as CD28,
4-1BB, OX40, Lck, inducible T-cell co-stimulator (ICOS),
CD27, 2B4 and DAP10 [45].
CAR-technology is now emerging as an approach for
redirecting the specificity of Tregs for the treatment of
autoimmunity (Table 1).
In 2008, Elinav et al. [49] generated Tregs expressing
a CAR specific for 2,4,6-trinitrophenol (TNP), a colitis-
associated model antigen. In this study, Tregs were isolated
from transgenic mice expressing the TNP-specific CAR
under the CD2 promoter. Upon adoptive transfer, these Tregs
prevented the development of 2,4,6-trinitrobenzene sulfonic
acid (TNBS)-induced colitis, but not oxazolone-induced
colitis, highlighting the antigen-specific nature of these Tregs.
Furthermore, in vivo imaging of the Tregs using fluorescence
showed that these cells accumulated in the colon, suggesting
that CAR Tregs traffic to sites where their cognate antigen is
present. These authors also showed that self-specific Tregs
retrovirally transduced to express the TNP-specific CAR
were equally capable of preventing colitis [48] and that similar
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results could be obtained through targeting different colitis-
associated antigens [47].
The protective capacity of CAR Tregs has also been
demonstrated for the treatment of MS. In 2012, Fransson et al.
[50] transduced murine CD4+ T-cells to express both a CAR
specific for myelin oligodendrocyte glycoprotein (MOG)
and the FoxP3 gene, resulting in cells which elicited both a
suppressive capacity and functioned in a MOG-dependent
manner. These cells were found to localize to the central
nervous system where they were capable of alleviating the
symptoms of experimental autoimmune encephalomyelitis
(EAE), following adoptive transfer.
Although the use of CARs to redirect the specificity of
Tregs has been explored in the context of autoimmunity,
we are aware of no publication which has demonstrated the
efficacy of CAR Tregs in a transplant context. However, with
the success CAR-expressing Tregs have had in protecting
from autoimmunity by targeting an antigen expressed in the
organ of interest, we believe similar results may be achieved
in a transplant setting by targeting donor MHC molecules.
These ideas are currently under investigation.
Conclusions
Recent developments and advancements of techniques
allowing for the isolation and expansion of GMP-grade Tregs
have progressed Treg therapy from a vision to a reality.
However, to escalate Treg therapy to a preferential treatment
option, the development of GMP-compatible approaches for
increasing the potency of Tregs in vivo is required. The use of
antigen-specific Tregs is believed by many to be a solution to
improve the efficacy of Tregs in vivo, as demonstrated by the
implementation of clinical trials now investigating the efficacy
of antigen-specific Tregs in the contexts of autoimmunity and
transplantation. We believe that gene modification for the
generation of antigen-specific Tregs is the next logical step
for Treg therapy.
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Abstract Direct allorecognition is the process by which
donor-derived major histocompatibility complex (MHC)-pep-
tide complexes, typically presented by donor-derived ‘passen-
ger’ dendritic cells, are recognised directly by recipient Tcells.
In this review, we discuss the two principle theories which
have been proposed to explain why individuals possess a
high-precursor frequency of T cells with direct allospecificity
and how self-restricted T cells recognise allogeneic MHC-
peptide complexes. These theories, both of which are support-
ed by functional and structural data, suggest that T cells
recognising allogeneic MHC-peptide complexes focus either
on the allopeptides bound to the allo-MHC molecules or the
allo-MHC molecules themselves. We discuss how direct
alloimmune responses may be sustained long term, the conse-
quences of this for graft outcome and highlight novel strate-
gies which are currently being investigated as a potential
means of reducing rejection mediated through this pathway.
Keywords Transplantation . Allospecificity .
Allorecognition .Multiple binary complexes . High
determinant density
Introduction
The ability of immune cells to distinguish between ‘self’ and
‘non-self’ is of fundamental importance. It ensures that invad-
ing pathogens are efficiently removed whilst tolerance to-
wards cells of self-origin is maintained. In transplantation,
the introduction of ‘non-self’ cells or tissues into a recipient
can trigger an immune response. This is initiated when anti-
gens derived from a genetically distinguishable member of the
same species are recognised as foreign, a process termed
‘allorecognition’. Subsequent immune cell activation and elic-
itation of an immune response directed towards alloantigen-
expressing cells ultimately results in graft-versus-host disease
(GvHD) following bone marrow transplantation (BMT) or
graft rejection following solid organ transplantation.
Organ transplantation is inherently an invasive surgical ap-
proach which is inevitably accompanied by ischemia/
reperfusion injury, inflammation and tissue damage [1].
Consequently, innate immune responses such as the comple-
ment cascade [2, 3] are initiated which contribute to graft
rejection [4]. However, studies conducted in neonatally
thymectomised [5] and irradiated adult [6–8] mice have dem-
onstrated that the most deleterious immune responses are driv-
en by recipient-derived T cells. These cells have been
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described to recognise alloantigens via three pathways of
allorecognition: the direct, indirect and semi-direct pathways.
The direct pathway is initiated by donor-derived antigen-pre-
senting cells (APC) which present allogeneic major histocom-
patibility complex (MHC)-peptide complexes to recipient T
cells. Conversely, the indirect pathway relies on recipient-
derived APCs which uptake, process and present allopeptides
in the context of self-MHC class II. More recently, the semi-
direct pathway was described in which recipient-derived
APCs present both acquired, intact allo-MHC-peptide com-
plexes (direct) and allopeptides in the context of self-MHC
(indirect). In this review, we focus on the direct and semi-
direct pathways of allorecognition.
Premise of Direct Allorecognition
The unusual strength and vigour of direct alloimmune responses
was first demonstrated by Bain et al. [9] through the use of
in vitro-mixed leukocyte reactions (MLR). It was discovered that
mixing leukocytes from two genetically unique individuals re-
sulted in significant leukocyte activation, a phenomenon which
was not observed by mixing leukocytes from genetically identi-
cal individuals. Subsequent in vivo studies demonstrated that
similarly aggressive immune responses were observed in rodents
which received allogeneic transplants [10]. This vigorous re-
sponse was attributed to the presence of donor-derived ‘passen-
ger’ leukocytes which were co-transferred into the recipient dur-
ing the transplant procedure. Depletion of these cells from thy-
roid [11] or pancreatic [12] allografts, achieved by culturing the
allografts in vitro to facilitate passenger leukocyte egression, re-
sulted in a prolonged graft survival. In the former study, this
prolongation was reversed by the infusion of donor peritoneal
exudate cells (PEC), suggesting that recipient T cells with direct
allospecificity must be activated by donor-derived APCs in order
to destroy transplanted allografts [11].
Subsequent investigations performed by Lechler and
Batchelor [13, 14] demonstrated that the principle ‘passenger’
leukocytes responsible for activating recipient T cells were den-
dritic cells (DC). In these studies, rat kidneys were ‘parked’ in
intermediate recipients to deplete passenger leukocytes, prior to
engraftment in a terminal recipient. The outcome was prolonged
allograft survival which was prevented by the repletion of donor
DCs, implicating a significant role for these cells in acute allo-
graft rejection. Additional studies proceeded to suggest that these
DCs prime and activate recipient T cells in secondary lymphoid
tissues [15, 16].
Models Explaining Direct Allorecognition
The strength and vigour with which direct alloimmune re-
sponses are elicited may be explained by the fact that all indi-
viduals have a high-precursor frequency of T cells specific for
allogeneic MHC-peptide complexes. Approximately 0.01 %
of the cells in a standard T cell repertoire are capable of
responding to a specific foreign peptide presented by a self-
MHCmolecule. However, 1–10% of these Tcells can engage
in tac t fo re ign MHC-pep t ide complexes (d i r ec t
allorecognition) [17•]. Two models have been proposed to
account for this unusually high frequency of Tcells with direct
allospecificity, each of which places an emphasis on the dif-
ferent components which comprise an MHC-peptide com-
plex: the allopeptide and the allo-MHC molecule.
Peptide-Centric Model
The first model focuses on the contribution of the allopeptide
bound in the groove of the allo-MHC. It is believed that spe-
cific structural components of self-MHCmolecules are ‘mim-
icked’ by allo-MHCmolecules. As such, self-restricted Tcells
dock andmake contacts with allo-MHCmolecules in the same
manner as they would with self-MHC molecules. However,
the binding groove of the self- and allo-MHC molecules is
vastly different, thus the peptides presented by each is signif-
icantly different, despite being derived from similar endoge-
nous proteins.
Given the random nature with which TCRs are genetically
rearranged, a standard repertoire comprises Tcells with a wide
spectrum of specificities. As such, the recognition frequency
of a self-MHC presenting a specific foreign peptide is low:
often, a very small proportion of T cells engage a specific
MHC-peptide complex. However, in this model, it is not one
foreign peptide which is presented by allo-MHC molecules
but instead, an entire pool of foreign peptides thus donor-
derived cells will activate a variety of recipient T cells with a
range of specificities. This hypothesis was initially proposed
by Matzinger and Bevan in 1977 and is termed the ‘multiple
binary complexes’ hypothesis (Fig. 1a) [18].
In 1988, Eckels et al. [19] demonstrated the importance of
allopeptides in the activation of T cells with direct allospecificity.
In this study, HLA-DR1-restricted alloreactive Tcell clones were
co-cultured with allogeneic APCs in the presence and absence of
a competing peptide. T cell proliferation induced by the presen-
tation of allopeptides in the context of HLA-DR1 was abrogated
when the allopeptides were displaced by competing influenza
haemagglutinin-based peptides. Subsequently, Panina-
Bordignon et al. [20] demonstrated that APC presentation of
peptides derived from endogenous proteins contributes signifi-
cantly to the activation of alloreactive T cell clones. Of 1489
CD4+ T cell clones analysed, 6.6 % specifically responded to
APCs which presented human serum albumin (HSA)-derived
peptides but not foetal calf serum (FCS)-derived peptides, despite
the peptides being presented by the same HLA-DR molecule.
Conversely, it has been shown that presentation of allo-MHC
molecules lacking allopeptides, achieved through the use of
MHC mutants [21] or acid-treatment of target cells [22], triggers
a limited response from alloreactive T cells. In the latter study, T
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cell responses were restored by the addition of synthetic
allopeptides. Furthermore, various groups have described
allopeptide sequence consensuses [23] and have demonstrated
that through disrupting the binding of these specific allopeptides,
there is a loss of response from alloreactive T cells [24]. More
recent studies have employed point mutation approaches to de-
termine which motifs in a TCR are important for eliciting T cell
activation and have concluded that TCR-peptide interactions are
fundamental in direct allorecognition [25].
MHC-Centric Model
The second model focuses on the fact that allo-MHCs are
structurally different to self-MHCs. Whilst the majority of
elements recognised by a TCR are conserved across various
MHC subtypes [26], specific amino acid polymorphisms pres-
ent in the allo-MHC molecule may modify the manner by
which a self-restricted TCR docks with an MHC, irrespective
of the peptide presented.
In this model, it is suggested that fundamental differences
exist between self- and allo-MHCs in specific polymorphic
residues which are exposed to potential docking TCRs.
These residues cause the MHC-peptide complex to be
recognised as foreign, thus the peptide presented stabilises
the MHC-peptide complex but has little influence in the rec-
ognition process. Additionally, the affinity with which this
TCR:allo-MHC interaction occurs may have implications in
the alloresponse observed. Whilst T cells are selected to bind
self-MHC-peptide complexes with a low affinity, it is possible
that they would bind allo-MHC-peptide complexes with a
high affinity, suggesting that a high affinity cross-reaction is
responsible for the allorecognition observed. Furthermore, the
high density of ligands expressed by donor APCs can further
facilitate the activation of alloreactive T cells. This hypothesis
is termed the ‘high determinant density’ hypothesis and was
originally proposed by Bevan in 1984 (Fig. 1b) [27].
In 1989, Schneck et al. [28] developed a peptide which
mimicked a specific region of the MHC class I molecule
H-2Kb. In the presence of this peptide, the cytotoxic activity
of H-2Kb-specific CD8+ Tcells against H-2Kb target cells was
inhibited, demonstrating the importance of the TCR:MHC
interaction in this alloresponse. Subsequently, and in contrast
to the results ofWang et al. [22], Smith et al. demonstrated in a
mouse setting that removal of peptides bound to MHC mole-
cules through the use of acid washing did not perturb the
ability of T cells to bind and react to allo-MHC molecules
[29]. Lombardi et al. [30] proceeded to present corresponding
findings in a human T cell setting. In this study, a site-directed
mutagenesis approach was employed to generate genetically
altered HLA-DR molecules which were transfected into mu-
rine DAP.3 cells. Using these artificial APCs, it was demon-
strated that specific mutagenesis of TCR contact regions in the
MHC molecule resulted in inhibition of T cell binding and
subsequent effector responses. As such, it was evident that
specific sites of the allo-MHCmolecule were critical for direct
allorecognition to occur. These findings were later confirmed
by Villadangos et al. who employed a similar approach whilst
mutating HLA-B27 [31].
Conundrum of Allorecognition
T cell progenitors must undergo a stepwise ‘education’ pro-
cess in the thymus to develop into mature Tcells. Thymocytes
expressing a TCR capable of recognising peptides presented
in the context of self-MHC molecules are ‘positively select-
ed’, whilst thymocytes that recognise self-MHC-peptide com-
plexes with a high affinity are ‘negatively selected’. As such,
Fig. 1 Comparison of the two principle theories explaining the high
frequency of T cells with direct allospecificity. a Multiple binary
complexes hypothesis. The elements of the allogeneic MHC molecule
which interact with the TCR mimic those which are found in self-MHC
molecules. As such, it is the presence of the allopeptide (red) which drives
recognition of the allogeneic MHC-peptide complex. Allograft
presentation of various allopeptides in the contexts of MHC molecules
which are perceived as ‘self’ results in the activation of a range of T cells,
each expressing a TCR specific for a different MHC-peptide complex. b
High determinant density hypothesis. Structural differences in the
polymorphic regions of the allo-MHC molecule are detected by the
TCR (red). The high density of cognate allo-MHC molecules which
possess these polymorphisms on donor-derived APCs facilitates the
efficient activation of recipient T cells which recognise the allogeneic
MHC molecule with a low, medium or high affinity
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the mature T cells which results from this process are able to
recognise self-MHC-peptide complexes with a low affinity.
The existence of this process reveals a conundrum: why do
self-restricted T cells [32] recognise allo-MHC-peptide com-
plexes? Studies have demonstrated that cross-reactivity between
self and allogeneic MHC-peptide complexes is the key for this
mode of allorecognition. In other words, T cells specific for pep-
tide ‘x’ presented by self-MHC ‘A’ are also able to recognise
peptide ‘y’ presented by allo-MHC ‘B’ [33]. Studies supporting
this have demonstrated that LFA-3+ [34] and CD45RO+ [35]
memory T cells primed against peptide ‘x’ presented by self-
MHC ‘A’ also respond to allo-MHC-peptide complexes (peptide
‘y’ presented by allo-MHC ‘B’). Furthermore, these cross-
reacting memory T cells comprise a significant proportion of
the total T cells which respond in a direct manner. This cross-
reactivity concept was further accentuated by Lombardi et al. in
1989 [36]. In this study, human alloreactive T cell clones which
were specific for HLA-DR1 were co-cultured with autologous
APCs presenting Candida albicans-derived antigens in the con-
text of HLA-DR4/HLA-DR13. Half of the alloreactive T cell
clones analysed responded in these co-cultures, suggesting that
cells which were capable of recognising the allo-MHCmolecule
HLA-DR1 had previously been activated by APCs presenting
self-MHC-peptide complexes.
Structural Importance of TCRs and MHCs
The hypotheses and accompanying functional studies described
have suggested that the attention of T cells with direct
allospecificity is either for the allopeptides or the allo-MHCmol-
ecules. However, further insight into the molecular mechanisms
of these interactions was provided by structural studies which
employed x-ray crystallography. In 1987, Bjorkman et al. first
published the structure of HLA-A2 [37]. Subsequent studies per-
formed with HLA-A2 [38] and HLA-B27 [39] suggested specif-
ic residues which were important for allorecognition. However,
significant progress in this field was not made until 1996 when
co-crystals containing a TCR interacting with an MHC-peptide
complex were generated [40, 41]. These studies confirmed for
the first time that TCRs bindMHC-peptide complexes in a diag-
onal orientation, demonstrating that both the MHC and the pep-
tide are recognised. Specifically, the variable Vα domain of the
TCR positions above the N-terminal half of the peptide and the
Vβ domain locates above the C-terminal half of the peptide [42,
43]. This places an emphasis on the complementarity-
determining region (CDR)3 loops of the TCR [44], the most
variable region of the TCR, for recognising the peptide whilst
the CDR1 and CDR2 loops primarily interact with the MHC.
These studies accentuate the plasticity with which a TCR is
able to cross-react and engage a variety of different MHC-
peptide complexes [45, 46]. Indeed, this TCR degeneracy
(ability of a single TCR to engage multiple MHC-peptide
complexes) has fundamental ramifications in that it allows a
finite number of T cells to recognise a potentially infinite
number of MHC-peptide complexes [46, 47]. Although vari-
ous theories exist to explain this degeneracy [48], it is clear
that the ability of a TCR to change conformation upon engage-
ment of a cognate MHC-peptide complex is paramount [42].
In 2007, Colf et al. [49] demonstrated that whilst a single
TCR could cross-react to recognise self-MHC and allo-MHC
molecules, different TCR conformations were required to ac-
complish this. The structure of the mouse-based TCR ‘2C’
was compared when engaged with the self-MHC-peptide
complex H2Kb-dEV8 and the allo-MHC-peptide complex
H2Ld-QL9 [50]. Genetic manipulation of the CDR3α to yield
a high-affinity variant of the 2C TCR did not influence the
orientation with which the allo-MHC-peptide complex H2Ld-
QL9 was bound. As such, interrupting the CDR3α-peptide
interaction had little effect on the binding of the TCR to the
allo-MHC-peptide complex, suggesting an MHC-centric
model may be prevalent in this setting [50].
Conversely, structural data has also suggested a crucial role
for allopeptides in driving direct allorecognition. Studies by
Reiser et al. [44, 51, 52] conducted using mouse-based TCRs
have detailed key conformational changes which occur in the
CDR3 loops of a TCR upon binding of an allogeneicMHC class
I molecule. Here, the CDR3α loop of the TCR ‘BM3.3’ was
found to adopt different conformations depending on the peptide
presented: presentation of the ‘pBM1’ peptide caused the
CDR3α loop to fold away from the peptide binding groove
[52] but when the ‘VSV8’ peptide was presented, the CDR3α
loop pointed towards the amino-terminal end of the peptide [51].
Furthermore, given the fact that relatively minor changes were
observed in the CDR1 and CDR2 loops, these results suggest
that the allopeptide is responsible for driving direct
allorecognition [48, 53]. Studies conducted with human TCRs
interacting with HLA-B molecules have also yielded results in
favour of a peptide-dependent direct allorecognitionmodel. It has
been suggested that MHCmolecular mimicry is the basis for the
cross-reactivity observed between self-HLA-B*0801 and allo-
HLA-B*3501 [54] as well as self-HLA-B*0801 and allo-HLA-
B*4402/4405 [55]. In the latter study, the nature with which the
TCR ‘LC13’ interacted with self-HLA-B*0801 and allo-HLA-
B*4405 was remarkably similar; a comparable number of van
der Waals interactions, hydrogen bonds and salt-bridges were
formed in each case. Additionally, despite the fact that drastically
different peptides were presented, very similar contacts were
made by the CDR loops interacting with the self- and allo-
HLA-B molecules.
Overall, the aforementioned high determinant density and
multiple binary complex models provide two explanations for
why T cells with direct allospecificity exist with a high-
precursor frequency. With functional and structural data
supporting both hypotheses, it is likely that in vivo, the high
frequency of direct allorecognition can be attributed to a combi-
nation of these theories.
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Consequences of Direct Allorecognition
Allorecognition typically leads to an effector response in
which CD8+ T cells with direct allospecificity actively kill
donor-derived target cells [56], leading to allograft dysfunc-
tion and failure. Various studies have investigated how recip-
ient graft-specific CD8+ and CD4+ T cells contribute to acute
and chronic transplant rejection [33, 57–60]. For example, in
2000, Pietra et al. [61] investigated the contribution of CD4+ T
cells in acute graft rejection through the use of severe com-
bined immunodeficiency (SCID) and recombination-
activating gene (RAG)-1 deficient mice which lack functional
T and B cells. C57BL/6 heart allografts, which survived in-
definitely in SCID mice, were acutely rejected (mean survival
time (MST) of 12 days) when BALB/c CD4+ T cells were
adoptively transferred on the day of transplant. Conversely,
heart allografts which lacked donor C57BL/6 MHC class II
molecules (C2D donor mice) were not rejected (7/8 allografts
survived >60 days), demonstrating that CD4+ T cells directly
specific for donor MHC class II molecules were necessary for
acute allograft rejection.
More recently, Brown et al. [62] further demonstrated the
contribution of recipient CD4+ T cells to allograft rejection
using a fully mismatched kidney transplant model in which
donor APCs were specifically depleted. In this study, one
native kidney of recipient (FVB) mice was replaced with an
allogeneic (C57BL/6 × CBA F1) kidney. In the absence of
treatment, transplanted kidneys were rejected acutely in
40% of cases. However, in recipients which were treated with
an immunotoxin-conjugated antibody specific for donor
MHC class II (I-Ak) to depleted donor APCs, kidney allo-
grafts were completely protected: histological analysis
showed no evidence of rejection and upon removal of the
second native kidney, the function of the transplanted kidney
(blood urea nitrogen score) was found to be intact.
Analysis of blood samples acquired from stable renal
transplant recipients has revealed that recipient CD4+ T
cells with direct allospecificity become hyporesponsive
towards alloantigens and are not deleted [63]. This work
was further extended by demonstrating that that human
CD4+ T cells co-cultured with MHC class II-expressing
thyroid follicular cells (TFC) [64] or epithelial cells [65]
do not proliferate or produce cytokines in the absence of
co-stimulation and are hyporesponsive upon subsequent
challenge with EBV-transformed lymphoblastoid B cell
lines (B-LCL) [66]. Together, these results suggest that
in the absence of donor-derived professional APCs, recip-
ient CD4+ T cells engage MHC class II molecules pre-
sented by transplanted tissue parenchymal cells which
lack co-stimulatory molecules. As a result, these T cells
become anergic [65] or polarised towards a Th2 pheno-
type [64], suggesting that prolonged alloimmune re-
sponses depend on an alternative mode of allorecognition.
Sustaining a Long-Term Direct Alloimmune Response
During a transplant procedure, donor APCs are transferred but
these cells are killed or die over time [56]. As such, it has
historically been believed that the direct pathway of
allorecognition predominates during acute graft rejection.
Furthermore, as previously discussed, in the absence of donor
APCs, T cells with direct allospecificity recognise allo-MHC
presented on the allograft parenchyma which leads to anergy
induction [66].
As previously discussed, Lechler and Batchelor [13, 14]
demonstrated that prolonged rat kidney allograft survival could
be achieved by ‘parking’ the allograft in an intermediate recip-
ient to deplete passenger leucocytes. However, the fact that
these allografts were eventually rejected led to the proposal of
the indirect pathway of allorecognition whereby recipient-
derived APCs consistently sample and present donor antigens
provided by the allograft. As such, the indirect pathway has
been believed to be the main mode of chronic rejection [67].
As antigens acquired from exogenous origins are naturally
presented in the context of MHC class II, it is primarily CD4+
Tcells which recognise alloantigens in an indirect manner, not
CD8+ T cells which are responsible for eliciting cytotoxicity.
Furthermore, efficient CD8+ T cell activation requires help
from CD4+ T cells [60]. As such, it is reasonable to conclude
that a link between the direct and indirect pathways of
allorecognition exists and that CD4+ T cells with indirect
allospecificity facilitate the activation of CD8+ T cells with
direct allospecificity [59, 68]. Theoretically, for this to occur,
two separate APCs should be present: a recipient APC pre-
senting allopeptides indirectly to the CD4+ T cell and a donor
APC presenting antigen directly to the CD8+ T cell. However,
from a practical viewpoint, it is highly unlikely that these two
APC:T cell interactions naturally occur in such close proxim-
ity, leading to a conundrum termed the ‘four-cell conundrum’.
This was resolved by the discovery of APCs which present
intact donor MHC-peptide complexes in a direct manner and
allopeptides in an indirect manner [69–71], the basis of a more
recently described third pathway of allorecognition: the semi-
direct pathway [70].
In a similar manner to the indirect pathway, the semi-direct
pathway relies on recipient-derived APCs which infiltrate the
allograft following engraftment. However, in addition to pre-
senting allopeptides indirectly, these cells acquire intact donor
MHC-peptide complexes from donor-derived cells/tissues, a
phenomenon termed ‘cross-dressing’, thus present allogeneic
MHC-peptide complexes in a direct manner [71]. Indeed, DCs
presenting both donor MHC class I-peptide complexes (direct
presentation) and allopeptides in the context of self-MHC (in-
direct presentation) have been observed following skin [72••],
kidney [73] and heart [74, 75••] transplantation. Through this
pathway, direct alloimmune responses can continue long after
donor-derived APCs have died, but the extent to which this
Curr Transpl Rep
pathway contributes to allograft rejection is not yet known.
Recently, we have shown that after removal of the direct path-
way and in the absence of cross-presentation, acquired allo-
MHC-peptide complexes, on recipient DCs, can drive allo-
graft rejection throughout the life-span of the transplant [72].
Targeting T cells with Direct Allospecificity
Over the past few decades, advances in surgical techniques
and the development of modern immunosuppressive regimens
have enabled transplantation of cells/organs to become a via-
ble treatment option for a plethora of different conditions.
Although the mechanisms by which these immunosuppres-
sive drugs function are not completely understood, it is be-
lieved their benefits stem through the suppression of T cells
with direct allospecificity [76]. However, drug-based immu-
nosuppression is inherently non-specific and associated with
undesirable side-effects, leaving recipients under consistent
nephrotoxic insult with an increased susceptibility to acquir-
ing infections and developing cancer [76]. As such, various
strategies are currently under investigation to reduce the re-
quirement for these drugs.
Following transplantation, recipient T cells with direct
allospecificity are initially activated by ‘passenger leuko-
cytes’. Given the deleterious consequences of these cells,
strategies have been explored to investigate whether depletion
of these cells from allografts can reduce the intensity of an
initial immune insult. Brown et al. [62] recently achieved this
through the use of a donor MHC class II-specific
immunotoxin-conjugated antibody. As described above, these
authors observed indefinite kidney allograft survival and func-
tion inmice which received this treatment. Additionally, Stone
et al. [77•] have demonstrated that the proportion of passenger
leukocytes in lung allografts can be significantly reduced
through the use of ex vivo lung perfusion (EVLP). These
authors employed a model whereby donor pig lungs are
explanted, perfused ex vivo and then transplanted into recip-
ient pigs. EVLP, which did not severely alter the viability of
the graft, reduced both donor leukocyte egression and recipi-
ent T cell infiltration post-transplantation, suggesting a poten-
tial clinical benefit of passenger leukocyte removal prior to
allograft implantation.
Luo et al. have explored the possibility of inducing donor-
specific transplant tolerance by infusing ethylene
carbodiimide (ECDI)-fixed donor-derived APCs before and
after a transplant procedure [78]. Fuelled by similar ap-
proaches which were applied to treat multiple sclerosis [79]
and diabetes [80] in mice, the authors of this study demon-
strated that indefinite survival (>100 days) of fully mis-
matched islets could be achieved by infusing recipient mice
intravenously with 100 million donor-derived ECDI-treated
splenocytes before and after the islet transplant procedure.
Furthermore, it was demonstrated that CD4+CD25+ Tregs
had a crucial role in tolerance induction. These authors have
also demonstrated that similar levels of tolerance can be
achieved through the use of biodegradable particles (poly
(lactide-co-glycolide); PLG) which present donor antigens
(PLG-dAg) as a substitute for the aforementioned ECDI-
treated splenocytes [81].
As suggested, Tregs play a fundamental role in inducing
tolerance in vivo. Allograft survival is significantly prolonged
by increasing the proportion of Tregs in recipient mice, either
by promoting endogenous Treg expansion [82] or adoptively
transferring ex vivo-expanded Tregs [83, 84]. Similarly, ob-
servational studies performed on human samples have noted a
correlation between the proportion of Tregs and allograft sur-
vival [85, 86]. These studies paved the way for phase I/II
clinical trials which are currently investigating the safety and
efficacy of polyclonal Treg therapy in kidney (The ONE
Study), liver (ThRIL) and bone marrow transplant recipients
[87]. Furthermore, we [88•, 89] and others [90] have demon-
strated that Tregs with direct allospecificity are superior to
polyclonal Tregs at prolonging allograft survival in vivo. In
these studies, human Tregs with direct allospecificity were
preferentially expanded using allogeneic DCs [88•] or B cells
[89, 90]. Using human skin xenograft transplant models, di-
rect allospecific Tregs were shown to inhibit direct
alloimmune-mediated skin injury significantly more effective-
ly than polyclonal Tregs. However, we have also observed in a
mouse setting that Tregs with direct allospecificity alone are
insufficient to prolong the survival of heart allografts [91]. To
achieve this, Tregs required both direct and indirect
allospecificity, suggesting that it is necessary to block both
direct and indirect allospecific Teffs in order to reduce allo-
graft damage in this setting. Given the superior efficacy of
Tregs with direct allospecificity, compared to polyclonal
Tregs, the safety and efficacy of these cells is currently being
assessed clinically in kidney (DART as part of The ONE
Study: NCT02244801) and liver (deLTa: NCT02188719 and
NCT01624077) transplant recipients.
Conclusions
The mechanisms of direct allorecognition have puzzled im-
munologists for decades. Why self-restricted T cells recognise
allo-MHC-peptide complexes and with a high-precursor fre-
quency remain a mystery. Theories proposed to offer an ex-
planation for these conundrums attribute the phenomenon of
direct allorecognition to either the presence of allopeptides or
allo-MHC molecules. Both theories are supported by func-
tional and structural data, suggesting that in vivo, both
allopeptides and allo-MHC molecules are responsible for
driving direct allorecognition. For many decades, the direct
pathway of allorecognition was believed to be solely respon-
sible for early alloimmune-mediated rejection. However, the
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more recent discovery of the semi-direct pathway by our
group has demonstrated how rejection mediated by T cells
with direct allospecificity can be sustained long-term. As
such, various strategies are currently being explored as poten-
tial means of limiting direct allorecognition and inducing
tolerance.
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Regulatory T cell (Treg) therapy using recipient-
derived Tregs expanded ex vivo is currently being
investigated clinically by us and others as a means
of reducing allograft rejection following organ trans-
plantation. Data from animal models has demon-
strated that adoptive transfer of allospecific Tregs
offers greater protection from graft rejection com-
pared to polyclonal Tregs. Chimeric antigen recep-
tors (CAR) are clinically translatable synthetic fusion
proteins that can redirect the specificity of T cells
toward designated antigens. We used CAR technol-
ogy to redirect human polyclonal Tregs toward
donor-MHC class I molecules, which are ubiquitously
expressed in allografts. Two novel HLA-A2-specific
CARs were engineered: one comprising a CD28-CD3f
signaling domain (CAR) and one lacking an intracel-
lular signaling domain (DCAR). CAR Tregs were
specifically activated and significantly more suppres-
sive than polyclonal or DCAR Tregs in the presence
of HLA-A2, without eliciting cytotoxic activity. Fur-
thermore, CAR and DCAR Tregs preferentially trans-
migrated across HLA-A2-expressing endothelial cell
monolayers. In a human skin xenograft transplant
model, adoptive transfer of CAR Tregs alleviated the
alloimmune-mediated skin injury caused by transfer-
ring allogeneic peripheral blood mononuclear cells
more effectively than polyclonal Tregs. Our results
demonstrated that the use of CAR technology is a
clinically applicable refinement of Treg therapy for
organ transplantation.
Abbreviations: ANOVA, analysis of variance; APC, anti-
gen-presenting cell; B-LCL, B-lymphoblastoid cell line;
BRG, BALB/c Rag2/cc
/; CAR, chimeric antigen
receptor; CLA, cutaneous lymphocyte antigen; eGFP,
enhanced green fluorescent protein; ELISA, enzyme-
linked immunosorbent assay; FACS, fluorescence-
assisted cell sorting; FOXP3, factor forkhead-box
protein 3; GMP, good manufacturing practice; GvHD,
graft-versus-host disease; HUVEC, human umbilical
cord endothelial cell; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; OCT, optimal cutting
temperature; PBMC, peripheral blood mononuclear
cell; RAG, recombination activating gene; scFv, single-
chain variable fragment; SD, standard deviation; SEM,
standard error of the mean; Teff, effector T cell; Treg,
regulatory T cells
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Introduction
The long-term benefits of organ transplantation are hin-
dered by graft rejection (1–5), a detrimental process dri-
ven by alloreactive T cells that recognize donor MHC
antigens via the direct, indirect, and semidirect pathways
of allorecognition (3,6). Current immunosuppressive
regimens target the direct pathway and reduce acute
allograft rejection (7) but are associated with severe
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side-effects (8) and do not effectively prevent chronic
rejection (2,9); thus, the half-life of allografts remains lim-
ited to 10–15 years (10,11).
Thymus-derived regulatory T cells (tTregs) are immuno-
suppressive T cells with a fundamental role in the
maintenance of tolerance in vivo (12–15). These cells
are characterized in humans as CD4+CD25hiCD127lo
and constitutively express the transcription factor
forkhead-box protein 3 (FOXP3) (7,12,16). In rodent
models, Tregs significantly prolong the survival of skin
(17–19) and heart (4) allografts and in humans, correla-
tions between the proportion of Tregs within allografts
and graft survival have been observed (20–22). With
the safety of Treg therapy having been demonstrated
in the contexts of graft-versus-host disease (GvHD)
(23–26) and type I diabetes (27,28), we are conducting
Phase I/II clinical trials to investigate the therapeutic
potential of adoptive polyclonal Treg therapy to pro-
mote tolerance in kidney (The ONE Study:
NCT02129881) and liver (ThRIL: NCT02166177) trans-
plant recipients (29,30).
However, we (4,17,19,31) and others (32,33) have
demonstrated in animal models that allospecific Tregs are
superior to polyclonal Tregs at reducing graft rejection,
upon adoptive transfer. Murine Tregs expanded with allo-
geneic antigen-presenting cells (APC) (direct allospeci-
ficity) and/or transduced to express an allospecific TCR
(indirect allospecificity) prolonged graft survival signifi-
cantly more effectively than polyclonal Tregs. These find-
ings were confirmed using human Tregs expanded with
allogeneic dendritic cells (19) and B cells (31,34) in human
skin xenograft transplant models. As such, clinical trials
are assessing the safety and efficacy of Tregs with direct
allospecificity in kidney (DART: NCT02188719) and liver
(deLTa: NCT02188719 and NCT01624077) transplant
recipients. Here, we investigated whether allospecificity
may be conferred onto Tregs using chimeric antigen
receptors (CAR) (35).
CARs are synthetic fusion proteins capable of redirecting
the specificity of T cells toward desired antigens. Classi-
cal CARs comprise an extracellular antigen-targeting moi-
ety that binds a specific antigen in an MHC-independent
manner and a series of customized intracellular TCR and
costimulatory signaling domains. As such, CARs translate
the binding of specific antigens into the activation of
desired signaling cascades (36). CARs are primarily used
clinically to generate tumor antigen–specific T cells (37–
43). However, preclinical studies have shown the effi-
cacy of CAR-modified Tregs for the treatment of colitis
(16,44,45) and multiple sclerosis (46). The functionality of
CARs has also been demonstrated in human Tregs
(47,48), most recently as a means of protecting against
xeno-GvHD (49). However, to date, no one has demon-
strated the capacity of CAR Tregs to protect from solid
transplant rejection.
In this study, we applied CAR technology to generate
allospecific Tregs with the aim of promoting organ
transplant tolerance. We redirected human CD4+CD25+
CD127loFOXP3+ Tregs toward an MHC class I molecule
(HLA-A2), an alloantigen that is ubiquitously expressed in
an allograft, with the hypothesis that they would be more
potent than polyclonal Tregs at protecting from graft
rejection, upon adoptive transfer.
Materials and Methods
CAR generation
A previously described (50) HLA-A2-specific single-chain variable frag-
ment (scFv) sequence (3PB2 VH and DPK1 VL) was validated by immuno-
precipitation (data not shown) and cloned upstream of (i) a 9E10 cMyc
epitope; (ii) a human CD28 hinge/transmembrane domain; (iii) a human
CD28-CD3f signaling domain; and (iv) an enhanced green fluorescent pro-
tein (eGFP) open reading frame in a second-generation pLNT/SFFV lentivi-
ral plasmid (provided by Prof. Adrian Thrasher; UCL, London, UK). A
truncated CAR (DCAR) was generated by removing the CD28-CD3f sig-
naling domain from the full-length CAR-eGFP fusion. All plasmids were
verified by sequencing (Beckman Coulter Genomics, Takeley, Essex, UK).
Human CD4+CD25+ Treg and CD4+CD25 − Teff isolation and
culture
Anonymized healthy donor peripheral blood was obtained from the
National Blood Service (NHS Blood and Transplantation, Tooting, London,
UK) with informed consent and ethical approval (Institutional Review
Board of Guy’s Hospital; reference 09/H0707/86). CD4+ T cells were
enriched using RosetteSepTM (StemCell Technologies, Waterbeach,
Cambridgeshire, UK), after which CD4+CD25− Tregs and CD4+CD25−
Teffs were separated using CD25 MicroBeads II (Miltenyi Biotec, Bisley,
Surrey, UK).
Tregs/effector T cells (Teffs) were activated with anti-CD3/CD28 beads
(1:1 bead:cell ratio; Thermo Fisher Scientific, Paisley, Renfrewshire, UK)
and cultured in X-vivoTM 15 (Lonza, Slough, Berkshire, UK) supplemented
with 5% human AB serum (BioSera, Uckfield East, Sussex, UK). Treg
were cultured with 100 nM rapamycin (LC-Laboratories, Woburn, MA)
and 1000 U/mL recombinant IL-2 (Proleukin-Novartis, Camberley, Surrey,
UK), whereas Teffs were cultured with 100 U/mL IL-2 only.
Flow cytometry and cell sorting
Cells were stained in phosphate-buffered saline (PBS) supplemented with
1% heat-inactivated fetal calf serum (FCS) and 5 mM EDTA (all from
Thermo Fisher Scientific) using fluorescently conjugated antibodies speci-
fic for HLA-A2 (BB7.2), CD4 (OKT4), FOXP3 (PCH101), CD39 (eBioA1),
CD69 (H1.2F3) (all from eBioscience, Hatfield, Hertfordshire, UK), CD25
(4E3 or 2A3), CTLA-4 (BNI3) (all from BD Biosciences, Oxford,
Oxfordshire, UK) CD127 (A019D5), CCR4 (L291H4), CCR9 (L053E8),
CCR10 (5688-5), CD62L (DREG-56), integrin b7 (FIB504), CLA (HECA-
452), HLA-DR (all from BioLegend, London, UK), HLA-A2 (REA142)
(Miltenyi-Biotec), and HLA class I (Tu149) (Thermo Fisher Scientific). Cells
were stained with PE-conjugated HLA-A*0201/CINGVCWTV and HLA-
B*0702/DPRRRSRNL dextramers (Immudex, Copenhagen, Denmark) pro-
vided by Dr. Marc Martinez-Llordella; KCL, London, UK. Dead cells were
excluded using live/dead near-IR staining (Thermo Fisher Scientific). Intra-
cellular staining was performed using the eBioscience Fix/Perm kit. Cells
were acquired and sorted using an LSRFortessa II and FACSAria II (BD),
respectively. Data were analyzed using FlowJo 7 or 10 (Tree Star,
Ashland, OR).
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Immortalized cell line culture
HEK293T, MCF-7, and T-47D epithelial cells were grown in DMEM-based
media. B-Lymphoblastoid cell lines (B-LCL) and K562s (donated by Dr.
Marc Martinez-Llordella) were grown in RPMI-based media. All culture
media were supplemented with 10% heat-inactivated FCS, 100 units/mL
penicillin, 100 lg/mL streptomycin, and 2 mM L-glutamine (all from
Thermo Fisher Scientific). HLA-transfected K562 cultures were supple-
mented with 5 lg/mL neomycin (Thermo Fisher Scientific). All cells were
grown at 37°C in the presence of 5% (vol/vol) CO2.
Lentivirus production and Treg/Teff transduction
HEK293T cells were cotransfected with pLNT/SFFV-CAR-eGFP or pLNT/
SFFV-DCAR-eGFP (Figure 1A), pD8.91 and pCMV-VSV-G plasmids at a
mass ratio of 4:3:1 using polyethylenimine (3:1 PEI:DNA wt/wt; Sigma-
Aldrich, Gillingham, Dorset, UK). Viral supernatant was harvested 48–56 h
posttransfection and lentiviral particles were concentrated using PEG-itTM
(System Biosciences, Bar Hill, Cambridgeshire, UK). Tregs/Teffs were
transduced in RetroNectin-treated plates (50 lg/lL; Takara Bio Inc.,
Saint-Germain-en-Laye, Yvelines, France) 3 days postisolation using four-
fold concentrated viral supernatant. eGFP+ cells were purified by fluores-
cence-assisted cell sorting (FACS) 7 days posttransduction.
T cell/epithelial cell coculture
Teffs/Tregs were cocultured overnight with confluent MCF-7 or T-47D
cell monolayers. Culture supernatants were collected to measure IL-2,
interferon (IFN)c, and IL-10 production by cytokine-specific enzyme-linked
immunosorbent assays (ELISA) (eBioscience). Monolayers were washed
and the viability of the monolayer cells was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Absor-
bance was measured at 560 nm. Results are shown as percent viability
relative to monolayers cultured alone.
Suppression assays
Tregs were cocultured with autologous CD4+CD25−‒ Teff responders that
were labeled with CellTrace Violet (CTV; Thermo Fisher Scientific) and
activated with anti-CD3/CD28 beads (1:40 bead:cell ratio) or irradiated
(12 000 cGy) allogeneic B-LCLs (3:1 T:B-LCL ratio); DBB (HLA-A2+DR7+),
MOU (HLA-A2DR7+), SPO (HLA-A2+DR11+), and BM21 (HLA-
A2DR11+). Teff CTV dilution was measured after 5 days using flow
cytometry. Results are shown as percent suppression (inverse of percent
Teff proliferation) relative to Teffs cultured alone.
In vitro flow chamber assay
Primary human umbilical vein endothelial cells (HUVECs) were isolated by
collagenase digestion using ethically approved protocols (East London &
The City Local Research Ethics Committee reference 05/Q0603/34
ELCHA). HUVECs were stimulated with 15 ng/mL IFNc (R&D Systems,
Abingdon, Oxfordshire, UK) for 72 h prior to experimentation and seeded
in l-Slides VI 0.4 (Ibidi, Planegg/Martinsried, Germany) coated with 0.5%
bovine gelatin. Tregs were suspended at 1 9 106 cells/mL in PBS (with
Ca2+ and Mg2+) and flowed across HUVEC layers using a shear stress of
1 dyn/cm2. The number of Tregs that migrated in 10-s frames was
assessed.
Animals
BALB/c recombination activating gene (RAG)2/cc
/ (BRG) mice were
maintained under sterile conditions (Biological Services Unit, New Hunt’s
House, King’s College London). All procedures were performed in accor-
dance with all legal, ethical, and institutional requirements (PPL70/7302).
Human skin xenograft transplant model
Human skin was obtained from routine surgical procedures with informed
consent and ethical approval (Guy’s and St. Thomas’ NHS Foundation
Trust and King’s College London; reference 06/Q0704/18). Donor HLA-A2
expression was determined by flow cytometry, staining skin-derived cells
obtained by collagenase digestion (100 lg/mL; Sigma-Aldrich). Split-
thickness skin grafts (1.5 cm2) were transplanted onto 10–11-week-old
recipient BRG mice as previously described (19) and mice were adminis-
tered 100 lg anti-mouse Gr-1 (BioXCell, Upper Heyford, Oxfordshire, UK)
intraperitoneally every 3–4 days. After 5–6 weeks (Figure S4), mice were
injected intravenously with 5 9 106 peripheral blood mononuclear cells
(PBMCs)  1 9 106 Tregs. Skin grafts were harvested for histological
analysis 5 weeks following PBMCs/Tregs transfer.
Histological analysis of human skin
Skin grafts were frozen in optimal cutting temperature (OCT) (Thermo
Fisher Scientific). Eight- or 16-lm-thick sections were fixed in 4%
paraformaldehyde, blocked with a mixture of 10% donkey serum, 0.1%
fish skin gelatin, 0.1% Triton X-100, and 0.5% Tween-20 (all from Sigma-
Aldrich) in PBS and stained with the following antibodies: anti-human
CD3 (polyclonal rabbit; DAKO, Stockport, Cheshire, UK), anti-FOXP3
(236A/E7; Abcam, Milton, Cambridgeshire, UK), anti-CD45 (HI30, eBio-
science), anti-involucrin (CY5; Sigma-Aldrich), anti-human CD31, and Ki67
(both polyclonal rabbit; Abcam). Sections were stained with secondary
donkey anti-mouse Alexa Fluor555 and anti-rabbit Alexa Fluor488 or
Alexa Fluor647 antibodies with 40,6-diamidino-2-phenylindole (DAPI) (all
from Thermo Fisher Scientific) and mounted with Fluorescence Mounting
Medium (DAKO). Maximum intensity projection images consisting of
10 z-stacks (1.1 lm apart) were acquired at 920 magnification using a
C2+ point scanning confocal microscope (Nikon, Kingston Upon Thames,
Surrey, UK) and analyzed/quantified with NIS Elements and FIJI imaging
software (51).
Statistical analysis
Data shown are mean  SEM or mean  SD. Statistical significance was
determined using two-tailed paired Student’s t-tests or analysis of vari-
ance (ANOVA) with the Tukey multiple comparison post-hoc test.
p < 0.05, p < 0.01, p < 0.001, and p < 0.0001.
Results
Generation and validation of a novel HLA-A2-specific
CAR
A HLA-A2-specific CAR incorporating a human CD28-
CD3f signaling domain was generated using a patient-
derived HLA-A2-specific scFv sequence (50) (Figure 1A
and B). A second-generation CAR was selected based on
the superior function of these CARs relative to first-
generation CARs (52–55) and the importance of CD28
signaling for Treg activation (56). To investigate the
importance of this signaling domain, a HLA-A2-specific
CAR lacking a CD28-CD3f signaling domain (DCAR) was
also generated (Figure 1A and B). This control was
selected, as opposed to a CAR containing a scrambled
ectodomain, to ascertain whether the ability of the Tregs
to engage HLA-A2 was sufficient to elicit protection
in vivo or whether Treg activation via the CAR was also
necessary.
To confirm the functionality and HLA-A2-specificity of
these CARs, polyclonal CD4+CD25− effector T cells
(Teffs) were transduced with VSV-G-pseudotyped lentivi-
ral particles containing the CAR or the DCAR constructs
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with an efficiency of 40–80% (54.3–62.8  11.9%;
Figure 1C). eGFP+ Teffs were purified by cell sorting and
cocultured overnight with confluent monolayers of
MCF-7 and T-47D cells, breast cancer epithelial cells that
differentially expressed HLA-A2 (Figure 1D (57)). CAR
Teffs specifically destroyed HLA-A2+ monolayers but
left HLA-A2 monolayers intact (Figure 1E). Compared to
epithelial cells cultured alone, CAR Teffs killed
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80.8  4.2% of the HLA-A2+ cells but not the HLA-A2
cells (Figure 1F). Untransduced and DCAR Teffs exhib-
ited no detectable level of cytotoxicity. High levels of IL-
2 (Figure 1G) and IFNc (Figure 1H) were also produced
by the CAR Teffs during coculture with HLA-A2+ cells.
These results demonstrated that CAR expression by T
cells mediated specific recognition of HLA-A2 antigens
resulting in Teff activation, cytotoxicity, and cytokine pro-
duction.
Human CD4+CD25+ Tregs maintained their
phenotype and function following lentiviral CAR
transduction
Having validated the CARs in Teffs, we next assessed
whether lentiviral transduction influenced the phenotype
and/or suppressive capacity of human Tregs. CD4+CD25+
Tregs were enriched using good manufacturing practice
(GMP)-compatible protocols (58) from the peripheral
blood of healthy HLA-A2‒ donors with a purity of approxi-
mately 90% (89.5  4.4%, n = 16; Figure S1A). A high
proportion of the cells were FOXP3+ with a low expres-
sion of CD127 (Figure S1B). These cells were activated
using anti-CD3/CD28 beads and expanded in the pres-
ence of 1000 U/mL recombinant human IL-2 and 100 nM
rapamycin (29,58). Tregs were transduced with the CAR
or DCAR construct 72 h postactivation (Figure 2A), with
efficiencies of 30–80% (55.1–69.2  20.3%, n = 15; Fig-
ure 2B). eGFP+ Tregs were purified by flow sorting
7 days posttransduction (Figure 2B) and expanded for an
additional 10 days (Figure 2A). All eGFP+ Tregs were
shown to have a detectable level of CAR expression on
the cell surface (Figure 2B), which facilitated in the speci-
fic recognition of a HLA-A2-based dextramer but not an
irrelevant HLA-B7-based dextramer (Figure 2C). Further-
more, engagement of HLA-A2 was shown to specifically
activate CAR Tregs but not untransduced or DCAR Tregs
(Figure 2D and Figure S2).
Following expansion, >95% (95.3–97.8  4.7%) of the
transduced Tregs remained eGFP+. These cells exhibited
a similar phenotype to untransduced Tregs (Figure 2E
and Figure S3A); they remained CD4+CD25+CD127lo with
a high proportion expressing FOXP3 (94.2–95.8  7.3%),
CTLA-4 (91.3–95.3  3.1%), and CD39 (72.4–81.7 
16.3%). Treg expression of specific homing receptors
was also unaltered (Figure 2F and Figure S3B). The Tregs
expressed the skin homing molecules CCR4 (96.7–
98.8  3.2%) and cutaneous lymphocyte antigen (CLA)
(48.4–51.0  26.4%) but few cells expressed CCR10
(0.6–1.5  0.7%), as previously published (58). All cells
expressed CD62L (93.7–95.6  3.9%) and with regards
to gut homing, a high proportion expressed integrin b7
(91.7–93.2  5.9%) but few cells expressed CCR9
(1.1–1.7  1.0%).
To assess the suppressive capacity of the Tregs,
untransduced, CAR and DCAR Tregs were cocultured
with CTV-labeled autologous CD4+CD25− responder
Teffs in the presence of anti-CD3/28 beads for 5 days.
At a 1:32 Treg:Teff ratio, untransduced, CAR and DCAR
Tregs inhibited Teff proliferation by 43.0  4.1%,
44.8  5.4%, and 39.4  5.7%, respectively, proving
the potency of these cells and indicating that the Treg
function following transduction was unaltered.
Taken together, these results demonstrated that human
Tregs isolated and expanded with clinically relevant pro-
tocols maintained their phenotype and function follow-
ing transduction with VSV-G-pseudotyped lentiviral
particles.
CAR-mediated alloantigen recognition by human
Tregs enhanced their potency
To assess whether CAR Tregs were functionally superior
to untransduced (polyclonal) Tregs in the presence of
HLA-A2, Tregs were cocultured with CTV-labeled
CD4+CD25− responder Teffs, and allogeneic B-LCLs
which differentially expressed HLA-A2 as APCs. The sup-
pressive profile of the polyclonal Tregs cultured with
HLA-A2+ and HLA-A2‒ B-LCLs was identical (Figure 3A),
whereas CAR Tregs inhibited Teff proliferation signifi-
cantly more effectively (p-values 0.0082–1.1 9 105) in
Figure 1: CD4+CD25 T cells expressing the full-length CAR were activated in the presence of HLA-A2+ cells. (A, B) Schematic
diagrams detailing the components of the CAR genes. A CAR–eGFP fusion protein was generated consisting of a HLA-A2-specific scFv
(white), a CD28 hinge/transmembrane (TM) domain (gray), a CD28/CD3f signaling domain (light gray), and an eGFP reporter gene (gray
dots). A control CAR (DCAR) comprising the same elements but no signaling domain was also generated. (C) Transduction efficiency
of CD4+CD25 Teffs, prior to cell sorting, as determined by flow cytometry analyzing eGFP expression. Data are representative of four
individual experiments. (D) Flow cytometry histogram plots showing the expression of HLA class I, HLA-DR and HLA-A2 (BB7.2 or
REA142 clone) by MCF-7 (solid line) and T-47D (dotted line), compared to an isotype control (solid gray). (E) Microscopic images of
MCF-7 and T-47D monolayers following overnight coculture with untransduced (UN-TDX), CAR, or DCAR T cells. Representative data
of four individual experiments. (F) Quantification of MCF-7 (HLA-A2+, black) and T-47D (HLA-A2, gray) viability following overnight
coculture with untransduced, CAR or DCAR T cells as measured by MTT assay. Percent viability is relative to monolayers cultured
alone. IL-2 (G) and IFNc (H) production by the T cells during coculture with cell monolayers, as measured by ELISA. Data shown are
mean  SEM pooled from four individual experiments and significance was determined by two-tailed paired Student’s t-test where
* = p < 0.05 and **** = p < 0.0001. ND = not detected. CAR, chimeric antigen receptor; DCAR, truncated chimeric antigen receptor;
eGFP, enhanced green fluorescent protein; ELISA, enzyme-linked immunosorbent assay; IFNc, interferon c; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; scFv, single-chain variable fragment; SEM, standard error of the mean; Teffs,
effector T cells; UN-TDX, untransduced.
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the presence of HLA-A2+ B-LCLs, compared to HLA-A2‒
B-LCLs (Figure 3B). At a 1:32 and 1:64 Treg:Teff ratio,
CAR Tregs inhibited Teff proliferation by 62.8  5.2%
and 38.1  3.6%, respectively, in the presence of HLA-
A2 but only 35.8  3.5% and 16.9  3.4%, respectively,
in the absence of HLA-A2. DCAR Tregs were significantly
more suppressive in the presence of HLA-A2 at Treg:Teff
ratios of 1:2 (p = 0.041) and 1:32 (p = 0.027) (Figure 3C).
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This minor increase in suppressive ability may have been
due to the antigen-targeting moiety of the DCAR facilitat-
ing an interaction between the DCAR Tregs and the
HLA-A2+ APCs, bringing the Treg into the vicinity of the
Teff:B-LCL interaction.
Tregs can function by secreting granzyme and perforin
(59,60). To exclude the risk of unwanted cytotoxicity,
Tregs were cocultured with confluent monolayers of
HLA-A2+ and HLA-A2 epithelial cells, as previously
described (Figure 1). Unlike CAR Teffs, CAR Tregs exhib-
ited no detectable level of cytotoxicity toward the HLA-
A2+ cells (Figure 3D). IL-2 secretion was undetectable in
all conditions analyzed (data not shown) and low levels
of IFNc (221  80 pg/lL; Figure 3E) were produced by
CAR Tregs cocultured with HLA-A2+ monolayers. In con-
trast, these cells produced significantly high levels of the
immunosuppressive cytokine IL-10 (1055  78 pg/lL)
compared to polyclonal Tregs (not detected) and DCAR
Tregs (8  1 pg/lL) (Figure 3F), suggesting that in vivo,
CAR Tregs would contribute to the establishment of an
intragraft immunosuppressive milieu in HLA-A2+ allo-
grafts.
Given the importance of Treg trafficking in vivo, we
investigated whether the expression of HLA-A2 by
endothelial cells influenced the rate with which CAR
Tregs transmigrated (61). Relative to polyclonal Tregs,
CAR and DCAR Tregs transmigrated through HLA-A2+
endothelial monolayers significantly faster than through
HLA-A2 endothelial monolayers (p = 0.042; Figure 3G),
suggesting a preferential migration into HLA-A2+ target
tissues.
Overall, these results demonstrated that compared to
polyclonal Tregs, donor-specific CAR Tregs exhibited a
greater suppressive capacity in the presence of HLA-A2
without eliciting cytotoxic activity and transmigrated at a
faster rate through HUVECs expressing HLA-A2.
CAR-mediated Treg allorecognition conferred a
functional advantage in preventing skin graft
rejection
We have previously demonstrated the superior efficacy of
human Tregs with direct allospecificity over polyclonal
Tregs at reducing alloimmune injury in a human skin xeno-
graft transplant model (19,31). To investigate whether
CAR Tregs elicited a similar protective role, the same
model was employed (Figure S4). Human skin was
obtained from routine abdominal angioplasty surgery and
HLA-A2 expression was determined using collagenase-
treated skin explants (Figure S5). BRG mice were trans-
planted with HLA-A2+ skin grafts and following skin
engraftment, were injected with allogeneic CD25-depleted
HLA-A2− PBMCs  autologous Tregs. Mice did not exhibit
any signs of GvHD throughout the experiments (Fig-
ure S6A). Skin grafts were explanted and analyzed histo-
logically for changes in the skin morphology and immune
cell infiltration 5 weeks post-PBMC transfer (Figure S4B).
Cryosections were stained with hematoxylin and eosin
(Figure S6B) or analyzed by immunofluorescence.
Significant alloimmune damage was observed in the
grafts of mice that received PBMCs, as demonstrated by
a high number of Ki67+ keratinocytes (Figure 4A), a loss
of CD31+ blood vessel integrity and loss of the involucrin-
expressing epidermal layer (Figure 4B). Grafts of mice
treated with PBMCs and Tregs had comparatively fewer
Ki67+ keratinocytes (Figure 4A), intact CD31+ blood ves-
sels, and a defined involucrin layer (62) (Figure 4B). Quan-
tification of these observations demonstrated that CAR
Treg treatment reduced the number of Ki67+ ker-
atinocytes to basal levels, exhibiting significantly more
protection than polyclonal Tregs (p = 0.042) (Figure 4D).
Figure 2: Human CD4+CD25+ Tregs maintained their phenotype and function following CAR lentiviral transduction and cell
sorting. (A) Timeline showing production of human CAR Tregs used for experimentation. (B) Representative flow cytometry data
showing the proportion of Tregs that were successfully transduced (eGFP expression) and the proportion of cells coexpressing the
CAR/DCAR construct on the cell surface (c-Myc expression) immediately before and after eGFP+ cell sorting. (C) Representative flow
cytometry data showing the recognition of a HLA-A2 or HLA-B7 (irrelevant)-based dextramer by untransduced, CAR and DCAR Tregs.
(D) Activation of untransduced, CAR and DCAR Tregs following coculture with HLA-A2+ APCs (solid line), HLA-A2 APCs (dotted line),
or no APCs (solid gray). Tregs were cocultured with K562 cells or B-LCLs as APCs for 18 h at a 4:1 Treg:APC ratio after which Treg
activation was measured by CD69 expression. K562s were stably transfected to express either HLA-A2 or HLA-A1. SPO (HLA-A2+)
and BM21 (HLA-A2) B-LCLs were used. Data shown are representative of two individual experiments. (E) Pooled flow cytometry
data comparing the expression of typical Treg markers by untransduced (black), CAR (light gray), and DCAR (dark gray) Tregs. Data
shown are mean  SD pooled from five individual experiments. (F) Pooled flow cytometry data comparing the expression of select
skin, gut, and secondary lymphoid organ homing receptors by untransduced (black), CAR (light gray), and DCAR (dark gray) Tregs. Data
shown are mean  SD pooled from five individual experiments. (G) Polyclonal suppression assay comparing the suppressive capacity
of untransduced (black line), CAR (light gray line), and DCAR (dark gray line) Tregs. Tregs and autologous Teffs activated in a polyclonal
manner were cocultured at differing ratios for 5 days, after which Teff proliferation was measured by CellTrace Violet dilution. Data
are expressed as percentage of inhibition of responder Teff proliferation, relative to Teffs cultured alone. Data shown are
mean  SEM pooled from five to six individual experiments. APCs, antigen-presenting cells; CAR, chimeric antigen receptor; DCAR,
truncated chimeric antigen receptor; eGFP, enhanced green fluorescent protein; FACS, fluorescence-assisted cell sorting; B-LCL,
B-lymphoblastoid cell lines; SD, standard deviation; SEM, standard error of the mean; Teffs, effector T cells; Tregs, regulatory T cells;
UN-TDX, untransduced.
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Interestingly, in this readout of graft damage, DCAR Tregs
also mediated superior protection to polyclonal Tregs,
although statistical significance was not reached
(p = 0.11). Conversely, when measuring damage in terms
of CD31+ blood vessel integrity, CAR Tregs (CD31+ clus-
ter size = 88.9  8.5; p < 0.0001) mediated protection
more effectively than both polyclonal (73.3  8.7;
p = 0.017) and DCAR (70.9  10.1; p = 0.026) Tregs
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(Figure 4E). Mice that received PBMCs with CAR or
DCAR Tregs (p < 0.0001 versus PBMCs alone) had a
greater FOXP3:CD3 ratio than mice that received PBMCs
with polyclonal Tregs (p = 0.019). Together, these results
suggested that CAR expression facilitated preferential
homing and retention of the Tregs in the HLA-A2+ allo-
grafts. This localization to the graft enabled the DCAR
Tregs to elicit more protection than polyclonal Tregs, likely
due to these cells being activated in a TCR-dependent
manner through direct allorecognition. However, the pro-
tection offered was further improved upon by the CAR
Tregs that were activated in both a TCR-dependent (direct
allorecognition) and CAR-dependent manner.
In conclusion, CAR-engineered HLA-A2-specific Tregs
inhibited alloimmune-mediated injury against HLA-A2+
skin allografts significantly more effectively than poly-
clonal or DCAR Tregs, demonstrating the increased
potency of these cells in vivo and the requirement for
Treg signaling to elicit this response.
Discussion
Animal models of transplantation have demonstrated that
allospecific Tregs are superior to polyclonal Tregs at pro-
tecting from allograft rejection (4,17,19,31–34). Here, we
isolated human Tregs using GMP-compatible protocols
and used CAR technology to generate donor-MHC class
I-allospecific CAR Tregs, which were functionally superior
to polyclonal Tregs in vitro and in a human skin xenograft
transplant model. These results demonstrated a promis-
ing new direction for clinical trials that are currently
assessing the safety and efficacy of polyclonal Treg ther-
apy in kidney (The ONE Study: NCT02129881) and liver
(ThRIL: NCT02166177) transplant recipients (29,30).
Tregs that recognize allo-MHC-peptide complexes (direct
allorecognition) and/or allopeptides presented in the con-
text of recipient MHC (indirect allospecificity) have been
shown to suppress alloimmune responses more effec-
tively than polyclonal Tregs (4,17–19,31–34). However,
the potential of CD4+ Tregs is limited as they are MHC
class II-restricted, thus activated primarily by professional
APCs. CARs recognize their target antigen in an MHC-
independent manner and as such, can confer specificity
for donor MHC class I, an alloantigen ubiquitously
expressed on tissue parenchyma throughout an allograft.
In this study, we selected HLA-A2 as a target antigen
due to its comparatively high prevalence (>40%) in UK
donors (63). The scFv used to construct the HLA-A2-
specific CAR cross-reacts with HLA-A28 and HLA-A68
(50). CARs that cross-react with various HLA alleles can
be used in a wide variety of donor–recipient combina-
tions; thus we believe that generating a library of HLA
class I-specific CARs using cross-reactive scFvs will
allow for an efficient adaptation into the clinic. Further-
more, we demonstrated that these CARs can be effi-
ciently delivered into human Tregs by lentiviral
transduction, which is currently employed clinically to
deliver CD19-specific CARs into Teffs for the treatment
of CLL (37,38). Progress based on the CRISPR/Cas9 sys-
tem may make more directed and safer gene delivery
accessible in the near future (33).
CAR Tregs demonstrably protected HLA-A2+ human skin
grafts more effectively than polyclonal Tregs. However,
interesting results were also obtained for the DCAR
Tregs. These cells exhibited a favored migration and
retention in HLA-A2+ target tissues, which enabled the
elicitation of greater graft protection than polyclonal
Tregs. However, in terms of CD31+ blood vessel integ-
rity, the protection offered by the DCAR Tregs was not
as great as the CAR Tregs. These findings suggested
that the Treg localization was an important factor in
determining the protection offered, particularly as TCR-
mediated direct allorecognition could facilitate activation
of these cells in the graft. However, to exploit the full
potential of CAR technology, a functional CAR that acti-
vated Tregs in the presence of HLA-A2 was required.
Although CARs have principally been used to generate
cancer-specific Teffs, studies investigating the therapeu-
tic potential of CAR Tregs have been performed.
Very recently, the efficacy of human CAR Tregs was
Figure 3: Human CAR Tregs functioned more effectively in the presence of HLA-A2 without eliciting cytotoxicity. The sup-
pressive capacity of untransduced (A), CAR (B), and DCAR (C) Tregs in the presence of HLA-A2+ B-LCLs (black line) or HLA-A2 B-
LCLs (gray line). Data shown are mean  SEM pooled from five individual experiments. Significance was determined by two-tailed
paired Student’s t-test where * = p < 0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001. (D) Quantification of MCF-7
(black) and T-47D (gray) viability following overnight coculture with untransduced, CAR or DCAR Tregs as measured by MTT assay.
Percent viability is relative to monolayers cultured alone. IFNc (E) and IL-10 (F) production by the Tregs during coculture with cell
monolayers, as measured by ELISA. Data shown are mean  SEM pooled from three to four individual experiments. Significance was
determined by two-tailed paired Student’s t-test where * = p < 0.05. ND = not detected. (G) Transmigratory capacity of CAR (black)
and DCAR (gray) Tregs across IFNc pretreated HLA-A2 and HLA-A2+ HUVEC endothelial cell monolayers. Data shown represent the
percentage of CAR and DCAR Tregs that transmigrated, relative to untransduced (UN-TDX) Tregs. Data shown are mean  SEM
pooled from two to six individual experiments. Significance was determined by two-way ANOVA where * = p < 0.05. ANOVA, analy-
sis of variance; CAR, chimeric antigen receptor; DCAR, truncated chimeric antigen receptor; ELISA, enzyme-linked immunosorbent
assay; HUVEC, human umbilical cord endothelial cell; IFNc, interferon c; B-LCL, B-lymphoblastoid cell lines; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Teff, effector T cell; Tregs, regulatory T cells.
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Figure 4: Human CAR Tregs inhibited alloimmune-mediated injury of human HLA-A2+ skin grafts more effectively than
polyclonal Tregs. Immunodeficient BRG mice that had received a HLA-A2+ human skin graft were injected with 5 9 106
PBMCs  1 9 106 Tregs. Control mice received saline only. Human skin grafts were removed 5 weeks postinjection and cryopre-
served sections were fixed and stained either for human CD45/Ki67/DAPI (A), CD31/involucrin/DAPI (B), or human FOXP3/human
CD3/DAPI (C). Images are representative immunofluorescence stains of human skin grafts. Quantification of the number of Ki67+ ker-
atinocytes (D), CD31+ cluster size (E), and FOXP3:CD3 ratio (F) per field of view was performed using NIS Elements and FIJI imaging
software (51). Results represent two to three mice/group where four to six fields of view were quantified per section and data are
representative of two individual experiments. Significance was determined by one-way ANOVA and the Tukey multiple comparison
post-hoc test where * = p < 0.05, *** = p < 0.001, and **** = p < 0.0001. ANOVA, analysis of variance; CAR, chimeric antigen recep-
tor; DCAR, truncated chimeric antigen receptor; DAPI, 40,6-diamidino-2-phenylindole; ns, not significant; PBMCs, peripheral blood
mononuclear cells; Tregs, regulatory T cells; UN-TDX, untransduced.
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demonstrated in the prevention of xeno-GvHD (49). Fur-
thermore, in preclinical models of colitis (16,44,45) and
multiple sclerosis (46), CAR Tregs were found to migrate
to locations where their cognate antigen was expressed
and suppress undesired immune responses more effec-
tively than polyclonal Tregs. Similarly, we have shown that
CAR Tregs redirected toward HLA-A2 preferentially trans-
migrate through alloantigen-expressing endothelial cells
and exhibit a favored homing and retention in allografts.
These observations suggest a clinical potential for CAR
Tregs outside of the transplant field, particularly in light of
ongoing clinical trials that are assessing the safety and effi-
cacy of polyclonal Treg therapy for the treatment of type I
diabetes (NCT01210664) (27), lupus erythematosus
(NCT02428309), and uveitis (NCT02494492).
In conclusion, polyclonal Treg therapy is currently being
investigated clinically by us and others as a means of lim-
iting graft rejection. However, to avoid the risk of pan-
immunosuppression and provide a tailored therapy, the
successful generation and expansion of alloantigen-
specific Tregs is required. We demonstrated that clini-
cally applicable CAR technology may be used to generate
donor antigen-specific Tregs that suppress alloimmune
responses, providing a future direction for Treg therapy
in the pursuit of transplant tolerance in solid organ trans-
plantation.
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Figure S1: Isolation purity of human CD4+CD25+
Tregs. (A) Following isolation, Tregs were costained for
CD4 (OKT4) and CD25 (4E3) and the purity was deter-
mined by flow cytometry to be 96.2%. Data are repre-
sentative of 15 individual experiments. (B) Following
live/dead discrimination, cells were assessed for expres-
sion of the following markers by flow cytometry: CD4
(OKT4), CD25 (4E3), CD127 (A019D5), FOXP3 (PCH101),
CTLA-4 (BNI3), and CD39 (eBioA1). Data shown are
mean  standard deviation pooled from six individual
experiments.
Figure S2: Proliferation of Tregs in the presence of
HLA-A2+ and HLA-A2 APCs. Proliferation of untrans-
duced (red), CAR (blue), and DCAR (green) Tregs follow-
ing coculture with HLA-A2+ and HLA-A2 APCs. Tregs
were cocultured with K562 cells (A) or B-LCLs (B) as
APCs for 72 hours at a 1:1 ratio. Treg proliferation was
measured by 3H-thymidine incorporation and is shown in
cpm (counts per minute) where the cpm of APCs cul-
tured alone was subtracted. K562s were stably trans-
fected to express either HLA-A2 or HLA-A1. SPO (HLA-
A2+) and BM21 (HLA-A2) B-LCLs were used. Data
shown are mean  standard deviation and are represen-
tative of two individual experiments. Significance was
determined by two-tailed paired Student’s t-test where
* = p < 0.05. ns, not significant.
Figure S3: Detailed phenotypic analysis of trans-
duced human Tregs. Representative flow cytometry
plots comparing the expression of typical Tregs markers
(A) and various homing receptors (B) by untransduced
(UN-TDX; red line), CAR (blue line), and DCAR (green
line) Tregs. Isotype control staining is shown in solid
gray. Data shown are representative of five individual
experiments.
Figure S4: Schematic diagrams detailing the experi-
mental design of the human skin xenograft trans-
plant experiments. (A) Human skin from HLA-A2+
donors was transplanted onto recipient immunodeficient
BRG mice and allowed to engraft for 5–6 weeks. These
mice were then injected intravenously with allogeneic
HLA-A2 PBMCs with or without autologous ex vivo-
expanded Tregs. Mice were sacrificed 5 weeks following
PBMC infusion and skin grafts were monitored histologi-
cally for changes in skin morphology and cell infiltration.
(B) Timeline showing when mice were transplanted with
human skin, injected with allogeneic PBMCs  Tregs,
and sacrificed to analyze skin graft histology.
Figure S5: HLA-A2 expression on skin-derived cells.
Small explants of human skin were tested for HLA-A2
expression by flow cytometry prior to transplantation.
Cells acquired by treating explants with collagenase for 1
hour were stained with two separate HLA-A2-specific
antibody clones (BB7.2 and REA142 denoted by blue and
green lines, respectively). HLA-A2-expression was com-
pared to cells stained with an isotype control, shown in
solid gray.
Figure S6: Mice transplanted with human skin allo-
grafts did not lose weight following PBMC transfer.
(A) Transplanted mice injected with allogeneic
PBMCs  Tregs showed no signs of graft-versus-host dis-
ease and no weight loss. (B) Representative hematoxylin/
eosin stains of skin grafts stained in Figure 4.
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“Finally, from so little sleeping and so much reading, his brain dried up 
and he went completely out of his mind.” 
Don Quixote de la Mancha, Miguel de Cervantes Saavedra 
